



EUROPEAN HEALTH AND DIGITAL EXECUTIVE AGENCY (HADEA)

HADEA.A – Health and Food
A.1 – EU4Health

GRANT AGREEMENT

Project 101056986 — BRAVEST

PREAMBLE

This **Agreement** ('the Agreement') is **between** the following parties:

on the one part,

the **European Health and Digital Executive Agency (HADEA)** ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and

on the other part,

1. 'the coordinator':

EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT), PIC 994118081, established in WESTERDOKSDIJK 423, AMSTERDAM 1013 BX, Netherlands,

and the following other beneficiaries, if they sign their 'accession form' (see Annex 3 and Article 40):

2. **ISTITUTO SUPERIORE DI SANITA (ISS - CNT)**, PIC 999978821, established in Viale Regina Elena 299, ROMA 00161, Italy,

3. **ORGANIZACION NACIONAL DE TRASPLANTES (ONT)**, PIC 941056365, established in CALLE SINESIO DELGADO 8, MADRID 28029, Spain,

4. **ZAVOD REPUBLIKE SLOVENIJE ZA PRESADITVE ORGANOV IN TKIV SLOVENIJA TRANSPLANT (ST)**, PIC 939758796, established in ZALOSKA CESTA 7, LJUBLJANA 1000, Slovenia,

5. **STICHTING EUROTRANSPLANT INTERNATIONAL FOUNDATION (ET)**, PIC 954188419, established in HAAGSE SCHOUW WEG 6, LEIDEN 2332 KG, Netherlands,

6. **AGENCE DE LA BIOMEDECINE (ABM)**, PIC 911988763, established in AVENUE DU STADE DE FRANCE 1, SAINT DENIS LA PLAINE CEDEX 93212, France,

7. **ORSZAGOS VERELLATO SZOLGALAT - OVSZ (OVSZ)**, PIC 933649251, established in KAROLINA UT 19-21, BUDAPEST 1113, Hungary,

8. **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)**, PIC 999997833, established in RUE DE TOLBIAC 101, PARIS 75654, France,

9. EUROPEAN PUBLIC HEALTH ALLIANCE (EPHA), PIC 955484436, established in RUE DE TREVES 49-51, BRUXELLES 1040, Belgium,

Unless otherwise specified, references to ‘beneficiary’ or ‘beneficiaries’ include the coordinator and affiliated entities (if any).

If only one beneficiary signs the grant agreement (‘mono-beneficiary grant’), all provisions referring to the ‘coordinator’ or the ‘beneficiaries’ will be considered — mutatis mutandis — as referring to the beneficiary.

The parties referred to above have agreed to enter into the Agreement.

By signing the Agreement and the accession forms, the beneficiaries accept the grant and agree to implement the action under their own responsibility and in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

The Agreement is composed of:

Preamble

Terms and Conditions (including Data Sheet)

Annex 1 Description of the action¹

Annex 2 Estimated budget for the action

Annex 2a Additional information on unit costs and contributions (if applicable)

Annex 3 Accession forms (if applicable)²

Annex 3a Declaration on joint and several liability of affiliated entities (if applicable)³

Annex 4 Model for the financial statements

Annex 5 Specific rules (if applicable)

¹ Template published on [Portal Reference Documents](#).

² Template published on [Portal Reference Documents](#).

³ Template published on [Portal Reference Documents](#).

TERMS AND CONDITIONS

TABLE OF CONTENTS

GRANT AGREEMENT.....	1
PREAMBLE.....	1
TERMS AND CONDITIONS.....	3
DATASHEET.....	8
CHAPTER 1 GENERAL.....	13
ARTICLE 1 — SUBJECT OF THE AGREEMENT	13
ARTICLE 2 — DEFINITIONS.....	13
CHAPTER 2 ACTION.....	14
ARTICLE 3 — ACTION.....	14
ARTICLE 4 — DURATION AND STARTING DATE.....	14
CHAPTER 3 GRANT.....	14
ARTICLE 5 — GRANT.....	14
5.1 Form of grant.....	14
5.2 Maximum grant amount.....	15
5.3 Funding rate.....	15
5.4 Estimated budget, budget categories and forms of funding.....	15
5.5 Budget flexibility.....	15
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS AND CONTRIBUTIONS.....	16
6.1 General eligibility conditions.....	16
6.2 Specific eligibility conditions for each budget category.....	17
6.3 Ineligible costs and contributions.....	21
6.4 Consequences of non-compliance.....	22
CHAPTER 4 GRANT IMPLEMENTATION.....	22
SECTION 1 CONSORTIUM: BENEFICIARIES, AFFILIATED ENTITIES AND OTHER PARTICIPANTS.....	22
ARTICLE 7 — BENEFICIARIES.....	22
ARTICLE 8 — AFFILIATED ENTITIES.....	24
ARTICLE 9 — OTHER PARTICIPANTS INVOLVED IN THE ACTION.....	24
9.1 Associated partners.....	24
9.2 Third parties giving in-kind contributions to the action.....	24
9.3 Subcontractors.....	25

9.4 Recipients of financial support to third parties.....	25
ARTICLE 10 — PARTICIPANTS WITH SPECIAL STATUS.....	25
10.1 Non-EU participants.....	25
10.2 Participants which are international organisations.....	26
10.3 Pillar-assessed participants.....	26
SECTION 2 RULES FOR CARRYING OUT THE ACTION.....	28
ARTICLE 11 — PROPER IMPLEMENTATION OF THE ACTION.....	28
11.1 Obligation to properly implement the action.....	28
11.2 Consequences of non-compliance.....	28
ARTICLE 12 — CONFLICT OF INTERESTS.....	29
12.1 Conflict of interests.....	29
12.2 Consequences of non-compliance.....	29
ARTICLE 13 — CONFIDENTIALITY AND SECURITY.....	29
13.1 Sensitive information.....	29
13.2 Classified information.....	30
13.3 Consequences of non-compliance.....	30
ARTICLE 14 — ETHICS AND VALUES.....	30
14.1 Ethics.....	30
14.2 Values.....	30
14.3 Consequences of non-compliance.....	31
ARTICLE 15 — DATA PROTECTION.....	31
15.1 Data processing by the granting authority.....	31
15.2 Data processing by the beneficiaries.....	31
15.3 Consequences of non-compliance.....	32
ARTICLE 16 — INTELLECTUAL PROPERTY RIGHTS (IPR) — BACKGROUND AND RESULTS — ACCESS RIGHTS AND RIGHTS OF USE.....	32
16.1 Background and access rights to background.....	32
16.2 Ownership of results.....	32
16.3 Rights of use of the granting authority on materials, documents and information received for policy, information, communication, dissemination and publicity purposes.....	32
16.4 Specific rules on IPR, results and background.....	33
16.5 Consequences of non-compliance.....	33
ARTICLE 17 — COMMUNICATION, DISSEMINATION AND VISIBILITY.....	34
17.1 Communication — Dissemination — Promoting the action.....	34
17.2 Visibility — European flag and funding statement.....	34
17.3 Quality of information — Disclaimer.....	35

17.4	Specific communication, dissemination and visibility rules.....	35
17.5	Consequences of non-compliance.....	35
ARTICLE 18 — SPECIFIC RULES FOR CARRYING OUT THE ACTION.....		35
18.1	Specific rules for carrying out the action.....	35
18.2	Consequences of non-compliance.....	35
SECTION 3 GRANT ADMINISTRATION.....		35
ARTICLE 19 — GENERAL INFORMATION OBLIGATIONS.....		35
19.1	Information requests.....	35
19.2	Participant Register data updates.....	36
19.3	Information about events and circumstances which impact the action.....	36
19.4	Consequences of non-compliance.....	36
ARTICLE 20 — RECORD-KEEPING.....		36
20.1	Keeping records and supporting documents.....	36
20.2	Consequences of non-compliance.....	37
ARTICLE 21 — REPORTING.....		37
21.1	Continuous reporting.....	37
21.2	Periodic reporting: Technical reports and financial statements.....	38
21.3	Currency for financial statements and conversion into euros.....	39
21.4	Reporting language.....	39
21.5	Consequences of non-compliance.....	39
ARTICLE 22 — PAYMENTS AND RECOVERIES — CALCULATION OF AMOUNTS DUE.....		39
22.1	Payments and payment arrangements.....	39
22.2	Recoveries.....	40
22.3	Amounts due.....	40
22.4	Enforced recovery.....	45
22.5	Consequences of non-compliance.....	45
ARTICLE 23 — GUARANTEES.....		46
23.1	Prefinancing guarantee.....	46
23.2	Consequences of non-compliance.....	46
ARTICLE 24 — CERTIFICATES.....		47
24.1	Operational verification report (OVR).....	47
24.2	Certificate on the financial statements (CFS).....	47
24.3	Certificate on the compliance of usual cost accounting practices (CoMUC).....	47
24.4	Systems and process audit (SPA).....	47
24.5	Consequences of non-compliance.....	47

ARTICLE 25 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF FINDINGS.....	48
25.1 Granting authority checks, reviews and audits.....	48
25.2 European Commission checks, reviews and audits in grants of other granting authorities.....	49
25.3 Access to records for assessing simplified forms of funding.....	49
25.4 OLAF, EPPO and ECA audits and investigations.....	49
25.5 Consequences of checks, reviews, audits and investigations — Extension of results of reviews, audits or investigations.....	50
25.6 Consequences of non-compliance.....	51
ARTICLE 26 — IMPACT EVALUATIONS.....	51
26.1 Impact evaluation.....	51
26.2 Consequences of non-compliance.....	52
CHAPTER 5 CONSEQUENCES OF NON-COMPLIANCE.....	52
SECTION 1 REJECTIONS AND GRANT REDUCTION.....	52
ARTICLE 27 — REJECTION OF COSTS AND CONTRIBUTIONS.....	52
27.1 Conditions.....	52
27.2 Procedure.....	52
27.3 Effects.....	52
ARTICLE 28 — GRANT REDUCTION.....	52
28.1 Conditions.....	52
28.2 Procedure.....	53
28.3 Effects.....	53
SECTION 2 SUSPENSION AND TERMINATION.....	53
ARTICLE 29 — PAYMENT DEADLINE SUSPENSION.....	53
29.1 Conditions.....	53
29.2 Procedure.....	54
ARTICLE 30 — PAYMENT SUSPENSION.....	54
30.1 Conditions.....	54
30.2 Procedure.....	54
ARTICLE 31 — GRANT AGREEMENT SUSPENSION.....	55
31.1 Consortium-requested GA suspension.....	55
31.2 EU-initiated GA suspension.....	56
ARTICLE 32 — GRANT AGREEMENT OR BENEFICIARY TERMINATION.....	57
32.1 Consortium-requested GA termination.....	57
32.2 Consortium-requested beneficiary termination.....	58
32.3 EU-initiated GA or beneficiary termination.....	59

SECTION 3 OTHER CONSEQUENCES: DAMAGES AND ADMINISTRATIVE SANCTIONS..... 62

ARTICLE 33 — DAMAGES..... 62

 33.1 Liability of the granting authority..... 62

 33.2 Liability of the beneficiaries..... 62

ARTICLE 34 — ADMINISTRATIVE SANCTIONS AND OTHER MEASURES..... 63

SECTION 4 FORCE MAJEURE..... 63

ARTICLE 35 — FORCE MAJEURE..... 63

CHAPTER 6 FINAL PROVISIONS..... 63

ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES..... 63

 36.1 Forms and means of communication — Electronic management..... 63

 36.2 Date of communication..... 64

 36.3 Addresses for communication..... 64

ARTICLE 37 — INTERPRETATION OF THE AGREEMENT..... 64

ARTICLE 38 — CALCULATION OF PERIODS AND DEADLINES..... 64

ARTICLE 39 — AMENDMENTS..... 65

 39.1 Conditions..... 65

 39.2 Procedure..... 65

ARTICLE 40 — ACCESSION AND ADDITION OF NEW BENEFICIARIES..... 65

 40.1 Accession of the beneficiaries mentioned in the Preamble..... 66

 40.2 Addition of new beneficiaries..... 66

ARTICLE 41 — TRANSFER OF THE AGREEMENT..... 66

ARTICLE 42 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE GRANTING
AUTHORITY..... 66

ARTICLE 43 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES..... 67

 43.1 Applicable law..... 67

 43.2 Dispute settlement..... 67

ARTICLE 44 — ENTRY INTO FORCE..... 67

DATA SHEET

1. General data

Project summary:

Project summary
Stemming from the lessons learned during the SARS-CoV2 pandemic, BRAVEST project aims at analysing organizational and management procedures in organ donation and transplantation based on real world evidence and cutting-edge analysis methodologies. This will allow to identify the most effective clinical practice; identify good clinical practice procedures; develop guidelines and propose sustainable innovative actions directed at improving the resilience of the donation and transplant systems and networks, ensure the continuity of supply of organs while maintaining the safety of donation and transplant, and ultimately increase the accessibility to transplantation for all patients with end-stage organ disease. Such resilience is meant to reinforce organizations, in order to cope with stress conditions, ranging from eventual additional epidemics, but also wars, earthquakes, ecological disasters, which are increasingly hitting several areas in Europe, as well as the world around.

Keywords: not defined

Project number: 101056986

Project name: Building Resilience Against crisis: a systematic and global approach to adVancE organ Safety and supply in Transplantation

Project acronym: BRAVEST

Call: EU4H-2021-PJ

Topic: EU4H-2021-PJ-05

Type of action: EU4H Project Grants

Granting authority: European Health and Digital Executive Agency

Grant managed through EU Funding & Tenders Portal: Yes (eGrants)

Project starting date: fixed date: 1 September 2022

Project end date: 28 February 2025

Project duration: 30 months

Consortium agreement: Yes

2. Participants

List of participants:

N°	Role	Short name	Legal name	Ctry	PIC	Total eligible costs (BEN and AE)	Max grant amount
1	COO	ESOT	EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION	NL	994118081	342 400.00	273 920.00
2	BEN	ISS - CNT	ISTITUTO SUPERIORE DI SANITA	IT	999978821	112 278.95	89 823.16
3	BEN	ONT	ORGANIZACION NACIONAL DE TRASPLANTES	ES	941056365	145 193.18	116 154.54
4	BEN	ST	ZAVOD REPUBLIKE SLOVENIJE ZA PRESADITVE ORGANOV IN TKIV SLOVENIJA TRANSPLANT	SI	939758796	123 897.87	99 118.30
5	BEN	ET	STICHTING EUROTRANSPLANT INTERNATIONAL FOUNDATION	NL	954188419	72 770.48	58 216.38
6	BEN	ABM	AGENCE DE LA BIOMEDECINE	FR	911988763	94 353.18	75 482.54

N°	Role	Short name	Legal name	Ctry	PIC	Total eligible costs (BEN and AE)	Max grant amount
7	BEN	OVSZ	ORSZAGOS VERELLATO SZOLGALAT - OVSZ	HU	933649251	87 686.50	70 149.20
8	BEN	INSERM	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	FR	999997833	97 691.00	78 152.80
9	BEN	EPHA	EUROPEAN PUBLIC HEALTH ALLIANCE	BE	955484436	108 605.00	86 884.00
Total						1 184 876.16	947 900.92

Coordinator:

- EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT)

3. Grant**Maximum grant amount, total estimated eligible costs and contributions and funding rate:**

Total eligible costs (BEN and AE)	Funding rate (%)	Maximum grant amount (Annex 2)	Maximum grant amount (award decision)
1 184 876.16	80	947 900.92	947 900.92

Grant form: Budget-based**Grant mode:** Action grant**Budget categories/activity types:**

- A. Personnel costs
 - A.1 Employees, A.2 Natural persons under direct contract, A.3 Seconded persons
 - A.4 SME owners and natural person beneficiaries
- B. Subcontracting costs
- C. Purchase costs
 - C.1 Travel and subsistence
 - C.2 Equipment
 - C.3 Other goods, works and services
- D. Other cost categories
 - D.1 Financial support to third parties
- E. Indirect costs

Cost eligibility options:

- Standard supplementary payments
- Limitation for subcontracting
- Travel and subsistence:
 - Travel: Unit or Actual costs
 - Accommodation: Unit or Actual costs
 - Subsistence: Unit or Actual costs
- Equipment: depreciation only

- Costs for providing financial support to third parties (actual cost; max amount for each recipient: EUR 0.00)
- Indirect cost flat-rate: 7% of the eligible direct costs (categories A-D, except volunteers costs and exempted specific cost categories, if any)
- VAT: Yes
- Other ineligible costs

Budget flexibility: Yes (no flexibility cap)

4. Reporting, payments and recoveries

4.1 Continuous reporting (art 21)

Deliverables: see Funding & Tenders Portal Continuous Reporting tool

4.2 Periodic reporting and payments

Reporting and payment schedule (art 21, 22):

Reporting					Payments	
Reporting periods			Type	Deadline	Type	Deadline (time to pay)
RP No	Month from	Month to				
					Initial prefinancing	30 days from entry into force/10 days before starting date/ financial guarantee (if required) – whichever is the latest
1	1	18	Periodic report	60 days after end of reporting period	Interim payment	90 days from receiving periodic report
2	19	30	Periodic report	60 days after end of reporting period	Final payment	90 days from receiving periodic report

Prefinancing payments and guarantees:

Prefinancing payment		Prefinancing guarantee		
Type	Amount	Guarantee amount	Division per participant	
Prefinancing 1 (initial)	284 370.28	n/a	1 - ESOT	n/a
			2 - ISS - CNT	n/a
			3 - ONT	n/a
			4 - ST	n/a
			5 - ET	n/a
			6 - ABM	n/a
			7 - OVSZ	n/a
			8 - INSERM	n/a
			9 - EPHA	n/a

Reporting and payment modalities (art 21, 22):

Mutual Insurance Mechanism (MIM): No

Restrictions on distribution of initial prefinancing: The prefinancing may be distributed only if the minimum number of beneficiaries set out in the call conditions (if any) have acceded to the Agreement and only to beneficiaries that have acceded.

Interim payment ceiling (if any): 90% of the maximum grant amount

No-profit rule: Yes

Late payment interest: ECB + 3.5%

Bank account for payments:

NL48ABNA0619645105

Conversion into euros: Double conversion

Reporting language: Language of the Agreement

4.3 Certificates (art 24):

Certificates on the financial statements (CFS):

Conditions:

Schedule: interim/final payment, if threshold is reached

Standard threshold (beneficiary-level):

- financial statement: requested EU contribution to costs \geq EUR 325 000.00

4.4 Recoveries (art 22)

First-line liability for recoveries:

Beneficiary termination: Beneficiary concerned

Final payment: Coordinator

After final payment: Beneficiary concerned

Joint and several liability for enforced recoveries (in case of non-payment):

Limited joint and several liability of other beneficiaries — up to the maximum grant amount of the beneficiary

Joint and several liability of affiliated entities — n/a

5. Consequences of non-compliance, applicable law & dispute settlement forum

Applicable law (art 43):

Standard applicable law regime: EU law + law of Belgium

Dispute settlement forum (art 43):

Standard dispute settlement forum:

EU beneficiaries: EU General Court + EU Court of Justice (on appeal)

Non-EU beneficiaries: Courts of Brussels, Belgium (unless an international agreement provides for the enforceability of EU court judgements)

6. Other

Specific rules (Annex 5): Yes

Standard time-limits after project end:

Confidentiality (for X years after final payment): 5

Record-keeping (for X years after final payment): 5 (or 3 for grants of not more than EUR 60 000)

Reviews (up to X years after final payment): 5 (or 3 for grants of not more than EUR 60 000)

Audits (up to X years after final payment): 5 (or 3 for grants of not more than EUR 60 000)

Extension of findings from other grants to this grant (no later than X years after final payment): 5 (or 3 for grants of not more than EUR 60 000)

Impact evaluation (up to X years after final payment): 5 (or 3 for grants of not more than EUR 60 000)

CHAPTER 1 GENERAL

ARTICLE 1 — SUBJECT OF THE AGREEMENT

This Agreement sets out the rights and obligations and terms and conditions applicable to the grant awarded for the implementation of the action set out in Chapter 2.

ARTICLE 2 — DEFINITIONS

For the purpose of this Agreement, the following definitions apply:

Actions — The project which is being funded in the context of this Agreement.

Grant — The grant awarded in the context of this Agreement.

EU grants — Grants awarded by EU institutions, bodies, offices or agencies (including EU executive agencies, EU regulatory agencies, EDA, joint undertakings, etc.).

Participants — Entities participating in the action as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties.

Beneficiaries (BEN) — The signatories of this Agreement (either directly or through an accession form).

Affiliated entities (AE) — Entities affiliated to a beneficiary within the meaning of Article 187 of EU Financial Regulation 2018/1046⁴ which participate in the action with similar rights and obligations as the beneficiaries (obligation to implement action tasks and right to charge costs and claim contributions).

Associated partners (AP) — Entities which participate in the action, but without the right to charge costs or claim contributions.

Purchases — Contracts for goods, works or services needed to carry out the action (e.g. equipment, consumables and supplies) but which are not part of the action tasks (see Annex 1).

Subcontracting — Contracts for goods, works or services that are part of the action tasks (see Annex 1).

In-kind contributions — In-kind contributions within the meaning of Article 2(36) of EU Financial

⁴ For the definition, see Article 187 Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general budget of the Union, amending Regulations (EU) No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013, (EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing Regulation (EU, Euratom) No 966/2012 ('EU Financial Regulation') (OJ L 193, 30.7.2018, p. 1): "**affiliated entities** [are]:

- (a) entities that form a sole beneficiary [(i.e. where an entity is formed of several entities that satisfy the criteria for being awarded a grant, including where the entity is specifically established for the purpose of implementing an action to be financed by a grant)];
- (b) entities that satisfy the eligibility criteria and that do not fall within one of the situations referred to in Article 136(1) and 141(1) and that have a link with the beneficiary, in particular a legal or capital link, which is neither limited to the action nor established for the sole purpose of its implementation".

Regulation 2018/1046, i.e. non-financial resources made available free of charge by third parties.

Fraud — Fraud within the meaning of Article 3 of EU Directive 2017/1371⁵ and Article 1 of the Convention on the protection of the European Communities' financial interests, drawn up by the Council Act of 26 July 1995⁶, as well as any other wrongful or criminal deception intended to result in financial or personal gain.

Irregularities — Any type of breach (regulatory or contractual) which could impact the EU financial interests, including irregularities within the meaning of Article 1(2) of EU Regulation 2988/95⁷.

Grave professional misconduct — Any type of unacceptable or improper behaviour in exercising one's profession, especially by employees, including grave professional misconduct within the meaning of Article 136(1)(c) of EU Financial Regulation 2018/1046.

Applicable EU, international and national law — Any legal acts or other (binding or non-binding) rules and guidance in the area concerned.

Portal — EU Funding & Tenders Portal; electronic portal and exchange system managed by the European Commission and used by itself and other EU institutions, bodies, offices or agencies for the management of their funding programmes (grants, procurements, prizes, etc.).

CHAPTER 2 ACTION

ARTICLE 3 — ACTION

The grant is awarded for the action **101056986 — BRAVEST** ('action'), as described in Annex 1.

ARTICLE 4 — DURATION AND STARTING DATE

The duration and the starting date of the action are set out in the Data Sheet (see Point 1).

CHAPTER 3 GRANT

ARTICLE 5 — GRANT

5.1 Form of grant

The grant is an action grant⁸ which takes the form of a budget-based mixed actual cost grant (i.e. a

⁵ Directive (EU) 2017/1371 of the European Parliament and of the Council of 5 July 2017 on the fight against fraud to the Union's financial interests by means of criminal law (OJ L 198, 28.7.2017, p. 29).

⁶ OJ C 316, 27.11.1995, p. 48.

⁷ Council Regulation (EC, Euratom) No 2988/95 of 18 December 1995 on the protection of the European Communities financial interests (OJ L 312, 23.12.1995, p. 1).

⁸ For the definition, see Article 180(2)(a) EU Financial Regulation 2018/1046: '**action grant**' means an EU grant to finance "an action intended to help achieve a Union policy objective".

grant based on actual costs incurred, but which may also include other forms of funding, such as unit costs or contributions, flat-rate costs or contributions, lump sum costs or contributions or financing not linked to costs).

5.2 Maximum grant amount

The maximum grant amount is set out in the Data Sheet (see Point 3) and in the estimated budget (Annex 2).

5.3 Funding rate

The funding rate for costs is 80% of the action's eligible costs.

Contributions are not subject to any funding rate.

5.4 Estimated budget, budget categories and forms of funding

The estimated budget for the action is set out in Annex 2.

It contains the estimated eligible costs and contributions for the action, broken down by participant and budget category.

Annex 2 also shows the types of costs and contributions (forms of funding)⁹ to be used for each budget category.

If unit costs or contributions are used, the details on the calculation will be explained in Annex 2a.

5.5 Budget flexibility

The budget breakdown may be adjusted — without an amendment (see Article 39) — by transfers (between participants and budget categories), as long as this does not imply any substantive or important change to the description of the action in Annex 1.

However:

- changes to the budget category for volunteers (if used) always require an amendment
- changes to budget categories with lump sums costs or contributions (if used; including financing not linked to costs) always require an amendment
- changes to budget categories with higher funding rates or budget ceilings (if used) always require an amendment
- addition of amounts for subcontracts not provided for in Annex 1 either require an amendment or simplified approval in accordance with Article 6.2
- other changes require an amendment or simplified approval, if specifically provided for in Article 6.2
- flexibility caps: not applicable.

⁹ See Article 125 EU Financial Regulation 2018/1046.

ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS AND CONTRIBUTIONS

In order to be eligible, costs and contributions must meet the **eligibility** conditions set out in this Article.

6.1 General eligibility conditions

The **general eligibility conditions** are the following:

(a) for actual costs:

- (i) they must be actually incurred by the beneficiary
- (ii) they must be incurred in the period set out in Article 4 (with the exception of costs relating to the submission of the final periodic report, which may be incurred afterwards; see Article 21)
- (iii) they must be declared under one of the budget categories set out in Article 6.2 and Annex 2
- (iv) they must be incurred in connection with the action as described in Annex 1 and necessary for its implementation
- (v) they must be identifiable and verifiable, in particular recorded in the beneficiary's accounts in accordance with the accounting standards applicable in the country where the beneficiary is established and with the beneficiary's usual cost accounting practices
- (vi) they must comply with the applicable national law on taxes, labour and social security and
- (vii) they must be reasonable, justified and must comply with the principle of sound financial management, in particular regarding economy and efficiency

(b) for unit costs or contributions (if any):

- (i) they must be declared under one of the budget categories set out in Article 6.2 and Annex 2
- (ii) the units must:
 - be actually used or produced by the beneficiary in the period set out in Article 4 (with the exception of units relating to the submission of the final periodic report, which may be used or produced afterwards; see Article 21)
 - be necessary for the implementation of the action and
- (iii) the number of units must be identifiable and verifiable, in particular supported by records and documentation (see Article 20)

(c) for flat-rate costs or contributions (if any):

- (i) they must be declared under one of the budget categories set out in Article 6.2 and Annex 2

- (ii) the costs or contributions to which the flat-rate is applied must:
 - be eligible
 - relate to the period set out in Article 4 (with the exception of costs or contributions relating to the submission of the final periodic report, which may be incurred afterwards; see Article 21)
- (d) for lump sum costs or contributions (if any):
 - (i) they must be declared under one of the budget categories set out in Article 6.2 and Annex 2
 - (ii) the work must be properly implemented by the beneficiary in accordance with Annex 1
 - (iii) the deliverables/outputs must be achieved in the period set out in Article 4 (with the exception of deliverables/outputs relating to the submission of the final periodic report, which may be achieved afterwards; see Article 21)
- (e) for unit, flat-rate or lump sum costs or contributions according to usual cost accounting practices (if any):
 - (i) they must fulfil the general eligibility conditions for the type of cost concerned
 - (ii) the cost accounting practices must be applied in a consistent manner, based on objective criteria, regardless of the source of funding
- (f) for financing not linked to costs (if any): the results must be achieved or the conditions must be fulfilled as described in Annex 1.

In addition, for direct cost categories (e.g. personnel, travel & subsistence, subcontracting and other direct costs) only costs that are directly linked to the action implementation and can therefore be attributed to it directly are eligible. They must not include any indirect costs (i.e. costs that are only indirectly linked to the action, e.g. via cost drivers).

6.2 Specific eligibility conditions for each budget category

For each budget category, the **specific eligibility conditions** are as follows:

Direct costs

A. Personnel costs

A.1 Costs for employees (or equivalent) are eligible as personnel costs if they fulfil the general eligibility conditions and are related to personnel working for the beneficiary under an employment contract (or equivalent appointing act) and assigned to the action.

They must be limited to salaries, social security contributions, taxes and other costs linked to the remuneration, if they arise from national law or the employment contract (or equivalent appointing act) and be calculated on the basis of the costs actually incurred, in accordance with the following method:

{daily rate for the person
multiplied by
number of day-equivalents worked on the action (rounded up or down to the nearest half-day)}.

The daily rate must be calculated as:

{annual personnel costs for the person
divided by
215}.

The number of day-equivalents declared for a person must be identifiable and verifiable (see Article 20).

The total number of day-equivalents declared in EU grants, for a person for a year, cannot be higher than 215.

The personnel costs may also include supplementary payments for personnel assigned to the action (including payments on the basis of supplementary contracts regardless of their nature), if:

- it is part of the beneficiary's usual remuneration practices and is paid in a consistent manner whenever the same kind of work or expertise is required
- the criteria used to calculate the supplementary payments are objective and generally applied by the beneficiary, regardless of the source of funding used.

A.2 and A.3 Costs for natural persons working under a direct contract other than an employment contract and costs for **seconded persons by a third party against payment** are also eligible as personnel costs, if they are assigned to the action, fulfil the general eligibility conditions and:

- (a) work under conditions similar to those of an employee (in particular regarding the way the work is organised, the tasks that are performed and the premises where they are performed) and
- (b) the result of the work belongs to the beneficiary (unless agreed otherwise).

They must be calculated on the basis of a rate which corresponds to the costs actually incurred for the direct contract or secondment and must not be significantly different from those for personnel performing similar tasks under an employment contract with the beneficiary.

A.4 The work of **SME owners** for the action (i.e. owners of beneficiaries that are small and medium-sized enterprises¹⁰ not receiving a salary) or **natural person beneficiaries** (i.e. beneficiaries that are natural persons not receiving a salary) may be declared as personnel costs, if they fulfil the general

¹⁰ For the definition, see Commission Recommendation 2003/361/EC: micro, small or medium-sized enterprise (SME) are enterprises

- engaged in an economic activity, irrespective of their legal form (including, in particular, self-employed persons and family businesses engaged in craft or other activities, and partnerships or associations regularly engaged in an economic activity) and
- employing fewer than 250 persons (expressed in 'annual working units' as defined in Article 5 of the Recommendation) and which have an annual turnover not exceeding EUR 50 million, and/or an annual balance sheet total not exceeding EUR 43 million.

eligibility conditions and are calculated as unit costs in accordance with the method set out in Annex 2a.

B. Subcontracting costs

Subcontracting costs for the action (including related duties, taxes and charges, such as non-deductible or non-refundable value added tax (VAT)) are eligible, if they are calculated on the basis of the costs actually incurred, fulfil the general eligibility conditions and are awarded using the beneficiary's usual purchasing practices — provided these ensure subcontracts with best value for money (or if appropriate the lowest price) and that there is no conflict of interests (see Article 12).

Beneficiaries that are 'contracting authorities/entities' within the meaning of the EU Directives on public procurement must also comply with the applicable national law on public procurement.

Subcontracting may cover only a limited part of the action.

The tasks to be subcontracted and the estimated cost for each subcontract must be set out in Annex 1 and the total estimated costs of subcontracting per beneficiary must be set out in Annex 2 (or may be approved ex post in the periodic report, if the use of subcontracting does not entail changes to the Agreement which would call into question the decision awarding the grant or breach the principle of equal treatment of applicants; 'simplified approval procedure').

C. Purchase costs

Purchase costs for the action (including related duties, taxes and charges, such as non-deductible or non-refundable value added tax (VAT)) are eligible if they fulfil the general eligibility conditions and are bought using the beneficiary's usual purchasing practices — provided these ensure purchases with best value for money (or if appropriate the lowest price) and that there is no conflict of interests (see Article 12).

Beneficiaries that are 'contracting authorities/entities' within the meaning of the EU Directives on public procurement must also comply with the applicable national law on public procurement.

C.1 Travel and subsistence

Purchases for **travel, accommodation and subsistence** must be calculated as follows:

- travel: as unit costs in accordance with the method set out in Annex 2a if covered by Decision C(2021)35¹¹ or otherwise as costs actually incurred and in line with the beneficiary's usual practices on travel
- accommodation: as unit costs in accordance with the method set out in Annex 2a if covered by Decision C(2021)35¹² or otherwise as costs actually incurred and in line with the beneficiary's usual practices on travel
- subsistence: as unit costs in accordance with the method set out in Annex 2a if covered by

¹¹ Commission Decision of 12 January 2021 authorising the use of unit costs for travel, accommodation and subsistence costs under an action or work programme under the 2021-2027 multi-annual financial framework (C(2021)35).

¹² Commission Decision of 12 January 2021 authorising the use of unit costs for travel, accommodation and subsistence costs under an action or work programme under the 2021-2027 multi-annual financial framework (C(2021)35).

Decision C(2021)35¹³ or otherwise as costs actually incurred and in line with the beneficiary's usual practices on travel.

C.2 Equipment

Purchases of **equipment, infrastructure or other assets** used for the action must be declared as depreciation costs, calculated on the basis of the costs actually incurred and written off in accordance with international accounting standards and the beneficiary's usual accounting practices.

Only the portion of the costs that corresponds to the rate of actual use for the action during the action duration can be taken into account.

Costs for **renting or leasing** equipment, infrastructure or other assets are also eligible, if they do not exceed the depreciation costs of similar equipment, infrastructure or assets and do not include any financing fees.

C.3 Other goods, works and services

Purchases of **other goods, works and services** must be calculated on the basis of the costs actually incurred.

Such goods, works and services include, for instance, consumables and supplies, promotion, dissemination, protection of results, translations, publications, certificates and financial guarantees, if required under the Agreement.

D. Other cost categories

D.1 Financial support to third parties

Costs for providing financial support to third parties (in the form of **grants, prizes** or similar forms of support; if any) are eligible, if and as declared eligible in the call conditions, if they fulfil the general eligibility conditions, are calculated on the basis of the costs actually incurred and the support is implemented in accordance with the conditions set out in Annex 1.

These conditions must ensure objective and transparent selection procedures and include at least the following:

(a) for grants (or similar):

- (i) the maximum amount of financial support for each third party ('recipient'); this amount may not exceed the amount set out in the Data Sheet (see Point 3) or otherwise agreed with the granting authority
- (ii) the criteria for calculating the exact amount of the financial support
- (iii) the different types of activity that qualify for financial support, on the basis of a closed list
- (iv) the persons or categories of persons that will be supported and
- (v) the criteria and procedures for giving financial support

¹³ Commission Decision of 12 January 2021 authorising the use of unit costs for travel, accommodation and subsistence costs under an action or work programme under the 2021-2027 multi-annual financial framework (C(2021)35).

- (b) for prizes (or similar):
 - (i) the eligibility and award criteria
 - (ii) the amount of the prize and
 - (iii) the payment arrangements.

Indirect costs

E. Indirect costs

Indirect costs will be reimbursed at the flat-rate of 7% of the eligible direct costs (categories A-D, except volunteers costs and exempted specific cost categories, if any).

Contributions

Not applicable

6.3 Ineligible costs and contributions

The following costs or contributions are **ineligible**:

- (a) costs or contributions that do not comply with the conditions set out above (Article 6.1 and 6.2), in particular:
 - (i) costs related to return on capital and dividends paid by a beneficiary
 - (ii) debt and debt service charges
 - (iii) provisions for future losses or debts
 - (iv) interest owed
 - (v) currency exchange losses
 - (vi) bank costs charged by the beneficiary's bank for transfers from the granting authority
 - (vii) excessive or reckless expenditure
 - (viii) deductible or refundable VAT (including VAT paid by public bodies acting as public authority)
 - (ix) costs incurred or contributions for activities implemented during grant agreement suspension (see Article 31)
 - (x) in-kind contributions by third parties
- (b) costs or contributions declared under other EU grants (or grants awarded by an EU Member State, non-EU country or other body implementing the EU budget), except for the following cases:
 - (i) Synergy actions: not applicable

- (ii) if the action grant is combined with an operating grant¹⁴ running during the same period and the beneficiary can demonstrate that the operating grant does not cover any (direct or indirect) costs of the action grant
- (c) costs or contributions for staff of a national (or regional/local) administration, for activities that are part of the administration’s normal activities (i.e. not undertaken only because of the grant)
- (d) costs or contributions (especially travel and subsistence) for staff or representatives of EU institutions, bodies or agencies
- (e) other :
 - (i) country restrictions for eligible costs: not applicable
 - (ii) costs or contributions declared specifically ineligible in the call conditions.

6.4 Consequences of non-compliance

If a beneficiary declares costs or contributions that are ineligible, they will be rejected (see Article 27).

This may also lead to other measures described in Chapter 5.

CHAPTER 4 GRANT IMPLEMENTATION

SECTION 1 CONSORTIUM: BENEFICIARIES, AFFILIATED ENTITIES AND OTHER PARTICIPANTS

ARTICLE 7 — BENEFICIARIES

The beneficiaries, as signatories of the Agreement, are fully responsible towards the granting authority for implementing it and for complying with all its obligations.

They must implement the Agreement to their best abilities, in good faith and in accordance with all the obligations and terms and conditions it sets out.

They must have the appropriate resources to implement the action and implement the action under their own responsibility and in accordance with Article 11. If they rely on affiliated entities or other participants (see Articles 8 and 9), they retain sole responsibility towards the granting authority and the other beneficiaries.

They are jointly responsible for the *technical* implementation of the action. If one of the beneficiaries fails to implement their part of the action, the other beneficiaries must ensure that this part is implemented by someone else (without being entitled to an increase of the maximum grant amount and subject to an amendment; see Article 39). The *financial* responsibility of each beneficiary in case of recoveries is governed by Article 22.

¹⁴ For the definition, see Article 180(2)(b) of EU Financial Regulation 2018/1046: ‘**operating grant**’ means an EU grant to finance “the functioning of a body which has an objective forming part of and supporting an EU policy”.

The beneficiaries (and their action) must remain eligible under the EU programme funding the grant for the entire duration of the action. Costs and contributions will be eligible only as long as the beneficiary and the action are eligible.

The **internal roles and responsibilities** of the beneficiaries are divided as follows:

(a) Each beneficiary must:

- (i) keep information stored in the Portal Participant Register up to date (see Article 19)
- (ii) inform the granting authority (and the other beneficiaries) immediately of any events or circumstances likely to affect significantly or delay the implementation of the action (see Article 19)
- (iii) submit to the coordinator in good time:
 - the prefinancing guarantees (if required; see Article 23)
 - the financial statements and certificates on the financial statements (CFS) (if required; see Articles 21 and 24.2 and Data Sheet, Point 4.3)
 - the contribution to the deliverables and technical reports (see Article 21)
 - any other documents or information required by the granting authority under the Agreement
- (iv) submit via the Portal data and information related to the participation of their affiliated entities.

(b) The coordinator must:

- (i) monitor that the action is implemented properly (see Article 11)
- (ii) act as the intermediary for all communications between the consortium and the granting authority, unless the Agreement or granting authority specifies otherwise, and in particular:
 - submit the prefinancing guarantees to the granting authority (if any)
 - request and review any documents or information required and verify their quality and completeness before passing them on to the granting authority
 - submit the deliverables and reports to the granting authority
 - inform the granting authority about the payments made to the other beneficiaries (report on the distribution of payments; if required, see Articles 22 and 32)
- (iii) distribute the payments received from the granting authority to the other beneficiaries without unjustified delay (see Article 22).

The coordinator may not delegate or subcontract the above-mentioned tasks to any other beneficiary or third party (including affiliated entities).

However, coordinators which are public bodies may delegate the tasks set out in Point (b)(ii) last indent and (iii) above to entities with ‘authorisation to administer’ which they have created or which are controlled by or affiliated to them. In this case, the coordinator retains sole responsibility for the payments and for compliance with the obligations under the Agreement.

Moreover, coordinators which are ‘sole beneficiaries’¹⁵ (or similar, such as European research infrastructure consortia (ERICs)) may delegate the tasks set out in Point (b)(i) to (iii) above to one of their members. The coordinator retains sole responsibility for compliance with the obligations under the Agreement.

The beneficiaries must have **internal arrangements** regarding their operation and co-ordination, to ensure that the action is implemented properly.

If required by the granting authority (see Data Sheet, Point 1), these arrangements must be set out in a written **consortium agreement** between the beneficiaries, covering for instance:

- the internal organisation of the consortium
- the management of access to the Portal
- different distribution keys for the payments and financial responsibilities in case of recoveries (if any)
- additional rules on rights and obligations related to background and results (see Article 16)
- settlement of internal disputes
- liability, indemnification and confidentiality arrangements between the beneficiaries.

The internal arrangements must not contain any provision contrary to this Agreement.

ARTICLE 8 — AFFILIATED ENTITIES

Not applicable

ARTICLE 9 — OTHER PARTICIPANTS INVOLVED IN THE ACTION

9.1 Associated partners

Not applicable

9.2 Third parties giving in-kind contributions to the action

Other third parties may give in-kind contributions to the action (i.e. personnel, equipment, other goods, works and services, etc. which are free-of-charge), if necessary for the implementation.

Third parties giving in-kind contributions do not implement any action tasks. They may not charge costs or contributions to the action and the costs for the in-kind contributions are not eligible.

¹⁵ For the definition, see Article 187(2) EU Financial Regulation 2018/1046: “Where several entities satisfy the criteria for being awarded a grant and together form one entity, that entity may be treated as the **sole beneficiary**, including where it is specifically established for the purpose of implementing the action financed by the grant.”

The third parties and their in-kind contributions should be set out in Annex 1.

9.3 Subcontractors

Subcontractors may participate in the action, if necessary for the implementation.

Subcontractors must implement their action tasks in accordance with Article 11. The costs for the subcontracted tasks (invoiced price from the subcontractor) are eligible and may be charged by the beneficiaries, under the conditions set out in Article 6. The costs will be included in Annex 2 as part of the beneficiaries' costs.

The beneficiaries must ensure that their contractual obligations under Articles 11 (proper implementation), 12 (conflict of interest), 13 (confidentiality and security), 14 (ethics), 17.2 (visibility), 18 (specific rules for carrying out action), 19 (information) and 20 (record-keeping) also apply to the subcontractors.

The beneficiaries must ensure that the bodies mentioned in Article 25 (e.g. granting authority, OLAF, Court of Auditors (ECA), etc.) can exercise their rights also towards the subcontractors.

9.4 Recipients of financial support to third parties

If the action includes providing financial support to third parties (e.g. grants, prizes or similar forms of support), the beneficiaries must ensure that their contractual obligations under Articles 12 (conflict of interest), 13 (confidentiality and security), 14 (ethics), 17.2 (visibility), 18 (specific rules for carrying out action), 19 (information) and 20 (record-keeping) also apply to the third parties receiving the support (recipients).

The beneficiaries must also ensure that the bodies mentioned in Article 25 (e.g. granting authority, OLAF, Court of Auditors (ECA), etc.) can exercise their rights also towards the recipients.

ARTICLE 10 — PARTICIPANTS WITH SPECIAL STATUS

10.1 Non-EU participants

Participants which are established in a non-EU country (if any) undertake to comply with their obligations under the Agreement and:

- to respect general principles (including fundamental rights, values and ethical principles, environmental and labour standards, rules on classified information, intellectual property rights, visibility of funding and protection of personal data)
- for the submission of certificates under Article 24: to use qualified external auditors which are independent and comply with comparable standards as those set out in EU Directive 2006/43/EC¹⁶
- for the controls under Article 25: to allow for checks, reviews, audits and investigations (including on-the-spot checks, visits and inspections) by the bodies mentioned in that Article (e.g. granting authority, OLAF, Court of Auditors (ECA), etc.).

¹⁶ Directive 2006/43/EC of the European Parliament and of the Council of 17 May 2006 on statutory audits of annual accounts and consolidated accounts or similar national regulations (OJ L 157, 9.6.2006, p. 87).

Special rules on dispute settlement apply (see Data Sheet, Point 5).

10.2 Participants which are international organisations

Participants which are international organisations (IOs; if any) undertake to comply with their obligations under the Agreement and:

- to respect general principles (including fundamental rights, values and ethical principles, environmental and labour standards, rules on classified information, intellectual property rights, visibility of funding and protection of personal data)
- for the submission of certificates under Article 24: to use either independent public officers or external auditors which comply with comparable standards as those set out in EU Directive 2006/43/EC
- for the controls under Article 25: to allow for the checks, reviews, audits and investigations by the bodies mentioned in that Article, taking into account the specific agreements concluded by them and the EU (if any).

For such participants, nothing in the Agreement will be interpreted as a waiver of their privileges or immunities, as accorded by their constituent documents or international law.

Special rules on applicable law and dispute settlement apply (see Article 43 and Data Sheet, Point 5).

10.3 Pillar-assessed participants

Pillar-assessed participants (if any) may rely on their own systems, rules and procedures, in so far as they have been positively assessed and do not call into question the decision awarding the grant or breach the principle of equal treatment of applicants or beneficiaries.

‘Pillar-assessment’ means a review by the European Commission on the systems, rules and procedures which participants use for managing EU grants (in particular internal control system, accounting system, external audits, financing of third parties, rules on recovery and exclusion, information on recipients and protection of personal data; see Article 154 EU Financial Regulation 2018/1046).

Participants with a positive pillar assessment may rely on their own systems, rules and procedures, in particular for:

- record-keeping (Article 20): may be done in accordance with internal standards, rules and procedures
- currency conversion for financial statements (Article 21): may be done in accordance with usual accounting practices
- guarantees (Article 23): for public law bodies, prefinancing guarantees are not needed
- certificates (Article 24):
 - certificates on the financial statements (CFS): may be provided by their regular internal or external auditors and in accordance with their internal financial regulations and procedures

- certificates on usual accounting practices (CoMUC): are not needed if those practices are covered by an ex-ante assessment

and use the following specific rules, for:

- recoveries (Article 22): in case of financial support to third parties, there will be no recovery if the participant has done everything possible to retrieve the undue amounts from the third party receiving the support (including legal proceedings) and non-recovery is not due to an error or negligence on its part
- checks, reviews, audits and investigations by the EU (Article 25): will be conducted taking into account the rules and procedures specifically agreed between them and the framework agreement (if any)
- impact evaluation (Article 26): will be conducted in accordance with the participant's internal rules and procedures and the framework agreement (if any)
- grant agreement suspension (Article 31): certain costs incurred during grant suspension are eligible (notably, minimum costs necessary for a possible resumption of the action and costs relating to contracts which were entered into before the pre-information letter was received and which could not reasonably be suspended, reallocated or terminated on legal grounds)
- grant agreement termination (Article 32): the final grant amount and final payment will be calculated taking into account also costs relating to contracts due for execution only after termination takes effect, if the contract was entered into before the pre-information letter was received and could not reasonably be terminated on legal grounds
- liability for damages (Article 33.2): the granting authority must be compensated for damage it sustains as a result of the implementation of the action or because the action was not implemented in full compliance with the Agreement only if the damage is due to an infringement of the participant's internal rules and procedures or due to a violation of third parties' rights by the participant or one of its employees or individual for whom the employees are responsible.

Participants whose pillar assessment covers procurement and granting procedures may also do purchases, subcontracting and financial support to third parties (Article 6.2) in accordance with their internal rules and procedures for purchases, subcontracting and financial support.

Participants whose pillar assessment covers data protection rules may rely on their internal standards, rules and procedures for data protection (Article 15).

The participants may however not rely on provisions which would breach the principle of equal treatment of applicants or beneficiaries or call into question the decision awarding the grant, such as in particular:

- eligibility (Article 6)
- consortium roles and set-up (Articles 7-9)
- security and ethics (Articles 13, 14)

- IPR (including background and results, access rights and rights of use), communication, dissemination and visibility (Articles 16 and 17)
- information obligation (Article 19)
- payment, reporting and amendments (Articles 21, 22 and 39)
- rejections, reductions, suspensions and terminations (Articles 27, 28, 29-32)

If the pillar assessment was subject to remedial measures, reliance on the internal systems, rules and procedures is subject to compliance with those remedial measures.

Participants whose assessment has not yet been updated to cover (the new rules on) data protection may rely on their internal systems, rules and procedures, provided that they ensure that personal data is:

- processed lawfully, fairly and in a transparent manner in relation to the data subject
- collected for specified, explicit and legitimate purposes and not further processed in a manner that is incompatible with those purposes
- adequate, relevant and limited to what is necessary in relation to the purposes for which they are processed
- accurate and, where necessary, kept up to date
- kept in a form which permits identification of data subjects for no longer than is necessary for the purposes for which the data is processed and
- processed in a manner that ensures appropriate security of the personal data.

Participants must inform the coordinator without delay of any changes to the systems, rules and procedures that were part of the pillar assessment. The coordinator must immediately inform the granting authority.

Pillar-assessed participants that have also concluded a framework agreement with the EU, may moreover — under the same conditions as those above (i.e. not call into question the decision awarding the grant or breach the principle of equal treatment of applicants or beneficiaries) — rely on the provisions set out in that framework agreement.

SECTION 2 RULES FOR CARRYING OUT THE ACTION

ARTICLE 11 — PROPER IMPLEMENTATION OF THE ACTION

11.1 Obligation to properly implement the action

The beneficiaries must implement the action as described in Annex 1 and in compliance with the provisions of the Agreement, the call conditions and all legal obligations under applicable EU, international and national law.

11.2 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 12 — CONFLICT OF INTERESTS

12.1 Conflict of interests

The beneficiaries must take all measures to prevent any situation where the impartial and objective implementation of the Agreement could be compromised for reasons involving family, emotional life, political or national affinity, economic interest or any other direct or indirect interest ('conflict of interests').

They must formally notify the granting authority without delay of any situation constituting or likely to lead to a conflict of interests and immediately take all the necessary steps to rectify this situation.

The granting authority may verify that the measures taken are appropriate and may require additional measures to be taken by a specified deadline.

12.2 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28) and the grant or the beneficiary may be terminated (see Article 32).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 13 — CONFIDENTIALITY AND SECURITY

13.1 Sensitive information

The parties must keep confidential any data, documents or other material (in any form) that is identified as sensitive in writing ('sensitive information') — during the implementation of the action and for at least until the time-limit set out in the Data Sheet (see Point 6).

If a beneficiary requests, the granting authority may agree to keep such information confidential for a longer period.

Unless otherwise agreed between the parties, they may use sensitive information only to implement the Agreement.

The beneficiaries may disclose sensitive information to their personnel or other participants involved in the action only if they:

- (a) need to know it in order to implement the Agreement and
- (b) are bound by an obligation of confidentiality.

The granting authority may disclose sensitive information to its staff and to other EU institutions and bodies.

It may moreover disclose sensitive information to third parties, if:

- (a) this is necessary to implement the Agreement or safeguard the EU financial interests and
- (b) the recipients of the information are bound by an obligation of confidentiality.

The confidentiality obligations no longer apply if:

- (a) the disclosing party agrees to release the other party
- (b) the information becomes publicly available, without breaching any confidentiality obligation
- (c) the disclosure of the sensitive information is required by EU, international or national law.

Specific confidentiality rules (if any) are set out in Annex 5.

13.2 Classified information

The parties must handle classified information in accordance with the applicable EU, international or national law on classified information (in particular, Decision 2015/444¹⁷ and its implementing rules).

Deliverables which contain classified information must be submitted according to special procedures agreed with the granting authority.

Action tasks involving classified information may be subcontracted only after explicit approval (in writing) from the granting authority.

Classified information may not be disclosed to any third party (including participants involved in the action implementation) without prior explicit written approval from the granting authority.

Specific security rules (if any) are set out in Annex 5.

13.3 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 14 — ETHICS AND VALUES

14.1 Ethics

The action must be carried out in line with the highest ethical standards and the applicable EU, international and national law on ethical principles.

Specific ethics rules (if any) are set out in Annex 5.

14.2 Values

The beneficiaries must commit to and ensure the respect of basic EU values (such as respect for

¹⁷ Commission Decision 2015/444/EC, Euratom of 13 March 2015 on the security rules for protecting EU classified information (OJ L 72, 17.3.2015, p. 53).

human dignity, freedom, democracy, equality, the rule of law and human rights, including the rights of minorities).

Specific rules on values (if any) are set out in Annex 5.

14.3 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 15 — DATA PROTECTION

15.1 Data processing by the granting authority

Any personal data under the Agreement will be processed under the responsibility of the data controller of the granting authority in accordance with and for the purposes set out in the Portal Privacy Statement.

For grants where the granting authority is the European Commission, an EU regulatory or executive agency, joint undertaking or other EU body, the processing will be subject to Regulation 2018/1725¹⁸.

15.2 Data processing by the beneficiaries

The beneficiaries must process personal data under the Agreement in compliance with the applicable EU, international and national law on data protection (in particular, Regulation 2016/679¹⁹).

They must ensure that personal data is:

- processed lawfully, fairly and in a transparent manner in relation to the data subjects
- collected for specified, explicit and legitimate purposes and not further processed in a manner that is incompatible with those purposes
- adequate, relevant and limited to what is necessary in relation to the purposes for which they are processed
- accurate and, where necessary, kept up to date
- kept in a form which permits identification of data subjects for no longer than is necessary for the purposes for which the data is processed and
- processed in a manner that ensures appropriate security of the data.

¹⁸ Regulation (EU) 2018/1725 of the European Parliament and of the Council of 23 October 2018 on the protection of natural persons with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC (OJ L 295, 21.11.2018, p. 39).

¹⁹ Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC ('GDPR') (OJ L 119, 4.5.2016, p. 1).

The beneficiaries may grant their personnel access to personal data only if it is strictly necessary for implementing, managing and monitoring the Agreement. The beneficiaries must ensure that the personnel is under a confidentiality obligation.

The beneficiaries must inform the persons whose data are transferred to the granting authority and provide them with the Portal Privacy Statement.

15.3 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 16 — INTELLECTUAL PROPERTY RIGHTS (IPR) — BACKGROUND AND RESULTS — ACCESS RIGHTS AND RIGHTS OF USE

16.1 Background and access rights to background

The beneficiaries must give each other and the other participants access to the background identified as needed for implementing the action, subject to any specific rules in Annex 5.

‘Background’ means any data, know-how or information — whatever its form or nature (tangible or intangible), including any rights such as intellectual property rights — that is:

- (a) held by the beneficiaries before they acceded to the Agreement and
- (b) needed to implement the action or exploit the results.

If background is subject to rights of a third party, the beneficiary concerned must ensure that it is able to comply with its obligations under the Agreement.

16.2 Ownership of results

The granting authority does not obtain ownership of the results produced under the action.

‘Results’ means any tangible or intangible effect of the action, such as data, know-how or information, whatever its form or nature, whether or not it can be protected, as well as any rights attached to it, including intellectual property rights.

16.3 Rights of use of the granting authority on materials, documents and information received for policy, information, communication, dissemination and publicity purposes

The granting authority has the right to use non-sensitive information relating to the action and materials and documents received from the beneficiaries (notably summaries for publication, deliverables, as well as any other material, such as pictures or audio-visual material, in paper or electronic form) for policy, information, communication, dissemination and publicity purposes — during the action or afterwards.

The right to use the beneficiaries’ materials, documents and information is granted in the form of a royalty-free, non-exclusive and irrevocable licence, which includes the following rights:

- (a) **use for its own purposes** (in particular, making them available to persons working for the granting authority or any other EU service (including institutions, bodies, offices, agencies, etc.) or EU Member State institution or body; copying or reproducing them in whole or in part, in unlimited numbers; and communication through press information services)
- (b) **distribution to the public** (in particular, publication as hard copies and in electronic or digital format, publication on the internet, as a downloadable or non-downloadable file, broadcasting by any channel, public display or presentation, communicating through press information services, or inclusion in widely accessible databases or indexes)
- (c) **editing or redrafting** (including shortening, summarising, inserting other elements (e.g. meta-data, legends, other graphic, visual, audio or text elements), extracting parts (e.g. audio or video files), dividing into parts, use in a compilation)
- (d) **translation**
- (e) **storage** in paper, electronic or other form
- (f) **archiving**, in line with applicable document-management rules
- (g) the right to authorise **third parties** to act on its behalf or sub-license to third parties the modes of use set out in Points (b), (c), (d) and (f), if needed for the information, communication and publicity activity of the granting authority
- (h) **processing**, analysing, aggregating the materials, documents and information received and **producing derivative works**.

The rights of use are granted for the whole duration of the industrial or intellectual property rights concerned.

If materials or documents are subject to moral rights or third party rights (including intellectual property rights or rights of natural persons on their image and voice), the beneficiaries must ensure that they comply with their obligations under this Agreement (in particular, by obtaining the necessary licences and authorisations from the rights holders concerned).

Where applicable, the granting authority will insert the following information:

“© – [year] – [name of the copyright owner]. All rights reserved. Licensed to the [name of granting authority] under conditions.”

16.4 Specific rules on IPR, results and background

Specific rules regarding intellectual property rights, results and background (if any) are set out in Annex 5.

16.5 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such a breach may also lead to other measures described in Chapter 5.

ARTICLE 17 — COMMUNICATION, DISSEMINATION AND VISIBILITY


17.1 Communication — Dissemination — Promoting the action

Unless otherwise agreed with the granting authority, the beneficiaries must promote the action and its results by providing targeted information to multiple audiences (including the media and the public), in accordance with Annex 1 and in a strategic, coherent and effective manner.

Before engaging in a communication or dissemination activity expected to have a major media impact, the beneficiaries must inform the granting authority.

17.2 Visibility — European flag and funding statement

Unless otherwise agreed with the granting authority, communication activities of the beneficiaries related to the action (including media relations, conferences, seminars, information material, such as brochures, leaflets, posters, presentations, etc., in electronic form, via traditional or social media, etc.), dissemination activities and any infrastructure, equipment, vehicles, supplies or major result funded by the grant must acknowledge EU support and display the European flag (emblem) and funding statement (translated into local languages, where appropriate):



The emblem must remain distinct and separate and cannot be modified by adding other visual marks, brands or text.

Apart from the emblem, no other visual identity or logo may be used to highlight the EU support.

When displayed in association with other logos (e.g. of beneficiaries or sponsors), the emblem must be displayed at least as prominently and visibly as the other logos.

For the purposes of their obligations under this Article, the beneficiaries may use the emblem without first obtaining approval from the granting authority. This does not, however, give them the right to

exclusive use. Moreover, they may not appropriate the emblem or any similar trademark or logo, either by registration or by any other means.

17.3 Quality of information — Disclaimer

Any communication or dissemination activity related to the action must use factually accurate information.

Moreover, it must indicate the following disclaimer (translated into local languages where appropriate):

“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or [name of the granting authority]. Neither the European Union nor the granting authority can be held responsible for them.”

17.4 Specific communication, dissemination and visibility rules

Specific communication, dissemination and visibility rules (if any) are set out in Annex 5.

17.5 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 18 — SPECIFIC RULES FOR CARRYING OUT THE ACTION

18.1 Specific rules for carrying out the action

Specific rules for implementing the action (if any) are set out in Annex 5.

18.2 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such a breach may also lead to other measures described in Chapter 5.

SECTION 3 GRANT ADMINISTRATION

ARTICLE 19 — GENERAL INFORMATION OBLIGATIONS

19.1 Information requests

The beneficiaries must provide — during the action or afterwards and in accordance with Article 7 — any information requested in order to verify eligibility of the costs or contributions declared, proper implementation of the action and compliance with the other obligations under the Agreement.

The information provided must be accurate, precise and complete and in the format requested, including electronic format.

19.2 Participant Register data updates

The beneficiaries must keep — at all times, during the action or afterwards — their information stored in the Portal Participant Register up to date, in particular, their name, address, legal representatives, legal form and organisation type.

19.3 Information about events and circumstances which impact the action

The beneficiaries must immediately inform the granting authority (and the other beneficiaries) of any of the following:

- (a) **events** which are likely to affect or delay the implementation of the action or affect the EU's financial interests, in particular:
 - (i) changes in their legal, financial, technical, organisational or ownership situation (including changes linked to one of the exclusion grounds listed in the declaration of honour signed before grant signature)
 - (ii) linked action information: not applicable
- (b) **circumstances** affecting:
 - (i) the decision to award the grant or
 - (ii) compliance with requirements under the Agreement.

19.4 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 20 — RECORD-KEEPING

20.1 Keeping records and supporting documents

The beneficiaries must — at least until the time-limit set out in the Data Sheet (see Point 6) — keep records and other supporting documents to prove the proper implementation of the action in line with the accepted standards in the respective field (if any).

In addition, the beneficiaries must — for the same period — keep the following to justify the amounts declared:

- (a) for actual costs: adequate records and supporting documents to prove the costs declared (such as contracts, subcontracts, invoices and accounting records); in addition, the beneficiaries' usual accounting and internal control procedures must enable direct reconciliation between the amounts declared, the amounts recorded in their accounts and the amounts stated in the supporting documents
- (b) for flat-rate costs and contributions (if any): adequate records and supporting documents to prove the eligibility of the costs or contributions to which the flat-rate is applied

- (c) for the following simplified costs and contributions: the beneficiaries do not need to keep specific records on the actual costs incurred, but must keep:
- (i) for unit costs and contributions (if any): adequate records and supporting documents to prove the number of units declared
 - (ii) for lump sum costs and contributions (if any): adequate records and supporting documents to prove proper implementation of the work as described in Annex 1
 - (iii) for financing not linked to costs (if any): adequate records and supporting documents to prove the achievement of the results or the fulfilment of the conditions as described in Annex 1
- (d) for unit, flat-rate and lump sum costs and contributions according to usual cost accounting practices (if any): the beneficiaries must keep any adequate records and supporting documents to prove that their cost accounting practices have been applied in a consistent manner, based on objective criteria, regardless of the source of funding, and that they comply with the eligibility conditions set out in Articles 6.1 and 6.2.

Moreover, the following is needed for specific budget categories:

- (e) for personnel costs: time worked for the beneficiary under the action must be supported by declarations signed monthly by the person and their supervisor, unless another reliable time-record system is in place; the granting authority may accept alternative evidence supporting the time worked for the action declared, if it considers that it offers an adequate level of assurance
- (f) additional record-keeping rules: not applicable

The records and supporting documents must be made available upon request (see Article 19) or in the context of checks, reviews, audits or investigations (see Article 25).

If there are on-going checks, reviews, audits, investigations, litigation or other pursuits of claims under the Agreement (including the extension of findings; see Article 25), the beneficiaries must keep these records and other supporting documentation until the end of these procedures.

The beneficiaries must keep the original documents. Digital and digitalised documents are considered originals if they are authorised by the applicable national law. The granting authority may accept non-original documents if they offer a comparable level of assurance.

20.2 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, costs or contributions insufficiently substantiated will be ineligible (see Article 6) and will be rejected (see Article 27), and the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 21 — REPORTING

21.1 Continuous reporting

The beneficiaries must continuously report on the progress of the action (e.g. **deliverables, milestones, outputs/outcomes, critical risks, indicators**, etc; if any), in the Portal Continuous Reporting tool and in accordance with the timing and conditions it sets out (as agreed with the granting authority).

Standardised deliverables (e.g. progress reports not linked to payments, reports on cumulative expenditure, special reports, etc; if any) must be submitted using the templates published on the Portal.

21.2 Periodic reporting: Technical reports and financial statements

In addition, the beneficiaries must provide reports to request payments, in accordance with the schedule and modalities set out in the Data Sheet (see Point 4.2):

- for additional prefinancings (if any): an **additional prefinancing report**
- for interim payments (if any) and the final payment: a **periodic report**.

The prefinancing and periodic reports include a technical and financial part.

The technical part includes an overview of the action implementation. It must be prepared using the template available in the Portal Periodic Reporting tool.

The financial part of the additional prefinancing report includes a statement on the use of the previous prefinancing payment.

The financial part of the periodic report includes:

- the financial statements (individual and consolidated; for all beneficiaries/affiliated entities)
- the explanation on the use of resources (or detailed cost reporting table, if required)
- the certificates on the financial statements (CFS) (if required; see Article 24.2 and Data Sheet, Point 4.3).

The **financial statements** must detail the eligible costs and contributions for each budget category and, for the final payment, also the revenues for the action (see Articles 6 and 22).

All eligible costs and contributions incurred should be declared, even if they exceed the amounts indicated in the estimated budget (see Annex 2). Amounts that are not declared in the individual financial statements will not be taken into account by the granting authority.

By signing the financial statements (directly in the Portal Periodic Reporting tool), the beneficiaries confirm that:

- the information provided is complete, reliable and true
- the costs and contributions declared are eligible (see Article 6)
- the costs and contributions can be substantiated by adequate records and supporting documents (see Article 20) that will be produced upon request (see Article 19) or in the context of checks, reviews, audits and investigations (see Article 25)
- for the final periodic report: all the revenues have been declared (if required; see Article 22).

Beneficiaries will have to submit also the financial statements of their affiliated entities (if any). In case of recoveries (see Article 22), beneficiaries will be held responsible also for the financial statements of their affiliated entities.

21.3 Currency for financial statements and conversion into euros

The financial statements must be drafted in euro.

Beneficiaries with general accounts established in a currency other than the euro must convert the costs recorded in their accounts into euro, at the average of the daily exchange rates published in the C series of the *Official Journal of the European Union* (ECB website), calculated over the corresponding reporting period.

If no daily euro exchange rate is published in the *Official Journal* for the currency in question, they must be converted at the average of the monthly accounting exchange rates published on the European Commission website (InforEuro), calculated over the corresponding reporting period.

Beneficiaries with general accounts in euro must convert costs incurred in another currency into euro according to their usual accounting practices.

21.4 Reporting language

The reporting must be in the language of the Agreement, unless otherwise agreed with the granting authority (see Data Sheet, Point 4.2).

21.5 Consequences of non-compliance

If a report submitted does not comply with this Article, the granting authority may suspend the payment deadline (see Article 29) and apply other measures described in Chapter 5.

If the coordinator breaches its reporting obligations, the granting authority may terminate the grant or the coordinator's participation (see Article 32) or apply other measures described in Chapter 5.

ARTICLE 22 — PAYMENTS AND RECOVERIES — CALCULATION OF AMOUNTS DUE

22.1 Payments and payment arrangements

Payments will be made in accordance with the schedule and modalities set out in the Data Sheet (see Point 4.2).

They will be made in euro to the bank account indicated by the coordinator (see Data Sheet, Point 4.2) and must be distributed without unjustified delay (restrictions may apply to distribution of the initial prefinancing payment; see Data Sheet, Point 4.2).

Payments to this bank account will discharge the granting authority from its payment obligation.

The cost of payment transfers will be borne as follows:

- the granting authority bears the cost of transfers charged by its bank
- the beneficiary bears the cost of transfers charged by its bank

- the party causing a repetition of a transfer bears all costs of the repeated transfer.

Payments by the granting authority will be considered to have been carried out on the date when they are debited to its account.

22.2 Recoveries

Recoveries will be made, if — at beneficiary termination, final payment or afterwards — it turns out that the granting authority has paid too much and needs to recover the amounts undue.

The general liability regime for recoveries (first-line liability) is as follows: At final payment, the coordinator will be fully liable for recoveries, even if it has not been the final recipient of the undue amounts. At beneficiary termination or after final payment, recoveries will be made directly against the beneficiaries concerned.

Beneficiaries will be fully liable for repaying the debts of their affiliated entities.

In case of enforced recoveries (see Article 22.4):

- the beneficiaries will be jointly and severally liable for repaying debts of another beneficiary under the Agreement (including late-payment interest), if required by the granting authority (see Data Sheet, Point 4.4)
- affiliated entities will be held liable for repaying debts of their beneficiaries under the Agreement (including late-payment interest), if required by the granting authority (see Data Sheet, Point 4.4).

22.3 Amounts due

22.3.1 Prefinancing payments

The aim of the prefinancing is to provide the beneficiaries with a float.

It remains the property of the EU until the final payment.

For **initial prefinancings** (if any), the amount due, schedule and modalities are set out in the Data Sheet (see Point 4.2).

For **additional prefinancings** (if any), the amount due, schedule and modalities are also set out in the Data Sheet (see Point 4.2). However, if the statement on the use of the previous prefinancing payment shows that less than 70% was used, the amount set out in the Data Sheet will be reduced by the difference between the 70% threshold and the amount used.

Prefinancing payments (or parts of them) may be offset (without the beneficiaries' consent) against amounts owed by a beneficiary to the granting authority — up to the amount due to that beneficiary.

For grants where the granting authority is the European Commission or an EU executive agency, offsetting may also be done against amounts owed to other Commission services or executive agencies.

Payments will not be made if the payment deadline or payments are suspended (see Articles 29 and 30).

22.3.2 Amount due at beneficiary termination — Recovery

In case of beneficiary termination, the granting authority will determine the provisional amount due for the beneficiary concerned. Payments (if any) will be made with the next interim or final payment.

The **amount due** will be calculated in the following step:

Step 1 — Calculation of the total accepted EU contribution

Step 1 — Calculation of the total accepted EU contribution

The granting authority will first calculate the ‘accepted EU contribution’ for the beneficiary for all reporting periods, by calculating the ‘maximum EU contribution to costs’ (applying the funding rate to the accepted costs of the beneficiary), taking into account requests for a lower contribution to costs and CFS threshold cappings (if any; see Article 24.5) and adding the contributions (accepted unit, flat-rate or lump sum contributions and financing not linked to costs, if any).

After that, the granting authority will take into account grant reductions (if any). The resulting amount is the ‘total accepted EU contribution’ for the beneficiary.

The **balance** is then calculated by deducting the payments received (if any; see report on the distribution of payments in Article 32), from the total accepted EU contribution:

$$\left\{ \begin{array}{l} \text{total accepted EU contribution for the beneficiary} \\ \text{minus} \\ \text{prefinancing and interim payments received (if any)} \end{array} \right\}.$$

If the balance is **positive**, the amount will be included in the next interim or final payment to the consortium.

If the balance is **negative**, it will be **recovered** in accordance with the following procedure:

The granting authority will send a **pre-information letter** to the beneficiary concerned:

- formally notifying the intention to recover, the amount due, the amount to be recovered and the reasons why and
- requesting observations within 30 days of receiving notification.

If no observations are submitted (or the granting authority decides to pursue recovery despite the observations it has received), it will confirm the amount to be recovered and ask this amount to be paid to the coordinator (**confirmation letter**).

The amounts will later on also be taken into account for the next interim or final payment.

22.3.3 Interim payments

Interim payments reimburse the eligible costs and contributions claimed for the implementation of the action during the reporting periods (if any).

Interim payments (if any) will be made in accordance with the schedule and modalities set out the Data Sheet (see Point 4.2).

Payment is subject to the approval of the periodic report. Its approval does not imply recognition of compliance, authenticity, completeness or correctness of its content.

The **interim payment** will be calculated by the granting authority in the following steps:

Step 1 — Calculation of the total accepted EU contribution

Step 2 — Limit to the interim payment ceiling

Step 1 — Calculation of the total accepted EU contribution

The granting authority will calculate the ‘accepted EU contribution’ for the action for the reporting period, by first calculating the ‘maximum EU contribution to costs’ (applying the funding rate to the accepted costs of each beneficiary), taking into account requests for a lower contribution to costs, and CFS threshold cappings (if any; see Article 24.5) and adding the contributions (accepted unit, flat-rate or lump sum contributions and financing not linked to costs, if any).

After that, the granting authority will take into account grant reductions from beneficiary termination (if any). The resulting amount is the ‘total accepted EU contribution’.

Step 2 — Limit to the interim payment ceiling

The resulting amount is then capped to ensure that the total amount of prefinancing and interim payments (if any) does not exceed the interim payment ceiling set out in the Data Sheet (see Point 4.2).

Interim payments (or parts of them) may be offset (without the beneficiaries’ consent) against amounts owed by a beneficiary to the granting authority — up to the amount due to that beneficiary.

For grants where the granting authority is the European Commission or an EU executive agency, offsetting may also be done against amounts owed to other Commission services or executive agencies.

Payments will not be made if the payment deadline or payments are suspended (see Articles 29 and 30).

22.3.4 Final payment — Final grant amount — Revenues and Profit — Recovery

The final payment (payment of the balance) reimburses the remaining part of the eligible costs and contributions claimed for the implementation of the action (if any).

The final payment will be made in accordance with the schedule and modalities set out in the Data Sheet (see Point 4.2).

Payment is subject to the approval of the final periodic report. Its approval does not imply recognition of compliance, authenticity, completeness or correctness of its content.

The **final grant amount for the action** will be calculated in the following steps:

Step 1 — Calculation of the total accepted EU contribution

Step 2 — Limit to the maximum grant amount

Step 3 — Reduction due to the no-profit rule

Step 1 — Calculation of the total accepted EU contribution

The granting authority will first calculate the ‘accepted EU contribution’ for the action for all reporting periods, by calculating the ‘maximum EU contribution to costs’ (applying the funding rate to the total accepted costs of each beneficiary), taking into account requests for a lower contribution to costs, CFS threshold cappings (if any; see Article 24.5) and adding the contributions (accepted unit, flat-rate or lump sum contributions and financing not linked to costs, if any).

After that, the granting authority will take into account grant reductions (if any). The resulting amount is the ‘total accepted EU contribution’.

Step 2 — Limit to the maximum grant amount

If the resulting amount is higher than the maximum grant amount set out in Article 5.2, it will be limited to the latter.

Step 3 — Reduction due to the no-profit rule

If the no-profit rule is provided for in the Data Sheet (see Point 4.2), the grant must not produce a profit (i.e. surplus of the amount obtained following Step 2 plus the action’s revenues, over the eligible costs and contributions approved by the granting authority).

‘Revenue’ is all income generated by the action, during its duration (see Article 4), for beneficiaries that are profit legal entities.

If there is a profit, it will be deducted in proportion to the final rate of reimbursement of the eligible costs approved by the granting authority (as compared to the amount calculated following Steps 1 and 2 minus the contributions).

The **balance** (final payment) is then calculated by deducting the total amount of prefinancing and interim payments already made (if any), from the final grant amount:

$$\begin{aligned} & \{\text{final grant amount} \\ & \text{minus} \\ & \{\text{prefinancing and interim payments made (if any)}\} \}. \end{aligned}$$

If the balance is **positive**, it will be **paid** to the coordinator.

The final payment (or part of it) may be offset (without the beneficiaries’ consent) against amounts owed by a beneficiary to the granting authority — up to the amount due to that beneficiary.

For grants where the granting authority is the European Commission or an EU executive agency, offsetting may also be done against amounts owed to other Commission services or executive agencies.

Payments will not be made if the payment deadline or payments are suspended (see Articles 29 and 30).

If the balance is **negative**, it will be **recovered** in accordance with the following procedure:

The granting authority will send a **pre-information letter** to the coordinator:

- formally notifying the intention to recover, the final grant amount, the amount to be recovered and the reasons why
- requesting observations within 30 days of receiving notification.

If no observations are submitted (or the granting authority decides to pursue recovery despite the observations it has received), it will confirm the amount to be recovered (**confirmation letter**), together with a **debit note** with the terms and date for payment.

If payment is not made by the date specified in the debit note, the granting authority will **enforce recovery** in accordance with Article 22.4.

22.3.5 Audit implementation after final payment — Revised final grant amount — Recovery

If — after the final payment (in particular, after checks, reviews, audits or investigations; see Article 25) — the granting authority rejects costs or contributions (see Article 27) or reduces the grant (see Article 28), it will calculate the **revised final grant amount** for the beneficiary concerned.

The **beneficiary revised final grant amount** will be calculated in the following step:

Step 1 — Calculation of the revised total accepted EU contribution

Step 1 — Calculation of the revised total accepted EU contribution

The granting authority will first calculate the ‘revised accepted EU contribution’ for the beneficiary, by calculating the ‘revised accepted costs’ and ‘revised accepted contributions’.

After that, it will take into account grant reductions (if any). The resulting ‘revised total accepted EU contribution’ is the beneficiary revised final grant amount.

If the revised final grant amount is lower than the beneficiary’s final grant amount (i.e. its share in the final grant amount for the action), it will be **recovered** in accordance with the following procedure:

The **beneficiary final grant amount** (i.e. share in the final grant amount for the action) is calculated as follows:

$$\left\{ \begin{array}{l} \text{total accepted EU contribution for the beneficiary} \\ \text{divided by} \\ \text{total accepted EU contribution for the action} \end{array} \right\} \times \left\{ \begin{array}{l} \text{final grant amount for the action} \end{array} \right\}.$$

The granting authority will send a **pre-information letter** to the beneficiary concerned:

- formally notifying the intention to recover, the amount to be recovered and the reasons why and
- requesting observations within 30 days of receiving notification.

If no observations are submitted (or the granting authority decides to pursue recovery despite the observations it has received), it will confirm the amount to be recovered (**confirmation letter**), together with a **debit note** with the terms and the date for payment.

Recoveries against affiliated entities (if any) will be handled through their beneficiaries.

If payment is not made by the date specified in the debit note, the granting authority will **enforce recovery** in accordance with Article 22.4.

22.4 Enforced recovery

If payment is not made by the date specified in the debit note, the amount due will be recovered:

- (a) by offsetting the amount — without the coordinator or beneficiary's consent — against any amounts owed to the coordinator or beneficiary by the granting authority.

In exceptional circumstances, to safeguard the EU financial interests, the amount may be offset before the payment date specified in the debit note.

For grants where the granting authority is the European Commission or an EU executive agency, debts may also be offset against amounts owed by other Commission services or executive agencies.

- (b) by drawing on the financial guarantee(s) (if any)
- (c) by holding other beneficiaries jointly and severally liable (if any; see Data Sheet, Point 4.4)
- (d) by holding affiliated entities jointly and severally liable (if any, see Data Sheet, Point 4.4)
- (e) by taking legal action (see Article 43) or, provided that the granting authority is the European Commission or an EU executive agency, by adopting an enforceable decision under Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 100(2) of EU Financial Regulation 2018/1046.

The amount to be recovered will be increased by **late-payment interest** at the rate set out in Article 22.5, from the day following the payment date in the debit note, up to and including the date the full payment is received.

Partial payments will be first credited against expenses, charges and late-payment interest and then against the principal.

Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive 2015/2366²⁰ applies.

For grants where the granting authority is an EU executive agency, enforced recovery by offsetting or enforceable decision will be done by the services of the European Commission (see also Article 43).

22.5 Consequences of non-compliance

22.5.1 If the granting authority does not pay within the payment deadlines (see above), the beneficiaries are entitled to **late-payment interest** at the rate applied by the European Central Bank (ECB) for its main refinancing operations in euros ('reference rate'), plus the rate specified in the

²⁰ Directive (EU) 2015/2366 of the European Parliament and of the Council of 25 November 2015 on payment services in the internal market, amending Directives 2002/65/EC, 2009/110/EC and 2013/36/EU and Regulation (EU) No 1093/2010, and repealing Directive 2007/64/EC (OJ L 337, 23.12.2015, p. 35).

Data Sheet (Point 4.2). The reference rate is the rate in force on the first day of the month in which the payment deadline expires, as published in the C series of the *Official Journal of the European Union*.

If the late-payment interest is lower than or equal to EUR 200, it will be paid to the coordinator only on request submitted within two months of receiving the late payment.

Late-payment interest is not due if all beneficiaries are EU Member States (including regional and local government authorities or other public bodies acting on behalf of a Member State for the purpose of this Agreement).

If payments or the payment deadline are suspended (see Articles 29 and 30), payment will not be considered as late.

Late-payment interest covers the period running from the day following the due date for payment (see above), up to and including the date of payment.

Late-payment interest is not considered for the purposes of calculating the final grant amount.

22.5.2 If the coordinator breaches any of its obligations under this Article, the grant may be reduced (see Article 29) and the grant or the coordinator may be terminated (see Article 32).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 23 — GUARANTEES

23.1 Prefinancing guarantee

If required by the granting authority (see Data Sheet, Point 4.2), the beneficiaries must provide (one or more) prefinancing guarantee(s) in accordance with the timing and the amounts set out in the Data Sheet.

The coordinator must submit them to the granting authority in due time before the prefinancing they are linked to.

The guarantees must be drawn up using the template published on the Portal and fulfil the following conditions:

- (a) be provided by a bank or approved financial institution established in the EU or — if requested by the coordinator and accepted by the granting authority — by a third party or a bank or financial institution established outside the EU offering equivalent security
- (b) the guarantor stands as first-call guarantor and does not require the granting authority to first have recourse against the principal debtor (i.e. the beneficiary concerned) and
- (c) remain explicitly in force until the final payment and, if the final payment takes the form of a recovery, until five months after the debit note is notified to a beneficiary.

They will be released within the following month.

23.2 Consequences of non-compliance

If the beneficiaries breach their obligation to provide the prefinancing guarantee, the prefinancing will not be paid.

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 24 — CERTIFICATES

24.1 Operational verification report (OVR)

Not applicable

24.2 Certificate on the financial statements (CFS)

If required by the granting authority (see Data Sheet, Point 4.3), the beneficiaries must provide certificates on their financial statements (CFS), in accordance with the schedule, threshold and conditions set out in the Data Sheet.

The coordinator must submit them as part of the periodic report (see Article 21).

The certificates must be drawn up using the template published on the Portal, cover the costs declared on the basis of actual costs and costs according to usual cost accounting practices (if any), and fulfil the following conditions:

- (a) be provided by a qualified approved external auditor which is independent and complies with Directive 2006/43/EC²¹ (or for public bodies: by a competent independent public officer)
- (b) the verification must be carried out according to the highest professional standards to ensure that the financial statements comply with the provisions under the Agreement and that the costs declared are eligible.

The certificates will not affect the granting authority's right to carry out its own checks, reviews or audits, nor preclude the European Court of Auditors (ECA), the European Public Prosecutor's Office (EPPO) or the European Anti-Fraud Office (OLAF) from using their prerogatives for audits and investigations under the Agreement (see Article 25).

If the costs (or a part of them) were already audited by the granting authority, these costs do not need to be covered by the certificate and will not be counted for calculating the threshold (if any).

24.3 Certificate on the compliance of usual cost accounting practices (CoMUC)

Not applicable

24.4 Systems and process audit (SPA)

Not applicable

24.5 Consequences of non-compliance

²¹ Directive 2006/43/EC of the European Parliament and of the Council of 17 May 2006 on statutory audits of annual accounts and consolidated accounts or similar national regulations (OJ L 157, 9.6.2006, p. 87).

If a beneficiary does not submit a certificate on the financial statements (CFS) or the certificate is rejected, the accepted EU contribution to costs will be capped to reflect the CFS threshold.

If a beneficiary breaches any of its other obligations under this Article, the granting authority may apply the measures described in Chapter 5.

ARTICLE 25 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF FINDINGS

25.1 Granting authority checks, reviews and audits

25.1.1 Internal checks

The granting authority may — during the action or afterwards — check the proper implementation of the action and compliance with the obligations under the Agreement, including assessing costs and contributions, deliverables and reports.

25.1.2 Project reviews

The granting authority may carry out reviews on the proper implementation of the action and compliance with the obligations under the Agreement (general project reviews or specific issues reviews).

Such project reviews may be started during the implementation of the action and until the time-limit set out in the Data Sheet (see Point 6). They will be formally notified to the coordinator or beneficiary concerned and will be considered to start on the date of the notification.

If needed, the granting authority may be assisted by independent, outside experts. If it uses outside experts, the coordinator or beneficiary concerned will be informed and have the right to object on grounds of commercial confidentiality or conflict of interest.

The coordinator or beneficiary concerned must cooperate diligently and provide — within the deadline requested — any information and data in addition to deliverables and reports already submitted (including information on the use of resources). The granting authority may request beneficiaries to provide such information to it directly. Sensitive information and documents will be treated in accordance with Article 13.

The coordinator or beneficiary concerned may be requested to participate in meetings, including with the outside experts.

For **on-the-spot visits**, the beneficiary concerned must allow access to sites and premises (including to the outside experts) and must ensure that information requested is readily available.

Information provided must be accurate, precise and complete and in the format requested, including electronic format.

On the basis of the review findings, a **project review report** will be drawn up.

The granting authority will formally notify the project review report to the coordinator or beneficiary concerned, which has 30 days from receiving notification to make observations.

Project reviews (including project review reports) will be in the language of the Agreement.

25.1.3 Audits

The granting authority may carry out audits on the proper implementation of the action and compliance with the obligations under the Agreement.

Such audits may be started during the implementation of the action and until the time-limit set out in the Data Sheet (see Point 6). They will be formally notified to the beneficiary concerned and will be considered to start on the date of the notification.

The granting authority may use its own audit service, delegate audits to a centralised service or use external audit firms. If it uses an external firm, the beneficiary concerned will be informed and have the right to object on grounds of commercial confidentiality or conflict of interest.

The beneficiary concerned must cooperate diligently and provide — within the deadline requested — any information (including complete accounts, individual salary statements or other personal data) to verify compliance with the Agreement. Sensitive information and documents will be treated in accordance with Article 13.

For **on-the-spot** visits, the beneficiary concerned must allow access to sites and premises (including for the external audit firm) and must ensure that information requested is readily available.

Information provided must be accurate, precise and complete and in the format requested, including electronic format.

On the basis of the audit findings, a **draft audit report** will be drawn up.

The auditors will formally notify the draft audit report to the beneficiary concerned, which has 30 days from receiving notification to make observations (contradictory audit procedure).

The **final audit report** will take into account observations by the beneficiary concerned and will be formally notified to them.

Audits (including audit reports) will be in the language of the Agreement.

25.2 European Commission checks, reviews and audits in grants of other granting authorities

Where the granting authority is not the European Commission, the latter has the same rights of checks, reviews and audits as the granting authority.

25.3 Access to records for assessing simplified forms of funding

The beneficiaries must give the European Commission access to their statutory records for the periodic assessment of simplified forms of funding which are used in EU programmes.

25.4 OLAF, EPPO and ECA audits and investigations

The following bodies may also carry out checks, reviews, audits and investigations — during the action or afterwards:

- the European Anti-Fraud Office (OLAF) under Regulations No 883/2013²² and No 2185/96²³
- the European Public Prosecutor's Office (EPPO) under Regulation 2017/1939
- the European Court of Auditors (ECA) under Article 287 of the Treaty on the Functioning of the EU (TFEU) and Article 257 of EU Financial Regulation 2018/1046.

If requested by these bodies, the beneficiary concerned must provide full, accurate and complete information in the format requested (including complete accounts, individual salary statements or other personal data, including in electronic format) and allow access to sites and premises for on-the-spot visits or inspections — as provided for under these Regulations.

To this end, the beneficiary concerned must keep all relevant information relating to the action, at least until the time-limit set out in the Data Sheet (Point 6) and, in any case, until any ongoing checks, reviews, audits, investigations, litigation or other pursuits of claims have been concluded.

25.5 Consequences of checks, reviews, audits and investigations — Extension of results of reviews, audits or investigations

25.5.1 Consequences of checks, reviews, audits and investigations in this grant

Findings in checks, reviews, audits or investigations carried out in the context of this grant may lead to rejections (see Article 27), grant reduction (see Article 28) or other measures described in Chapter 5.

Rejections or grant reductions after the final payment will lead to a revised final grant amount (see Article 22).

Findings in checks, reviews, audits or investigations during the action implementation may lead to a request for amendment (see Article 39), to change the description of the action set out in Annex 1.

Checks, reviews, audits or investigations that find systemic or recurrent errors, irregularities, fraud or breach of obligations in any EU grant may also lead to consequences in other EU grants awarded under similar conditions ('extension to other grants').

Moreover, findings arising from an OLAF or EPPO investigation may lead to criminal prosecution under national law.

25.5.2 Extension from other grants

Results of checks, reviews, audits or investigations in other grants may be extended to this grant, if:

- (a) the beneficiary concerned is found, in other EU grants awarded under similar conditions, to have committed systemic or recurrent errors, irregularities, fraud or breach of obligations that have a material impact on this grant and

²² Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013 concerning investigations conducted by the European Anti-Fraud Office (OLAF) and repealing Regulation (EC) No 1073/1999 of the European Parliament and of the Council and Council Regulation (Euratom) No 1074/1999 (OJ L 248, 18/09/2013, p. 1).

²³ Council Regulation (Euratom, EC) No 2185/1996 of 11 November 1996 concerning on-the-spot checks and inspections carried out by the Commission in order to protect the European Communities' financial interests against fraud and other irregularities (OJ L 292, 15/11/1996, p. 2).

- (b) those findings are formally notified to the beneficiary concerned — together with the list of grants affected by the findings — within the time-limit for audits set out in the Data Sheet (see Point 6).

The granting authority will formally notify the beneficiary concerned of the intention to extend the findings and the list of grants affected.

If the extension concerns **rejections of costs or contributions**: the notification will include:

- (a) an invitation to submit observations on the list of grants affected by the findings
- (b) the request to submit revised financial statements for all grants affected
- (c) the correction rate for extrapolation, established on the basis of the systemic or recurrent errors, to calculate the amounts to be rejected, if the beneficiary concerned:
 - (i) considers that the submission of revised financial statements is not possible or practicable or
 - (ii) does not submit revised financial statements.

If the extension concerns **grant reductions**: the notification will include:

- (a) an invitation to submit observations on the list of grants affected by the findings and
- (b) the **correction rate for extrapolation**, established on the basis of the systemic or recurrent errors and the principle of proportionality.

The beneficiary concerned has **60 days** from receiving notification to submit observations, revised financial statements or to propose a duly substantiated **alternative correction method/rate**.

On the basis of this, the granting authority will analyse the impact and decide on the implementation (i.e. start rejection or grant reduction procedures, either on the basis of the revised financial statements or the announced/alternative method/rate or a mix of those; see Articles 27 and 28).

25.6 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, costs or contributions insufficiently substantiated will be ineligible (see Article 6) and will be rejected (see Article 27), and the grant may be reduced (see Article 28).

Such breaches may also lead to other measures described in Chapter 5.

ARTICLE 26 — IMPACT EVALUATIONS

26.1 Impact evaluation

The granting authority may carry out impact evaluations of the action, measured against the objectives and indicators of the EU programme funding the grant.

Such evaluations may be started during implementation of the action and until the time-limit set out

in the Data Sheet (see Point 6). They will be formally notified to the coordinator or beneficiaries and will be considered to start on the date of the notification.

If needed, the granting authority may be assisted by independent outside experts.

The coordinator or beneficiaries must provide any information relevant to evaluate the impact of the action, including information in electronic format.

26.2 Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the granting authority may apply the measures described in Chapter 5.

CHAPTER 5 CONSEQUENCES OF NON-COMPLIANCE

SECTION 1 REJECTIONS AND GRANT REDUCTION

ARTICLE 27 — REJECTION OF COSTS AND CONTRIBUTIONS

27.1 Conditions

The granting authority will — at beneficiary termination, interim payment, final payment or afterwards — reject any costs or contributions which are ineligible (see Article 6), in particular following checks, reviews, audits or investigations (see Article 25).

The rejection may also be based on the extension of findings from other grants to this grant (see Article 25).

Ineligible costs or contributions will be rejected.

27.2 Procedure

If the rejection does not lead to a recovery, the granting authority will formally notify the coordinator or beneficiary concerned of the rejection, the amounts and the reasons why. The coordinator or beneficiary concerned may — within 30 days of receiving notification — submit observations if it disagrees with the rejection (payment review procedure).

If the rejection leads to a recovery, the granting authority will follow the contradictory procedure with pre-information letter set out in Article 22.

27.3 Effects

If the granting authority rejects costs or contributions, it will deduct them from the costs or contributions declared and then calculate the amount due (and, if needed, make a recovery; see Article 22).

ARTICLE 28 — GRANT REDUCTION

28.1 Conditions

The granting authority may — at beneficiary termination, final payment or afterwards — reduce the grant for a beneficiary, if:

- (a) the beneficiary (or a person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed:
 - (i) substantial errors, irregularities or fraud or
 - (ii) serious breach of obligations under this Agreement or during its award (including improper implementation of the action, non-compliance with the call conditions, submission of false information, failure to provide required information, breach of ethics or security rules (if applicable), etc.), or
- (b) the beneficiary (or a person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed — in other EU grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant (see Article 25).

The amount of the reduction will be calculated for each beneficiary concerned and proportionate to the seriousness and the duration of the errors, irregularities or fraud or breach of obligations, by applying an individual reduction rate to their accepted EU contribution.

28.2 Procedure

If the grant reduction does not lead to a recovery, the granting authority will formally notify the coordinator or beneficiary concerned of the reduction, the amount to be reduced and the reasons why. The coordinator or beneficiary concerned may — within 30 days of receiving notification — submit observations if it disagrees with the reduction (payment review procedure).

If the grant reduction leads to a recovery, the granting authority will follow the contradictory procedure with pre-information letter set out in Article 22.

28.3 Effects

If the granting authority reduces the grant, it will deduct the reduction and then calculate the amount due (and, if needed, make a recovery; see Article 22).

SECTION 2 SUSPENSION AND TERMINATION

ARTICLE 29 — PAYMENT DEADLINE SUSPENSION

29.1 Conditions

The granting authority may — at any moment — suspend the payment deadline if a payment cannot be processed because:

- (a) the required report (see Article 21) has not been submitted or is not complete or additional information is needed
- (b) there are doubts about the amount to be paid (e.g. ongoing audit extension procedure, queries

about eligibility, need for a grant reduction, etc.) and additional checks, reviews, audits or investigations are necessary, or

- (c) there are other issues affecting the EU financial interests.

29.2 Procedure

The granting authority will formally notify the coordinator of the suspension and the reasons why.

The suspension will **take effect** the day the notification is sent.

If the conditions for suspending the payment deadline are no longer met, the suspension will be **lifted** — and the remaining time to pay (see Data Sheet, Point 4.2) will resume.

If the suspension exceeds two months, the coordinator may request the granting authority to confirm if the suspension will continue.

If the payment deadline has been suspended due to the non-compliance of the report and the revised report is not submitted (or was submitted but is also rejected), the granting authority may also terminate the grant or the participation of the coordinator (see Article 32).

ARTICLE 30 — PAYMENT SUSPENSION

30.1 Conditions

The granting authority may — at any moment — suspend payments, in whole or in part for one or more beneficiaries, if:

- (a) a beneficiary (or a person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed or is suspected of having committed:
 - (i) substantial errors, irregularities or fraud or
 - (ii) serious breach of obligations under this Agreement or during its award (including improper implementation of the action, non-compliance with the call conditions, submission of false information, failure to provide required information, breach of ethics or security rules (if applicable), etc.), or
- (b) a beneficiary (or a person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed — in other EU grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant.

If payments are suspended for one or more beneficiaries, the granting authority will make partial payment(s) for the part(s) not suspended. If suspension concerns the final payment, the payment (or recovery) of the remaining amount after suspension is lifted will be considered to be the payment that closes the action.

30.2 Procedure

Before suspending payments, the granting authority will send a **pre-information letter** to the beneficiary concerned:

- formally notifying the intention to suspend payments and the reasons why and
- requesting observations within 30 days of receiving notification.

If the granting authority does not receive observations or decides to pursue the procedure despite the observations it has received, it will confirm the suspension (**confirmation letter**). Otherwise, it will formally notify that the procedure is discontinued.

At the end of the suspension procedure, the granting authority will also inform the coordinator.

The suspension will **take effect** the day after the confirmation notification is sent.

If the conditions for resuming payments are met, the suspension will be **lifted**. The granting authority will formally notify the beneficiary concerned (and the coordinator) and set the suspension end date.

During the suspension, no prefinancing will be paid to the beneficiaries concerned. For interim payments, the periodic reports for all reporting periods except the last one (see Article 21) must not contain any financial statements from the beneficiary concerned (or its affiliated entities). The coordinator must include them in the next periodic report after the suspension is lifted or — if suspension is not lifted before the end of the action — in the last periodic report.

ARTICLE 31 — GRANT AGREEMENT SUSPENSION

31.1 Consortium-requested GA suspension

31.1.1 Conditions and procedure

The beneficiaries may request the suspension of the grant or any part of it, if exceptional circumstances — in particular *force majeure* (see Article 35) — make implementation impossible or excessively difficult.

The coordinator must submit a request for **amendment** (see Article 39), with:

- the reasons why
- the date the suspension takes effect; this date may be before the date of the submission of the amendment request and
- the expected date of resumption.

The suspension will **take effect** on the day specified in the amendment.

Once circumstances allow for implementation to resume, the coordinator must immediately request another **amendment** of the Agreement to set the suspension end date, the resumption date (one day after suspension end date), extend the duration and make other changes necessary to adapt the action to the new situation (see Article 39) — unless the grant has been terminated (see Article 32). The suspension will be **lifted** with effect from the suspension end date set out in the amendment. This date may be before the date of the submission of the amendment request.

During the suspension, no prefinancing will be paid. Costs incurred or contributions for activities implemented during grant suspension are not eligible (see Article 6.3).

31.2 EU-initiated GA suspension

31.2.1 Conditions

The granting authority may suspend the grant or any part of it, if:

- (a) a beneficiary (or a person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed or is suspected of having committed:
 - (i) substantial errors, irregularities or fraud or
 - (ii) serious breach of obligations under this Agreement or during its award (including improper implementation of the action, non-compliance with the call conditions, submission of false information, failure to provide required information, breach of ethics or security rules (if applicable), etc.), or
- (b) a beneficiary (or a person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed — in other EU grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant
- (c) other:
 - (i) linked action issues: not applicable
 - (ii) additional GA suspension grounds: not applicable.

31.2.2 Procedure

Before suspending the grant, the granting authority will send a **pre-information letter** to the coordinator:

- formally notifying the intention to suspend the grant and the reasons why and
- requesting observations within 30 days of receiving notification.

If the granting authority does not receive observations or decides to pursue the procedure despite the observations it has received, it will confirm the suspension (**confirmation letter**). Otherwise, it will formally notify that the procedure is discontinued.

The suspension will **take effect** the day after the confirmation notification is sent (or on a later date specified in the notification).

Once the conditions for resuming implementation of the action are met, the granting authority will formally notify the coordinator a **lifting of suspension letter**, in which it will set the suspension end date and invite the coordinator to request an amendment of the Agreement to set the resumption date (one day after suspension end date), extend the duration and make other changes necessary to adapt the action to the new situation (see Article 39) — unless the grant has been terminated (see

Article 32). The suspension will be **lifted** with effect from the suspension end date set out in the lifting of suspension letter. This date may be before the date on which the letter is sent.

During the suspension, no prefinancing will be paid. Costs incurred or contributions for activities implemented during suspension are not eligible (see Article 6.3).

The beneficiaries may not claim damages due to suspension by the granting authority (see Article 33).

Grant suspension does not affect the granting authority's right to terminate the grant or a beneficiary (see Article 32) or reduce the grant (see Article 28).

ARTICLE 32 — GRANT AGREEMENT OR BENEFICIARY TERMINATION

32.1 Consortium-requested GA termination

32.1.1 Conditions and procedure

The beneficiaries may request the termination of the grant.

The coordinator must submit a request for **amendment** (see Article 39), with:

- the reasons why
- the date the consortium ends work on the action ('end of work date') and
- the date the termination takes effect ('termination date'); this date must be after the date of the submission of the amendment request.

The termination will **take effect** on the termination date specified in the amendment.

If no reasons are given or if the granting authority considers the reasons do not justify termination, it may consider the grant terminated improperly.

32.1.2 Effects

The coordinator must — within 60 days from when termination takes effect — submit a **periodic report** (for the open reporting period until termination).

The granting authority will calculate the final grant amount and final payment on the basis of the report submitted and taking into account the costs incurred and contributions for activities implemented before the end of work date (see Article 22). Costs relating to contracts due for execution only after the end of work are not eligible.

If the granting authority does not receive the report within the deadline, only costs and contributions which are included in an approved periodic report will be taken into account (no costs/contributions if no periodic report was ever approved).

Improper termination may lead to a grant reduction (see Article 28).

After termination, the beneficiaries' obligations (in particular Articles 13 (confidentiality and security), 16 (IPR), 17 (communication, dissemination and visibility), 21 (reporting), 25 (checks, reviews, audits and investigations), 26 (impact evaluation), 27 (rejections), 28 (grant reduction) and 42 (assignment of claims)) continue to apply.

32.2 Consortium-requested beneficiary termination

32.2.1 Conditions and procedure

The coordinator may request the termination of the participation of one or more beneficiaries, on request of the beneficiary concerned or on behalf of the other beneficiaries.

The coordinator must submit a request for **amendment** (see Article 39), with:

- the reasons why
- the opinion of the beneficiary concerned (or proof that this opinion has been requested in writing)
- the date the beneficiary ends work on the action ('end of work date')
- the date the termination takes effect ('termination date'); this date must be after the date of the submission of the amendment request.

If the termination concerns the coordinator and is done without its agreement, the amendment request must be submitted by another beneficiary (acting on behalf of the consortium).

The termination will **take effect** on the termination date specified in the amendment.

If no information is given or if the granting authority considers that the reasons do not justify termination, it may consider the beneficiary to have been terminated improperly.

32.2.2 Effects

The coordinator must — within 60 days from when termination takes effect — submit:

- (i) a **report on the distribution of payments** to the beneficiary concerned
- (ii) a **termination report** from the beneficiary concerned, for the open reporting period until termination, containing an overview of the progress of the work, the financial statement, the explanation on the use of resources, and, if applicable, the certificate on the financial statement (CFS; see Articles 21 and 24.2 and Data Sheet, Point 4.3)
- (iii) a second **request for amendment** (see Article 39) with other amendments needed (e.g. reallocation of the tasks and the estimated budget of the terminated beneficiary; addition of a new beneficiary to replace the terminated beneficiary; change of coordinator, etc.).

The granting authority will calculate the amount due to the beneficiary on the basis of the report submitted and taking into account the costs incurred and contributions for activities implemented before the end of work date (see Article 22). Costs relating to contracts due for execution only after the end of work are not eligible.

The information in the termination report must also be included in the periodic report for the next reporting period (see Article 21).

If the granting authority does not receive the termination report within the deadline, only costs and contributions which are included in an approved periodic report will be taken into account (no costs/contributions if no periodic report was ever approved).

If the granting authority does not receive the report on the distribution of payments within the deadline, it will consider that:

- the coordinator did not distribute any payment to the beneficiary concerned and that
- the beneficiary concerned must not repay any amount to the coordinator.

If the second request for amendment is accepted by the granting authority, the Agreement is **amended** to introduce the necessary changes (see Article 39).

If the second request for amendment is rejected by the granting authority (because it calls into question the decision awarding the grant or breaches the principle of equal treatment of applicants), the grant may be terminated (see Article 32).

Improper termination may lead to a reduction of the grant (see Article 31) or grant termination (see Article 32).

After termination, the concerned beneficiary's obligations (in particular Articles 13 (confidentiality and security), 16 (IPR), 17 (communication, dissemination and visibility), 21 (reporting), 25 (checks, reviews, audits and investigations), 26 (impact evaluation), 27 (rejections), 28 (grant reduction) and 42 (assignment of claims)) continue to apply.

32.3 EU-initiated GA or beneficiary termination

32.3.1 Conditions

The granting authority may terminate the grant or the participation of one or more beneficiaries, if:

- (a) one or more beneficiaries do not accede to the Agreement (see Article 40)
- (b) a change to the action or the legal, financial, technical, organisational or ownership situation of a beneficiary is likely to substantially affect the implementation of the action or calls into question the decision to award the grant (including changes linked to one of the exclusion grounds listed in the declaration of honour)
- (c) following termination of one or more beneficiaries, the necessary changes to the Agreement (and their impact on the action) would call into question the decision awarding the grant or breach the principle of equal treatment of applicants
- (d) implementation of the action has become impossible or the changes necessary for its continuation would call into question the decision awarding the grant or breach the principle of equal treatment of applicants
- (e) a beneficiary (or person with unlimited liability for its debts) is subject to bankruptcy proceedings or similar (including insolvency, winding-up, administration by a liquidator or court, arrangement with creditors, suspension of business activities, etc.)
- (f) a beneficiary (or person with unlimited liability for its debts) is in breach of social security or tax obligations
- (g) a beneficiary (or person having powers of representation, decision-making or control, or person

essential for the award/implementation of the grant) has been found guilty of grave professional misconduct

- (h) a beneficiary (or person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed fraud, corruption, or is involved in a criminal organisation, money laundering, terrorism-related crimes (including terrorism financing), child labour or human trafficking
- (i) a beneficiary (or person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) was created under a different jurisdiction with the intent to circumvent fiscal, social or other legal obligations in the country of origin (or created another entity with this purpose)
- (j) a beneficiary (or person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed:
 - (i) substantial errors, irregularities or fraud or
 - (ii) serious breach of obligations under this Agreement or during its award (including improper implementation of the action, non-compliance with the call conditions, submission of false information, failure to provide required information, breach of ethics or security rules (if applicable), etc.)
- (k) a beneficiary (or person having powers of representation, decision-making or control, or person essential for the award/implementation of the grant) has committed — in other EU grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant (extension of findings from other grants to this grant; see Article 25)
- (l) despite a specific request by the granting authority, a beneficiary does not request — through the coordinator — an amendment to the Agreement to end the participation of one of its affiliated entities or associated partners that is in one of the situations under points (d), (f), (e), (g), (h), (i) or (j) and to reallocate its tasks, or
- (m) other:
 - (i) linked action issues: not applicable
 - (ii) additional GA termination grounds: not applicable.

32.3.2 Procedure

Before terminating the grant or participation of one or more beneficiaries, the granting authority will send a **pre-information letter** to the coordinator or beneficiary concerned:

- formally notifying the intention to terminate and the reasons why and
- requesting observations within 30 days of receiving notification.

If the granting authority does not receive observations or decides to pursue the procedure despite the observations it has received, it will confirm the termination and the date it will take effect (**confirmation letter**). Otherwise, it will formally notify that the procedure is discontinued.

For beneficiary terminations, the granting authority will — at the end of the procedure — also inform the coordinator.

The termination will **take effect** the day after the confirmation notification is sent (or on a later date specified in the notification; ‘termination date’).

32.3.3 Effects

(a) for **GA termination**:

The coordinator must — within 60 days from when termination takes effect — submit a **periodic report** (for the last open reporting period until termination).

The granting authority will calculate the final grant amount and final payment on the basis of the report submitted and taking into account the costs incurred and contributions for activities implemented before termination takes effect (see Article 22). Costs relating to contracts due for execution only after termination are not eligible.

If the grant is terminated for breach of the obligation to submit reports, the coordinator may not submit any report after termination.

If the granting authority does not receive the report within the deadline, only costs and contributions which are included in an approved periodic report will be taken into account (no costs/contributions if no periodic report was ever approved).

Termination does not affect the granting authority’s right to reduce the grant (see Article 28) or to impose administrative sanctions (see Article 34).

The beneficiaries may not claim damages due to termination by the granting authority (see Article 33).

After termination, the beneficiaries’ obligations (in particular Articles 13 (confidentiality and security), 16 (IPR), 17 (communication, dissemination and visibility), 21 (reporting), 25 (checks, reviews, audits and investigations), 26 (impact evaluation), 27 (rejections), 28 (grant reduction) and 42 (assignment of claims)) continue to apply.

(b) for **beneficiary termination**:

The coordinator must — within 60 days from when termination takes effect — submit:

- (i) a **report on the distribution of payments** to the beneficiary concerned
- (ii) a **termination report** from the beneficiary concerned, for the open reporting period until termination, containing an overview of the progress of the work, the financial statement, the explanation on the use of resources, and, if applicable, the certificate on the financial statement (CFS; see Articles 21 and 24.2 and Data Sheet, Point 4.3)
- (iii) a **request for amendment** (see Article 39) with any amendments needed (e.g. reallocation of the tasks and the estimated budget of the terminated beneficiary; addition of a new beneficiary to replace the terminated beneficiary; change of coordinator, etc.).

The granting authority will calculate the amount due to the beneficiary on the basis of the

report submitted and taking into account the costs incurred and contributions for activities implemented before termination takes effect (see Article 22). Costs relating to contracts due for execution only after termination are not eligible.

The information in the termination report must also be included in the periodic report for the next reporting period (see Article 21).

If the granting authority does not receive the termination report within the deadline, only costs and contributions included in an approved periodic report will be taken into account (no costs/contributions if no periodic report was ever approved).

If the granting authority does not receive the report on the distribution of payments within the deadline, it will consider that:

- the coordinator did not distribute any payment to the beneficiary concerned and that
- the beneficiary concerned must not repay any amount to the coordinator.

If the request for amendment is accepted by the granting authority, the Agreement is **amended** to introduce the necessary changes (see Article 39).

If the request for amendment is rejected by the granting authority (because it calls into question the decision awarding the grant or breaches the principle of equal treatment of applicants), the grant may be terminated (see Article 32).

After termination, the concerned beneficiary's obligations (in particular Articles 13 (confidentiality and security), 16 (IPR), 17 (communication, dissemination and visibility), 21 (reporting), 25 (checks, reviews, audits and investigations), 26 (impact evaluation), 27 (rejections), 28 (grant reduction) and 42 (assignment of claims)) continue to apply.

SECTION 3 OTHER CONSEQUENCES: DAMAGES AND ADMINISTRATIVE SANCTIONS

ARTICLE 33 — DAMAGES

33.1 Liability of the granting authority

The granting authority cannot be held liable for any damage caused to the beneficiaries or to third parties as a consequence of the implementation of the Agreement, including for gross negligence.

The granting authority cannot be held liable for any damage caused by any of the beneficiaries or other participants involved in the action, as a consequence of the implementation of the Agreement.

33.2 Liability of the beneficiaries

The beneficiaries must compensate the granting authority for any damage it sustains as a result of the implementation of the action or because the action was not implemented in full compliance with the Agreement, provided that it was caused by gross negligence or wilful act.

The liability does not extend to indirect or consequential losses or similar damage (such as loss of

profit, loss of revenue or loss of contracts), provided such damage was not caused by wilful act or by a breach of confidentiality.

ARTICLE 34 — ADMINISTRATIVE SANCTIONS AND OTHER MEASURES

Nothing in this Agreement may be construed as preventing the adoption of administrative sanctions (i.e. exclusion from EU award procedures and/or financial penalties) or other public law measures, in addition or as an alternative to the contractual measures provided under this Agreement (see, for instance, Articles 135 to 145 EU Financial Regulation 2018/1046 and Articles 4 and 7 of Regulation 2988/95²⁴).

SECTION 4 FORCE MAJEURE

ARTICLE 35 — FORCE MAJEURE

A party prevented by force majeure from fulfilling its obligations under the Agreement cannot be considered in breach of them.

‘Force majeure’ means any situation or event that:

- prevents either party from fulfilling their obligations under the Agreement,
- was unforeseeable, exceptional situation and beyond the parties’ control,
- was not due to error or negligence on their part (or on the part of other participants involved in the action), and
- proves to be inevitable in spite of exercising all due diligence.

Any situation constituting force majeure must be formally notified to the other party without delay, stating the nature, likely duration and foreseeable effects.

The parties must immediately take all the necessary steps to limit any damage due to force majeure and do their best to resume implementation of the action as soon as possible.

CHAPTER 6 FINAL PROVISIONS

ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES

36.1 Forms and means of communication — Electronic management

EU grants are managed fully electronically through the EU Funding & Tenders Portal (‘Portal’).

All communications must be made electronically through the Portal, in accordance with the Portal Terms and Conditions and using the forms and templates provided there (except if explicitly instructed otherwise by the granting authority).

²⁴ Council Regulation (EC, Euratom) No 2988/95 of 18 December 1995 on the protection of the European Communities financial interests (OJ L 312, 23.12.1995, p. 1).

Communications must be made in writing and clearly identify the grant agreement (project number and acronym).

Communications must be made by persons authorised according to the Portal Terms and Conditions. For naming the authorised persons, each beneficiary must have designated — before the signature of this Agreement — a ‘legal entity appointed representative (LEAR)’. The role and tasks of the LEAR are stipulated in their appointment letter (see Portal Terms and Conditions).

If the electronic exchange system is temporarily unavailable, instructions will be given on the Portal.

36.2 Date of communication

The sending date for communications made through the Portal will be the date and time of sending, as indicated by the time logs.

The receiving date for communications made through the Portal will be the date and time the communication is accessed, as indicated by the time logs. Formal notifications that have not been accessed within 10 days after sending, will be considered to have been accessed (see Portal Terms and Conditions).

If a communication is exceptionally made on paper (by e-mail or postal service), general principles apply (i.e. date of sending/receipt). Formal notifications by registered post with proof of delivery will be considered to have been received either on the delivery date registered by the postal service or the deadline for collection at the post office.

If the electronic exchange system is temporarily unavailable, the sending party cannot be considered in breach of its obligation to send a communication within a specified deadline.

36.3 Addresses for communication

The Portal can be accessed via the Europa website.

The address for paper communications to the granting authority (if exceptionally allowed) is the official mailing address indicated on its website.

For beneficiaries, it is the legal address specified in the Portal Participant Register.

ARTICLE 37 — INTERPRETATION OF THE AGREEMENT

The provisions in the Data Sheet take precedence over the rest of the Terms and Conditions of the Agreement.

Annex 5 takes precedence over the Terms and Conditions; the Terms and Conditions take precedence over the Annexes other than Annex 5.

Annex 2 takes precedence over Annex 1.

ARTICLE 38 — CALCULATION OF PERIODS AND DEADLINES

In accordance with Regulation No 1182/71²⁵, periods expressed in days, months or years are calculated from the moment the triggering event occurs.

The day during which that event occurs is not considered as falling within the period.

‘Days’ means calendar days, not working days.

ARTICLE 39 — AMENDMENTS

39.1 Conditions

The Agreement may be amended, unless the amendment entails changes to the Agreement which would call into question the decision awarding the grant or breach the principle of equal treatment of applicants.

Amendments may be requested by any of the parties.

39.2 Procedure

The party requesting an amendment must submit a request for amendment signed directly in the Portal Amendment tool.

The coordinator submits and receives requests for amendment on behalf of the beneficiaries (see Annex 3). If a change of coordinator is requested without its agreement, the submission must be done by another beneficiary (acting on behalf of the other beneficiaries).

The request for amendment must include:

- the reasons why
- the appropriate supporting documents and
- for a change of coordinator without its agreement: the opinion of the coordinator (or proof that this opinion has been requested in writing).

The granting authority may request additional information.

If the party receiving the request agrees, it must sign the amendment in the tool within 45 days of receiving notification (or any additional information the granting authority has requested). If it does not agree, it must formally notify its disagreement within the same deadline. The deadline may be extended, if necessary for the assessment of the request. If no notification is received within the deadline, the request is considered to have been rejected.

An amendment **enters into force** on the day of the signature of the receiving party.

An amendment **takes effect** on the date of entry into force or other date specified in the amendment.

ARTICLE 40 — ACCESSION AND ADDITION OF NEW BENEFICIARIES

²⁵ Regulation (EEC, Euratom) No 1182/71 of the Council of 3 June 1971 determining the rules applicable to periods, dates and time-limits (OJ L 124, 8/6/1971, p. 1).

40.1 Accession of the beneficiaries mentioned in the Preamble

The beneficiaries which are not coordinator must accede to the grant by signing the accession form (see Annex 3) directly in the Portal Grant Preparation tool, within 30 days after the entry into force of the Agreement (see Article 44).

They will assume the rights and obligations under the Agreement with effect from the date of its entry into force (see Article 44).

If a beneficiary does not accede to the grant within the above deadline, the coordinator must — within 30 days — request an amendment (see Article 39) to terminate the beneficiary and make any changes necessary to ensure proper implementation of the action. This does not affect the granting authority's right to terminate the grant (see Article 32).

40.2 Addition of new beneficiaries

In justified cases, the beneficiaries may request the addition of a new beneficiary.

For this purpose, the coordinator must submit a request for amendment in accordance with Article 39. It must include an accession form (see Annex 3) signed by the new beneficiary directly in the Portal Amendment tool.

New beneficiaries will assume the rights and obligations under the Agreement with effect from the date of their accession specified in the accession form (see Annex 3).

Additions are also possible in mono-beneficiary grants.

ARTICLE 41 — TRANSFER OF THE AGREEMENT

In justified cases, the beneficiary of a mono-beneficiary grant may request the transfer of the grant to a new beneficiary, provided that this would not call into question the decision awarding the grant or breach the principle of equal treatment of applicants.

The beneficiary must submit a request for **amendment** (see Article 39), with

- the reasons why
- the accession form (see Annex 3) signed by the new beneficiary directly in the Portal Amendment tool and
- additional supporting documents (if required by the granting authority).

The new beneficiary will assume the rights and obligations under the Agreement with effect from the date of accession specified in the accession form (see Annex 3).

ARTICLE 42 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE GRANTING AUTHORITY

The beneficiaries may not assign any of their claims for payment against the granting authority to any third party, except if expressly approved in writing by the granting authority on the basis of a reasoned, written request by the coordinator (on behalf of the beneficiary concerned).

If the granting authority has not accepted the assignment or if the terms of it are not observed, the assignment will have no effect on it.

In no circumstances will an assignment release the beneficiaries from their obligations towards the granting authority.

ARTICLE 43 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES

43.1 Applicable law

The Agreement is governed by the applicable EU law, supplemented if necessary by the law of Belgium.

Special rules may apply for beneficiaries which are international organisations (if any; see Data Sheet, Point 5).

43.2 Dispute settlement

If a dispute concerns the interpretation, application or validity of the Agreement, the parties must bring action before the EU General Court — or, on appeal, the EU Court of Justice — under Article 272 of the Treaty on the Functioning of the EU (TFEU).

For non-EU beneficiaries (if any), such disputes must be brought before the courts of Brussels, Belgium — unless an international agreement provides for the enforceability of EU court judgements.

For beneficiaries with arbitration as special dispute settlement forum (if any; see Data Sheet, Point 5), the dispute will — in the absence of an amicable settlement — be settled in accordance with the Rules for Arbitration published on the Portal.

If a dispute concerns administrative sanctions, offsetting or an enforceable decision under Article 299 TFEU (see Articles 22 and 34), the beneficiaries must bring action before the General Court — or, on appeal, the Court of Justice — under Article 263 TFEU.

For grants where the granting authority is an EU executive agency (see Preamble), actions against offsetting and enforceable decisions must be brought against the European Commission (not against the granting authority; see also Article 22).


ARTICLE 44 — ENTRY INTO FORCE

The Agreement will enter into force on the day of signature by the granting authority or the coordinator, depending on which is later.

SIGNATURES

For the coordinator

For the granting authority



ANNEX 1



EU4 Health Programme (EU4H)

Description of the action (DoA)

Part A

Part B

DESCRIPTION OF THE ACTION (PART A)

COVER PAGE

Part A of the Description of the Action (DoA) must be completed directly on the Portal Grant Preparation screens.

PROJECT	
<i>Grant Preparation (General Information screen) — Enter the info.</i>	
Project number:	101056986
Project name:	Building Resilience Against crisis: a systematic and global approach to adVancE organ Safety and supply in Transplantation
Project acronym:	BRAVEST
Call:	EU4H-2021-PJ
Topic:	EU4H-2021-PJ-05
Type of action:	EU4H-PJG
Service:	HADEA/A/01
Project starting date:	fixed date: 1 September 2022
Project duration:	30 months

TABLE OF CONTENTS

Project summary	3
List of participants	3
List of work packages	4
Staff effort	12
List of deliverables	13
List of milestones (outputs/outcomes)	21
List of critical risks	22
Project reviews	23

PROJECT SUMMARY

Project summary

Grant Preparation (General Information screen) — Provide an overall description of your project (including context and overall objectives, planned activities and main achievements, and expected results and impacts (on target groups, change procedures, capacities, innovation etc)). This summary should give readers a clear idea of what your project is about.

Use the project summary from your proposal.

Stemming from the lessons learned during the SARS-CoV2 pandemic, BRAVEST project aims at analysing organizational and management procedures in organ donation and transplantation based on real world evidence and cutting-edge analysis methodologies.

This will allow to identify the most effective clinical practice; identify good clinical practice procedures; develop guidelines and propose sustainable innovative actions directed at improving the resilience of the donation and transplant systems and networks, ensure the continuity of supply of organs while maintaining the safety of donation and transplant, and ultimately increase the accessibility to transplantation for all patients with end-stage organ disease.

Such resilience is meant to reinforce organizations, in order to cope with stress conditions, ranging from eventual additional epidemics, but also wars, earthquakes, ecological disasters, which are increasingly hitting several areas in Europe, as well as the world around.

LIST OF PARTICIPANTS

PARTICIPANTS

Grant Preparation (Beneficiaries screen) — Enter the info.

Number	Role	Short name	Legal name	Country	PIC
1	COO	ESOT	EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION	NL	994118081
2	BEN	ISS - CNT	ISTITUTO SUPERIORE DI SANITA	IT	999978821
3	BEN	ONT	ORGANIZACION NACIONAL DE TRASPLANTES	ES	941056365
4	BEN	ST	ZAVOD REPUBLIKE SLOVENIJE ZA PRESADITVE ORGANOV IN TKIV SLOVENIJA TRANSPLANT	SI	939758796
5	BEN	ET	STICHTING EUROTRANSPLANT INTERNATIONAL FOUNDATION	NL	954188419
6	BEN	ABM	AGENCE DE LA BIOMEDECINE	FR	911988763
7	BEN	OVSZ	ORSZAGOS VERELLATO SZOLGALAT - OVSZ	HU	933649251
8	BEN	INSERM	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	FR	999997833
9	BEN	EPHA	EUROPEAN PUBLIC HEALTH ALLIANCE	BE	955484436

LIST OF WORK PACKAGES

Work packages						
<i>Grant Preparation (Work Packages screen) — Enter the info.</i>						
Work Package No	Work Package name	Lead Beneficiary	Effort (Person-Months)	Start Month	End Month	Deliverable No(s)
WP1	Coordination, management and evaluation	1 - ESOT	26.84	1	30	D1.3, D1.1, D1.2
WP2	Communication, dissemination and exploitation	1 - ESOT	37.51	1	30	D2.4, D2.1, D2.2, D2.6, D2.3, D2.5
WP3	Analysis of COVID- 19 pandemic impact on participating countries	3 - ONT	63.78	1	17	D3.5, D3.1, D3.3, D3.2, D3.4
WP4	Guidelines and prospective solutions for building up resilient organ donation and transplant systems	1 - ESOT	45.49	13	22	D4.1, D4.2
WP5	Implementation and sustainability	4 - ST	39.40	20	29	D5.2, D5.1

Work package WP1 – Coordination, management and evaluation

Work Package Number	WP1	Lead Beneficiary	1. ESOT
Work Package Name	Coordination, management and evaluation		
Start Month	1	End Month	30

Objectives
<p>This WP is aimed at managing and coordinating the project and making sure that it is implemented as planned, abiding by EU rules and procedures. Additionally, this WP aims to ensure that the project reaches its objectives and produces high quality deliverables, especially by closely monitoring activities within WP3-WP5 (e.g. for all meetings and events under such WPs, questionnaires will be distributed to ascertain how participants evaluated their usefulness and organisation). In addition, an evaluation of whether project outputs fit the purpose will be carried out. This WP task will also take advantage of the contribution of an External Advisory Board (EAB) to be set up at the beginning of the Action. The members of such board will be selected among internationally acknowledged experts with no link to any of the partner authorities. Scientific project officers from the EU Commission will be asked to approve the list of EAB members. The Board will be managed by coordinator and involved in plenary meetings and will deliver inputs for both deliverables and evaluation reports for this WP. The composition of the EAB will take into account the different fields covered by the project in terms of expertise.</p> <p>The coordination role, assumed by the project leader, is intended to:</p> <ul style="list-style-type: none"> • coordinate the action horizontally and vertically; • supervise the design and implementation of the single WPs, supporting WP leaders; • supervise vertically the work carried out in each WP ensuring that the expected deadlines and deliverables are met; • ensure a steady information on WP progress; • monitor transversally the compliance of each partner and assess whether the activities are balanced or not, and in this case allowing to jeopardize the performance of the beneficiaries in the other WPs; • guarantee quality working procedures, oriented to results and aims, transparent and balanced within the transnational consortium; • design a General Working Plan for the project and coordinate specific working plans within each WP; • ensure a permanent and transparent communication within the consortium, as well as proper project implementation motivating all partner organisations for guaranteeing a balanced participation, avoiding any inactivity during specific periods of the project lifetime. • measurement of the implementation impact and long-term outcomes of the project

Description
<p>Actions undertaken to manage the action and to make sure that it is being implemented and reaches the objectives.</p> <p>T1.1 Organization of general meetings and coordination Beneficiaries and EAB will meet in three plenary meeting: Kick-off (M1), intermediate meetings (M15) and final meeting (M30); Interim WP meetings for reaching agreements on specific issues, developing work, and exchanging relevant information, including working progress will be held by conference calls.</p> <p>T1.2 Setting up of the External Advisory Board A board of experts covering the different fields addressed by the project, will be nominated among internationally acknowledged experts with no link to any of the partner authorities, to evaluate project outcomes.</p> <p>T1.3 Monitoring of technical WPs To ensure that the project reaches its objectives and produces high quality deliverables, a close monitoring of the activities within WP3-WP5 will be performed and specifically for all meetings and events under such WPs, questionnaires will be distributed to ascertain how participants evaluated their usefulness and organisation.</p>

Work package WP2 – Communication, dissemination and exploitation

Work Package Number	WP2	Lead Beneficiary	1. ESOT
Work Package Name	Communication, dissemination and exploitation		

Start Month	1	End Month	30
--------------------	---	------------------	----

Objectives
<p>The overall objective is to identify and reach the target audience and stakeholders, including EU and national policy makers, academic institutes, professional associations, end users and the general public, in order to raise their awareness regarding the findings of the consortium and to encourage them to support and adopt the guideline and other relevant outputs of the project. More specifically, the objectives of WP2 are:</p> <ul style="list-style-type: none"> ▪ To define and establish the project dissemination and communication strategy/plan ▪ To manage the external communication and proper dissemination of the project results and its deliverables. ▪ To ensure the proper visibility of EU co-funding ▪ To define and reach the target audience and stakeholders at the level of institutions, professional societies, policy makers and final users. ▪ To raise awareness of the target audience, stakeholders and community in general, as regards the project activities. ▪ To provide the means for dissemination and communication of the JA actions and outputs. ▪ To pay attention to the transfer of knowledge and to the processes needed for embedding and future take-up; in particular, some contribution from this WP will be given to support the analysis of sustainability issues foreseen under WP5 - Task 2 <p>More specifically, this WP aims to foster the commercial and non-commercial exploitation of our results and communicate about the project to the public. This WP is aimed at developing targeted and well-thought outreach activities and measures which are a necessity to boost the impact of the project.</p>

Description
<p>T2.1 Dissemination and communication strategy The task will define a detailed dissemination strategy to ensure high visibility and impact for the project. The plan, covering all the duration of the project, will be authored describing the aims and objectives of the project, the actions to be disseminated, the target audiences/groups and stakeholders, the benefits to end-users, the dissemination methods/activities, the timescales and responsibilities of the members of the team, the targets, the estimated costs, the evaluation and criteria for success. The dissemination strategy will be revised periodically based on the feedback and the achieved results to ensure that the targeted events maximize visibility and that the dissemination activities reach the targeted audience.</p> <p>T2.2 Project identity Design the project logo, production of a design for printed material, production of banners, posters, flyers, preparation of the newsletters, production of video material, as well as official project templates for PowerPoint presentation and deliverables.</p> <p>T2.3 Design, launch and maintenance of the project website as devoted section of ESOT website The website - consisting of a public and private area – is a key dissemination deliverable with multiple roles in the promotion and support of the JA activities during and beyond the project.</p> <p>T2.4 Promotional Video A promotional video describing project activities and main outcomes will be published on project website, ESOT, EPHA and all beneficiaries media channels</p> <p>T2.5 Promotion via social media Project results may be disseminated through popular social networks such as LinkedIn or Twitter. The project will take advantage of any well-established social media channels of beneficiaries.</p> <p>T2.6 Organization of final dissemination conference and stakeholder webinar The final dissemination conference will be organised back to back to a stakeholder webinar whose recording will be stored on ESOT media channel</p>

Work package WP3 – Analysis of COVID- 19 pandemic impact on participating countries

Work Package Number	WP3	Lead Beneficiary	3. ONT
Work Package Name	Analysis of COVID- 19 pandemic impact on participating countries		
Start Month	1	End Month	17

Objectives

Building a repository of relevant data obtained from the national competent authorities included in the consortium. These data will include clinical features and epidemiology of solid organ donors and transplantation activities performed in the period 2018-2022. In addition, data will be collected regarding the impact of the COVID-19 pandemic on the healthcare and Intensive Care Unit (ICU) systems in the respective region/country during the different waves. This will be accompanied by a thorough description of the procedures implemented by the EU participating countries during the pandemic to ensure the continuity of the transplant program. Finally, the analysis of the raw data will be enriched by an AI-based algorithm directed at determining the main determinants of SOT activity in the participating EU states during the pandemic.

Specific objectives:

- feeding a repository of retrospective granular data about organ donors signalled and procured, in European countries (period 2018-2022), from the data prospectively collected by National Transplant Authorities and organ allocation organisations.
- implementing a survey of the procedures implemented during COVID-19 pandemic at national/regional level.
- developing an AI algorithm to predict main determinants of transplantation activity with specific focus on the contribution of COVID-19 pandemic as a covariate

Description

This WP will focus on building up a comprehensive picture of how the recent COVID-19 pandemic has impacted upon solid organ donation and transplantation activities, and how transplant systems in the EU have dealt with the challenges posed by the pandemic. To this purpose, three different tasks will be performed:

T3.1 – Description of the COVID-19 impact on SOT programs

Study methodology will be defined during the first months of the WP, identifying the variables to be collected by the EU-Organ Transplant database, to be developed by ESOT partner. ESOT will be responsible for the development of the BRAVEST study-oriented web-based platform, to be populated with data gathered under the specifications and identification of variables to be collected, as per input by this WP, when defining study methodology. Full account will be taken of methodologies and indicators developed under previous EU-funded work (DOPKI, ACCORD, ODEQUS). The database will bring together data concerning existing national/regional donors and recipients gathered between 2018-2022. The cohort data will be centralized in this core facility. Standardized data will be collected by technical staff following a common thesaurus. Codes will be used to ensure strict donor and recipient anonymity, individual donor data collection will be performed in compliance with GDPR. Detailed definition of the database collecting the data retrievable from competent authorities datasets will be a deliverable of this WP and will be agreed in a meeting including at least one representative of each partner.

A thorough analysis of solid organ donation and transplantation practices in the EU before (year of analysis 2018-2019), during and after the pandemic will be performed. This will include the time-dependent analysis of the following data:

- Potential deceased donors (Donors after Brain Death - DBD and Donors after Circulatory Death - DCD);
- Characteristics of potential deceased donors (e.g. donors after the neurological [DBD] and after the circulatory death [DCD]);
- Actual deceased donors (DBD and DCD);
- Consent to organ donation;
- Living donors;
- Solid Organ Transplants (SOT) performed;
- Trans-national offers of SOT and number of transplants performed with these organs;
- Patients on the waiting list for SOT.

This analysis will be accompanied by retrieval of data about the COVID-19 pandemic in the participating EU states, including:

- COVID-19 cases;
- COVID-19 hospitalised patients;
- COVID-19 deaths;
- Hospital beds occupancy by COVID-19 patients;
- COVID-19 patients in ICU;
- ICU beds occupancy by COVID-19 patients.

Analysis of GDPR compliance of identified selected variables as per study plan will be performed early during WP development.

The analysis of these macro data will be stratified on a national/regional basis (when feasible, depending on data

availability), in order to analyse the magnitude of the impact of the different waves of COVID-19 on donation and transplantation activities and the capacity of the SOT systems to adapt to the different ICU and hospital situations. The data generated by this WP will be contrasted to the data from the pre-pandemic era (2018-2019) in order to generate solid evidence on the impact of the pandemic on the different SOT programs.

T3.1.1 - Development of BRAVEST study-oriented web-based platform

BRAVEST study-oriented web-based platform to be populated with data gathered under specifications supplied by WP3, where also the algorithm developed under that WP will be hosted and run.

T3.1.2 - Data collection of SOT activity 2018-2022

Data retrieval on SOT activity at national/regional level of the participating EU states

T3.1.3 - Data collection of COVID-19 data 2018-2022

Data retrieval on COVID-19-related epidemiology and use of health resources at national/regional level of the participating EU states

T3.2 – Description of the procedures implemented by the participating EU states to face the challenges posed to the SOT programs by the COVID-19 pandemic.

This task is meant to investigate the overall impact of the COVID-19 pandemic in organ transplantation, laying the groundwork to understand how healthcare systems adapted to the pandemic and improve decision-making if the pandemic persists (in case of emergence of SARS-CoV-2 variants of concern) or other emergencies come up. Due to the COVID-19 pandemic, new challenges for health-care systems in all countries have arisen and there has been inflexible prioritization of capability of hospital facilities and human resources toward COVID-19 patients. Depending on the severity of the wave of infections, there was also an unavailability of resources by actual capacity or by governmental and/or hospital policies in the sense of strategic preparedness. In both cases, treatment was restricted for all other patient cohorts but emergencies. Transplant Societies and National Authorities drew-up lists of procedures that could be performed during the pandemic, including life-saving procedures. Additionally, the impact of COVID-19 on SOT was limited at the beginning of the pandemic and is still unclear and controversial. Since there were no evidence-based guidelines to deal with COVID-19 and transplantation, many centres have considered restricting (urgency, risk stratification) or even stopping their activities.

All these conditions have shown a particular vulnerability of the system and a difference in behaviour at the super-national level.

Therefore, in order to evaluate the framework for SOT in Europe during the COVID-19 pandemic, to revise clinical behaviours adopted during the pandemic's pick and to propose new procedures to ensure the safety of organ donation and recovery and management of transplantation activities, as well as procedures to ensure proper use of available donation resources and the safety of organ recipients at the time of transplant surgery and during the subsequent follow-up, we will conduct an online dedicated survey to design and to convey the participating SOT organizations of the EU countries. The questionnaire will collect information on restrictions on SOT, protective measures, (non)governmental information policies, and individual opinion on how to deal with SOT during COVID-19 will be designed.

T3.3 – Big Data and AI to better manage the COVID-19 pandemic

- Describing the currently ongoing COVID-19 outbreak: All transplant data will be smoothed in two steps, by calculating a 14-day moving average and by applying locally estimated scatterplot smoothing to the 14-day moving average. We will compare the trends and the diminutions in the number of transplants between 2018 and 2023, by organ transplant structure, by country and across all included countries. The correlation between COVID-19-related deaths organ transplant activity will be assessed, including the following information: COVID-19 death per million inhabitants calculated from data retrieved from the John Hopkins COVID-19 Data Repository and the World Bank and transplant rates according label, country name etc. We will estimate the number of patient-life years lost during the different COVID-19 pandemic waves compared with the 2018-2019 period using computer-assisted simulation. The regionally stratified macro data will be able to be used to examine the protocols against COVID-19 pandemics within countries.

- Big data can enable monitoring of the disease outbreak in real-time with the potential to develop quick and effective pandemic alerts: we will develop an EU-web-based dashboard that will provide three data visualisation: line graphs displaying total COVID-19 cases, three-dimensional scatter plots displaying the percent diminution in transplants between 2022 and the same time period in 2018-2019, geographical heatmaps for each country. The system will be built in such a way to be prospectively updated in a potential followup of the project.

- Artificial neural networks, i.e. deep learning, especially, long short-term memory (LSTM) with big data can foresee the SOT trend in the future. We will develop an AI-based prediction system to monitor and find worrisome trends of SOT and COVID-19 pandemic.

- Facilitating the implementation of Public Health interventions by identifying at-risk subjects and identifying potential personalized prophylaxis strategies and treatment.

In the long term, AI and Big data appear to have enormous potential to design new standardized protocols and guidelines for sharing data and information during emergencies.

T3.3.1 - Prediction algorithm

Development of AI-based algorithms aimed at discovering the main determinants of good adaptability of the different SOT programs to the pandemic waves in order to ensure sufficiency of organ transplantation in future crisis.

T3.3.2 - Data analysis

Analysis of the variation in the SOT activity according to the pandemic phase in the different regions and EU countries

Work package WP4 – Guidelines and prospective solutions for building up resilient organ donation and transplant systems

Work Package Number	WP4	Lead Beneficiary	1. ESOT
Work Package Name	Guidelines and prospective solutions for building up resilient organ donation and transplant systems		
Start Month	13	End Month	22

Objectives

This WP is aimed at delivering policies and recommendations among the participating Countries, based on the output of WP3 and published literature; at developing a common denominator endorsed by the Competent Authorities in the context of: 1. donor screening, 2. recipient selection, 3. waitlist access, 4. follow up recommendation; at optimizing the resource of organ donation within each Country as well as in a vision of organ sharing

Specific objectives:

- Identifying a common approach for donor screening, recipient selection, waitlist access, followup recommendation
- Developing a set of proposed solutions for improving quality and safety of organ supply and subsequent transplantation
- Provide guidance for the staff organization of transplant units in response to a crisis

Description

On the basis of the outcomes of WP3, this WP will perform tasks meant to translate lessons learned into recommendations for organ donation and transplant communities, with a particular focus on the analysis of risk and critical factors; risk management and containment through shared strategies with verification of their adequacy; support the ICUs for the reporting of potential donors; identification at regional or national level of Transplant Centers where activity in times of crisis should be always guaranteed, in order to safeguard transplant procedures for patients in life danger, evaluating the possibility of moving teams and/or specialized personnel through agreements between hospitals; guarantee the possibility of transporting organ harvesting teams in conditions of health emergency; sensitize transplant communities to keep trust in health care, in health professionals, in transparent and ethical systems of organ donation and transplantation. In addition, we will perform a review of the workloads of transplant teams, repurposing of transplant unit and of transplant dedicated personnel that have happened during the pandemic in order to identify minimal requirements in in terms of staff and resources in order to guarantee a safe and functioning transplant activity

T4.1: Production of guidelines and sharing of good clinical practices.

The evidence gathered by the systematic review will provide the basis for the development of clinical practice guidelines. Specific guidelines will be developed, which will include guidelines regarding donor assessment, recipient selection, prioritization and transplant service provision. The guideline development process will follow evidence-based, structured methodologies for guideline development such as the AGREE II tool to produce guidelines that are consistent with the evidence and expert understanding.

1- A review of the content and timing of release of the procedures/documents/guidelines during the recent pandemic will be performed and analyzed in the context of the epidemiological data gathered by WP3, including the donor data and outcomes of the donation process, in the context of specific procedures implemented.

2- Bibliographic searches (e.g., Medline, Embase) and searches of relevant websites will identify guidelines and recommendations published by single or multiple authoritative centres, panels of experts, (inter)national authorities and relevant societies. Independent reviewers will extract all relevant recommendations from each guideline. Data will be summarised regarding the different aspects of the transplant pathway, such as organisation of resources, organ allocation,

transplant service provision, donor assessment and pre and post-transplant patient care. The systematic review will be conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.
 3- Developing comprehensive communication guidelines for times of crisis (target groups: professionals, general public and patients) during social and healthcare crises (T4.1.1).

T4.2 To develop a set of proposed solutions worked out on the basis of the results of data analysis and of expected procedures efficacy

With the T4.2, the consortium is aiming at developing a set of proposed solutions worked out on the basis of the results of data analysis and of expected procedures efficacy.

Among possible solutions to increase continuity and safety of organ supply with appropriate risk management, the feasibility of the following will be explored in detail:

1. Improving digital connectivity by building dedicated systems for clinical data and imaging sharing among transplant centres and donor centres. In particular, the implementation of the digital pathology, a dynamic, image-based environment that enables the acquisition, management and interpretation of pathological information, may have a significant impact on healthcare system by facilitation primary diagnosis, diagnostic consultation, intraoperative diagnosis, multidisciplinary team meetings and educational tasks organization, medical student and resident training, manual and semi-quantitative review of immunohistochemistry (IHC), clinical research and diagnostic decision support.
2. Specific focus on the impact of the policies for the use of organ machine perfusion in increasing the organ supply and overall interference with the timings of organ procurement in the context of DBD and DCD, including availability and competitive use of extracorporeal membrane circulation for normothermic regional perfusion.
3. Strategies for facilitating and Increasing volume of cross-border organ sharing – in particular in kidney donation and transplant setting.

During the course of the recent pandemic, some geographical areas were unable to perform transplant procedures although deceased donor recruitment was still feasible and active. In such conditions, the prerequisites for a successful organ sharing among Countries (preeminently kidney, due to the affordable cold ischemic time) resulted generally lacking. Using the common denominator for donor assessment and recipient prioritization obtained with the Task 1 activities, a faster and wider accepted data collection and policy-sharing will allow to optimize the allocation of the available organs among Countries. Prototypes of this collaboration will be analyzed and optimized per i. geographical distance, ii. legal framework, iii. sustainability.

Work package WP5 – Implementation and sustainability

Work Package Number	WP5	Lead Beneficiary	4. ST
Work Package Name	Implementation and sustainability		
Start Month	20	End Month	29

Objectives

The general purpose of this WP is defining a strategy to grant implementation and sustainability of project outcome, as well as assuring that the project outputs and consortium will be durable and sustainable after the project end. In WP5 we aim to analyse the consistency and sustainability of the guidelines and recommendations that will be proposed with the ethical and legal framework of Member States. This objective is crucial in order to propose solutions that can be implemented at European level and harmonised with current country regulations. For example there is a significant variability in the timing and procedures for brain and circulatory death declaration in member states. Although the proposed good practices will be based on the evidence derived by a thorough data analysis, they need to be applicable irrespective of differences, or prompt solutions to change the regulatory framework. This WP is coordinated by ST with the help of ESOT via the sections involved in organ procurement (EDTCO) and in research on ethical and legal aspects in transplantation (ELPAT). In collaboration with a subcontracted expert, a cost-effectiveness analysis of proposed solutions will also be performed (e.g. it is anticipated that measures to improve organ supply and safety may require increased use of organ recovery technology, such as machine perfusion devices. It is relevant to balance the cost of the increase of this technology with the expected benefit and the affordability at country and centre level).

Specific objectives:

- 1) analysis of the consistency of WP4 guidelines and/or proposed solutions with local legal and ethical framework
- 2) analysis of the sustainability of WP4 guidelines and/or proposed solutions with local legal and ethical framework
- 3) simulation of WP4 guidelines application in a selection of transplant centres.

This WP will also aim to verify the terms of applicability and sustainability within the legal and ethical framework of member states, of the guidelines developed and good clinical practices identified under WP4, at a national and local/hospital level.

Description

WP5 will encompass three tasks:

Task 5.1: analysis of coherence of the WP4 output with local legal and ethical framework.

The proposed solutions in WP4 will be derived from the comprehensive analysis and comparison of donor procurement and local procedures implemented by the competent authorities represented in this consortium.

- Task 5.2: analysis of affordability and sustainability of the WP4 outputs.

In collaboration with a subcontracted organization, ESOT will perform an analysis of the cost impact for healthcare services of the proposed guidelines and recommendations, as compared with the current standard of care.

- Task 5.3: Simulation of the applicability of WP4 output in a selection of transplant centres, representative of the spectrum of current practices and outcomes in the participating countries.

In order to define the applicability and feasibility of the guidelines and the proposed solutions developed as output of WP4, this WP will perform a simulation within an identified network of transplant centres with a diversity of volume of activity and performance.

STAFF EFFORT

Staff effort per participant						
<i>Grant Preparation (Work packages - Effort screen) — Enter the info.</i>						
Participant	WP1	WP2	WP3	WP4	WP5	Total Person-Months
1 - ESOT	19.50	19.50		20.50	20.50	80.00
2 - ISS - CNT	2.50	3.50	2.80	2.80	0.80	12.40
3 - ONT	0.66	1.30	15.13	5.00		22.09
4 - ST	2.00	2.00	6.50	8.50	12.70	31.70
5 - ET	0.65	1.25	3.25	0.60	0.40	6.15
6 - ABM	0.53	0.21	4.90	5.04	2.50	13.18
7 - OVSZ	1.00	0.50	17.00	2.00	2.50	23.00
8 - INSERM			14.20	1.05		15.25
9 - EPHA		9.25				9.25
Total Person-Months	26.84	37.51	63.78	45.49	39.40	213.02

LIST OF DELIVERABLES

Deliverables						
<i>Grant Preparation (Deliverables screen) — Enter the info.</i>						
<i>The labels used mean:</i>						
<i>Public — fully open (⚠ automatically posted online)</i>						
<i>Sensitive — limited under the conditions of the Grant Agreement</i>						
<i>EU classified —RESTREINT-UE/EU-RESTRICTED, CONFIDENTIEL-UE/EU-CONFIDENTIAL, SECRET-UE/EU-SECRET under Decision 2015/444</i>						
Deliverable No	Deliverable Name	Work Package No	Lead Beneficiary	Type	Dissemination Level	Due Date (month)
D1.1	Minute of the KoM	WP1	1 - ESOT	R — Document, report	SEN - Sensitive	3
D1.2	Intermediate EAB evaluation report	WP1	1 - ESOT	R — Document, report	SEN - Sensitive	15
D1.3	Final EAB evaluation report	WP1	1 - ESOT	R — Document, report	SEN - Sensitive	30
D2.1	Project website	WP2	1 - ESOT	DEC —Websites, patent filings, videos, etc	PU - Public	4
D2.2	Project brochure	WP2	9 - EPHA	R — Document, report	PU - Public	4
D2.3	First newsletter	WP2	9 - EPHA	R — Document, report	PU - Public	10
D2.4	Promotional Video	WP2	1 - ESOT	DEC —Websites, patent filings, videos, etc	PU - Public	10
D2.5	Second newsletter	WP2	9 - EPHA	R — Document, report	PU - Public	20
D2.6	Final layman report	WP2	9 - EPHA	R — Document, report	PU - Public	30
D3.1	Study plan of BRAVEST data collection, including GDPR compliance study	WP3	3 - ONT	R — Document, report	SEN - Sensitive	2
D3.2	BRAVEST study- oriented web-based platform	WP3	1 - ESOT	DEC —Websites, patent filings, videos, etc	SEN - Sensitive	6
D3.3	Survey on EU practices to ensure	WP3	7 - OVSZ	R — Document, report	PU - Public	10

Deliverables						
<i>Grant Preparation (Deliverables screen) — Enter the info.</i>						
<i>The labels used mean:</i>						
<i>Public — fully open (⚠ automatically posted online)</i>						
<i>Sensitive — limited under the conditions of the Grant Agreement</i>						
<i>EU classified — RESTREINT-UE/EU-RESTRICTED, CONFIDENTIEL-UE/EU-CONFIDENTIAL, SECRET-UE/EU-SECRET under Decision 2015/444</i>						
Deliverable No	Deliverable Name	Work Package No	Lead Beneficiary	Type	Dissemination Level	Due Date (month)
	sufficiency, safety and quality of Organs Transplant during the COVID-19 pandemic					
D3.4	Development of AI-based algorithm to predict SOT sustainability , quality and safety in time of crisis	WP3	8 - INSERM	R — Document, report	SEN - Sensitive	12
D3.5	Data analysis	WP3	8 - INSERM	R — Document, report	PU - Public	17
D4.1	Guideline on good clinical practice for building up resilient organ donation and transplant systems	WP4	2 - ISS - CNT	R — Document, report	PU - Public	22
D4.2	Report on identified solutions to increase continuity and safety of organ supply in time of crises	WP4	1 - ESOT	R — Document, report	SEN - Sensitive	22
D5.1	Results of the simulation	WP5	4 - ST	R — Document, report	SEN - Sensitive	29
D5.2	Sustainability and implementation plan	WP5	1 - ESOT	R — Document, report	SEN - Sensitive	29

Deliverable – Minute of the KoM

Deliverable Number	D1.1	Lead Beneficiary	1. ESOT
Deliverable Name	Minute of the KoM		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	3	Work Package No	WP1

Description
Minute of the KoM with the list of appointed EAB members.

Deliverable – Intermediate EAB evaluation report

Deliverable Number	D1.2	Lead Beneficiary	1. ESOT
Deliverable Name	Intermediate EAB evaluation report		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	15	Work Package No	WP1

Description
The document will provide a preliminary evaluation done by the EAB members on the performed activities and their suggestion for the way forward. The document will be drafted in English and made available to the consortium in electronic version (pdf) only.

Deliverable – Final EAB evaluation report

Deliverable Number	D1.3	Lead Beneficiary	1. ESOT
Deliverable Name	Final EAB evaluation report		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	30	Work Package No	WP1

Description
The document will provide an overall evaluation on the project outcomes. The document will be drafted in English and made available to the consortium in electronic version (pdf) only.

Deliverable – Project website

Deliverable Number	D2.1	Lead Beneficiary	1. ESOT
Deliverable Name	Project website		
Type	DEC — Websites, patent filings, videos, etc	Dissemination Level	PU - Public
Due Date (month)	4	Work Package No	WP2

Description
The website will be in English it will include 5 main sections: Home, Beneficiaries (with information about individual

beneficiary), Documents (work plan and deliverables), Events (JA events as well as related events), Resources (other initiatives or projects), Outreach, and Contact. It will be designed to be informative with clear language to ensure wide communication with diverse categories of stakeholders and external audience/general public. The private area of the website will contain working documents and confidential deliverables, as well as all other documents (presentation, minutes, agenda of the meeting), or dissemination and communication materials.

The website will include a link to the HaDEA, DG Sante and to all beneficiaries websites. The website will be established immediately at the start of the project and no later than month 4, and will be maintained for at least one year after the project ends.

Deliverable – Project brochure

Deliverable Number	D2.2	Lead Beneficiary	9. EPHA
Deliverable Name	Project brochure		
Type	R — Document, report	Dissemination Level	PU - Public
Due Date (month)	4	Work Package No	WP2

Description

The project brochure will describe the aim and expected outcomes of the project, its consortium and give visibility to EU funding. The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders.

A printable version in online PDF format will be available for the partners to use if needed at the in person events.

Deliverable – First newsletter

Deliverable Number	D2.3	Lead Beneficiary	9. EPHA
Deliverable Name	First newsletter		
Type	R — Document, report	Dissemination Level	PU - Public
Due Date (month)	10	Work Package No	WP2

Description

The first newsletter will include the activities from M1 to M10.

The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders.

The newsletters will be available on the project website.

Deliverable – Promotional Video

Deliverable Number	D2.4	Lead Beneficiary	1. ESOT
Deliverable Name	Promotional Video		
Type	DEC — Websites, patent filings, videos, etc	Dissemination Level	PU - Public
Due Date (month)	10	Work Package No	WP2

Description

The promotional video will describe project activities and main outcomes. The video will be in English and it will be made available on project website and beneficiaries website.

Deliverable – Second newsletter

Deliverable Number	D2.5	Lead Beneficiary	9. EPHA
Deliverable Name	Second newsletter		
Type	R — Document, report	Dissemination Level	PU - Public
Due Date (month)	20	Work Package No	WP2

Description
<p>The second newsletter will include the activities from M11 to M20.</p> <p>The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders.</p> <p>The newsletters will be available on the project website.</p>

Deliverable – Final layman report

Deliverable Number	D2.6	Lead Beneficiary	9. EPHA
Deliverable Name	Final layman report		
Type	R — Document, report	Dissemination Level	PU - Public
Due Date (month)	30	Work Package No	WP2

Description
<p>The final layman report will describe all project outcomes and their possible implementation. The final layman report will be prepared by all beneficiaries and in close collaboration with WP5 leaders.</p> <p>The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders as well as available on the project's website.</p>

Deliverable – Study plan of BRAVEST data collection, including GDPR compliance study

Deliverable Number	D3.1	Lead Beneficiary	3. ONT
Deliverable Name	Study plan of BRAVEST data collection, including GDPR compliance study		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	2	Work Package No	WP3

Description
<p>The Study protocol will include the list of variables to be collected, the methodology of analysis and a study of GDPR compliance for data collection. This last will take advantage of the already existing analyses performed by partners for similar studies performed in this specific field.</p>

Deliverable – BRAVEST study- oriented web-based platform

Deliverable Number	D3.2	Lead Beneficiary	1. ESOT
Deliverable Name	BRAVEST study- oriented web-based platform		
Type	DEC — Websites, patent filings, videos, etc	Dissemination Level	SEN - Sensitive

Due Date (month)	6	Work Package No	WP3
-------------------------	---	------------------------	-----

Description
Development of a dedicated electronic repository for the database.

Deliverable – Survey on EU practices to ensure sufficiency, safety and quality of Organs Transplant during the COVID-19 pandemic

Deliverable Number	D3.3	Lead Beneficiary	7. OVSZ
Deliverable Name	Survey on EU practices to ensure sufficiency, safety and quality of Organs Transplant during the COVID-19 pandemic		
Type	R — Document, report	Dissemination Level	PU - Public
Due Date (month)	10	Work Package No	WP3

Description
Document report in the English language on the different policies adopted by the individual EU SOT organisations for maintaining the SOT programs opened and running during the different pandemic phases.

Deliverable – Development of AI-based algorithm to predict SOT sustainability , quality and safety in time of crisis

Deliverable Number	D3.4	Lead Beneficiary	8. INSERM
Deliverable Name	Development of AI-based algorithm to predict SOT sustainability , quality and safety in time of crisis		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	12	Work Package No	WP3

Description
Report of the development of AI-based algorithm to predict SOT sustainability, quality and safety in time of crisis

Deliverable – Data analysis

Deliverable Number	D3.5	Lead Beneficiary	8. INSERM
Deliverable Name	Data analysis		
Type	R — Document, report	Dissemination Level	PU - Public
Due Date (month)	17	Work Package No	WP3

Description
Analysis of the data generated by task 3.1 and 3.2 aimed at predicting which are the main determinants of maintaining the SOT programs running and ensuring the best safety and quality during time of crisis.

Deliverable – Guideline on good clinical practice for building up resilient organ donation and transplant systems

Deliverable Number	D4.1	Lead Beneficiary	2. ISS - CNT
Deliverable Name	Guideline on good clinical practice for building up resilient organ donation and transplant systems		
Type	R — Document, report	Dissemination Level	PU - Public
Due Date (month)	22	Work Package No	WP4

Description
The guideline will be drafted in English and translated in the 27EU official languages. The document will be distributed in pdf format to all EU CAs and relevant stakeholders.

Deliverable – Report on identified solutions to increase continuity and safety of organ supply in time of crises

Deliverable Number	D4.2	Lead Beneficiary	1. ESOT
Deliverable Name	Report on identified solutions to increase continuity and safety of organ supply in time of crises		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	22	Work Package No	WP4

Description
The report will provide the basis for the cost-effectiveness analysis to be conducted under WP5. It will be drafted in English and made available in electronic format only.

Deliverable – Results of the simulation

Deliverable Number	D5.1	Lead Beneficiary	4. ST
Deliverable Name	Results of the simulation		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	29	Work Package No	WP5

Description
This deliverable will describe the outcome of the simulation performed in the identified hospitals. The document will highlight the pros and cons and any possible obstacles that hinders the adoption of the guidelines.

Deliverable – Sustainability and implementation plan

Deliverable Number	D5.2	Lead Beneficiary	1. ESOT
Deliverable Name	Sustainability and implementation plan		
Type	R — Document, report	Dissemination Level	SEN - Sensitive
Due Date (month)	29	Work Package No	WP5

Description
<p>Deliverable 5.2 will provide recommendations to Member states in order to implement the guideline in their national settings. The document will provide useful information related to the financial viability of implementing developed guidelines and proposed suggestions.</p> <p>D5.2 will include evaluation of the impact of the proposed guidelines in selected transplant centers from countries within and outside the consortium.</p>

LIST OF MILESTONES

Milestones					
<i>Grant Preparation (Milestones screen) — Enter the info.</i>					
Milestone No	Milestone Name	Work Package No	Lead Beneficiary	Means of Verification	Due Date (month)
1	Setting up of the EAB	WP1	1-ESOT	The EAB Members will be nominated and appointed by the General Assembly during the KoM. Minute of the meeting (D1.1) will report the composition of the EAB	3
2	Dissemination Strategy	WP2	9-EPHA	Submission of Deliverables D2.1 and D2.2.	4
3	Stakeholder involvement	WP2	9-EPHA	Distribution of project brochure and newsletter to the list of national and wider ESOT and EPHA stakeholders network.	15
4	Dissemination/exchange of good practices	WP2	9-EPHA	Distribution of good practice guidelines developed under WP4 to the list of national and wider ESOT and EPHA stakeholders network, medical/professional association and to the 27 EU Competent Authorities.	30
5	Finalization of data collection	WP3	3-ONT	All collected data will be made available to INSERM for the purpose of the study. If possible, a paper will be submitted for publication on Transplant International or other peer-reviewed paper	12
6	Distribution of survey	WP3	7-OVSZ	All beneficiaries will receive the link to fill the survey.	4
7	Setting up of working groups for guideline drafting	WP4	2-ISS - CNT	Established working groups will be communicated to DG Sante and HaDEA Officers through the Participant portal communication tool.	14
8	Approval of guideline table of content	WP4	2-ISS - CNT	The table of content will be shared with DG Sante	17

Milestones					
<i>Grant Preparation (Milestones screen) — Enter the info.</i>					
Milestone No	Milestone Name	Work Package No	Lead Beneficiary	Means of Verification	Due Date (month)
				Officers and communicated to HaDEA through the Participant portal communication tool.	
9	Selection of transplant centres	WP5	4-ST	The list of hospitals and reference persons will be made available to HaDEA through the Participant Portal communication service and the project coordination will also acknowledge DG Sante Officers with official communication.	20

LIST OF CRITICAL RISKS

Critical risks & risk management strategy			
<i>Grant Preparation (Critical Risks screen) — Enter the info.</i>			
Risk number	Description	Work Package No(s)	Proposed Mitigation Measures
1	Partner withdrawal from project consortium	WP4, WP5, WP3, WP1, WP2	Submission of amendment request to HaDEA due to budget reshape and redistribution of workloads among remaining beneficiaries.
2	Lack of active participation of the partners and consequent delay in project activities.	WP4, WP5, WP3	A proper timetable will be shared among the beneficiaries, WP leaders will report to the coordinator about any problem and the coordinator will take care of reminding the silent partner their contribution.
3	Partners do not agree on the principles or guidelines to be proposed.	WP4	Consortium meetings will be meticulously documented including the rationale for decisions. Rules will be agreed upon for how conclusions will be reached when the partners do not agree. EAB will play an important role in providing strategic guidance when decision making is difficult.

Critical risks & risk management strategy			
<i>Grant Preparation (Critical Risks screen) — Enter the info.</i>			
Risk number	Description	Work Package No(s)	Proposed Mitigation Measures
4	Guideline and other outputs are agreed but not implemented	WP4, WP5	A strong dissemination and communication plan will be built in order to involve relevant stakeholders and get them familiar with project activities and outcomes before project end.
5	Changes in the political and economic situations that could lead to staff changes	WP4, WP5, WP3, WP1, WP2	Most consortium partners represent long-standing scientific society, international organizations or National Ministries of Health. Should any new National setting affect the composition of the project consortium, measure foreseen for risk n.1 will be adopted.

PROJECT REVIEWS

Project Reviews			
<i>Grant Preparation (Reviews screen) — Enter the info.</i>			
Review No	Timing (month)	Location	Comments
RV1	16	External evaluation	Upon the request by PO



EU4Health Programme (EU4H)

Description of the action (DoA)

ANNEX1 - Part B

COVER PAGE

PROJECT	
Project name:	Building Resilience Against crisis: a systematic and global approach to adVance organ Safety and supply in Transplantation
Project acronym:	BRAVEST
Coordinator contact:	Luciano POTENA European Society for Organ Transplantation

TABLE OF CONTENTS

PROJECT SUMMARY	2
1. RELEVANCE	3
1.1 Background and general objectives	3
1.2 Needs analysis and specific objectives	4
1.3 Complementarity with other actions and innovation — European added value.....	6
2 QUALITY	7
2.1 Concept and methodology.....	7
2.2 Consortium set-up	7
2.3 Project teams, staff and experts	10
2.4 Consortium management and decision-making	14
2.5 Project management, quality assurance and monitoring and evaluation strategy	15
2.6 Cost effectiveness and financial management.....	16
2.7 Risk management	17
3 IMPACT	18
3.1 Impact and ambition	18
3.2 Communication, dissemination and visibility	18
3.3 Sustainability and continuation	19
4 WORK PLAN, WORK PACKAGES, TIMING AND SUBCONTRACTING	22
4.1 Work plan.....	23
4.2 Work packages and activities.....	24
4.3 Timetable	45
4.4 Subcontracting	47
5 OTHER.....	48
5.1 Ethics	48
5.2 Security	48
6 DECLARATIONS.....	48
6.1 Higher funding rate (if applicable).....	48
6.2 Double funding	48
6.3 Financial support to third parties (if applicable).....	48
HISTORY OF CHANGES	49

PROJECT SUMMARY

Project summary

Stemming from the lessons learned during the SARS-Cov2 pandemic, BRAVEST project aims at analysing organizational and management procedures in organ donation and transplantation, based on real-world evidence and cutting-edge analysis methodologies. This will allow to identify the most effective clinical practice; identify good clinical practice procedures; develop guidelines and propose sustainable innovative actions directed at improving the resilience of the donation and transplant systems and networks, ensure the continuity of supply of organs while maintaining the safety of donation and transplant, and ultimately increase the accessibility to transplantation for all patients with end-stage organ disease. Such resilience is meant to reinforce organizations, in order to cope with stress conditions, ranging from eventual additional epidemics, but also wars, earthquakes, ecological disasters, which are increasingly hitting several areas in Europe, as well as the world around.

1. RELEVANCE

1.1 Background and general objectives

Equitable access to solid organ transplantation (SOT) and the effectiveness of SOT as treatment for endo-organ disease are rooted in adequate supply of organs and on safety of organ procurement. In the past, EU developed action plans to achieve self-sufficiency in organ supply across member states, but these measures reached partial success highlighting wide variability in member states' response. In this context, where multiple operational, clinical and regulatory variables influence the ability of healthcare systems to procure and effectively allocate organs, the COVID-19 pandemic further amplified differences across Europe, ultimately limiting the access to care to many patients on transplant waiting lists.

The COVID-19 pandemic has been a stress test for the solid organ transplantation networks at multiple levels, significantly impacting procedures for organ recovery, transplantation and recipient management. In a limited time-frame, hospitals, transplant programs, and competent authorities had to adjust practices and procedures to face the management of a novel and unknown donor risk, unprecedented shortage of personnel for all transplant-related procedures, need for protection of recipients, and allocation of limited healthcare resources.

Intensive Care Unit (ICU) beds are, in general, a limited and expensive resource for all healthcare organizations: during the peaks of the pandemic waves, many hospitals dedicated most of their beds to the COVID-19 patients, with the consequent need to defer all other routine activities, including donation and transplantation. Organ procurement and transplantation have competed with COVID-19 as far as ICU beds occupation is concerned. Especially in those countries where Intensive Care to facilitate Organ Donation (ICOD) is routinely practiced, the usage of an ICU bed “only for the purpose of organ donation” in brain injured patients in whom treatments have been deemed futile, has become a critical issue. In some areas the “permanent emergency” status in healthcare organizations created by the pandemic because of the unpredictable relapses of the pandemic waves and exacerbated by the unusual personnel turnover had a tremendous impact in the hospital routine and a disruptive effect in all those pathways leading to organ donation and transplantation. The pandemic has proved once again that organ donation and transplantation are transversal to all departments within a hospital: conditions of unusual, overwhelming and prolonged stress in some crucial areas (ICU) and modifications in the usual management of time-dependent diseases will necessarily interfere with the conduction of the donation processes.

These tasks have been tackled with a wide variability of actions and outcomes across EU Member States and within single countries, depending on pandemic pressure, local healthcare organization, and resources availability: in some areas transplantation activity had to be completely withheld, while in others the system showed greater resilience and continuity of supply of organs was ensured, granting the accessibility to transplant at least for the sickest candidates (Aubert O, Yoo D, Zielinski D, et al. COVID- 19 pandemic and worldwide organ transplantation: a population-based study, *The Lancet Public Health* 2021. [https://doi.org/10.1016/S2468-2667\(21\)00200-0](https://doi.org/10.1016/S2468-2667(21)00200-0); Global Observatory on Donation and Transplantation. Available at: <http://www.transplant-observatory.org/> last access September 2021). Eventually, from the Newsletter Transplant 2020 (EDQM, 2021 - in press) we learnt that in the EU-28 transplantation activities decreased by about 18% in 2020 compared with 2019. Evolution by transplant type is the following:

Kidney: 16,890 vs 21,235 (- 20,46%)

Liver: 6,917 vs 7,900 (- 12,44%)

Heart: 2,081 vs 2,269 (- 8,29%)

Lung: 1,740 vs 2, 136 (- 18,54%)

Pancreas: 548 vs 710 (- 22,82%)

Small bowel: 36 vs 35 (+2,86%)

Total: 28,212 vs 34,285 (- 17,71%)

In this project we aim to analyze the factors that have influenced the organ procurement processes before, during and after the onset of SARS-CoV2 pandemic, focusing on specific clinical features of the donors, outcomes of the allocation procedures, and operational protocols and practices put in place to ensure safety and continuity of supply of organ donation. In particular we will compare procedures and practices for organ procurement and risk management before, during and following the pandemic peaks. The rate per million inhabitants of donor signaled and procured, the organ successfully transplanted and the recipient short term outcome will be the main outcome measure. Of note, this analysis will focus also on recipient management

procedures during the pandemic, aiming to capture adverse events related to the donation process, and the obstacles faced by transplant candidates to be allocated an available organ during the pandemic (i.e. transplant programs unable to accept available organs because of lack of personnel).

Data analysis based on artificial intelligence algorithms will allow us to derive evidences that, integrated with existing published data, will support the production of documents for good clinical practice procedures, guidelines and **proposing sustainable innovative actions directed at improving the resilience of the donation and transplant systems and networks**, ultimately favoring a more equitable access to transplantation for all patients with end-stage organ disease. Such resilience is meant to reinforce organizations, in order to cope with stress conditions, ranging from eventual additional epidemics, wars, earthquakes to ecological disasters, which are increasingly hitting several areas in Europe, as well as around the world.

1.2 Needs analysis and specific objectives

COVID 19 pandemic was a stressor to transplant organizations proving that, when limited economical and logistical resources are allocated according to the best interest of public health, aiming to cover the vast majority of the population, donation and transplantation are not immune from the effects of such a resource redistribution. Donation and transplantation processes are considered as excellence areas within each organisation, but keeping these systems alive is costly, not only from an economical perspective, but also in terms of organization. This need was especially stressed in the discussion of relevant literature, which analyzes the trends in organ donation and transplantation in the EU during the period 2009-2015 (Van der Spiegel, S., Schröder-Back, P., Brand, H. Organ transplantation and the European Union 2009-2015, *Transpl Intern* 2020, 33: 603-611) and the different activity trends during the pandemic analyzed by Aubert et al, 2021 confirm the importance of the organizational strategies, while this same paper reports the unbearable burden of more than 48000 lost patient life-years by comparing patients remaining waitlisted with those transplanted for each organ.

Medical practice can reveal opportunities to improve public health. This project is meant to supply evidence-based, clear, agreed-upon and tested inputs to Member States in order to make organizational capacity in this specific health-care system resilient to predicaments. BRAVEST will achieve this goal by a three-step approach (developed by WP3, WP4 and WP5) which includes 1) gathering of the evidences and multiparametric analysis of the efficiency in pandemic management by the project partners (WP3: M1-M17), 2) interpretation of the data and development of specific recommendations in form of evidence-based guidelines (WP4: M13-M22), and 3) analysis of the sustainability of the proposed measures (WP5: M20-M29). The actions to be taken and their details will therefore be the main output of this project.

In the recent past, based on the specific pattern of a pandemic spread and/or pressure on the health system in terms of numbers of affected cases, hospital occupancy, ICU availability and mortality, each Competent Authority in different Countries has reacted independently with the development of policies, regulations, recommendations and guidelines, with the ultimate goal to preserve transplant activity without affecting the global well-being and taking into account the available resources. A number of documents have been released in relation to the management of the deceased donors, the prioritization and selection of transplant recipients, the access to transplantation for patients affected by end-stage organ disease, and the appropriate follow-up care for the transplant patients. A crucial aspect of the production of multiple procedures and guidelines by different Competent Authorities was the lack of synchronization, the absence of a structured sharing of information among Countries, whereas a prompt connection and dissemination of the information acquired by the Countries on the basis of their current status as well as the subsequent reactions during a fast-changing environment would have been desirable. For this purpose, the creation of a common platform to share among Countries information regarding: 1. COVID-19 data and health resources utilization, 2. country-specific recommendations and policies, 3. results on donation and transplantation activities of the application of such policies - would be of a great help, in order to be able to predict evolution of activity under stress conditions.

BRAVEST consortium will allow to collect data from 11 countries (ES, ITA, FRA, SLO, HUN plus the rest EuroTransplant area). The countries represented showed in 2020 a wide span of transplant activity, ranging from 32.4 to 92.2 transplants per million population (as reported in <https://www.statista.com/statistics/537926/total-number-of-patients-transplanted-in-europe/>). BRAVEST consortium will therefore be able to exploit the impact of the project results also to countries with low transplantation rate, and not included in the current consortium. In this specific setting, the sustainability analysis of the good clinical practice guidelines that will be implemented will provide a key exploitable outcome for the benefit of those countries.

The specific objectives, related to performance indicators, are specified in the following table:

WP3	
Specific Objective Number	3.1
Specific Objective	Feeding a repository of data about impact of COVID-19 on SOT programs in European countries (period 2018-2019 vs pandemic period).
Indicator	Target
Collection and analysis of identified variables	Data collected from at least 7 countries.
Specific Objective Number	3.2
Specific Objective	Implementing a survey of the procedures implemented during COVID-19 pandemic at national/regional level.
Indicator	Target
Collection of documents and data	Data collected from at least 7 countries
Specific Objective Number	3.3
Specific Objective	Developing an AI algorithm to predict main determinants of transplantation activity
Indicator	Target
Number of algorithms developed for analysing collected data.	1 algorithm developed and applied to available data.

WP4	
Specific Objective Number	4.1
Specific Objective	Identifying a common approach for donor screening, recipient selection, waitlist access, follow up recommendation.
Indicator	Target
Number of guidelines approved	1 common approach document approved by the consortium.
Specific Objective Number	4.2
Specific Objective	Develop a set of proposed solutions for improving quality and safety of organ supply and subsequent transplantation.
Indicator	Target
Number of solutions developed	At least 2 possible solutions described and analysed in detail
Specific Objective Number	4.3
Specific Objective	Provide guidance for staff organization of transplant units in response to crisis.
Indicator	Target
Percentage of consensus reached by experts and Competent Authorities concerning staff organization of transplant units in response to stress conditions	90% of participants approving the specific guidance

WP5	
Specific Objective Number	5.1
Specific Objective	Analysis of consistency of WP4 guidelines and/or proposed solutions with local legal and ethical framework.
Indicator	Target
Number of countries where the consistency of WP4 guidelines and feasibility of proposed solutions is tested	Analysis performed for at least 4 countries
Specific Objective Number	5.2
Specific Objective	Analysis of the sustainability of WP4 guidelines and/or proposed solutions with local legal and ethical framework.
Indicator	Target
Number of countries where the analysis is performed	Analysis to be performed for at least 4 countries
Specific Objective Number	5.3
Specific Objective	Simulation of WP4 guidelines application in a selection of transplant centres.
Indicator	Target
Number of centres where simulation of guidelines application is performed	Simulation performed in at least 3 transplant centres from different geographical areas of the EU

1.3 Complementarity with other actions and innovation — European added value

The project will take full advantage of the activities carried out under a series of projects and joint actions, funded under previous editions of Public Health program, namely:

- ODEQUS (2010-2013), aimed at identifying a system of quality criteria and quality indicators for organ donation to be used as tool for hospital self-assessment, external evaluation and developing audit models. (Manyalich, M. Guasch, X, Gomez, MP, Páez, G, et al, Organ Donation European Quality System: ODEQUS Project Methodology. *Transpl. Proc.*, 45 (10), 2013, 3462- 3465);
- COORENOR (Coordinating a European initiative among national organizations for organ transplantation-2010-2012) meant to establish a coordinated network between national programmes existing in the participating European Member States in the field of organ transplantation and including activities to investigate, compare and benchmarking transplantation programs;
- MODE (2011-2012), the main objective of which was the transfer of best-practices in the field of organ donation and transplantation and the creation of positive synergies among participating Member States apt to support authorities in possible decision-making and policy contexts (Di Ciaccio, P., Ferraro, C., Brezovsky, P. et al. The joint action MODE (Mutual Organ Donation and Transplantation Exchanges): a sound contribution to implementation of health policies in organ donation and transplantation. *Arch Public Health* 71, 3 (2013));
- ACCORD (Achieving Comprehensive Coordination in Organ Donation throughout the European Union - www.accord-ja.eu), aimed at developing and testing methods for improving end-of-life management that promotes organ donation, as well as at implementing practical collaborations between European Union countries for the transfer of knowledge and expertise, by developing an authorization and audit system for transplant centres (<http://www.accord-ja.eu/>);
- FOEDUS (Facilitating Exchange of Organs donated in EU member states), aimed at improving daily practices of cross-border organ exchanges removing identified barriers whenever possible and eventually increasing bilateral and multilateral agreements.

The undeniable novelty of this project relies on strong partnership between the in-the-field professional society and a number of Competent Authorities (CAs), which have indeed taken part in most, if not all, the above-mentioned projects. While ESOT ensures frontline expertise and knowledge as well as direct contact to virtually all EU professionals, CAs can contribute with targeted initiatives of policy making. Transfer of results and best practices on a full EU dimension is on one side guaranteed by ESOT coverage, on the other by the role played by participating CAs and their representatives within the network of national CAs. Models to develop resilience versus predicaments are among the project results, which the consortium aims at disseminating through a network of centres. A special attention for transfer of results will be devoted to the Eastern Europe area, thanks to the participation of some relevant CAs.

2 QUALITY

2.1 Concept and methodology

The past experience led so far in the field of organ donation and transplantation from an international perspective has proved that EU funding can serve as propellant for transfer of best practices (Van der Spiegel et al, 2020), even if some aspects of healthcare fall exclusively under the aegis of national mandates. The synergy between expertise of supranational technical working groups and the European network of Competent Authorities have contributed to an indisputable growth of activities, which needs however still to be strengthened and in some cases fostered. BRAVEST approach is grounded in the partnership among professional associations and Competent Authorities (CAs), which will combine efforts in order to:

- 1) gather reliable, complete information of:
 - a. The clinical features and epidemiology of solid organ donors and transplantation activities performed in the period 2018-2022;
 - b. the impact of the COVID-19 pandemic on the healthcare and Intensive Care Unit (ICU) systems in the respective region/country during the different waves;
 - c. the procedures implemented by the EU participating countries during the pandemic to ensure the continuity of the transplant program.
- 2) develop an AI algorithm to predict main determinants of transplantation activity with specific focus on the contribution of COVID-19 pandemic as a covariate
- 3) develop agreed-upon guidelines and good practices to be shared among clinicians and policy makers and a set of possible solutions for
 - a. ensuring continuity of care delivered to patients;
 - b. improving safety, quality and transparency of existing procedures;
 - c. fostering continuity of supply of organs in precarious conditions.
- 4) analysis of the sustainability of the proposed measures.

Professional expertise will guarantee the quality of solutions, whereas commitments by CAs can pave the way to prospective implementation. A pilot test of guidelines and solutions will be carried out in a number of selected centres, where sustainability issues and cost-effectiveness of proposed approach will be analysed as well.

Guidelines will be developed by ESOT by means of working groups involving members from ESOT scientific community and representatives of the partnering competent authorities, as well as representatives of relevant countries not involved in the consortium, with a specific focus on countries with low transplant activity, in order to ensure the widest applicability of the recommendation.

2.2 Consortium set-up

The Consortium gathers 9 Participants from Belgium, France, Hungary, Italy, Slovenija, Spain, the Netherlands. It has an excellent geographical coverage in all the main areas of Europe (northern, central, western, eastern and southern).


The main feature of partners is their nature of institutional and/or governmental bodies (ONT, ISS-CNT, ABM, ST, OVSZ: all EU Organs Competent Authorities) or scientific/professional/academic institutions (ESOT, EPHA, INSERM), that are playing their role in the organ donation and transplantation field, both at national and international level. In addition, one supranational Organ Exchange Organization, Eurotransplant, is also

taking part with an undeniable added value, to be able to broaden consortium coverage, thanks to their expertise and competence as hub of organ allocation in 8 EU countries (Austria, the Netherlands, Luxembourg, Belgium, Germany, Croatia, Slovenia and Hungary).

Moreover, the proposed consortium is made of several partners that have fruitfully cooperated for many years together in the context of the European Organ Exchange Organizations, in the CD-P-TO group of experts of the Council of Europe and within the network of Competent Authorities set up under Directive 2010/53/EU. Therefore, the action also takes advantage of such a high level of experience and interdisciplinary collaboration for the promotion of proper use of organs harvested for national and international purposes. Most of the organizations have then a consolidated experience in sharing their expertise in the field of organ donation and transplantation, in projects such as DOPKI (Improving Knowledge of Potential Organ Donation 2006-08 - VI FP), ALLIANCE O (Alliance for Organ Donation 2004-07 - ERANET VI FP), ETPOD (European Training Program on Organ Donation 2007-09 - Public Health), EFRETOS (European Framework for evaluation of Organ Transplantation, 2009-2011 - Public Health), COORENOR (Coordinating a European Initiative among national organizations for organ transplantation, 2010-12 - Public Health), Joint Action MODE (Mutual Organ Donation Exchanges 2011- 12 - Public Health) and FOEDUS (Facilitating exchange of organs donated in EU Member States, 2008- 2013 - Public Health).

Eventually, within the consortium the South Alliance for Transplant is also represented. SAT was inaugurated in Rome on October 1st, 2012. The national organizations for organ transplantation of France, Italy and Spain joined the forces to increase and implement the cooperation between National Transplant Agencies in the South-West of Europe. It is actually composed by 7 countries, five members namely France, Italy, Spain, Portugal and Greece and two observers Czech Republic and Switzerland with their respective national competent authorities. It covers a population of almost 212 million inhabitants. Over the years SAT members have consolidated some relevant activities such as: the exchange of surplus organs for pediatric and adult patients in the absence of a national recipient and sharing organ requests for urgent pediatric patients through the FOEDUS platform for organ exchanges; hosts an international paired exchange living kidney programme among its members; organize a training course for liver surgeons.

MS and Organizations in the project



Beneficiaries:

The project will be coordinated by the **European Society for Organ Transplantation (ESOT)**, an influential international non-profit organisation of over 1500 active members from around the world, founded over 30 years ago with headquarters in Amsterdam (NL), under which organ transplant activities are structured in Europe and worldwide. ESOT's core mission is to facilitate international clinical trials and research collaborations, to promote educational programmes, sharing of scientific information and building of evidence-based international practice and medical guidelines, and to foster changes in European policy, in order to

reach its primary aim: improving patient outcomes in transplantation. Moreover, ESOT has decided to strengthen its engagement in the collection of data on organ transplantation, and is launching a platform to host pan-European registries on transplant recipients and living donors. It will bring in the project the right expertise ([see list of contributing experts](#)) and the resources involving some of its different “souls” (The European Kidney Transplant Association “EKITA”, The European Platform on Ethical, Legal and Psychosocial Aspects of Organ Transplantation “ELPAT”, The European Donation and Transplant Coordination Organisation “EDTCO”).

The European Public Health Alliance (EPHA) will co-lead WP2 together with ESOT. Since its formal establishment in 1993, EPHA has built a solid network of 80 members (public health NGOs, patient groups, health professionals and disease groups) dedicated to providing better health for all. It is an International non-for-profit Organization under Belgian law. It monitors the policy making process within the EU institutions and supports the flow of information on health promotion and public health policy developments amongst all interested players including: politicians, civil servants, NGOs, stakeholders and the public. It participates in policy debates and stakeholder dialogues to raise the profile of health in all policy areas, supporting collaboration and partnerships between non-governmental organisations and other organisations active at European, national and local level on health promotion and public health.

The Spanish National Transplant Organization, **Organización Nacional de Trasplantes (ONT)** has experience in data collection in the field of organ donation and transplantation for the Council of Europe, (Newsletter Transplant) and the World Health Organization (Global Observatory on donation and transplantation - GODT). Along with the Paris Transplant Group (INSERM), ONT will be in charge for the data collection and analysis part, carrying out the WP3. ONT is the technical coordinating institution that belongs to the Spanish Ministry of Health. The ONT coordinates donations and transplantations performed on a national scale, assuring the best use of cells, tissues and organs in accordance with the principles of cooperation, efficacy and solidarity. Its main objective is to promote altruistic donations with the sole goal that each Spanish citizen who needs a transplant will have the best chance to obtain it. The ONT also acts as a service agency for the national health system, promoting a continuous increase of availability of cells, tissues and organs for transplantation. Since the creation of ONT in 1989, Spain has progressively reached the highest rate of organ donation thanks to the implementation of the so-called Spanish Model. This model takes into consideration key measures for the success of the transplant system. Thus, the Spanish Model has become the international reference when facing the problem of scarcity of organ donors. Finally, ONT cowork the European Committed on Organ Transplantation of the Council of Europe (CD-P-TO) to produce the Newsletter Transplant, a comprehensive statistical transplant database, providing essential information for the sake of transparency and international benchmarking.

The **Paris Transplant Group (research unit which is part of INSERM)** has developed its network for more than a decade and now collaborates with more than 13 centres and hospitals in France, 12 centres in 6 countries in Europe, 14 centres in 4 countries in America on more than 30 different projects. Its first step is to create an accurate landscape of the heterogeneity of a transplant's function, disease, activity, stage and response to therapy. The second one is to provide transplant clinicians with innovative and accessible tools for early prediction of individual risk of allograft rejection and transplant loss, offer them the possibility to personalize clinical management and treatment and improve transplant outcome. The final product is being developed as an integrated diagnostic system in the form of a diagnostic/prognostic score.

The **Italian National Institute of Health with the Italian National Transplant Centre (ISS-CNT)** will help ESOT to co-lead the WP4 on Guidelines and prospective solutions for building up resilient organ donation and transplant systems, and participating in all the other WPs. ISS is a public technical and scientific body of the Italian NHS, under the control of the Ministry of Health. ISS major activities include the management and coordination of research activities and it acts as consultant for the Ministry of Health, for the government and regions. CNT is a technical body of the Ministry of Health; it was set up under the Law 91 of 1999 and it is located at the ISS where it performs its activities as a department of the same body. It acts as Italian Competent Authority for Organs, Tissues and Cells, coordinates all activities regarding donation, allocation and transplantation of organs; donation, banking and transplantation of tissues; waiting lists of patients. It manages the Transplant Information System, where data regarding donation, allocation and transplantation of organs are collected, including transplanted organ quality, defines protocols about safety and security of organ donation and criteria for operational protocols for organ and tissue allocation, allocation of organs for urgencies and national programs. It fixes parameters for transplant quality assessment, promotes information campaigns for the general public, in collaboration with the Italian Health Ministry and patients' Associations, promotes and develops training courses regarding organ donation. Both ISS and CNT have vast experience in project participation and coordination.

Slovenija Transplant (ST) will be the leader of WP5. Established in 2000, the institute is an independent public body and operates as a national competent authority, central coordination office and it is responsible for all aspects of organ donation and transplant activities on a national level (as defined by national law) and cooperation with international institutions. For 21 years, ST manages cooperation with Eurotransplant. Organizational, scientific, legislative, educational and ethical aspects are covered by professionals in related fields. Special attention is devoted to the communication, promotion of organ donation in the general public for increasing public awareness and supporting non-profit and transparent donation and transplantation. Memberships in most prominent international professional committees, extensive publications record, active participation at international conferences and cooperation in more than 15 EU projects has given ST an equal footing in the international arena. In 2020, ST has made numerous actions leading to successful management of the covid-19 crisis. In Slovenija, deceased donation programmes remained active, the number of deceased donors and transplantations was even higher compared to 2019.

Other beneficiaries contributing to project tasks and outcomes: **OVSZ (Országos Vérellátó Szolgálat)**, is the Hungarian National Blood Transfusion Service and especially the Transplantation Directorate is the National Competent Authority, the National Organ Procurement Organization, and the Eurotransplant contracting partner. It is responsible for the coordination of organ donation and transplantation, for the international organ exchange, for the management of organ transplant waiting lists and for the maintenance of the National Organ Donation and Transplant Follow-up Registry. OVSZ participated in numerous EU co-funded projects before (DOPKI, ACCORD, COORENOR, MODE, FOEDUS, EDITH) and was responsible for the dissemination WP in some of them. It proposed regular consultations between the Competent Authorities of the Eurotransplant MS at the beginning of the COVID-19 pandemic, agreeing on the epidemiological measures of the Member States related to organ donation and exchange and also deciding on common procedures. In addition, OVSZ has developed and updated a national standard operating procedure for organ donation during COVID-19. This experience will be helpful for the WP3, Task 2. Some activities foreseen under WP5 - namely inputs on the sustainability and potential cost effectiveness of the procedures and processes that will be subcontracted, given the lack of specific expertise within the consortium.

Eurotransplant Foundation (ET) is responsible for the allocation of donor organs in Austria, the Netherlands, Luxembourg, Belgium, Germany, Croatia, Slovenija and partially Hungary. This international collaborative framework includes all transplant hospitals, tissue-typing laboratories and hospitals where organ donations take place. Eurotransplant is fully connected with the members of its community. The organization successfully led EFRETOS project and took part in DGINFO EUODONOR and EUROCET.

The **French Agence de la biomédecine (ABM)** is the Competent Authority for organ transplantation. Among its missions are the management of waiting lists, rules of allocation, procurements and allocation in France/abroad and evaluation of transplantation activities. ABM has a long history of supporting transplantation systems in Maghreb and in Eastern Europe, and was the coordinator of "Alliance-O", the first EU funded transplantation project. Since, ABM participated in numerous European projects, contributing to the harmonisation of European practices.

Additionally, Prof Ray Vanholder, President of the **European Kidney Health Alliance (EKHA)** will act as **external expert** contributing to the dissemination actions of the project. EKHA is a Non-Profit Association under Belgian law since 2019. It is a common effort by stakeholders to propose solutions for the challenges of chronic kidney diseases in Europe through effective prevention and a more efficient care pathway intended to facilitate the provision of appropriate and affordable kidney care to all Europeans equally, while promoting the highest quality of care. Moreover, EKHA was instrumental in the EU-funded EDITH project, assessing differences in uptake of kidney replacement therapies including transplantation in Europe. EKHA also coordinated the EU-commissioned Joint Statement on improving organ donation and transplantation throughout Europe (2020) (see below section 2.3).

2.3 Project teams, staff and experts

Project teams and staff

Name and function	Organisation	Role/tasks/professional profile and expertise
Luciano Potena	ESOT	MD PhD, Medical Director Heart Failure and Heart Transplant Program/ESOT President
to be nominated	ESOT	part time coordinator
Giovanna Piantella	ESOT	Administrative coordinator

Name and function	Organisation	Role/tasks/professional profile and expertise
Devi Mey	ESOT	Chief Executive Officer
Umberto Cillo	ESOT	ESOT Secretary
Agata Petcov	EPHA	Finance and Administration Manager
Milka Socolovic	EPHA	Director General
Aleksandar Socolovic	EPHA	Senior Development Consultant Membership, Funding & Governance
Olga Polyeva	EPHA	Junior Communications Manager
Beatriz Dominguez-Gil	ONT	Director General, MD PhD, Project manager. Coordination of the ONT participation in the project
Elisabeth Coll	ONT	MD PhD, senior expert in data analysis
Beatriz Mahillo	ONT	MD PhD, senior expert in data analysis
Itziar Martinez	ONT	Nurse. Expert in data analysis
Lola Perojo	ONT	Technician. Technical personnel. Support to ONT tasks in the project. Communication/dissemination. Technical and administrative tasks
Carmen Lefaucheur	INSERM	Senior Expert
Alexandre Loupy	INSERM	Senior Expert
Maud Racape	INSERM	Project Manager
to be hired	INSERM	Biostatistician
to be hired	INSERM	Data Manager
Massimo Cardillo	ISS-CNT	CNT Director
Davide Stabile	ISS-CNT	Medical expert
Paola Di Ciaccio	ISS-CNT	Senior Project manager
Claudia Carella	ISS-CNT	Technical coworker- project assistant
Maura Mareri	ISS-CNT	Technical coworker - project assistant
Danica Avsec	ST	Director of Slovenija-transplant, Senior expert and project manager, trainer, expert in quality of OD, OD policy, communication, ethics, chair of UEMS, European Board of Surgery and ETCO (2018-2021)
Andrej Gadžijev	ST	MD, Specialist of traumatology, lead of quality assurance programme
Ana Simenc	ST	PhD in cultural/medical anthropology, an experienced researcher, trainer, expert in communication, social aspect of OD, social media manager
Sandor Mihaly	OVSZ	Director of Transplantation at the Hungarian National Blood Transfusion Service (OVSZ).
Orsolya Deme	OVSZ	Senior National Coordinator
Emese Holtzinger	OVSZ	National Coordinator
Serge Vogelaar	ET	Medical director
to be confirmed	ET	Member Medical Staff
Jacqueline Smit	ET	Biostatistician

Name and function	Organisation	Role/tasks/professional profile and expertise
to be confirmed	ET	Data Manager
to be confirmed	ET	Registry employee
to be confirmed	ET	Communication consultant
to be confirmed	ET	Manager Finance
to be confirmed	ET	Executive Secretary
Danic Avsec	ST	Senior expert and project manager
Andrej Gadžijev	ST	MD, Specialist of traumatology
Jana Simenc	ST	PhD in cultural/medical anthropology is an experienced
Barbara Uštar	ST	BA works as a professional associate at ST
Samuel Arrabal	ABM	Head of Research Department, Leader of the project coordination team for ABM.
Petra HESKY	ABM	Assistant – Research Department, Project coordinator providing support to experts with organizational and administrative tasks.
Haidetou GANDEGA	ABM	Financial controller, Financial advisor and controller for all budget-related questions regarding the project
to be nominated	ABM	Deputy General Director for Medical and Scientific Policy, Medical director providing expertise regarding medical and scientific policies.
Nigel STRANG	ABM	Medical Informatics Advisor, Project coordinator providing support to experts with organizational and administrative tasks.
Sophie LUCAS SAMUEL	ABM	Head of Quality and Safety Department, Expert on quality and safety of organs, tissues and cells.
François KERBAUL	ABM	Head of Organ and Tissue Transplant Department, Expert in ICU care before and after transplantation, organ allocation, medical transportation logistics, preservation of grafts and ethics.
Richard DORENT	ABM	Expert in heart and lungs transplantation
Corinne ANTOINE	ABM	Referent physician for Liver and Small Bowel Transplant, Expert in kidney, liver and small bowel transplantation.
Myriam PASTURAL	ABM	MD Transplant Strategy Division, Expert in kidneytransplantation.
Aurélie DESHAYES	ABM	Head of Data Quality Department, Expert in management, quality and extraction of data.
Camille LEGEAI	ABM	Head of Biostatistics and Evaluation Department, Expert in epidemiology conducting all statistical analysis for the Agency.
Biostatistician (to be hired)	ABM	Expert in collecting, analyzing, and summarizing the data

Outside resources (subcontracting, seconded staff, etc)

Three subcontracts are foreseen to perform the following activities:

1. WP5 cost analysis: an external expertise is needed to carry out this activity due to the lack of internal experts
2. IT company to set up the BRAVEST study-oriented web-based platform. As for the first subcontract this is due to the lack of internal expertise
3. Medical Writing: the developed guideline will be revised according to scientific guideline requirements.

Experts (if applicable)

Prof. Raymond VANHOLDER, President of EKHA (European Kidney Health Alliance) and chair of European Chronic Disease Alliance, will be involved in the project as an expert for WP2 activities. He will focus on the dissemination strategy, providing his expertise to identify the right target audiences/groups and end users. He is particularly skilled in relationship with the organ transplant international stakeholders, having been in the past chairman of: the European Uremic Toxin Work Group (EUTox), the European Renal Best Practice (ERBP), the Renal Disaster Relief Task Force (RDRTF) of the International Society of Nephrology (ISN), and member of the Executive Board and treasurer of Kidney Disease Improving Global Outcomes (KDIGO). He was founding president of the Belgian Society of Nephrology (BVN-SBN), and past president of the European Society of Artificial Organs (ESAO) and ERA-EDTA. He is now retired as Prof Em at Ghent University, but the choice of an expert in organ transplant communication fell on him taking into account his presentation on October 2019 at the EU Health Policy Platform Annual Meeting in Brussels of the Joint Statement entitled “A Shared Vision for Improving Organ Donation and Transplantation in the EU”, the main output of the EKHA-led 2019 Thematic Network, developed in conjunction with National Competent Authorities, transplant organisations, medical professionals and patient associations, and endorsed by co-signing organisations and Members of the European Parliament to describe practical possibilities and provide recommendations to positively influence organ donation and transplantation rates, and prevalence of patients living with a functioning transplant throughout Europe. Moreover, with the same Network he published a Roadmap presenting an outline of the challenges to increasing transplantation rates. Organ donation and transplantation: a multi-stakeholder call to action. *Nature Reviews Nephrology* (17): 554–568 (2021).

The following members of different ESOT Committees will take part in the design of the study, validation of the results as well as in drafting and finalization of the guidelines (WP3-WP4):

Lucrezia FURIAN is EKITA Chair (2021-2023) and Associate Professor of Surgery at the Department of Surgical Oncological and Gastroenterological Sciences, University of Padua, Italy. She received part of her training in the USA as Research Fellow and Clinical Transplantation Fellow at the University of Texas at Houston. Dr. Furian has performed basic research in tolerance induction and signal transduction pathways, with particular interest on IL-2 receptor signaling inhibition by antisense technology, new immunosuppressive drugs (Jak3 inhibitors), and murine models of humoral and cellular rejection in Stat4,5 a/b, 6 knockout. Her clinical and experimental research activities include xenotransplantation, organ preservation, pancreas transplantation, extended criteria donors and kidney paired donation. Prof. Furian's clinical and surgical activity is particularly focused on kidney and pancreas transplantation and laparoscopic and robotic nephrectomy of living donors.

Gianluigi ZAZA is a member of EKITA Board. The scientific activity of Prof. Zaza, Chief of the Renal Translational Research Group of the University of Verona, resulted in more than 100 publications in national and international journals (80 articles published in peer-reviewed journals and included in the Scopus and Web of Science database) on the following research fields: 1. Recognition of biological elements regulating chronic inflammation and oxidative stress in patients with chronic kidney disease in conservative and dialysis treatment; 2. Study of mitochondrial oxidative phosphorylation system in circulating inflammatory-immune cells of uremic patients; 3. Identification of new diagnostic biomarkers for organ transplant complications, glomerular diseases, tubule-interstitial renal diseases and systemic transplant comorbidities; 4. Selection of key biological elements involved in delayed graft function (DGF) by using microarray technology associated with classical biomolecular research methodologies; 5. In vitro and in vivo definition of the biomolecular machinery associated with the onset and development of organ fibrosis and chronic allograft dysfunction in renal transplant patients undergoing immunosuppressive treatment (in particular mtor inhibitors); 6. Development of biomarkers for IgA nephropathy and Medullary Sponge Kidney Disease (MSK); 7. Pharmacogenomics/genetics of the main immunosuppressive agents employed in renal transplantation.

David CUCCHIARI is ESOT- EKITA member. He is consultant Nephrologist in the Department of Nephrology and Kidney Transplantation of the Hospital Clínic of Barcelona, Spain. He is especially implicated in kidney transplantation from both living and cadaveric donors, with a focus on high immunological risk patients. He received his medical training at the University of Milan and his Specialty in Nephrology at the Humanitas Clinical and Research Center also in Milan. From 2016 he moved to Barcelona where he completed his specialty training and finally earned his PhD in Medicine and Translational Research in 2020. He is involved in different research projects, both clinical and experimental, and he is member of additional national and international societies, including ERA-EDTA, the Catalan Society of Transplantation and the Italian Society of Nephrology.


Giuseppe FELTRIN, MD, PHD is a board member of EDTCO (the European donation and transplant coordination organization) of ESOT and treasurer of SITO (Italian Society for Organ Transplantation) and will

be involved in the project as an expert for WP3 activities. He is a specialist in cardiac surgery, working in heart transplantation for nearly twenty years. More recently he was appointed as the regional transplant coordinator of Veneto region. With 5 million inhabitants and 10 active transplantation programs Veneto is among the first procurement and transplantation areas of Italy. During his mandate in Veneto, Dr Feltrin has started ICOD and DCD programs, contributing to a significant increase in donor procurement in the area. Dr. Feltrin has developed particular skills in the analysis of the major determinants of the procurement performances within complex health organisations with a main focus on the analysis of the organizational interactions leading to successful hospital donation pathways. Dr Feltrin works in a strict institutional and scientific cooperation with CNT, the national competent authority.

2.4 Consortium management and decision-making

Management activities are needed to ensure that the overall project will work as a whole and will be greater than the sum of its parts. The following paragraph details the planned management structure, the distribution of responsibilities, communication flow, decision making procedures and conflict management.

Two different levels of management (Steering and Executive) will be adopted to ensure an effective control of the project in terms of activities, time, resources and costs, and to ensure prompt reaction to all issues that may arise during the project.



The management organisation is composed by the following bodies (represented in the figure):

- The **Coordinator** will be ultimately responsible for the overall project coordination and acts as intermediary between the Consortium and the Granting Authority.
- The **General Assembly (GA)**, chaired by the Coordinator and composed by one member from each partner institution, will be the *steering and decision-making body*.
- The **Management Board (MB)**, chaired by the Coordinator and composed by WP Leaders, is in charge of supervising the activities carried out in the respective WPs, will be the *executive body*.
- The **Project Manager (PM)** will assist the Coordinator and the General Assembly in the day-by-day technical management.
- The **Financial Assistance** will assist the Coordinator and the General Assembly in all administrative and financial duties.
- The **External Advisory Board (EAB)** will provide suggestions and recommendations to the General Assembly and the Coordinator as required.

Coordinator

The project will be coordinated by ESOT - European Society of Organ Transplantation. The Coordinator shall be the intermediary between the Parties and the Granting Authority and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium Agreement. In particular, the Coordinator shall be responsible for:

- monitor that the action is implemented properly
- collecting, reviewing to verify consistency and submitting reports, other deliverables (including financial statements and related certifications) and specific requested documents to the Granting Authority

- administering the financial contribution of the Granting Authority organize and ensure appropriate communication among the partners;
- chair the meetings of the General Assembly and Management Board.

For strategic and scientific guidance of all Parties involved in the Project, the Coordinator has appointed a **Project Coordinator** who will also be responsible to identify key performance indicators for quality objectives. The Project Coordinator will be supported in the day-to-day technical management by a **Project Manager** (PM). On the administrative, financial, and legal side, the PC will be supported by the **Financial Assistance**. PM and Financial Assistance will be officially appointed at the kick-off meeting of the project. The Project Coordinator together with Project Manager and Financial Assistance will constitute the **Project Management Office**.

General Assembly

The General Assembly consists of one representative from each partner and is chaired by the Coordinator. It is responsible for discussing the general direction of the project and for ensuring the completion of the work plan within the scheduled time frame. The General Assembly will meet at least **one time a year** to evaluate any necessary steps or work needed to achieve the strategic objectives.

Management Board

As far as the work plan implementation is concerned, the Management Board (MB) will support operatively the General Assembly. The MB will be chaired by the Coordinator and gather all WP Leaders. More in depth MB shall be responsible for:

- Coordination and monitoring of the progress of the tasks included in each WPs;
- Organization, collection and quality control of the deliverables;
- Ensure exchange of information between WPs;
- Informing the GA and the Coordinator of any event within WPs that may affect work schedule.

Management Board will meet at least **quarterly**.

External Advisory Board

To strengthen the continuous communication and feedback with key stakeholders, the General Assembly will be aided by an External Advisory Board (EAB). Candidate EAB members, with no link to any of the Parties, will be presented during the first General Assembly meeting, selected and then officially appointed by the General Assembly. EAB will include at least 5 members with expertise in organ donation, kidney, liver, heart, lung transplantation, respectively.

The EAB is mainly in charge of:

- guide and give feedback to the GA on its ongoing activities, with a dedicated commission for the clinical issues;
- serving as the first contact point in communicating and applying the results of the project, strengthening the dissemination part of the project.

Members of the EAB will have access to all project documents and outputs upon signature of an NDA. The EAB members shall be allowed to participate to plenary meetings and in General Assembly meetings upon invitation but have not any voting rights.

Management tools and decision making

The decision mechanisms in the project are planned to suit the size of the project, which last 30 months and involves 9 partners. In principle, the voting system will be kept as simple and as direct as possible. First of all, any decision requiring a vote at a meeting must be identified as such on the pre-meeting agenda. Each Consortium Body shall not deliberate and decide validly unless the 2/3 of its member are present or represented (quorum). Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast, except for the ones related to the evolution of the consortium to be taken by the General Assembly for which a unanimous vote is necessary instead. Each Member of a Consortium Body present or represented in the meeting shall have one vote.

2.5 Project management, quality assurance and monitoring and evaluation strategy

Monitoring

The governance structure integrated under the lead of ESOT ensures an effective monitoring of the progress of activities, results achieved, possible cost or schedule variance, quality performance, risk prevention detection & mitigation. The project plan is structured in work packages grouping activities and tasks and following the logical phases of the project. Each work package will have specific deliverables and a verifiable end-point which represents an important milestone in the overall project. This structure will enable adequate and effective monitoring by the project partners and by the Agency. The governance structure ensures an effective monitoring of the progress of activities, results achieved, possible cost or schedule variance, quality performance, risk prevention/detection/mitigation.

Management procedures on decisions and conflict resolution

In general, it is expected that possible conflicting views will be solved bilaterally within the WP or task where they may emerge. In the exceptional case when conflicts cannot be solved so, the GA may be called to solve the conflict. The GA will make a final binding decision, if necessary, by voting. All pending conflicts will be solved within reasonable time frames and the GA shall decide within 20 working days. A Consortium Agreement, detailing responsibilities of partners, financial provisions, and other contractual provisions.

Deliverable preparation procedure

For each deliverable will be identified:

- one leading person, in charge of collecting contribution and drafting the document;
- one internal reviewer, in charge of review the deliverable draft. The internal reviewer will be selected, at least one month before the delivery date according to the specific topic of the deliverable and the competences/roles of the Partners.

The following preparation and delivery procedure is established:

WHO	WHAT	WHEN
Deliverable leader	Collects contributions for the involved partner, drafts a first version of the deliverable and sends it to the internal reviewer	4 weeks before the delivery date (end of month due)
Deliverable internal reviewer	Reads the deliverable draft and sends a revised version to the deliverable leader	3 weeks before the delivery date
Deliverable leader	Sends the second draft to all the partners for a final ok	2 weeks before the delivery date
Deliverable leader	Sends the final version of the deliverable to the Coordinator	1 week before the delivery date
Coordinator	Sends the deliverable to the Agency	Within the deadline

2.6 Cost effectiveness and financial management

The costs of the BRAVEST project (1.184.876,16 euro) have been dimensioned to give to the project the necessary critical mass to achieve the project milestones and deliverables. All the resources have been estimated analytically per costs category.

Travel costs: the main project events have been carefully planned. To avoid an over estimation of travel costs, the coordinator decided to allocate 500€ (300€ for travel and 200€ for subsistence allowances) to each technical meeting. Whenever possible WPs technical meetings will be organized jointly in order to avoid the multiplication of travels, short update calls will be organized monthly to be up-to-date on ongoing activities.

Personnel costs: as far as distribution of costs are concerned, staff costs were built after asking for real staff monthly rates and prospective efforts, with profiles and skills for each single person (see attached CV of key person involved). So, the cost spread is based on reality, therefore it is no surprise that the staff costs in some countries are much higher than in others, as a natural consequence of greatly different monthly rates. Funds will be used for natural staff, seconded contracts and new people to be hired.

Subcontract: a subcontract is foreseen under WP5 to perform the cost analysis. The appointment of a subcontracted company is to cope with the absence of internal expertise to carry out this activity. An IT company will be assigned the development of the BRAVEST study-oriented web-based platform and an additional medical writing contract will be assigned to support the preparation of the guideline.

The **Other costs** of the project have been allocated to perform the widest dissemination activity through website, educational webinar, congress, open access publication of project results. The Licence fee of a project management tool will be covered with project budget to properly follow the activities and avoid any delay in delivering project outcomes. Funds to cover the translation of the Guideline in the 27 EU official languages were allocated under the coordination WP. No purchase of equipment is foreseen under this project.

The 20% of co-funding will be covered with working hours of beneficiaries' internal staff.

To tackle the delicate **management of financial aspects**, the Coordinator will be supported by the Financial Assistant appointed within ESOT.

The Administrative and Financial Management activities will include:

- Receive the EU funding from the Agency and distribute them among other beneficiaries,
- ensuring that all the appropriate payments are made without unjustified delay;
- Inform the Agency of the amounts paid to each beneficiary when required;
- Support beneficiaries with the financial statements to be included in the intermediate and final reports of the project;
- Implement and maintain an internal cost controlling tool, which is updated in case of any budget amendments.

2.7 Risk management

Critical risks and risk management strategy			
Risk No	Description	Work package No	Proposed risk-mitigation measures
1	LOW: Partner withdrawal from project consortium	All	Submission of amendment request to HaDEA due to budget reshape and redistribution of workloads among remaining beneficiaries.
2	MEDIUM: Lack of active participation of the partners and consequent delay in project activities	3,4,5	A proper timetable will be shared among the beneficiaries, WP leaders will report to the coordinator about any problem and the coordinator will take care of reminding the silent partner their contribution.
3	MEDIUM: Partners do not agree on the principles or guidelines to be proposed.	4	Consortium meetings will be meticulously documented including the rationale for decisions. Rules will be agreed for how conclusions will be reached when the partners do not agree. EAB will play an important role in providing strategic guidance when decision making is difficult.
4	HIGH: Guideline and other outputs are agreed but not implemented	4, 5	A strong dissemination and communication plan will be built in order to involve relevant stakeholders and get them familiar with project activities and outcomes before project end.
5	MEDIUM: Changes in political and economic situation that could lead to staff changes	All	Most consortium partners represent long-standing scientific society, international organizations or National Ministries of Health. Should any new National setting affect the composition of the project consortium, measure foreseen for risk n.1 will be adopted.

3 IMPACT

3.1 Impact and ambition

Impact and ambition — Progress beyond the state-of-the-art

The short-term effects of the BRAVEST project include:

1. an evidence-based, data-based thorough knowledge of how COVID-19 pandemic was impacted donation and transplant activities, how it was managed and dealt with by participating countries;
2. development of agreed-upon, professionally-validated guidelines for improving resilience of donation and transplant systems

Medium term effects: possibility to predict outcomes of donations processes, based on inputs of selected factors, proven to influence the process

Long-term effects:

1. Transferability of developed models, on the basis of performed sustainability and cost-effectiveness analysis to European countries, where some improvement in the management of donations processes may be needed (see Van der Spiegel et al, 2020 for detail), to serve possible as basis for national/supranational action plans to be launched in this specific field.
2. Availability of a large dataset regarding organ donors which may represent the source for subsequent prospective data collection to test the effectiveness of the guidelines and procedures implemented in BRAVEST. At this regard, the BRAVEST dataset will be integrated in the ESOT funded project of the European Transplant Registry. This project involves most of EU Competent Authorities, which will be invited to contribute prospectively to the BRAVEST donor dataset.

As far as **target groups** are concerned the BRAVEST project will address and involve the following groups: EU/non EU institutions; Competent Authorities/Health Ministries; Organ Exchange Organizations, Procurement Organizations, Intensive Care and Transplant Professionals, Transplantation Centres, Policy makers at national/regional level; Patients Associations. Such groups will have the opportunity to become acquainted with a tested, proven viable strategy for increasing resilience of donation and transplant systems, contributing to a sustainable supply and administration of organ-based essential therapies

The novelty of BRAVEST approach relies on the joint, combined effort of professional societies, Competent Authorities and public health experts to select and identify such strategies, also through the proper application of cutting-edge, AI based methodologies. With results, project aims at making an EU policy impact by helping shaping common EU action plan on ODT and contributing to the research progress in the field.

3.2 Communication, dissemination and visibility

The development of the BRAVEST dissemination and communication strategy will be led by WP2 and aims at a tailor-made outreach program for generating awareness and visibility for project results.

The table here below gives an overview about planned measures, particular target groups and key performance indicators for maximizing the projects impacts. This initial strategy will be the basis for the dissemination and communication plan, delivered in month 6 and updated throughout the whole project. The final plan will include a follow-up strategy for activities after project lifetime.

Further, the dissemination and communication plan include a variety of events with different purposes. They are either aiming at informing (webinars, presentations), at networking & identifying collaboration/ synergy partners (conferences, discussion roundtables) or at co-creating outputs with selected stakeholder groups (workshops). The latter are very output-oriented and intend to support the exploitation activities in WP2.

Activities	Target audience	Description	Short- and long-term impact and KPI
Project Web Page	All	Homebase for all BRAVEST related information, including a news section, a download section, intranet access, etc. Maintenance for at least 24 months beyond project lifetime The project Web site will include a blog section “my transplant story” with Patient and healthcare professional experiences.	Creation of a project identity to increase awareness about the project and its results. Communicate information about the project, raise interest and public knowledge and involvement also featuring patients and HCP. KPI: >3.000 website visitors; >300 total views at the end of the project; Online and graphic tool kit M4
Visual identity	All	Logo, colour code and design for BRAVEST promotional materials and for templates to provide a recognizable visual appearance	
Promotional video	All	The promotional video will be prepared and published on the project website and Transplant Live	
Social Media	All	Multiplicator for information (publications, events, news, etc.), tool for community building LinkedIn: creating business network Facebook: providing general information for public Twitter: distributing scientific news	Raising the awareness about the project, keeping the interest about the potential of its results. Including input from and interaction with ESOT “Social Ambassadors”. KPI: >300 followers at the end of the project; >1 post/week; Online M4
Stakeholder webinars	All	EPHA and ESOT will organise a stakeholder webinar – recorded and promoted on Transplant Live	KPI: >100 total views at the end of the project
Conference and workshop participation	Scientists and physicians in the field of organ transplantation.	Presentations at ESOT Congress 2023 in Athens, Attendance to European National Society meetings	KPI: >3 events/ conferences attended by project partners
Publications: peer-reviewed publications in journals, conferences and workshops.	All	Project guidelines will be disseminated and a devoted paper will be published on Transplant International - Official journal of the European Society for Organ Transplantation	KPI: >3 open access peer reviewed publications;

3.3 Sustainability and continuation

Organ transplantation benefits more than 30,000 patients in the European Union every year, but the availability of organs does not satisfy the needs, unequally met by Member States, notably due to variability in living and deceased donation rates, to the variations in registration on the waiting list, developments of medicine, economic factors, the fact that transplant teams with a high activity level will be more prone to register patients in waiting list, etc. This heterogeneous European scenario has led to the need to establish a common framework for quality and safety of human organs intended for transplantation especially in times of health emergencies.

It is of key importance to develop a strategy to achieve this sustainability, since the major benefits of

BRAVEST project will only become evident in the long-term, both in case a new pandemic outbreak or other major calamity affecting the access to transplantation in terms of hospitals capacities and staff availabilities but also thanks to the assessment of factors, which affect the outcome of organ donation (including those associated with COVID pandemic), therefore potentially increasing organ availability and proper use and granting the quality and safety of solid organ transplantation in time of emergency. To this end, designing a dissemination strategy that enables a sound and sustainable basis for the good practice guideline will be the main aim of WP2. WP5 will in addition identify how the system can be sustained beyond the end of this project.

The sustainability and continuation of this project should be achieved at different level: According to the different levels, different goals and activities are set as follows:

Organizational Level: Assure continuous cooperation of project consortium after the project is finished and efficient use of the resources.

- Integration of the BRAVEST dataset in the ESOT funded Registry
- 1-day virtual follow-up consortium meetings (first, second and third year after project end)
- Frequent updates on professional development and crisis resilience success – through meetings of professional bodies (e.g. ESOT, Eurotransplant etc.)
- Funding prospects: monitoring open calls for a follow-up project (EU funds—e.g. schemes Horizon, Health4All, Erasmus+, Digital Europe scheme etc.)
- Establishment of a special working group for crisis resilience within ESOT - consortium members will continue to collaborate and contribute their internal expertise and social capital (outreach) after the project ends by including cooperation with institutions representing also countries not involved in the consortium, such as DG-Santè and CD-P-TO.



Professional Level: More resilient transplant programs in time of crisis, increased professional community cooperation, exchange of practices and progress in the field

- Transfer of key exploitable results/recommendations into national policies and practice
- Assuring visibility of professional open-access article in Transplant International
- Assuring visibility and use of key results on new media channels (esp. #TransplantCommunity, #ESOT etc.)
- Establishment of virtual consultation office for support for less developed countries in SE Europe
- Working group crisis resilience within ESOT
- Transfer of outputs to wider area of preventing disease transmission and assuring quality and safety in organ donation and transplantation
- Contribution to EU strategic document: Content suggestions and further steps towards development of new EU Action Plan on Organ Donation and Transplantation
- Enhancement of new interdisciplinary cooperation and pan-EU collaboration
- Action aiming towards synergy with EU4Health programme (2021-2024)
- Enhancing further research and development in the field
- Interaction with all stakeholders.

Societal Level: Equal access to transplant treatment, less consumption, less CO2 emission, less negative impact on environment, positive impact on society with regards to health and solidarity

- Actions contributing towards green and digital Europe (reduction of air travel, the use of virtual tool for material sharing and meetings, use of recycling materials, awareness towards ecological aspects of everyday life ...)

- implementing allocation algorithms which optimise time and distances for organ transportation
- For patients: Assuring equal access to ethically and high-quality organ transplantation treatment all over Europe
- For citizens: enabling ethical, transparent, voluntary organ donation (life and deceased programs) even in times of healthcare crisis (emphasis on the prevention of possible manipulations of the procedure profiting from crisis circumstances and organ trafficking)
- Raising human solidarity
- Assuring gender balance and equity during project and after
- Costs saving and prevention of death and complication by assuring transplantation treatment
- Action for good cooperation and exchange of knowledge between health authorities, civil society and transplantation professional community.


Ethical Level: Respectful communication, high ethical standards embedded in project activities and deliverables, ethical relationship towards society and environments.

- Integration of high ethical standards into all project actions from the start – on the level of project consortium, activities, output development, gender balance, wider social and professional goals.
- In close connection with WP 1 – Management, building awareness on sustainability objectives and long-term goals among the consortium from the project start (at the meetings, during preparation of documents, outputs ...etc.)
- Respect of ethics in the field of data protection
- High respect of ethical standards in organ donation and transplantation programmes
- High ethical standards in communication (respect of autonomy, transparency, non-paternalistic approach, no manipulations - e.g. by playing on the emotions of the public - on social media).

The follow-up of BRAVEST project and its outcomes is granted by the participation of ESOT, the major scientific society for organ transplantation in Europe that will promote and support the implementation of the guideline at international level. Moreover, the close involvement of partners with heterogeneous interests is seen as an important pillar of the partnership. Integrating stakeholders from different areas (professional associations, National Competent Authorities, patient associations, etc.) is considered to support the sustainability of the project's results as it allows for a more integrated perspective.

Eventually, a network of transplant centres with a diversity of volume of activity and performance will be identified thanks to the support of the national CAs involved in the project and via ESOT experts, in order to define the applicability and feasibility of the guidelines and the proposed solutions developed as output of WP4, thus establishing the financial viability of the proposed solutions.

4 WORK PLAN, WORK PACKAGES, TIMING AND SUBCONTRACTING



4.1 Work plan

Work plan						
WP n. and Title	Description	Lead Partner	Global Effort	Global Cost	Start-End date	Deliverable n.
1 - Coordination, management and evaluation	Actions undertaken to manage the action and to make sure that it is being implemented and reaches the objectives.	ESOT	26,84	109.699,11 €	M1-M30	D1.1 - D1.2. - D1.3
2 - Communication, dissemination and exploitation	Management of external communication, to ensure that the results and deliverables of the action will be made available to the identified stakeholders and to the European Union reference community of medical/professional actors. Support the analysis of sustainability issues foreseen under WP5 - Task 2. Moreover, this WP aims to foster the commercial and non-commercial exploitation of the results and communicate about the project to the public.	ESOT	37,51	217.220,81 €	M1-M30	D2.1 - D2.2. - D2.3 -D2.4 - D2.5 - D2.6
3 - Analysis of COVID-19 pandemic impact on participating countries	Building a repository of relevant data obtained from the national competent authorities included in the consortium. The analysis of the raw data will be enriched by an AI-based algorithm directed at determining the main determinants of SOT activity in the participating EU states during the pandemic.	ONT	63,78	441.478,73 €	M1-M17	D3.1 - D3.2. - D3.3 -D3.4 - D3.5
4 - Guidelines and prospective solutions for building up resilient organ donation and transplant systems	Creation of a common platform to share among Countries information regarding: epidemiological data (see WP3) and country-specific recommendations and policies	ESOT	45,49	262.798,12 €	M13 – M22	D4.1 - D4.2
5 - Implementation and sustainability	Checking of the terms of applicability of the guidelines developed under WP4 and the feasibility of implementing the proposed solutions. Analysis of sustainability issues for the different solutions and their economic viability.	ST	39,40	153.679,39 €	M20 – M29	D5.1 – D5.2

4.2 Work packages and activities

WORK PACKAGES		
<i>Work Package 1</i>		
Work Package 1: Coordination, management and evaluation		
<i>Ensure consistence with the detailed budget table (if applicable).</i>		
Duration:	M1 - M30	Lead Beneficiary: 1 - ESOT
<p>Objectives <i>List the specific objectives to which this work package is linked.</i></p> <p>This WP is aimed at managing and coordinating the project and making sure that it is implemented as planned, abiding by EU rules and procedures. Additionally, this WP aims to ensure that the project reaches its objectives and produces high quality deliverables, especially by closely monitoring activities within WP3-WP5 (e.g. for all meetings and events under such WPs, questionnaires will be distributed to ascertain how participants evaluated their usefulness and organisation). In addition, an evaluation of whether project outputs fit the purpose will be carried out. This WP task will also take advantage of the contribution of an External Advisory Board (EAB) to be set up at the beginning of the Action. The members of such board will be selected among internationally acknowledged experts with no link to any of the partner authorities. Scientific project officers from the EU Commission will be asked to approve the list of EAB members. The Board will be managed by coordinator and involved in plenary meetings and will deliver inputs for both deliverables and evaluation reports for this WP. The composition of the EAB will take into account the different fields covered by the project in terms of expertise. The coordination role, assumed by the project leader, is intended to:</p> <ul style="list-style-type: none"> • coordinate the action horizontally and vertically; • supervise the design and implementation of the single WPs, supporting WP leaders; • supervise vertically the work carried out in each WP ensuring that the expected deadlines and deliverables are met; • ensure a steady information on WP progress; • monitor transversally the compliance of each partner and assess whether the activities are balanced or not, and in this case allowing to jeopardize the performance of the beneficiaries in the other WPs; • guarantee quality working procedures, oriented to results and aims, transparent and balanced within the transnational consortium; • design a General Working Plan for the project and coordinate specific working plans within each WP; • ensure a permanent and transparent communication within the consortium, as well as proper project implementation motivating all partner organisations for guaranteeing a balanced participation, avoiding any inactivity during specific periods of the project lifetime. • measurement of the implementation impact and long-term outcomes of the project. 		

Activities (what, how, where) and division of work						
Task No	Task Name	Description	Participants		In-kind Contributions and Subcontracting (Yes/No and which)	
			Name	Role (COO, BEN, AE, AP, OTHER)		
T1.1	Organization of general meetings and coordination	Beneficiaries and EAB will meet in three plenary meeting: Kick-off (M1), intermediate meetings (M15) and final meeting (M30); Interim WP meetings for reaching agreements on specific issues, developing work, and exchanging relevant information, including working progress will be held by conference calls.	ESOT	COO	NO	
T1.2	Setting up of the External Advisory Board	A board of experts covering the different fields addressed by the project will be nominated among internationally acknowledged experts with no link to any of the partner authorities, to evaluate project outcomes.	ESOT, all beneficiaries	COO	NO	
T1.3	Monitoring of technical WPs	To ensure that the project reaches its objectives and produces high quality deliverables, a close monitoring of the activities within WP3-WP5 will be performed and specifically for all meetings and events under such WPs, questionnaires will be distributed to ascertain how participants evaluated their usefulness and organisation	ESOT	COO	NO	

Milestones and deliverables (outputs/outcomes)

Milestone No (continuous numbering not linked to WP)	Milestone Name	Work Package No	Lead Beneficiary	Description	Due Date (month number)	Means of Verification
MS1	Setting up of the EAB	1	ESOT	The EAB will be composed by 5 appointed members, with expertise in organ donation, kidney, liver, heart, lung transplantation respectively	M3	The EAB Members will be nominated and appointed by the General Assembly during the KoM. Minute of the meeting (D1.1) will report the composition of the EAB.

Deliverable No (continuous numbering linked to WP)	Deliverable Name	Work Package No	Lead Beneficiary	Type	Dissemination Level	Due Date (month number)	Description (including format and language)
D1.1	Minute of the KoM	1	ESOT	/R — Document, report/	/SEN — Sensitive/	M3	Minute of the KoM with the list of appointed EAB members
D1.2	Intermediate EABevaluation report	1	ESOT	/R — Document, report/	/SEN — Sensitive/	M15	The document will provide a preliminary evaluation done by the EAB members on the performed activities and their suggestion for the way forward. The document will be drafted in English and made available to the consortium in electronic version (pdf) only.
D1.3	Final EAB evaluation report	1	ESOT	/R — Document, report/	/SEN — Sensitive/	M30	The document will provide an overall evaluation on the project outcomes. The document will be drafted in English and made available to the consortium in electronic version (pdf) only.

Work Package 2

Work Package 2: Communication, dissemination and exploitation		
<i>Ensure consistence with the detailed budget table (if applicable).</i>		
Duration:	M1 - M30	Lead Beneficiary: 1 - ESOT
Objectives <i>List the specific objectives to which this work package is linked.</i>		
<p>The overall objective is to identify and reach the target audience and stakeholders, including EU and national policy makers, academic institutes, professional associations, end users and the general public, in order to raise their awareness regarding the findings of the consortium and to encourage them to support and adopt the guideline and other relevant outputs of the project. More specifically, the objectives of WP2 are:</p> <ul style="list-style-type: none"> • To define and establish the project dissemination and communication strategy/plan • To manage the external communication and proper dissemination of the project results and its deliverables. • To ensure the proper visibility of EU co-funding • To define and reach the target audience and stakeholders at the level of institutions, professional societies, policy makers and final users. • To raise awareness of the target audience, stakeholders and community in general, as regards the project activities. • To provide the means for dissemination and communication of the JA actions and outputs. • To pay attention to the transfer of knowledge and to the processes needed for embedding and future take-up; in particular, some contribution from this WP will be given to support the analysis of sustainability issues foreseen under WP5 - Task 2 <p>More specifically, this WP aims to foster the commercial and non-commercial exploitation of our results and communicate about the project to the public. This WP is aimed at developing targeted and well-thought outreach activities and measures which are a necessity to boost the impact of the project.</p>		

Activities (what, how, where) and division of work					
Task No	Task Name	Description	Participants		In-kind Contributions and Subcontracting (Yes/No and which)
			Name	Role (COO, BEN, AE, AP, OTHER)	
T2.1	Dissemination and communication strategy	The task will define a detailed dissemination strategy to ensure high visibility and impact for the project. The plan, covering all the duration of the project, will be authored describing the aims and objectives of the project, the actions to be disseminated, the target audiences/groups and stakeholders, the benefits to end-users, the dissemination methods/activities, the timescales and responsibilities of the members of the team, the targets, the estimated costs, the evaluation and criteria for success. The dissemination strategy will be revised periodically based on the feedback and the achieved results to ensure that the targeted events maximize visibility and that the dissemination activities reach the targeted audience.	EPHA, ESOT, ISS-CNT, ONT, ABM, ST, OVSZ	BEN, COO	NO
T2.2	Project identity	Design the project logo, production of a design for printed material, production of banners, posters, flyers, preparation of the newsletters, production of video material, as well as official project templates for PowerPoint presentation and deliverables.	EPHA, ESOT, ISS-CNT, ONT, ABM, ST, OVSZ	BEN, COO	NO
T2.3	Design, launch and maintenance of the project website as devoted section of ESOT website	The website - consisting of a public and private area – is a key dissemination deliverable with multiple roles in the promotion and support of the JA activities during and beyond the project.	ESOT, EPHA, ISS-CNT, ONT, ABM, ST, OVSZ	BEN, COO	NO
T2.4	Promotional Video	A promotional video describing project activities and main outcomes will be published on project website, ESOT, EPHA and all beneficiaries media channels.	EPHA, ESOT, ISS-CNT, ONT, ABM, ST, OVSZ	BEN, COO	NO

Activities (what, how, where) and division of work					
Task No	Task Name	Description	Participants		In-kind Contributions and Subcontracting (Yes/No and which)
			Name	Role (COO, BEN, AE, AP, OTHER)	
T2.5	Promotion via social media	Project results may be disseminated through popular social networks such as LinkedIn or Twitter. The project will take advantage of any well-established social media channels of beneficiaries.	EPHA, ESOT, ISS-CNT, ONT, ABM, ST, OVSZ	BEN, COO	NO
T2.6	Organization of final dissemination conference and stakeholder webinar	The final dissemination conference will be organised back to back to stakeholder webinar whose recording will be stored on ESOT media channel.	EPHA, ESOT, ISS-CNT, ONT, ABM, ST, OVSZ	BEN, COO	NO

Milestones and deliverables (outputs/outcomes)						
Milestone No (continuous numbering not linked to WP)	Milestone Name	Work Package No	Lead Beneficiary	Description	Due Date (month number)	Means of Verification
MS2	Dissemination Strategy	2	EPHA	A dissemination plan will be prepared to structure the WP activity	4	Submission of Deliverables D2.1 and D2.2.
MS3	Stakeholder involvement	2	EPHA,	All relevant stakeholders will receive relevant information on ongoing activities	15	Distribution of project brochure and newsletter to the list of national and wider ESOT and EPHA stakeholders network.
MS4	Dissemination /exchange of good practices	2	EPHA,	All relevant stakeholders will receive copies of project outcomes	30	Distribution of good practice guidelines developed under WP4 to the list of national and wider ESOT and EPHA stakeholders network, medical/professional association and to the 27 EU Competent Authorities.

Deliverable No (continuous numbering linked to WP)	Deliverable Name	Work Package No	Lead Beneficiary	Type	Dissemination Level	Due Date (month number)	Description (including format and language)
D2.1	Project website	2	ESOT	[DEC — Websites, patent filings, videos, etc]	[PU — Public]	4	The website will be in English it will include 5 main sections: Home, Beneficiaries (with information about individual beneficiary), Documents (work plan and deliverables), Events (JA events as well as related events), Resources (other initiatives or projects), Outreach, and Contact. It will be designed to be informative with clear language to ensure wide communication with diverse categories of stakeholders and external audience/general public. The private area of the website will contain working documents and confidential deliverables, as well as all other documents (presentation, minutes, agenda of the meeting), or dissemination and communication materials. The website will include a link to the HaDEA, DG Sante and to all beneficiaries websites. The website will be established immediately at the start of the project and no later than month 4, and will be maintained for at least one year after the project ends.
D2.2	Project brochure	2	EPHA	[R — Document, report]	[PU — Public]	4	The project brochure will describe the aim and expected outcomes of the project, its consortium and give visibility to EU funding. The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders. A printable version in online PDF format will be available for the partners to use if needed at the in person events

Deliverable No (continuous numbering linked to WP)	Deliverable Name	Work Package No	Lead Beneficiary	Type	Dissemination Level	Due Date (month number)	Description (including format and language)
D2.3	First newsletter	2	EPHA	[R — Document, report]	[PU — Public]	10	The first newsletter will include the activities from M1 to M10. The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders. The newsletters will be available on the project website.
D2.4	Promotional Video	2	ESOT	[DEC — Websites, patent filings, videos, etc]	[PU — Public]	10	The promotional video will describe project activities and main outcomes. The video will be in English and it will be made available on project website and beneficiaries website.
D2.5	Second newsletter	2	EPHA	[R — Document, report]	[PU — Public]	20	The second newsletter will include the activities from M11 to M20. The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders. The newsletters will be available on the project website.
D2.6	Final layman report	2	EPHA	[R — Document, report]	[PU — Public]	30	The final layman report will describe all project outcomes and their possible implementation. The final layman report will be prepared by all beneficiaries and in close collaboration with WP5 leaders. The document will be produced in English version and distributed electronically to all beneficiaries and external stakeholders as well as available on the project's website

Work Package 3

Work Package 3: Analysis of COVID-19 pandemic impact on participating countries		
<i>Ensure consistence with the detailed budget table (if applicable).</i>		
Duration:	M1 - M17	Lead Beneficiary: 3 – ONT
Objectives <i>List the specific objectives to which this work package is linked.</i>		
<p>Building a repository of relevant data obtained from the national competent authorities included in the consortium. These data will include clinical features and epidemiology of solid organ donors and transplantation activities performed in the period 2018-2022. In addition, data will be collected regarding the impact of the COVID-19 pandemic on the healthcare and Intensive Care Unit (ICU) systems in the respective region/country during the different waves. This will be accompanied by a thorough description of the procedures implemented by the EU participating countries during the pandemic to ensure the continuity of the transplant program. Finally, the analysis of the raw data will be enriched by an AI-based algorithm directed at determining the main determinants of SOT activity in the participating EU states during the pandemic.</p> <p>Specific objectives:</p> <ol style="list-style-type: none"> 1) feeding a repository of retrospective granular data about organ donors signalled and procured, in European countries (period 2018-2022), from the data prospectively collected by National Transplant Authorities and organ allocation organisations. 2) implementing a survey of the procedures implemented during COVID-19 pandemic at national/regional level. 3) developing an AI algorithm to predict main determinants of transplantation activity with specific focus on the contribution of COVID-19 pandemic as covariate <p>This WP will focus on building up a comprehensive picture of how the recent COVID-19 pandemic has impacted upon solid organ donation and transplantation activities, and how transplant systems in the EU have dealt with the challenges posed by the pandemic. To this purpose, three different tasks will be performed:</p> <p>T3.1 – Description of the COVID-19 impact on SOT programs Study methodology will be defined during the first months of the WP, identifying the variables to be collected by the EU-Organ Transplant database, to be developed by ESOT partner. ESOT will be responsible for the development of the BRAVEST study-oriented web-based platform, to be populated with data gathered under the specifications and identification of variables to be collected, as per input by this WP, when defining study methodology. Full account will be taken of methodologies and indicators developed under previous EU-funded work (DOPKI, ACCORD, ODEQUS). The database will bring together data concerning existing national/regional donors and recipients gathered between 2018-2022. The cohort data will be centralized in this core facility. Standardized data will be collected by technical staff following a common thesaurus. Codes will be used to ensure strict donor and recipient anonymity. Individual donor data collection will be performed in compliance with GDPR. Detailed definition of the database collecting the data retrievable from competent authorities datasets will be a deliverable of this WP and will be agreed in a meeting including at least one representative of each partner. A thorough analysis of solid organ donation and transplantation practices in the EU before (year of analysis 2018-2019), during and after the pandemic will be performed. This will include the time-dependent analysis of the following data:</p>		

- Potential deceased donors (Donors after Brain Death - DBD and Donors after Circulatory Death - DCD);
- Characteristics of potential deceased donors (e.g. donors after the neurological [DBD] and after the circulatory death [DCD]);
- Actual deceased donors (DBD and DCD);
- Consent to organ donation;
- Living donors;
- Solid Organ Transplants (SOT) performed;
- Trans-national offers of SOT and number of transplants performed with these organs;
- Patients on the waiting list for SOT.

This analysis will be accompanied by retrieval of data about the COVID-19 pandemic in the participating EU states, including:

- COVID-19 cases;
- COVID-19 hospitalised patients;
- COVID-19 deaths;
- Hospital beds occupancy by COVID-19 patients;
- COVID-19 patients in ICU;
- ICU beds occupancy by COVID-19 patients.

Analysis of GDPR compliance of identified selected variables as per study plan will be performed early during WP development.

The analysis of these macro data will be stratified on a national/regional basis (when feasible, depending on data availability), in order to analyse the magnitude of the impact of the different waves of COVID-19 on donation and transplantation activities and the capacity of the SOT systems to adapt to the different ICU and hospital situations. The data generated by this WP will be contrasted to the data from the pre-pandemic era (2018-2019) in order to generate solid evidence on the impact of the pandemic on the different SOT programs.

T3.2 – Description of the procedures implemented by the participating EU states to face the challenges posed to the COVID-19 programs by the COVID-19 pandemic.

This task is meant to investigate the overall impact of the COVID-19 pandemic in organ transplantation, laying the groundwork to understand how healthcare systems adapted to the pandemic and improve decision-making if the pandemic persists (in case of emergence of SARS-CoV-2 variants of concern) or other emergencies come up. Due to the COVID-19 pandemic, new challenges for health-care systems in all countries have arisen and there has been inflexible prioritization of capability of hospital facilities and human resources toward COVID-19 patients. Depending on the severity of the wave of infections, there was also an unavailability of resources by actual capacity or by governmental and/or hospital policies in the sense of strategic preparedness. In both cases, treatment was restricted for all other patient cohorts but emergencies. Transplant Societies and National Authorities drew-up lists of procedures that could be performed during the pandemic, including life-saving procedures. Additionally, the impact of COVID-19 on SOT was limited at the beginning of the pandemic and is still unclear and controversial. Since there were no evidence-based guidelines to deal with COVID-19 and transplantation, many centres have considered restricting (urgency, risk stratification) or even stopping their activities.

All these conditions have shown a particular vulnerability of the system and a difference in behaviour at the super-national level.

Therefore, in order to evaluate the framework for SOT in Europe during the COVID-19 pandemic, to revise clinical behaviours adopted during the pandemic's pick and to propose new procedures to ensure the safety of organ donation and recovery and management of transplantation activities, as well as procedures to ensure proper use of available donation resources and the safety of organ recipients at the time of transplant surgery and during the subsequent follow-up,

we will conduct an online dedicated survey to design and to convey the participating SOT organizations of the EU countries. The questionnaire will collect information on restrictions on SOT, protective measures, (non)governmental information policies, and individual opinion on how to deal with SOT during COVID-19 will be designed.

T3.3 – Big Data and AI to better manage the COVID-19 pandemic.

- Describing the currently ongoing COVID-19 outbreak: All transplant data will be smoothed in two steps, by calculating a 14-day moving average and by applying locally estimated scatterplot smoothing to the 14-day moving average. We will compare the trends and the diminutions in the number of transplants between 2018 and 2023, by organ transplant structure, by country and across all included countries. The correlation between COVID-19-related deaths organ transplant activity will be assessed, including the following information: COVID-19 death per million inhabitants calculated from data retrieved from the John Hopkins COVID-19 Data Repository and the World Bank and transplant rates according label, country name etc. We will estimate the number of patient-life years lost during the different COVID-19 pandemic waves compared with the 2018-2019 period using computer-assisted simulation. The regionally stratified macro data will be able to be used to examine the protocols against COVID-19 pandemics within countries.
- Big data can enable monitoring of the disease outbreak in real-time with the potential to develop quick and effective pandemic alerts: we will develop an EU-web-based dashboard that will provide three data visualisation: line graphs displaying total COVID-19 cases, three-dimensional scatter plots displaying the percent diminution in transplants between 2022 and the same time period in 2018-2019, geographical heatmaps for each country. The system will be built in such a way to be prospectively updated in a potential followup of the project.
- Artificial neural networks, i.e. deep learning, especially, long short-term memory (LSTM) with big data can foresee the SOT trend in the future. We will develop an AI-based prediction system to monitor and find worrisome trends of SOT and COVID-19 pandemic.
- Facilitating the implementation of Public Health interventions by identifying at-risk subjects and identifying potential personalized prophylaxis strategies and treatment.

In the long term, AI and Big data appear to have enormous potential to design new standardized protocols and guidelines for sharing data and information during emergencies.

Activities (what, how, where) and division of work					
Task No	Task Name	Description	Participants		In-kind Contributions and Subcontracting (Yes/No and which)
			Name	Role (COO, BEN, AE, AP, OTHER)	
T3.1.1	Development of BRAVEST study-oriented web-based platform	BRAVEST study-oriented web- based platform to be populated with data gathered under specifications supplied by WVP3, where also the algorithm developed under that WVP will be hosted and run.	ESOT, ISS-CNT, ONT, ET, ST, ABM, OVVSZ	COO, BEN	YES
T3.1.2	Data collection of SOT activity 2018-2022	Data retrieval on SOT activity at national/regional level of the participating EU states.	ONT, INSERM, ET, ISS-CNT, ABM, ST, OVVSZ	BEN	NO
T3.1.3	Data collection of COVID 19 data 2018-2022	Data retrieval on COVID-19-related epidemiology and use of health resources at national/regional level of the participating EU states.	ONT, INSERM, ET, ISS-CNT, ABM, ST, OVVSZ	BEN	NO
T3.2	Procedures survey	Reporting by the different SOT organisations on the procedures implemented by the different EU states and (macro)regions to ensure safety and quality of organtransplantation	OVVSZ, ISS-CNT, ONT, ET, ST, ABM	BEN	NO
T3.3.1	Prediction algorithm	Development of AI-based algorithms aimed at discovering the main determinants of good adaptability of the different SOT programs to the pandemic waves in order to ensure sufficiency of organ transplantation in future crisis.	INSERM	BEN	NO
T3.3.2	Data analysis	Analysis of the variation in the SOT activity according to the pandemic phase in the different regions and EU countries	INSERM	BEN	NO

Milestones and deliverables (outputs/outcomes)							
Milestone No (continuous numbering not linked to WP)	Milestone Name	Work Package No	Lead Beneficiary	Description	Due Date (month number)	Means of Verification	
MS5	Finalization of data collection	3	ONT	Collection and insertion of data in the study-oriented web-based platform as per study protocol	M12	All collected data will be made available to INSERM for the purpose of the study. If possible, a paper will be submitted for publication on Transplant International or other peer-reviewed paper	
MS6	Distribution of survey	3	OVSZ	Distribution of a survey on the procedures implemented during COVID-19 pandemic at national and regional level	M4	All beneficiaries will receive the link to fill the survey.	
Deliverable No (continuous numbering linked to WP)	Deliverable Name	Work Package No	Lead Beneficiary	Type	Dissemination Level	Due Date (month number)	Description (including format and language)
D 3.1	Study plan of BRAVEST data collection, including GDPR compliance study	3	ONT	[R — Document, report]	[SEN — Sensitive]	M2	The Study protocol will include the list of variables to be collected, the methodology of analysis and a study o GDPR compliance for data collection. This last will take advantage of the already existing analyses performed by partners for similar studies performed in this specific field.
D 3.2	BRAVEST study-oriented web-based platform	3	ESOT	[DEC — Websites, patent filings, videos, etc]	[SEN — Sensitive]	M6	Development of dedicated electronic repository for data base.

Deliverable No (continuous numbering linked to WP)	Deliverable Name	Work PackageNo	Lead Beneficiary	Type	Dissemination Level	Due Date (month number)	Description (including format and language)
D3.3	Survey on EU practices to ensure sufficiency, safety and quality of Organs Transplant during the COVID-19 pandemic	3	OVSZ	[R — Document, report]	[PU — Public]	M10	Document report in the English language on the different policies adopted by the individual EU SOT organisations for maintaining the SOT programs opened and running during the different pandemic phases.
D3.4	Development of AI-based algorithm to Predict SOT sustainability, quality and safety in time of crisis	3	INSERM	[R — Document, report]	[SEN — Sensitive]	M12	Report of the development of AI-based algorithm to predict SOT sustainability, quality and safety in time of crisis
D3.5	Data analysis	3	INSERM	[R — Document, report]	[PU — Public]	M17	Analysis of the data generated by task 3.1 and 3.2 aimed at predicting which are the main determinants of maintaining the SOT programs running and ensuring the best safety and quality during time of crisis

Work Package 4

Work Package 4: Guidelines and prospective solutions for building up resilient organ donation and transplant systems		
<i>Ensure consistence with the detailed budget table (if applicable).</i>		
Duration:	M13-M22	Lead Beneficiary: 1 - ESOT
<p>Objectives <i>List the specific objectives to which this work package is linked.</i></p> <p>This WP is aimed at delivering policies and recommendations among the participating Countries, based on the output of WP3 and published literature; at developing a common denominator endorsed by the Competent Authorities in the context of: 1. donor screening, 2. recipient selection, 3. waitlist access, 4. follow up recommendation; at optimizing the resource of organ donation within each Country as well as in a vision of organ sharing</p> <p>Specific objectives:</p> <ol style="list-style-type: none"> 1) Identifying a common approach for donor screening, recipient selection, waitlist access, follow-up recommendation 2) Developing a set of proposed solutions for improving quality and safety of organ supply and subsequent transplantation 3) Provide guidance for the staff organization of transplant units in response to a crisis <p>Description On the basis of the outcomes of WP3, this WP will perform tasks meant to translate lessons learned into recommendations for organ donation and transplant communities, with a particular focus on the analysis of risk and critical factors; risk management and containment through shared strategies with verification of their adequacy; support the ICUs for the reporting of potential donors; identification at regional or national level of Transplant Centers where activity in times of crisis should be always guaranteed, in order to safeguard transplant procedures for patients in life danger, evaluating the possibility of moving teams and/or specialized personnel through agreements between hospitals; guarantee the possibility of transporting organ harvesting teams in conditions of health emergency; sensitize transplant communities to keep trust in health care, in health professionals, in transparent and ethical systems of organ donation and transplantation. In addition, we will perform a review of the workloads of transplant teams, repurposing of transplant unit and of transplant dedicated personnel that have happened during the pandemic in order to identify minimal requirements in terms of staff and resources in order to guarantee a safe and functioning transplant activity.</p>		

T4.1: Production of guidelines and sharing of good clinical practices

The evidence gathered by the systematic review will provide the basis for the development of clinical practice guidelines. Specific guidelines will be developed, which will include guidelines regarding donor assessment, recipient selection, prioritization and transplant service provision. The guideline development process will follow evidence-based, structured methodologies for guideline development such as the AGREE II tool to produce guidelines that are consistent with the evidence and expert understanding.

- 1- A review of the content and timing of release of the procedures/documents/guidelines during the recent pandemic will be performed and analyzed in the context of the epidemiological data gathered by WP3, including the donor data and outcomes of the donation process, in the context of specific procedures implemented.
- 2-Bibliographic searches (e.g., Medline, Embase) and searches of relevant websites will identify guidelines and recommendations published by single or multiple authoritative centres, panels of experts, (inter)national authorities and relevant societies. Independent reviewers will extract all relevant recommendations from each guideline. Data will be summarised regarding the different aspects of the transplant pathway, such as organisation of resources, organ allocation, transplant service provision, donor assessment and pre and post-transplant patient care. The systematic review will be conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.
- 3-Developing comprehensive communication guidelines for times of crisis (target groups: professionals, general public and patients) during social and healthcare crises (T4.1.1).

T4.2: To develop a set of proposed solutions worked out on the basis of the results of data analysis and of expected procedures efficacy.

Among possible solutions to increase continuity and safety of organ supply with appropriate risk management, the feasibility of the following will be explored in detail:

1. Improving digital connectivity by building dedicated systems for clinical data and imaging sharing among transplant centres and donor centres. In particular, the implementation of the digital pathology, a dynamic, image-based environment that enables the acquisition, management and interpretation of pathological information, may have a significant impact on healthcare system by facilitation primary diagnosis, diagnostic consultation, intraoperative diagnosis, multidisciplinary team meetings and educational tasks organization, medical student and resident training, manual and semi-quantitative review of immunohistochemistry (IHC), clinical research and diagnostic decision support.
2. Specific focus on the impact of the policies for the use of organ machine perfusion in increasing the organ supply and overall interference with the timings of organ procurement in the context of DBD and DCD, including availability and competitive use of extracorporeal membrane circulation for normothermic regional perfusion.
3. Strategies for facilitating and Increasing volume of *cross-border* organ sharing — in particular in kidney donation and transplant setting. During the course of the recent pandemic, some geographical areas were unable to perform transplant procedures although deceased donor recruitment was still feasible and active. In such conditions, the prerequisites for a successful organ sharing among Countries (preeminently kidney, due to the affordable cold ischemic time) resulted generally lacking. Using the common denominator for donor assessment and recipient prioritization obtained with the Task 1 activities, a faster and wider accepted data collection and policy-sharing will allow to optimize the allocation of the available organs among Countries. Prototypes of this collaboration will be analyzed and optimized per i. geographical distance, ii. legal framework, iii. sustainability.

Activities (what, how, where) and division of work					
Task No	Task Name	Description	Participants		In-kind Contributions and Subcontracting (Yes/No and which)
			Name	Role (COO, BEN, AE, AP, OTHER)	
T4.1	Production of guidelines and sharing of good clinical practices	Based on the outcome of WP3 this document will translate the lessons learned into recommendations and good clinical practice guidelines for organ donation and transplant communities	ESOT, ISS-CNT, ONT, ST, ABM, OVSZ	COO, BEN	YES, Medical writer
T4.1.1	Communication in times of crises	A chapter of the Guide will be devoted to communication guidelines for times of crisis	ST, ESOT, ISS-CNT, ONT, ABM, OVSZ	BEN	NO
T4.2	To develop of a set of proposed solutions worked out on the basis of the results of data analysis and of expected procedures efficacy	Explore the feasibility of a set of proposed solutions to increase continuity and safety of organ supply with appropriate risk management	ESOT, ISS-CNT, ONT, ST, ABM, OVSZ	BEN	NO



Milestones and deliverables (outputs/outcomes)						
Milestone No (continuous numbering not linked to WP)	Milestone Name	Work Package No	Lead Beneficiary	Description	Due Date (month number)	Means of Verification
MS7	Setting up of working groups for guideline drafting	4	ISS-CNT	Beneficiaries suggest and collaborate in the definition of the working groups members	M14	Established working groups will be communicated to DG Sante and HaDEA Officers through the Participant portal communication tool.
MS8	Approval of guideline table of content	4	ISS-CNT	Beneficiaries agreement on the content to be drafted in the guideline	M17	The table of content will be shared with DG Sante Officers and communicated to HaDEA through the Participant portal communication tool

Deliverable No (continuous numbering linked to WP)	Deliverable Name	Work PackageNo	Lead Beneficiary	Type	Dissemination Level	Due Date (month number)	Description (including format and language)
D4.1	Guideline on good clinical practice for building up resilient organ donation and transplant systems	4	ISS-CNT	/R — Document, report/	/PU — Public/	M22	The guideline will be drafted in English and translated in the 27 EU official languages. The document will be distributed in pdf format to all EU CAs and relevant stakeholders.
D4.2	Report on identified solutions to increase continuity and safety of organ supply in time of crises	4	ESOT	/R — Document, report/	/SEN — Sensitive/	M22	The report will provide the basis for the cost-effectiveness analysis to be conducted under WP5. It will be drafted in English and made available in electronic format only.

Work Package 5

Work Package 5: Implementation and sustainability	
<i>Ensure consistence with the detailed budget table (if applicable).</i>	
Duration:	M20-M29
Lead Beneficiary:	4 - ST
Objectives	
<i>List the specific objectives to which this work package is linked.</i>	
<p>The general purpose of this WP is defining a strategy to grant implementation and sustainability of project outcome, as well as assuring that the project outputs and consortium will be durable and sustainable after the project end. In WP5 we aim to analyse the consistency and sustainability of the guidelines and recommendations that will be proposed with the ethical and legal framework of Member States. This objective is crucial in order to propose solutions that can be implemented at European level and harmonised with current country regulations. For example there is a significant variability in the timing and procedures for brain and circulatory death declaration in member states. Although the proposed good practices will be based on the evidence derived by a thorough data analysis, they need to be applicable irrespective of differences, or prompt solutions to change the regulatory framework. This task will be coordinated by ESOT via the sections involved in organ procurement (EDTCO) and in research on ethical and legal aspects in transplantation (ELPAT). In collaboration with a subcontracted expert, a cost-effectiveness analysis of proposed solutions will also be performed (e.g. it is anticipated that measures to improve organ supply and safety may require increased use of organ recovery technology, such as machine perfusion devices. It is relevant to balance the cost of the increase of this technology with the expected benefit and the affordability at country and centre level).</p> <p>Specific objectives:</p> <ol style="list-style-type: none"> 1) analysis of the consistency of WP4 guidelines and/or proposed solutions with local legal and ethical framework 2) analysis of the sustainability of WP4 guidelines and/or proposed solutions with local legal and ethical framework 3) simulation of WP4 guidelines application in a selection of transplant centres. <p>This WP will also aim to verify the terms of applicability and sustainability within the legal and ethical framework of member states, of the guidelines developed and good clinical practices identified under WP4, at a national and local/hospital level.</p> <p>In particular, WP5 will encompass three tasks:</p> <ul style="list-style-type: none"> • Task 5.1. analysis of coherence of the WP4 output with local legal and ethical framework; • Task 5.2. analysis of affordability and sustainability of the WP4 outputs; • Task 5.3. Simulation of the applicability of WP4 output in a selection of transplant centres, representative of the spectrum of current practices and outcomes in the participating countries. 	

Activities (what, how, where) and division of work						
Task No	Task Name	Description	Participants		In-kind Contributions and Subcontracting (Yes/No and which)	
			Name	Role (COO, BEN, AE, AP, OTHER)		
T5.1	Analysis of coherence of the WP4 output	The proposed solutions in WP4 will be derived from the comprehensive analysis and comparison of donor procurement and local procedures implemented by the competent authorities represented in this consortium.	ST, ESOT, ISS-CNT, ONT, ABM, OVSZ, ET	COO, BEN	NO	
T5.2	Sustainability and cost-effectiveness analysis	In collaboration with a subcontracted organization, ESOT will perform an analysis of the cost impact for healthcare services of the proposed guidelines and recommendations, as compared with the current standard of care.	ESOT, ST, ISS-CNT, ONT, ABM, OVSZ, ET	COO, BEN	YES, subcontract of an external company	
T5.3	Simulation of applicability and feasibility of WP4 output in a selection of transplant centres, representative of the spectrum of current practices and outcomes in the participating countries.	In order to define the applicability and feasibility of the guidelines and the proposed solutions developed as output of WP4, this WP will perform a simulation within an identified network of transplant centres with a diversity of volume of activity and performance.	ST, ESOT, ISS-CNT, ONT, OVSZ, ABM, ET, INSERM	BEN, COO	No	



Milestones and deliverables (outputs/outcomes)						
Milestone No (continuous numbering not linked to WP)	Milestone Name	Work Package No	Lead Beneficiary	Description	Due Date (month number)	Means of Verification
MS9	Selection of transplant centres	5	ST	A network of transplant centres with a diversity of volume of activity and performance will be identified thanks to the support of the national CAs involved in the project and via ESOT experts	M20	The list of hospitals and reference persons will be made available to HaDEA through the Participant Portal communication service and the project coordination will also acknowledge DG Sante Officers with official communication.

Deliverable No (continuous numbering linked to WP)	Deliverable Name	Work Package No	Lead Beneficiary	Type	Dissemination Level	Due Date (month number)	Description (including format and language)
D5.1	Results of the simulation	5	ST	/R — Document, report/	/SEN — Sensitive/	M29	This deliverable will describe the outcome of the simulation performed in the identified hospitals. The document will highlight the pros and cons and any possible obstacles that hinder the adoption of the guidelines.
D5.2	Sustainability and implementation plan	5	ESOT	/R — Document, report/	/SEN — Sensitive/	M29	Deliverable 5.2 will provide recommendations to Member states in order to implement the guideline in their national settings. The document will provide useful information related to the financial viability of implementing developed guidelines and proposed suggestions. D5.2 will include evaluation of the impact of the proposed guidelines in selected transplant centers from countries within and outside the consortium.

4.3 Timetable

Timetable (projects of more than 2 years)
 Fill in cells in beige to show the duration of activities. Repeat lines/columns as necessary.
 Note: Use actual, calendar years and quarters. In the timeline you should indicate the timing of each activity per WP. You may add additional columns if your project is longer than 6 year

ACTIVITY	YEAR 1				YEAR 2				Half YEAR 3	
	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2
WP1										
Task 1.1 - Organization of general meetings and coordination	D1.1				D1.2					D1.3
Task 1.2 - Setting up of the External Advisory Board	MS1									
Task 1.3 - Monitoring of technical WPs										
WP2										
Task 2.1 - Dissemination and communication strategy		MS2								
Task 2.2 - Project identity							D2.5			D2.6
Task 2.3 - Design, launch and maintenance of the project Website		D2.1 D2.2		D2.3						
Task 2.4 - Promotional Video				D2.4						
Task 2.5 - Promotion via social media					MS3					MS4
Task 2.6 - Organization of final dissemination conference and stakeholder webinar										

4.4 Subcontracting

Work Package No	Subcontract No (continuous numbering linked to WP)	Subcontract Name (subcontracted action tasks)	Description (including task number and BEN to which it is linked)	Estimated Costs (EUR)	Justification (why is subcontracting necessary?)	Best-Value-for-Money (how do you intend to ensure it?)
3	S1.1	BRAVEST study-oriented web-based platform	T3.1.1 ESOT BRAVEST study-oriented web-based platform	70.000	Lack of internal expertise to develop a study specific platform under the requirement to be set by WP3	a call will be launched to identify the best option
4	S1.2	Medical Writing	T4.1 ESOT	10.000	ESOT will subcontract an expert in medical writings to support the activity	a call will be launched to identify the best option
5	S1.3	Cost Analysis	T5.2 (ESOT) - Sustainability and cost-effectiveness analysis of the cost impact for healthcare services of the proposed guidelines and recommendations, as compared with the current standard of care.	20.000	Lack of internal expertise	a call will be launched to identify the best option
Other issues: <i>If subcontracting for the project goes beyond 30% of the total eligible costs, give specific reasons.</i>						
				Not applicable		

5 OTHER

5.1 Ethics

This project is based on retrospective data collection and will deliver evidence-based recommendations, and good clinical practice guidelines. We envision two potential ethical issues that may arise during the project: 1. Privacy compliance in management of donor data 2. Issue of recommendations that may be in contrast with the legal or ethical framework of a single member state. We will tackle the first point with a specific task in WP3, focusing on the design of a full GDPR compliant database. The second point will be specifically addressed in WP5 in which implementation and sustainability of the project will be tested with particular focus on the local ethical and legal frameworks

5.2 Security

NOT APPLICABLE

6 DECLARATIONS

6.1 Higher funding rate (if applicable)

Do you fulfil the conditions set out in the Call document for a higher funding rate?

(If YES, explain and provide details)

YES

The project meets the condition of allocating at least 30% of project budget to countries, namely to partners from Spain, Slovenia and Hungary, whose GNI per inhabitant is less than 90% of the Union average.

For this project the total funding allocated to these countries is equal to 30,10% (356.774,38 €)

6.2 Double funding

Information concerning other EU grants for this project

We confirm that to our best knowledge neither the project as a whole nor any parts of it have benefitted from any other EU grant (including EU funding managed by authorities in EU Member States or other funding bodies, e.g. Erasmus, EU Regional Funds, EU Agricultural Funds, European Investment Bank, etc).

We confirm that to our best knowledge neither the project as a whole nor any parts of it are (nor will be) submitted for any other EU grant (including EU funding managed by authorities in EU Member States or other funding bodies, e.g. Erasmus, EU

6.3 Financial support to third parties (if applicable)

NOT APPLICABLE

HISTORY OF CHANGES		
VERSION	SUBMISSION	CHANGE
1.0	21.02.2022	<p>Part A (uploaded online):</p> <p>WP1:</p> <ul style="list-style-type: none"> - Deliverable “Intermediate technical and financial report” and Deliverable “Final technical and financial report” have been deleted since they are already foreseen in the Grant Agreement. - The dissemination level of Deliverable “Intermediate EAB evaluation report” and Deliverable “Final EAB evaluation report” has been changed (from “C-UE/EU-C — EU Classified” to “SEN – Sensitive”) - Milestone MS2 mid term financial check (M15) → deleted <p>WP2:</p> <ul style="list-style-type: none"> - From 2 Leaders (ESOT and EPHA) to only one: ESOT - D2.2 project brochure (EPHA, M3) will be delivered together with D2.1 at M4 - MS3 → MS2 - MS4 (Lead Beneficiary EPHA, ESOT) → MS3 Leded by EPHA - MS5 (Lead Beneficiaries EPHA, ESOT) → MS4 Leded by EPHA <p>WP3:</p> <ul style="list-style-type: none"> - The leader has been updated (from ONT and PTG → only ONT) - MS6 → MS5 - MS7 → MS6 <p>WP4:</p> <ul style="list-style-type: none"> - The leader has been updated (from ESOT and CNT → only ESOT) - MS8 → MS7 (description and means of verification have been inserted) - MS9 → MS8 <p>WP5:</p> <ul style="list-style-type: none"> - The leader has been updated (from ESOT to ST) - MS10 → MS9 <p>Part B (DoA):</p> <ul style="list-style-type: none"> - The GANTT has been updated accordingly.
2.0	05.05.2022	<p>Part A (uploaded online):</p> <p>WP1:</p> <p>Task T1.2 Setting up of the External Advisory Board. The sentence “<i>Scientific project officers from the EU Commission will be asked to approve the list of EAB members</i>” has been deleted. Members of the EAB will be appointed by the GA during the KoM.</p> <p>Deliverable D1.1 “Financial Manual” has been deleted. The new D1.1 will be the minutes of the KoM with the list of the appointed members of EAB (M3). The new deliverable D1.1 will be the “new” means of verification for Milestone MS1 “Setting up the EAB”.</p>

	<p>WP2:</p> <p>Milestone MS2 due date updated from M3 to M4. Means of verification: Deliverables D2.1 and D2.2 foreseen at M4.</p> <p>WP5:</p> <p>Deliverable D5.2, description updated to consider the shortcoming “Sustainability plan has a major shortcoming, that it does not clearly consider those countries, which are not involved in project implementation and does not regard any specific forthcoming initiatives.”</p> <p>Annex Budget details:</p> <p>Correction of some errors in order to have consistency with the approved budget (present in form A). Differences are visible in the last table.</p> <p>Part B (DoA):</p> <ul style="list-style-type: none"> - Partners’ short names made coherent with information in DoA - Part A - Section 2.3: Minor changes to “Project teams and staff” table - Section 2.7: Risk Management table added - Section 4.2: WP and activities (already in DoA - Part A) added - Section 4.3: Timetable updated on the basis of the changes applied to the delivery date of D1.1, MS2, MS8. - Section 4.4: subcontracts’ description has been updated to ensure consistency of information <p>Following the indication of ESR:</p> <p>Section 1.1 updated in response to:</p> <p>“Overall project outline is though clear, yet it is a rather generic and lacks specific details. Insufficient details are elaborated and specified on what exact actions will be taken in the face of pandemic crisis.”</p> <p>Section 1.2 updated in response to:</p> <p>“Overall project outline is though clear, yet it is a rather generic and lacks specific details. Insufficient details are elaborated and specified on what exact actions will be taken in the face of pandemic crisis.”</p> <p>“Sustainability of the developed database is also lacking details on how it will be maintained after the EU funding ends and whether it intends to link to other pre-existing European databases.”</p> <p>“Impact/interest for the other European countries, especially those with the lower rates of organ donations and transplantations are not considered in details.”</p> <p>Section 2.1 updated in response to:</p> <p>“Impact/interest for the other European countries, especially those with the lower rates of organ donations and transplantations are not considered in details.” and “Sustainability plan has a major shortcoming, that it does not clearly consider those countries, which are not involved in project implementation and does not regard any specific forthcoming initiatives.”</p> <p>Sections 2.4, 2.5 and 2.6 updated in response to:</p> <p>“Managerial procedures are generally explained, yet specific actions are very vaguely addressed. Monitoring is inclusively planned, however explicit details on indicators and their values are not clearly elaborated.”</p>
--	--

		<p>“However, minor shortcomings are that cooperation procedures within the project team and problem solving mechanisms are not described clearly.”</p> <p>Section 2.7 Risk management table has been updated. In particular we have replaced the role of DG SANTE with the EAB. In response to:</p> <p>“Some risk mitigation measures (e.g. role of DG SANTE) are not adequately considered.”</p> <p>Section 3.1 updated in response to:</p> <p>“Sustainability of the developed database is also lacking details on how it will be maintained after the EU funding ends and whether it intends to link to other pre-existing European databases.”</p> <p>Section 3.2 updated in response to:</p> <p>“Dissemination strategy is not described with substantial details.”</p> <p>Section 3.3 updated in response to:</p> <p>“Sustainability of the developed database is also lacking details on how it will be maintained after the EU funding ends and whether it intends to link to other pre-existing European databases.”</p> <p>Section 4.1 updated in response to:</p> <p>“Sustainability of the developed database is also lacking details on how it will be maintained after the EU funding ends and whether it intends to link to other pre-existing European databases”</p> <p>Section 4.2 updated in response to:</p> <p>“Dissemination strategy is not described with substantial details.”</p> <p>Section 4.3 updated in response to:</p> <p>“Sustainability of the developed database is also lacking details on how it will be maintained after the EU funding ends and whether it intends to link to other pre-existing European databases.”</p> <p>and</p> <p>“Sustainability plan has a major shortcoming, that it does not clearly consider those countries, which are not involved in project implementation and does not regard any specific forthcoming initiatives.</p> <p>Annex “CVs” has been added.</p> <p>Annex “List of previous projects” has been added.</p>
3.0	01.06.2022	<p>Annex 1 - Description of the action - Part A</p> <ul style="list-style-type: none"> - the short name of Beneficiary 8 - INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE has been changed from PTG to INSERM - in the “General Information” section, the start date option has been changed in “A specific fixed date” and the 01 September 2022 has been indicated as fixed date, providing the justification for this choice. <p>Annex 1 - Description of the action - Part B</p> <ul style="list-style-type: none"> - the short name of Beneficiary 8 - INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE has been changed from PTG to INSERM - Section 2.6: total costs value has been updated to have it consistent with the information in “Annex 1 - Description of the action - Part B - Annex - Detailed Budget Table” and “Annex 2 – Estimated budget for the action”.

		<ul style="list-style-type: none"> - Section 4.1: in the work plan table, global cost data per WP have been corrected and updated to have them consistent with the values reported in “Annex 1 - Description of the action - Part B - Annex - Detailed Budget Table”. <p>Annex 1 - Description of the action - Part B - Annex - Detailed Budget Table</p> <ul style="list-style-type: none"> - calculated Personnel Costs of the partners have been corrected and updated to have them consistent with the ones from the proposal. <p>Annex 2 – Estimated budget for the action</p> <ul style="list-style-type: none"> - “Personnel costs” amounts have been corrected and updated to have them fully aligned with the ones reported in “Annex 1 - Description of the action - Part B - Annex - Detailed Budget Table” - “Travel and subsistence costs” amounts have been splitted among the sub-categories “Travel”, “Accommodation”, “Subsistence” and they are consistent with the ones reported in “Annex 1 - Description of the action - Part B - Annex - Detailed Budget Table” - Consequently to the changes applied to “Personnel costs”: “Indirect costs”, “Total costs”, “Maximum EU contribution”, “Requested EU contribution” and “Maximum Grant Amount” data are different from the ones of the previous version of Annex 2.
--	--	--

LIST OF PREVIOUS PROJECTS

List of previous projects					
<i>Please provide a list of your previous projects for the last 4 years.</i>					
Participant	Project Reference No and Title, Funding programme	Period (start and end date)	Role (COO, BEN, AE, OTHER)	Amount (EUR)	Website (if any)
ESOT, ET, ISS, OVSZ, ABM	EDITH	01.01.2017 - 31.12.2020	BEN, OTHER	999.980,91	https://edith-project.eu/
ISS, Slovenija Transplant	EUDONORGAN	Sept 2016 - August 2019	BEN	576.000	http://eudonorgan.eu/
ABM, ISS	ARTHIQS	May 2014 - April 2018	COO, BEN	1.864.757	NO WEBSITE
ISS, ABM	GAPP Joint Action	01.05.2018 - ongoing	COO, BEN	1.199.824,37	https://www.gapp-ja.eu/
ISS, OVSZ	VISTART Joint Action	10/10/2015 2019	COO, BEN	2.328.664	https://vistart-ja.eu/
ISS, ONT	EUROGTP-II	01.04.2016 - 30.03.2019	BEN	1.032.030	http://www.goodtis suepractices.eu/
ESOT, PTG	EU-TRAIN	Aug 2018 - Dec 2022	BEN	6.641.546	https://eu-train-project.eu/
ESOT	VANGUARD	01/01/2020 – 31/12/2024	BEN	6.800.000	https://vanguard-project.eu/

HISTORY OF CHANGES		
VERSION	PUBLICATION DATE	CHANGE
1.0	15.04.2021	Initial version (new MFF).

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	1-ESOT
Participant PIC:	994118081

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
Technical personnel	monthly	2.000,00	7,50	15.000,00		YES (WP2, WP4 and WP5)	Part time coordinator
Project managers	monthly	2.000,00	4,50	9.000,00		YES (WP2, WP4 and WP5)	senior project manager
Administrative personnel	monthly	1.000,00	7,50	7.500,00		YES (WP2, WP4 and WP5)	Administrative support
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)				31.500,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons						
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary						
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary				0,00			
Total personnel for this WP				31.500,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						

	A.1 Employees (or equivalent)							
	Technical personnel	monthly	2.000,00	7,50	15.000,00		YES (WP1, WP4 and WP5)	Part time coordinator
	Project managers	monthly	2.000,00	4,50	9.000,00		YES (WP1, WP4 and WP5)	senior project manager
	Administrative personnel	monthly	1.000,00	7,50	7.500,00		YES (WP1, WP4 and WP5)	Administrative support
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				31.500,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				31.500,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	A.1 Employees (or equivalent)							
		monthly	2.000,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				0,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	A.1 Employees (or equivalent)							
	Technical personnel	monthly	2.000,00	7,50	15.000,00		YES (WP1, WP2, WP5)	Part time coordinator
	Project managers	monthly	2.000,00	5,00	10.000,00		YES (WP1, WP2, WP5)	senior project manager
	Administrative personnel	monthly	1.000,00	8,00	8.000,00		YES (WP1, WP2, WP5)	Administrative support

Associated with document Ref. Ares(2022)4356368 - 13/06/2022							
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				33.000,00		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total natural persons under direct contract and seconded persons				0,00		
	A.4 SME owners and natural person beneficiaries without salary						
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
	Total SME owners and natural person beneficiaries without salary				0,00		
	Total personnel for this WP				33.000,00		
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY						
	A.1 Employees (or equivalent)						
	Technical personnel	monthly	2.000,00	7,50	15.000,00	YES (WP1, WP2, WP4)	Part time coordinator
	Project managers	monthly	2.000,00	5,00	10.000,00	YES (WP1, WP2, WP4)	senior project manager
	Administrative personnel	monthly	1.000,00	8,00	8.000,00	YES (WP1, WP2, WP4)	Administrative support
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				33.000,00		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total natural persons under direct contract and seconded persons				0,00		
	A.4 SME owners and natural person beneficiaries without salary						
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
	Total SME owners and natural person beneficiaries without salary				0,00		
	Total personnel for this WP				33.000,00		
Total personnel (all WPs)					129.000,00		
B. Subcontracting costs							
			Costs (actual costs)			Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	1 [Subcontract short name]		0,00				

	2 [Subcontract short name]	0,00								
	Total subcontracting for this WP	0,00							Associated with document Ref. Ares(2022)4356368 - 13/06/2022	
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION									
	1 [Subcontract short name]	0,00								
	2 [Subcontract short name]	0,00								
	Total subcontracting for this WP	0,00								
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES									
	Study-oriented web-based platform	70.000,00					NO	T1.4 BRAVEST study-oriented web-based platform. Lack of internal expertise to develop a study specific platform under the requirement to be set by WP3		
		0,00								
	Total subcontracting for this WP	70.000,00								
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS									
	Medical Writing	10.000,00					NO	T4.1 CNT. ESOT will subcontract an expert in medical writings to support the activity.		
	2 [Subcontract short name]	0,00								
	Total subcontracting for this WP	10.000,00								
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY									
	Cost Analysis	20.000,00					NO	T5.2 Sustainability and cost- effectiveness analysis of the cost impact for healthcare services of the proposed guidelines and recommendations, as compared with the current standard of care.		
	2 [Subcontract short name]	0,00								
	Total subcontracting for this WP	20.000,00								
		Total subcontracting (all WPs)	100.000,00							
C. Purchase costs										
C.1 Travel and subsistence										
		Costs (actual costs)	Costs (unit cost)				Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)		
			Amount per unit	Number of units	Total (EUR)					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION									
	1 project meeting									
	Speakers									
	Travel costs		0,00	0,00	0,00					
	Accommodation costs		0,00	0,00	0,00					
	Subsistence costs		0,00	0,00	0,00					
	Personnel									
	Travel costs	900,00	0,00	0,00	0,00		NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)		
	Accommodation costs	450,00	0,00	0,00	0,00					
	Subsistence costs	150,00	0,00	0,00	0,00					
	Participants									
	Travel costs	2.100,00	0,00	0,00	0,00		NO	Project meeting, 2days, 7 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)		
	Accommodation costs	1.050,00	0,00	0,00	0,00					

Subsistence costs	350,00	0,00	0,00	0,00	0,00
Total travel costs for this travel	3.000,00				
Total accomodation costs for this travel	1.500,00				
Total subsistence costs for this travel	500,00				
Total travel	5.000,00				

2 project meeting					
Speakers					
Travel costs		0,00	0,00	0,00	0,00
Accomodation costs		0,00	0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00	0,00
Personnel					
Travel costs	900,00	0,00	0,00	0,00	0,00
Accomodation costs	450,00	0,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00	0,00
Participants					
Travel costs	1.800,00	0,00	0,00	0,00	0,00
Accomodation costs	900,00	0,00	0,00	0,00	0,00
Subsistence costs	300,00	0,00	0,00	0,00	0,00
Total travel costs for this travel	2.700,00				
Total accomodation costs for this travel	1.350,00				
Total subsistence costs for this travel	450,00				
Total travel	4.500,00				

NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
NO	Project meeting, 2days, 6 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)

3 project meeting					
Speakers					
Travel costs		0,00	0,00	0,00	0,00
Accomodation costs		0,00	0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00	0,00
Personnel					
Travel costs	900,00	0,00	0,00	0,00	0,00
Accomodation costs	450,00	0,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00	0,00
Participants					
Travel costs	1.800,00	0,00	0,00	0,00	0,00
Accomodation costs	900,00	0,00	0,00	0,00	0,00
Subsistence costs	300,00	0,00	0,00	0,00	0,00
Total travel costs for this travel	2.700,00				
Total accomodation costs for this travel	1.350,00				
Total subsistence costs for this travel	450,00				
Total travel	4.500,00				

NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
NO	Project meeting, 2days, 6 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)

	Total travel costs for this WP	8.400,00				
	Total accomodation costs for this WP	4.200,00				
	Total subsistence costs for this WP	1.400,00				
	Total travel for this WP	14.000,00				

WORK PACKAGE 2 COMMUNICATION DISSEMINATION AND EXPLOITATION


1 stakeholder final dissemination conference						
Speakers						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Personnel						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Participants						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Total travel costs for this travel	0,00				
	Total accomodation costs for this travel	0,00				
	Total subsistence costs for this travel	0,00				
	Total travel	0,00				
	Total travel costs for this WP	0,00				
	Total accomodation costs for this WP	0,00				
	Total subsistence costs for this WP	0,00				
	Total travel for this WP	0,00				

WORK PACKAGE 3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

1 Technical Meeting						
Speakers						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Personnel						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Participants						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Total travel costs for this travel	0,00				
	Total accomodation costs for this travel	0,00				
	Total subsistence costs for this travel	0,00				


	Total travel	0,00					
	2 Technical Meeting						
	Speakers						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Personnel						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accommodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					
	3 Technical Meeting						
	Speakers						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Personnel						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accommodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					
	Total travel costs for this WP	0,00					
	Total accommodation costs for this WP	0,00					
	Total subsistence costs for this WP	0,00					
	Total travel for this WP	0,00					
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS						
	1 Technical Meeting						
	Speakers						

	Travel costs		0,00	0,00	0,00				
	Accommodation costs		0,00	0,00	0,00				
	Subsistence costs		0,00	0,00	0,00				
	Personnel								
	Travel costs	900,00	0,00	0,00	0,00		NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	450,00	0,00	0,00	0,00				
	Subsistence costs	150,00	0,00	0,00	0,00				
	Participants								
	Travel costs	2.100,00	0,00	0,00	0,00		NO	Project meeting, 2days, 7 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	1.050,00	0,00	0,00	0,00				
	Subsistence costs	350,00	0,00	0,00	0,00				
	Total travel costs for this travel	3.000,00							
	Total accommodation costs for this travel	1.500,00							
	Total subsistence costs for this travel	500,00							
	Total travel	5.000,00							
	2 Technical meeting								
	Speakers								
	Travel costs		0,00	0,00	0,00				
	Accommodation costs		0,00	0,00	0,00				
	Subsistence costs		0,00	0,00	0,00				
	Personnel								
	Travel costs	900,00	0,00	0,00	0,00		NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	450,00	0,00	0,00	0,00				
	Subsistence costs	150,00	0,00	0,00	0,00				
	Participants								
	Travel costs	1.800,00	0,00	0,00	0,00		NO	Project meeting, 2days, 6 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	900,00	0,00	0,00	0,00				
	Subsistence costs	300,00	0,00	0,00	0,00				
	Total travel costs for this travel	2.700,00							
	Total accommodation costs for this travel	1.350,00							
	Total subsistence costs for this travel	450,00							
	Total travel	4.500,00							
	3 Technical meeting								
	Speakers								
	Travel costs		0,00	0,00	0,00				
	Accommodation costs		0,00	0,00	0,00				
	Subsistence costs		0,00	0,00	0,00				
	Personnel								

	Travel costs	900,00	0,00	0,00	0,00	0,00	NO	 Associated with the project. Reference: 4356368 - 13/06/2022	
	Accommodation costs	450,00	0,00	0,00	0,00	0,00			
	Subsistence costs	150,00	0,00	0,00	0,00	0,00			
	Participants								
	Travel costs	1.800,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 6 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	900,00	0,00	0,00	0,00	0,00			
	Subsistence costs	300,00	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	2.700,00							
	Total accommodation costs for this travel	1.350,00							
	Total subsistence costs for this travel	450,00							
	Total travel	4.500,00							
	Total travel costs for this WP	8.400,00							
	Total accommodation costs for this WP	4.200,00							
	Total subsistence costs for this WP	1.400,00							
	Total travel for this WP	14.000,00							
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY								
	1 Technical Meeting								
	Speakers								
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
	Personnel								
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
	Participants								
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	0,00							
	Total accommodation costs for this travel	0,00							
	Total subsistence costs for this travel	0,00							
	Total travel	0,00							
	Total travel costs for this WP	0,00							
	Total accommodation costs for this WP	0,00							
	Total subsistence costs for this WP	0,00							
	Total travel for this WP	0,00							
	Total travel costs (all WPs)					16.800,00			
	Total accommodation (all WPs)					8.400,00			
	Total subsistence (all WPs)					2.800,00			

Total travel and subsistence (all WPs)

28.000,00

 Associated with document Ref. Ares(2022)4356368 - 13/06/2022

C.2 Equipment

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	$e = (c/b * d) * a$		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total depreciation					0,00	
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b		c	$d = a * b * c$		
	1 [Equipment short name]	0,00	0,00		0%	0,00	
	2 [Equipment short name]	0,00	0,00		0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total rental and leasing					0,00	
	Total equipment for this WP					0,00	
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	$e = (c/b * d) * a$		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total depreciation					0,00	
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b		c	$d = a * b * c$		
	1 [Equipment short name]	0,00	0,00		0%	0,00	
	2 [Equipment short name]	0,00	0,00		0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total rental and leasing					0,00	
	Total equipment for this WP					0,00	
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	$e = (c/b * d) * a$		

1 [Equipment short name]	a	b	c	d	e = (c/b * d) * a	WP	Description of tasks/activities for which the equipment is needed
	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
Costs (actual costs)							
1 [Equipment short name]	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	d = a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00			
2 [Equipment short name]	0,00	0,00	0%	0,00			
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00		
Total equipment for this WP					0,00		

WORK PACKAGE 4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS

C.2.1 Purchase (depreciation/full cost)							
Costs (actual costs)							
1 [Equipment short name]	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
Costs (actual costs)							
1 [Equipment short name]	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	d = a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00			
2 [Equipment short name]	0,00	0,00	0%	0,00			
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00		
Total equipment for this WP					0,00		

WORK PACKAGE 5 IMPLEMENTATION AND SUSTAINABILITY

C.2.1 Purchase (depreciation/full cost)							
Costs (actual costs)							
1 [Equipment short name]	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							

	Monthly rent/fee	Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
		Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
		a	b	c		
1 [Equipment short name]	0,00	0,00	0%	0,00		
2 [Equipment short name]	0,00	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
Total rental and leasing				0,00		
Total equipment for this WP				0,00		

Total equipment (all WPs) 0,00

C.3 Other goods, works and services

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION			
	Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
Consumables	2.000,00		NO	Project management licensing fee
Conferences, seminars, workshops, trainings & events				
Information & publications	0,00			
Other expenses				
1 IPR costs	0,00			
2 Bank fees (pre-financing guarantee)	0,00			
3 Audit fees (CFS)	0,00			
4 Project evaluation	0,00			
[5 short name other]	0,00			
[6 short name other]	0,00			
Total goods, works and services for this WP		2.000,00		

WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION			
	Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
Consumables	0,00			
Conferences, seminars, workshops, trainings & events	21.000,00		NO	Costs for the organization of the Symposium of the Transplant Learning Journey, Symposium at the ESOT congress 2023 for the presentation of general outcomes
Information & publications	10.000,00		NO	open access publication
Other expenses				
1 IPR costs	0,00			
2 Bank fees (pre-financing guarantee)	0,00			
3 Audit fees (CFS)	0,00			
4 Project evaluation	0,00			
[5 short name other]	0,00			
[6 short name other]	0,00			
Total goods, works and services for this WP		31.000,00		

WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES			
	Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
Consumables	0,00			

	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	30.000,00		NO	translation of guideliens in the 27EU official languages and online tool to suport hosting of the guideline (WIKI page)
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	30.000,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
	Total goods, works and services (all WPs)	63.000,00			
			Total purchase costs (all WPs)	91.000,00	
D. Other cost categories					

D.1. Financial support to third parties

WORK PACKAGE 1		COORDINATION, MANAGEMENT AND EVALUATION			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 2		COMMUNICATION DISSEMINATION AND EXPLOITATION			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 3		ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 4		GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 5		IMPLEMENTATION AND SUSTAINABILITY			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			

		Total D.1 (all WPs)	0,00	Associated with document Ref. Ares(2022)4356368 - 13/06/2022	
		Total other cost categories (all WPs)	0,00		
E. Indirect costs					
		Costs (flat-rate)			
ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	320.000,00			
	Flat-rate (%)	7%			
	Total indirect costs	22.400,00			
		Total indirect costs	22.400,00		
			TOTAL COSTS PARTICIPANT	342.400,00	
PROJECT INCOME					
EU CONTRIBUTION (GRANT)					
		Amount (EUR)			
	Total costs	342.400,00			
	Single Funding rate (%)	80%			
	Maximum EU contribution	273.920,00			
	Requested EU contribution	273.920,00			
		EU CONTRIBUTION	273.920,00		
REVENUES AND CONTRIBUTIONS BY THIRD PARTIES					
Revenues					
Income generated by the action					
		Amount (EUR)		Description of the income (type of generated income and number of users, etc)	
ALL WORK PACKAGES	Estimated income generated by the action	0,00			
	Total income generated by the action	0,00			
		Revenues	0,00		
In-kind contributions by third parties					
In-kind contributions by third parties					
		Amount (EUR)		Description of the contribution (type of contribution, donor, purpose etc)	
ALL WORK PACKAGES	Estimated in-kind contributions by third parties	0,00			
	Total in-kind contributions	0,00			
		In-kind contributions	0,00		

Financial contributions by third parties

Financial contributions by third parties

		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	Estimated financial contributions by third parties	0,00	
	Total financial contributions	0,00	
Financial contributions		0,00	
TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES		0,00	
OWN RESOURCES			
		Amount (EUR)	
	Own resources	68.480,00	
OWN RESOURCES		68.480,00	
TOTAL INCOME PARTICIPANT		342.400,00	

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	1-ESOT
Participant PIC:	994118081

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE

	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories D.1 Financial support to third parties d1	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3			
WP1 COORDINATION, MANAGEMENT AND EVALUATION	31.500,00	0,00	0,00	14.000,00	8.400,00	4.200,00	1.400,00	0,00	2.000,00	0,00	3.325,00	50.825,00
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	31.500,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	31.000,00	0,00	4.375,00	66.875,00
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	0,00	0,00	70.000,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4.900,00	74.900,00
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	33.000,00	0,00	10.000,00	14.000,00	8.400,00	4.200,00	1.400,00	0,00	30.000,00	0,00	6.090,00	93.090,00
WP5 IMPLEMENTATION AND SUSTAINABILITY	33.000,00	0,00	20.000,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3.710,00	56.710,00
TOTAL COSTS PARTICIPANT	129.000,00	0,00	100.000,00	28.000,00	16.800,00	8.400,00	2.800,00	0,00	63.000,00	0,00	22.400,00	342.400,00

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	2-ISS-CNT
Participant PIC:	999978821

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
Project managers	monthly	6.065,00	0,25	1.516,25		YES (WP2, WP3, WP4 and WP5)	senior project manager
Technical personnel	monthly	3.903,00	1,10	4.293,30		YES (WP2, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
Technical personnel	monthly	3.903,00	1,15	4.488,45		YES (WP2, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)				10.298,00			
A.2 + A.3 Natural persons under direct contract and seconded persons							
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons				0,00			
A.4 SME owners and natural person beneficiaries without salary							
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary				0,00			
Total personnel for this WP				10.298,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						

	A.1 Employees (or equivalent)							
	Project managers	monthly	6.065,00	0,25	1.516,25		YES (WP1, WP3, WP4 and WP5)	senior project manager
	Technical personnel	monthly	3.903,00	2,00	7.806,00		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Technical personnel	monthly	3.903,00	1,25	4.878,75		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				14.201,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				14.201,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	16.725,00	0,15	2.508,75		YES (WP4, WP5)	DIRECTOR GENERAL / SCIENTIFIC MANAGER
	Project managers	monthly	6.065,00	0,25	1.516,25		YES (WP1, WP3, WP4 and WP5)	senior project manager
	Technical personnel	monthly	3.903,00	0,20	780,60		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Technical personnel	monthly	3.903,00	0,20	780,60		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				5.586,20			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Senior experts/advisors/researchers	monthly	9.669,00	2,00	19.338,00		YES (WP4)	MEDICAL EXPERT
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				19.338,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				24.924,20			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	A.1 Employees (or equivalent)							

	Senior experts/advisors/researchers	monthly	16.725,00	0,15	2.508,75		YES (WP3, WP5)	DIRECTOR GENERAL / SCIENTIFIC MANAGER
	Project managers	monthly	6.065,00	0,25	1.516,25		YES (WP1, WP3, WP4 and WP5)	senior project manager
	Technical personnel	monthly	3.903,00	0,20	780,60		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Technical personnel	monthly	3.903,00	0,20	780,60		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				5.586,20			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Senior experts/advisors/researchers	monthly	9.669,00	2,00	19.338,00		YES (WP3)	MEDICAL EXPERT
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				19.338,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				24.924,20			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	16.725,00	0,15	2.508,75		YES (WP3, WP4)	DIRECTOR GENERAL / SCIENTIFIC MANAGER
	Project managers	monthly	6.065,00	0,25	1.516,25		YES (WP1, WP3, WP4 and WP5)	senior project manager
	Technical personnel	monthly	3.903,00	0,20	780,60		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Technical personnel	monthly	3.903,00	0,20	780,60		YES (WP1, WP3, WP4 and WP5)	SENIOR PROJECT EXECUTIVE
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				5.586,20			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				5.586,20			
Total personnel (all WPs)					79.933,60			

B. Subcontracting costs

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
		Total subcontracting (all WPs)	100.000,00		

C. Purchase costs

C.1 Travel and subsistence

		Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
			Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	1 project meeting						
	Speakers						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Personnel						
	Travel costs	900,00	0,00	0,00	0,00	NO	
	Accommodation costs	450,00	0,00	0,00	0,00	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Subsistence costs	150,00	0,00	0,00	0,00		
	Participants						

	Travel costs	2.100,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 7 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)	
	Accomodation costs	1.050,00	0,00	0,00	0,00	0,00			
	Subsistence costs	350,00	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	3.000,00							
	Total accomodation costs for this travel	1.500,00							
	Total subsistence costs for this travel	500,00							
	Total travel	5.000,00							
2 project meeting									
Speakers									
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accomodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
Personnel									
	Travel costs	900,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)	
	Accomodation costs	450,00	0,00	0,00	0,00	0,00			
	Subsistence costs	150,00	0,00	0,00	0,00	0,00			
Participants									
	Travel costs	1.500,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 5 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)	
	Accomodation costs	750,00	0,00	0,00	0,00	0,00			
	Subsistence costs	250,00	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	2.400,00							
	Total accomodation costs for this travel	1.200,00							
	Total subsistence costs for this travel	400,00							
	Total travel	4.000,00							
3 project meeting									
Speakers									
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accomodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
Personnel									
	Travel costs	900,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)	
	Accomodation costs	450,00	0,00	0,00	0,00	0,00			
	Subsistence costs	150,00	0,00	0,00	0,00	0,00			
Participants									
	Travel costs	1.500,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 5 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)	
	Accomodation costs	750,00	0,00	0,00	0,00	0,00			
	Subsistence costs	250,00	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	2.400,00							

	Total accomodation costs for this travel	1.200,00				
	Total subsistence costs for this travel	400,00				
	Total travel	4.000,00				
	Total travel costs for this WP	7.800,00				
	Total accomodation costs for this WP	3.900,00				
	Total subsistence costs for this WP	1.300,00				
	Total travel for this WP	13.000,00				

WORK PACKAGE 2 COMMUNICATION DISSEMINATION AND EXPLOITATION

1 stakeholder final dissemination conference						
Speakers						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Personnel						
	Travel costs	600,00	0,00	0,00	0,00	NO stakeholder final dissemination conference, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
	Accomodation costs	300,00	0,00	0,00	0,00	
	Subsistence costs	100,00	0,00	0,00	0,00	
Participants						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Total travel costs for this travel	600,00				
	Total accomodation costs for this travel	300,00				
	Total subsistence costs for this travel	100,00				
	Total travel	1.000,00				
	Total travel costs for this WP	600,00				
	Total accomodation costs for this WP	300,00				
	Total subsistence costs for this WP	100,00				
	Total travel for this WP	1.000,00				

WORK PACKAGE 3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

1 Technical Meeting						
Speakers						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Personnel						
	Travel costs	900,00	0,00	0,00	0,00	NO Technical meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
	Accomodation costs	450,00	0,00	0,00	0,00	
	Subsistence costs	150,00	0,00	0,00	0,00	
Participants						
	Travel costs	0,00	0,00	0,00	0,00	

Accommodation costs	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00		
Total travel costs for this travel	900,00					
Total accomodation costs for this travel	450,00					
Total subsistence costs for this travel	150,00					
Total travel	1.500,00					

2 Technical Meeting						
Speakers						
Travel costs	0,00	0,00	0,00	0,00		
Accommodation costs	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00		
Personnel						
Travel costs	900,00	0,00	0,00	0,00	NO	Technical meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
Accommodation costs	450,00	0,00	0,00	0,00		
Subsistence costs	150,00	0,00	0,00	0,00		
Participants						
Travel costs	0,00	0,00	0,00	0,00		
Accommodation costs	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00		
Total travel costs for this travel	900,00					
Total accomodation costs for this travel	450,00					
Total subsistence costs for this travel	150,00					
Total travel	1.500,00					

3 Technical Meeting						
Speakers						
Travel costs	0,00	0,00	0,00	0,00		
Accommodation costs	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00		
Personnel						
Travel costs	600,00	0,00	0,00	0,00	NO	Technical meeting, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
Accommodation costs	300,00	0,00	0,00	0,00		
Subsistence costs	100,00	0,00	0,00	0,00		
Participants						
Travel costs	0,00	0,00	0,00	0,00		
Accommodation costs	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00		
Total travel costs for this travel	600,00					
Total accomodation costs for this travel	300,00					
Total subsistence costs for this travel	100,00					
Total travel	1.000,00					
Total travel costs for this WP	2.400,00					

	Total accomodation costs for this WP	1.200,00			
	Total subsistence costs for this WP	400,00			
	Total travel for this WP	4.000,00			

WORK PACKAGE 4 **GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS**

1 Technical Meeting					
Speakers					
	Travel costs	0,00	0,00	0,00	0,00
	Accomodation costs	0,00	0,00	0,00	0,00
	Subsistence costs	0,00	0,00	0,00	0,00
Personnel					
	Travel costs	900,00	0,00	0,00	0,00
	Accomodation costs	450,00	0,00	0,00	0,00
	Subsistence costs	150,00	0,00	0,00	0,00
Participants					
	Travel costs	0,00	0,00	0,00	0,00
	Accomodation costs	0,00	0,00	0,00	0,00
	Subsistence costs	0,00	0,00	0,00	0,00
	Total travel costs for this travel	900,00			
	Total accomodation costs for this travel	450,00			
	Total subsistence costs for this travel	150,00			
	Total travel	1.500,00			

NO	Technical meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)

2 Technical meeting					
Speakers					
	Travel costs	0,00	0,00	0,00	0,00
	Accomodation costs	0,00	0,00	0,00	0,00
	Subsistence costs	0,00	0,00	0,00	0,00
Personnel					
	Travel costs	900,00	0,00	0,00	0,00
	Accomodation costs	450,00	0,00	0,00	0,00
	Subsistence costs	150,00	0,00	0,00	0,00
Participants					
	Travel costs	0,00	0,00	0,00	0,00
	Accomodation costs	0,00	0,00	0,00	0,00
	Subsistence costs	0,00	0,00	0,00	0,00
	Total travel costs for this travel	900,00			
	Total accomodation costs for this travel	450,00			
	Total subsistence costs for this travel	150,00			
	Total travel	1.500,00			

NO	Technical meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)

3 Technical meeting					
Speakers					
	Travel costs		0,00	0,00	0,00

	Accommodation costs		0,00	0,00	0,00		
	Subsistence costs		0,00	0,00	0,00		Associated with document Ref. Ares(2022)4356368 - 13/06/2022
Personnel							
	Travel costs	600,00	0,00	0,00	0,00	NO	Technical meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00		
Participants							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00					
	Total accommodation costs for this travel	300,00					
	Total subsistence costs for this travel	100,00					
	Total travel	1.000,00					
	Total travel costs for this WP	2.400,00					
	Total accommodation costs for this WP	1.200,00					
	Total subsistence costs for this WP	400,00					
	Total travel for this WP	4.000,00					
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY						
	1 Technical Meeting						
Speakers							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Personnel							
	Travel costs	1.200,00	0,00	0,00	0,00	NO	Technical meeting, 2days, 4 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	600,00	0,00	0,00	0,00		
	Subsistence costs	200,00	0,00	0,00	0,00		
Participants							
	Travel costs	600,00	0,00	0,00	0,00	NO	Technical meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00		
	Total travel costs for this travel	1.800,00					
	Total accommodation costs for this travel	900,00					
	Total subsistence costs for this travel	300,00					
	Total travel	3.000,00					
	Total travel costs for this WP	1.800,00					
	Total accommodation costs for this WP	900,00					
	Total subsistence costs for this WP	300,00					
	Total travel for this WP	3.000,00					

Total travel costs (all WPs)	15.000,00
Total accomodation (all WPs)	7.500,00
Total subsistence (all WPs)	2.500,00
Total travel and subsistence (all WPs)	25.000,00

C.2 Equipment

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	$e = (c/b * d) * a$		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total depreciation				0,00		
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b		c	$d = a * b * c$		
1 [Equipment short name]	0,00	0,00		0%	0,00		
2 [Equipment short name]	0,00	0,00		0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total rental and leasing				0,00		
	Total equipment for this WP				0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	$e = (c/b * d) * a$		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total depreciation				0,00		
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b		c	$d = a * b * c$		
1 [Equipment short name]	0,00	0,00		0%	0,00		
2 [Equipment short name]	0,00	0,00		0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total rental and leasing				0,00		

Total equipment for this WP

0,00

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

WORK PACKAGE 3

ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

C.2.1 Purchase (depreciation/full cost)

	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		

C.2.2 Rental and leasing (rate of use/full cost)

	Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
	a	b	c	d = a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00			
2 [Equipment short name]	0,00	0,00	0%	0,00			
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
Total rental and leasing				0,00			
Total equipment for this WP					0,00		

WORK PACKAGE 4

GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS

C.2.1 Purchase (depreciation/full cost)

	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		

C.2.2 Rental and leasing (rate of use/full cost)

	Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
	a	b	c	d = a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00			
2 [Equipment short name]	0,00	0,00	0%	0,00			
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
Total rental and leasing				0,00			
Total equipment for this WP					0,00		

WORK PACKAGE 5

IMPLEMENTATION AND SUSTAINABILITY

C.2.1 Purchase (depreciation/full cost)

	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		

1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
Costs (actual costs)							
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b		c	d= a*b*c		
1 [Equipment short name]	0,00	0,00		0%	0,00		
2 [Equipment short name]	0,00	0,00		0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00		
Total equipment for this WP					0,00		
Total equipment (all WPs)					0,00		

C.3 Other goods, works and services

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
		Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00					
	Conferences, seminars, workshops, trainings & events	0,00					
	Information & publications	0,00					
	Other expenses						
	1 IPR costs	0,00					
	2 Bank fees (pre-financing guarantee)	0,00					
	3 Audit fees (CFS)	0,00					
	4 Project evaluation	0,00					
	[5 short name other]	0,00					
	[6 short name other]	0,00					
Total goods, works and services for this WP		0,00					
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
		Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00					
	Conferences, seminars, workshops, trainings & events	0,00					
	Information & publications	0,00					
	Other expenses						
	1 IPR costs	0,00					
	2 Bank fees (pre-financing guarantee)	0,00					
	3 Audit fees (CFS)	0,00					
	4 Project evaluation	0,00					
	[5 short name other]	0,00					
	[6 short name other]	0,00					

Total goods, works and services for this WP		0,00	Associated with document Ref. Ares(2022)4356368 - 13/06/2022			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES					
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00				
	Conferences, seminars, workshops, trainings & events	0,00				
	Information & publications	0,00				
	Other expenses					
	1 IPR costs	0,00				
	2 Bank fees (pre-financing guarantee)	0,00				
	3 Audit fees (CFS)	0,00				
	4 Project evaluation	0,00				
	[5 short name other]	0,00				
[6 short name other]	0,00					
Total goods, works and services for this WP		0,00				
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS					
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00				
	Conferences, seminars, workshops, trainings & events	0,00				
	Information & publications	0,00				
	Other expenses					
	1 IPR costs	0,00				
	2 Bank fees (pre-financing guarantee)	0,00				
	3 Audit fees (CFS)	0,00				
	4 Project evaluation	0,00				
	[5 short name other]	0,00				
[6 short name other]	0,00					
Total goods, works and services for this WP		0,00				
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY					
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00				
	Conferences, seminars, workshops, trainings & events	0,00				
	Information & publications	0,00				
	Other expenses					
	1 IPR costs	0,00				
	2 Bank fees (pre-financing guarantee)	0,00				
	3 Audit fees (CFS)	0,00				
	4 Project evaluation	0,00				
	[5 short name other]	0,00				
[6 short name other]	0,00					
Total goods, works and services for this WP		0,00				

Total goods, works and services (all WPs) 0,00

Total purchase costs (all WPs) 25.000,00

D. Other cost categories

D.1. Financial support to third parties

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			

	[Support scheme short name]	0,00			
		0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
	Total other cost category D.1 for this WP	0,00			
			Total D.1 (all WPs)	0,00	
			Total other cost categories (all WPs)	0,00	
E. Indirect costs					
		Costs (flat-rate)			
ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	104.933,60			
	Flat-rate (%)	7%			
	Total indirect costs	7.345,35			
	Total indirect costs	7.345,35			
			TOTAL COSTS PARTICIPANT	112.278,95	
PROJECT INCOME					
EU CONTRIBUTION (GRANT)					
		Amount (EUR)			
	Total costs	112.278,95			
	Single Funding rate (%)	80%			
	Maximum EU contribution	89.823,16			
	Requested EU contribution	89.823,16			
	EU CONTRIBUTION	89.823,16			
REVENUES AND CONTRIBUTIONS BY THIRD PARTIES					
Revenues					
Income generated by the action					
		Amount (EUR)			Description of the income (type of generated income and number of users, etc)
ALL WORK PACKAGES	Estimated income generated by the action	0,00			
	Total income generated by the action	0,00			
	Revenues	0,00			
In-kind contributions by third parties					
In-kind contributions by third parties					

		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	Estimated in-kind contributions by third parties	0,00	
	Total in-kind contributions	0,00	
	In-kind contributions	0,00	
Financial contributions by third parties			
Financial contributions by third parties			
		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	Estimated financial contributions by third parties	0,00	
	Total financial contributions	0,00	
	Financial contributions	0,00	
TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES		0,00	
OWN RESOURCES			
		Amount (EUR)	
	Own resources	22.455,79	
OWN RESOURCES		22.455,79	
TOTAL INCOME PARTICIPANT		112.278,95	

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	2-ISS-CNT
Participant PIC:	999978821

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE

	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories D.1 Financial support to third parties d1	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3			
WP1 COORDINATION, MANAGEMENT AND EVALUATION	10.298,00	0,00	0,00	13.000,00	7.800,00	3.900,00	1.300,00	0,00	0,00	0,00	1.630,86	24.928,86
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	14.201,00	0,00	0,00	1.000,00	600,00	300,00	100,00	0,00	0,00	0,00	1.064,07	16.265,07
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	24.924,20	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	2.024,69	30.948,89
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	24.924,20	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	2.024,69	30.948,89
WP5 IMPLEMENTATION AND SUSTAINABILITY	5.586,20	0,00	0,00	3.000,00	1.800,00	900,00	300,00	0,00	0,00	0,00	601,03	9.187,23
TOTAL COSTS PARTICIPANT	79.933,60	0,00	0,00	25.000,00	15.000,00	7.500,00	2.500,00	0,00	0,00	0,00	7.345,35	112.278,95

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	3-ONT
Participant PIC:	941056365

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
Project managers	monthly	6.150,00	0,20	1.230,00		YES (WP2, WP3, WP4)	Director General; MD, Project manager
Senior experts/advisors/researchers	monthly	6.150,00	0,05	328,41		YES (WP2, WP3, WP4)	MD, senior expert in data analysis
Senior experts/advisors/researchers	monthly	6.150,00	0,05	328,41		YES (WP2, WP3, WP4)	MD, senior expert in data analysis
Senior experts/advisors/researchers	monthly	3.600,00	0,05	192,24		YES (WP2, WP3, WP4)	Nurse, expert in data analysis
Technical personnel	monthly	3.600,00	0,30	1.080,00		YES (WP2, WP3, WP4)	Tecnical personnel
	Other						
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)			3.159,06			
	A.2 + A.3 Natural persons under direct contract and seconded persons						
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
	Other						
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons			0,00			
	A.4 SME owners and natural person beneficiaries without salary						
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary			0,00			

		Total personnel for this WP		3.159,06		Associated with document Ref. Ares(2022)4356368 - 13/06/2022	
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
A.1 Employees (or equivalent)							
Project managers	monthly	6.150,00	0,40	2.460,00	YES (WP1, WP3, WP4)	Director General; MD, Project manager	
Senior experts/advisors/researchers	monthly	6.150,00	0,20	1.230,00	YES (WP1, WP3, WP4)	MD, senior expert in data analysis	
Senior experts/advisors/researchers	monthly	6.150,00	0,20	1.230,00	YES (WP1, WP3, WP4)	MD, senior expert in data analysis	
Senior experts/advisors/researchers	monthly	3.600,00	0,20	720,00	YES (WP1, WP3, WP4)	Nurse, expert in data analysis	
Technical personnel	monthly	3.600,00	0,30	1.080,00	YES (WP1, WP3, WP4)	Tecnical personnel	
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)				6.720,00			
A.2 + A.3 Natural persons under direct contract and seconded persons							
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons				0,00			
A.4 SME owners and natural person beneficiaries without salary							
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary				0,00			
Total personnel for this WP				6.720,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
A.1 Employees (or equivalent)							
Project managers	monthly	6.150,00	3,55	21.832,50	YES (WP1, WP2, WP4)	Director General; MD, Project manager	
Senior experts/advisors/researchers	monthly	6.150,00	3,55	21.832,50	YES (WP1, WP2, WP4)	MD, senior expert in data analysis	
Senior experts/advisors/researchers	monthly	6.150,00	3,55	21.832,50	YES (WP1, WP2, WP4)	MD, senior expert in data analysis	
Senior experts/advisors/researchers	monthly	3.600,00	2,24	8.064,00	YES (WP1, WP2, WP4)	Nurse, expert in data analysis	
Technical personnel	monthly	3.600,00	2,24	8.064,00	YES (WP1, WP2, WP4)	Tecnical personnel	
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)				81.625,50			
A.2 + A.3 Natural persons under direct contract and seconded persons							
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons				0,00			
A.4 SME owners and natural person beneficiaries without salary							
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			

	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				81.625,50			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	A.1 Employees (or equivalent)							
	Project managers	monthly	6.150,00	1,50	9.225,00		YES (WP1, WP2, WP3)	Director General; MD, Project manager
	Senior experts/advisors/researchers	monthly	6.150,00	1,15	7.072,50		YES (WP1, WP2, WP3)	MD, senior expert in data analysis
	Senior experts/advisors/researchers	monthly	6.150,00	1,15	7.072,50		YES (WP1, WP2, WP3)	MD, senior expert in data analysis
	Senior experts/advisors/researchers	monthly	3.600,00	0,60	2.160,00		YES (WP1, WP2, WP3)	Nurse, expert in data analysis
	Technical personnel	monthly	3.600,00	0,60	2.160,00		YES (WP1, WP2, WP3)	Tecnical personnel
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				27.690,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				27.690,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
	A.1 Employees (or equivalent)							
		monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				0,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				0,00			

Total personnel (all WPs) 119.194,56

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

B. Subcontracting costs

		Costs (actual costs)				Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	1 [Subcontract short name]	0,00					
	2 [Subcontract short name]	0,00					
	Total subcontracting for this WP	0,00					
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	1 [Subcontract short name]	0,00					
	2 [Subcontract short name]	0,00					
	Total subcontracting for this WP	0,00					
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
	1 [Subcontract short name]	0,00					
	2 [Subcontract short name]	0,00					
	Total subcontracting for this WP	0,00					
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS						
	1 [Subcontract short name]	0,00					
	2 [Subcontract short name]	0,00					
	Total subcontracting for this WP	0,00					
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY						
	1 [Subcontract short name]	0,00					
	2 [Subcontract short name]	0,00					
	Total subcontracting for this WP	0,00					
		Total subcontracting (all WPs)			100.000,00		

C. Purchase costs

C.1 Travel and subsistence

		Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
			Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	1 project meeting						
	Speakers						
	Travel costs		0,00	0,00	0,00		
	Accommodation costs		0,00	0,00	0,00		
	Subsistence costs		0,00	0,00	0,00		
	Personnel						
	Travel costs	600,00	0,00	0,00	0,00	NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00	0,00		

Subsistence costs	100,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			

2 project meeting				
Speakers				
Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00
Personnel				
Travel costs	300,00	0,00	0,00	0,00
Accommodation costs	150,00	0,00	0,00	0,00
Subsistence costs	50,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	300,00			
Total accommodation costs for this travel	150,00			
Total subsistence costs for this travel	50,00			
Total travel	500,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 project meeting				
Speakers				
Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00
Personnel				
Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

	Total subsistence costs for this travel	100,00				
	Total travel	1.000,00				
	Total travel costs for this WP	1.500,00				
	Total accomodation costs for this WP	750,00				
	Total subsistence costs for this WP	250,00				
	Total travel for this WP	2.500,00				

WORK PACKAGE 2 COMMUNICATION DISSEMINATION AND EXPLOITATION

1 stakeholder final dissemination conference						
Speakers						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Personnel						
	Travel costs	600,00	0,00	0,00	0,00	NO
	Accomodation costs	300,00	0,00	0,00	0,00	Final dissemination conference, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
	Subsistence costs	100,00	0,00	0,00	0,00	
Participants						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Total travel costs for this travel	600,00				
	Total accomodation costs for this travel	300,00				
	Total subsistence costs for this travel	100,00				
	Total travel	1.000,00				
	Total travel costs for this WP	600,00				
	Total accomodation costs for this WP	300,00				
	Total subsistence costs for this WP	100,00				
	Total travel for this WP	1.000,00				

WORK PACKAGE 3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

1 Technical Meeting						
Speakers						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
Personnel						
	Travel costs	900,00	0,00	0,00	0,00	NO
	Accomodation costs	450,00	0,00	0,00	0,00	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
	Subsistence costs	150,00	0,00	0,00	0,00	
Participants						
	Travel costs	0,00	0,00	0,00	0,00	
	Accomodation costs	0,00	0,00	0,00	0,00	

Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	900,00			
Total accomodation costs for this travel	450,00			
Total subsistence costs for this travel	150,00			
Total travel	1.500,00			

2 Technical Meeting

Speakers

Travel costs	0,00	0,00	0,00	0,00
Accomodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Personnel

Travel costs	900,00	0,00	0,00	0,00
Accomodation costs	450,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00

NO

Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

Participants

Travel costs	0,00	0,00	0,00	0,00
Accomodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	900,00			
Total accomodation costs for this travel	450,00			
Total subsistence costs for this travel	150,00			
Total travel	1.500,00			

3 Technical Meeting

Speakers

Travel costs	0,00	0,00	0,00	0,00
Accomodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Personnel

Travel costs	600,00	0,00	0,00	0,00
Accomodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00

NO

Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

Participants

Travel costs	0,00	0,00	0,00	0,00
Accomodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	600,00			
Total accomodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			

Total travel costs for this WP	2.400,00			
Total accomodation costs for this WP	1.200,00			

Total subsistence costs for this WP **400,00**

Total travel for this WP **4.000,00**

WORK PACKAGE 4

GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS

1 Technical Meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	900,00	0,00	0,00	0,00
Accommodation costs	450,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel **900,00**

Total accommodation costs for this travel **450,00**

Total subsistence costs for this travel **150,00**

Total travel **1.500,00**

NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

2 Technical meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	900,00	0,00	0,00	0,00
Accommodation costs	450,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel **900,00**

Total accommodation costs for this travel **450,00**

Total subsistence costs for this travel **150,00**

Total travel **1.500,00**

NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 Technical meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00

	Subsistence costs		0,00	0,00	0,00				
	Personnel								
	Travel costs	600,00	0,00	0,00	0,00	0,00			
	Accommodation costs	300,00	0,00	0,00	0,00	0,00			
	Subsistence costs	100,00	0,00	0,00	0,00	0,00			
	Participants								
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	600,00							
	Total accommodation costs for this travel	300,00							
	Total subsistence costs for this travel	100,00							
	Total travel	1.000,00							
	Total travel costs for this WP	2.400,00							
	Total accommodation costs for this WP	1.200,00							
	Total subsistence costs for this WP	400,00							
	Total travel for this WP	4.000,00							
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY								
	1 Technical Meeting								
	Speakers								
	Travel costs		0,00	0,00	0,00	0,00			
	Accommodation costs		0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
	Personnel								
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
	Participants								
	Travel costs	0,00	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	0,00							
	Total accommodation costs for this travel	0,00							
	Total subsistence costs for this travel	0,00							
	Total travel	0,00							
	Total travel costs for this WP	0,00							
	Total accommodation costs for this WP	0,00							
	Total subsistence costs for this WP	0,00							
	Total travel for this WP	0,00							
	Total travel costs (all WPs)					6.900,00			
	Total accommodation (all WPs)					3.450,00			

NO Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

Total subsistence (all WPs) 1.150,00

Total travel and subsistence (all WPs) 11.500,00

C.2 Equipment

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)						
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	0,00	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	$e = (c/b * d) * a$		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total depreciation					0,00	
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)						
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	$d = a * b * c$			
	1 [Equipment short name]	0,00	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
Total rental and leasing					0,00		
Total equipment for this WP					0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)						
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	$e = (c/b * d) * a$		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total depreciation					0,00	
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)						
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	$d = a * b * c$			
	1 [Equipment short name]	0,00	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
Total rental and leasing					0,00		
Total equipment for this WP					0,00		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
	C.2.1 Purchase (depreciation/full cost)						

		Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)			
		a	b	c	d			
					e = (c/b * d) * a			
1 [Equipment short name]		0,00	0	0,00	0%	0,00		
2 [Equipment short name]		0,00	0	0,00	0%	0,00		
3 [Equipment short name]		0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation						0,00		
C.2.2 Rental and leasing (rate of use/full cost)								
		Costs (actual costs)			Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)				
		a	b	c				
					d = a*b*c			
1 [Equipment short name]		0,00	0,00	0%	0,00			
2 [Equipment short name]		0,00	0,00	0%	0,00			
3 [Equipment short name]		0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing						0,00		
Total equipment for this WP						0,00		
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
C.2.1 Purchase (depreciation/full cost)								
		Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)			
		a	b	c	d			
					e = (c/b * d) * a			
1 [Equipment short name]		0,00	0	0,00	0%	0,00		
2 [Equipment short name]		0,00	0	0,00	0%	0,00		
3 [Equipment short name]		0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation						0,00		
C.2.2 Rental and leasing (rate of use/full cost)								
		Costs (actual costs)			Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)				
		a	b	c				
					d = a*b*c			
1 [Equipment short name]		0,00	0,00	0%	0,00			
2 [Equipment short name]		0,00	0,00	0%	0,00			
3 [Equipment short name]		0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing						0,00		
Total equipment for this WP						0,00		
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
C.2.1 Purchase (depreciation/full cost)								
		Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)			
		a	b	c	d			
					e = (c/b * d) * a			
1 [Equipment short name]		0,00	0	0,00	0%	0,00		
2 [Equipment short name]		0,00	0	0,00	0%	0,00		
3 [Equipment short name]		0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		

				Total depreciation	0,00		
Associated with document Ref. Ares(2022)4356368 - 13/06/2022							
C.2.2 Rental and leasing (rate of use/full cost)							
		Costs (actual costs)			Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)				
	a	b	c	d= a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00			
2 [Equipment short name]	0,00	0,00	0%	0,00			
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
Total rental and leasing				0,00			
Total equipment for this WP				0,00			
Total equipment (all WPs)				0,00			
C.3 Other goods, works and services							
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
		Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
Consumables		0,00					
Conferences, seminars, workshops, trainings & events		0,00					
Information & publications		0,00					
Other expenses							
	1 IPR costs	0,00					
	2 Bank fees (pre-financing guarantee)	0,00					
	3 Audit fees (CFS)	0,00					
	4 Project evaluation	0,00					
	[5 short name other]	0,00					
	[6 short name other]	0,00					
Total goods, works and services for this WP		0,00					
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
		Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
Consumables		0,00					
Conferences, seminars, workshops, trainings & events		0,00					
Information & publications		0,00					
Other expenses							
	1 IPR costs	0,00					
	2 Bank fees (pre-financing guarantee)	0,00					
	3 Audit fees (CFS)	0,00					
	4 Project evaluation	0,00					
	[5 short name other]	0,00					
	[6 short name other]	0,00					
Total goods, works and services for this WP		0,00					
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
		Costs			Also part of other work	Description of tasks/activities for which the goods/services	

		(actual costs)		packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00		NO	Associated with document Ref. Ares(2022)4356368 - 13/06/2022 catering for wp technical meeting	
	Conferences, seminars, workshops, trainings & events	5.000,00				
	Information & publications	0,00				
	Other expenses					
	1 IPR costs	0,00				
	2 Bank fees (pre-financing guarantee)	0,00				
	3 Audit fees (CFS)	0,00				
	4 Project evaluation	0,00				
	[5 short name other]	0,00				
[6 short name other]	0,00					
Total goods, works and services for this WP		5.000,00				
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS					
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00				
	Conferences, seminars, workshops, trainings & events	0,00				
	Information & publications	0,00				
	Other expenses					
	1 IPR costs	0,00				
	2 Bank fees (pre-financing guarantee)	0,00				
	3 Audit fees (CFS)	0,00				
	4 Project evaluation	0,00				
	[5 short name other]	0,00				
[6 short name other]	0,00					
Total goods, works and services for this WP		0,00				
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY					
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00				
	Conferences, seminars, workshops, trainings & events	0,00				
	Information & publications	0,00				
	Other expenses					
	1 IPR costs	0,00				
	2 Bank fees (pre-financing guarantee)	0,00				
	3 Audit fees (CFS)	0,00				
	4 Project evaluation	0,00				
	[5 short name other]	0,00				
[6 short name other]	0,00					
Total goods, works and services for this WP		0,00				
Total goods, works and services (all WPs)		5.000,00				
			Total purchase costs (all WPs)	16.500,00		

D. Other cost categories

D.1. Financial support to third parties

WORK PACKAGE 1		COORDINATION, MANAGEMENT AND EVALUATION			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 2		COMMUNICATION DISSEMINATION AND EXPLOITATION			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 3		ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 4		GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 5		IMPLEMENTATION AND SUSTAINABILITY			
Financial support to third parties		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			

Total other cost category D.1 for this WP 0,00

Total D.1 (all WPs) 0,00

Total other cost categories (all WPs) 0,00

E. Indirect costs

		Costs (flat-rate)
ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	135.694,56
	Flat-rate (%)	7%
	Total indirect costs	9.498,62
Total indirect costs		9.498,62

TOTAL COSTS PARTICIPANT 145.193,18

PROJECT INCOME

EU CONTRIBUTION (GRANT)

		Amount (EUR)
	Total costs	145.193,18
	Single Funding rate (%)	80%
	Maximum EU contribution	116.154,54
	Requested EU contribution	116.154,54
EU CONTRIBUTION		116.154,54

REVENUES AND CONTRIBUTIONS BY THIRD PARTIES

Revenues

Income generated by the action

		Amount (EUR)	Description of the income (type of generated income and number of users, etc)
ALL WORK PACKAGES	Estimated income generated by the action	0,00	
	Total income generated by the action	0,00	
Revenues		0,00	

In-kind contributions by third parties

In-kind contributions by third parties

		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose etc)
ALL WORK PACKAGES	Estimated in-kind contributions by third parties	0,00	

		Total in-kind contributions	0,00				
		In-kind contributions	0,00				
Financial contributions by third parties							
Financial contributions by third parties							
			Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)			
ALL WORK PACKAGES	Estimated financial contributions by third parties		0,00				
	Total financial contributions		0,00				
		Financial contributions	0,00				
		TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES	0,00				
OWN RESOURCES							
			Amount (EUR)				
	Own resources		29.038,64				
		OWN RESOURCES	29.038,64				
		TOTAL INCOME PARTICIPANT	145.193,18				

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	3-ONT
Participant PIC:	941056365

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE

	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3	D.1 Financial support to third parties d1		
				WP1 COORDINATION, MANAGEMENT AND EVALUATION	3.159,06	0,00	0,00	2.500,00	1.500,00	750,00		
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	6.720,00	0,00	0,00	1.000,00	600,00	300,00	100,00	0,00	0,00	0,00	540,40	8.260,40
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	81.625,50	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	5.000,00	0,00	6.343,79	96.969,29
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	27.690,00	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	2.218,30	33.908,30
WP5 IMPLEMENTATION AND SUSTAINABILITY	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
TOTAL COSTS PARTICIPANT	119.194,56	0,00	0,00	11.500,00	6.900,00	3.450,00	1.150,00	0,00	5.000,00	0,00	9.498,62	145.193,18

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	4-ST
Participant PIC:	939758796

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
Technical personnel	monthly	2.146,00	2,00	4.292,00		YES (WP2)	EXPERT IN COMMUNICATION AND PROJECT MANAGMENT
	Other						
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)			4.292,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons						
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
	Other						
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons			0,00			
	A.4 SME owners and natural person beneficiaries without salary						
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary			0,00			
	Total personnel for this WP			4.292,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	A.1 Employees (or equivalent)						
Technical personnel	monthly	2.146,00	2,00	4.292,00		YES (WP1)	EXPERT IN COMMUNICATION AND PROJECT MANAGMENT

	Other							
	[category 1]	monthly	0,00	0,00	0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				4.292,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				4.292,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	3.764,00	2,00	7.528,00		YES (WP4, WP5)	Senior expert and project manager
	Senior experts/advisors/researchers	monthly	3.559,00	2,00	7.118,00		YES (WP4, WP5)	MD, Specialist of traumatology
	Senior experts/advisors/researchers	monthly	2.847,00	2,50	7.117,50		YES (WP4, WP5)	PhD in cultural/medical anthropology is an experienced researcher
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				21.763,50			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				21.763,50			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	3.764,00	2,50	9.410,00		YES (WP3, WP5)	Senior expert and project manager
	Senior experts/advisors/researchers	monthly	3.559,00	2,50	8.897,50		YES (WP3, WP5)	MD, Specialist of traumatology
	Senior experts/advisors/researchers	monthly	2.847,00	3,50	9.964,50		YES (WP3, WP5)	PhD in cultural/medical anthropology is an experienced researcher
	Other							
	[category 1]	monthly	0,00	0,00	0,00			

	[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)					28.272,00			
A.2 + A.3 Natural persons under direct contract and seconded persons								
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
Other								
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons					0,00			
A.4 SME owners and natural person beneficiaries without salary								
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary					0,00			
Total personnel for this WP					28.272,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
A.1 Employees (or equivalent)								
	Senior experts/advisors/researchers	monthly	3.764,00	4,00	15.056,00	YES (WP3, WP4)	Senior expert and project manager	
	Senior experts/advisors/researchers	monthly	3.559,00	4,00	14.236,00	YES (WP3, WP4)	MD, Specialist of traumatology	
	Senior experts/advisors/researchers	monthly	2.847,00	4,70	13.380,90	YES (WP3, WP4)	PhD in cultural/medical anthropology is an experienced researcher	
Other								
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)					42.672,90			
A.2 + A.3 Natural persons under direct contract and seconded persons								
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
Other								
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons					0,00			
A.4 SME owners and natural person beneficiaries without salary								
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary					0,00			
Total personnel for this WP					42.672,90			
Total personnel (all WPs)					101.292,40			
B. Subcontracting costs								
		Costs (actual costs)				Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities	
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION							
	1 [Subcontract short name]		0,00					
	2 [Subcontract short name]		0,00					
Total subcontracting for this WP			0,00					

WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
			Total subcontracting (all WPs)	100.000,00

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

C. Purchase costs

C.1 Travel and subsistence

	Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
		Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION					
1 project meeting						
Speakers						
	Travel costs		0,00	0,00		
	Accommodation costs		0,00	0,00		
	Subsistence costs		0,00	0,00		
Personnel						
	Travel costs	600,00	0,00	0,00		
	Accommodation costs	300,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00		
Participants						
	Travel costs	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00		
	Total travel costs for this travel	600,00				
	Total accommodation costs for this travel	300,00				
	Total subsistence costs for this travel	100,00				
	Total travel	1.000,00				
					NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

2 project meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	300,00	0,00	0,00	0,00
Accommodation costs	150,00	0,00	0,00	0,00
Subsistence costs	50,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	300,00			
Total accommodation costs for this travel	150,00			
Total subsistence costs for this travel	50,00			
Total travel	500,00			

NO	Project meeting, 2days, 1 person. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 project meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			

Total travel costs for this WP	1.500,00			
Total accommodation costs for this WP	750,00			
Total subsistence costs for this WP	250,00			
Total travel for this WP	2.500,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

WORK PACKAGE 2

COMMUNICATION DISSEMINATION AND EXPLOITATION

1 stakeholder final dissemination conference

Speakers

	Travel costs	0,00	0,00	0,00	0,00	0,00				
	Accommodation costs	0,00	0,00	0,00	0,00	0,00				
	Subsistence costs	0,00	0,00	0,00	0,00	0,00				
	Personnel									
	Travel costs	600,00	0,00	0,00	0,00	0,00			NO	Project final conference, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00	0,00	0,00				
	Subsistence costs	100,00	0,00	0,00	0,00	0,00				
	Participants									
	Travel costs	0,00	0,00	0,00	0,00	0,00				
	Accommodation costs	0,00	0,00	0,00	0,00	0,00				
	Subsistence costs	0,00	0,00	0,00	0,00	0,00				
	Total travel costs for this travel	600,00								
	Total accommodation costs for this travel	300,00								
	Total subsistence costs for this travel	100,00								
	Total travel	1.000,00								
	Total travel costs for this WP	600,00								
	Total accommodation costs for this WP	300,00								
	Total subsistence costs for this WP	100,00								
	Total travel for this WP	1.000,00								
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES									
	1 Technical Meeting									
	Speakers									
	Travel costs	0,00	0,00	0,00	0,00	0,00				
	Accommodation costs	0,00	0,00	0,00	0,00	0,00				
	Subsistence costs	0,00	0,00	0,00	0,00	0,00				
	Personnel									
	Travel costs	900,00	0,00	0,00	0,00	0,00			NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	450,00	0,00	0,00	0,00	0,00				
	Subsistence costs	150,00	0,00	0,00	0,00	0,00				
	Participants									
	Travel costs	0,00	0,00	0,00	0,00	0,00				
	Accommodation costs	0,00	0,00	0,00	0,00	0,00				
	Subsistence costs	0,00	0,00	0,00	0,00	0,00				
	Total travel costs for this travel	900,00								
	Total accommodation costs for this travel	450,00								
	Total subsistence costs for this travel	150,00								
	Total travel	1.500,00								
	2 Technical Meeting									
	Speakers									
	Travel costs	0,00	0,00	0,00	0,00	0,00				
	Accommodation costs	0,00	0,00	0,00	0,00	0,00				

	Subsistence costs	0,00	0,00	0,00	0,00			
	Personnel							
	Travel costs	900,00	0,00	0,00	0,00	NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	450,00	0,00	0,00	0,00			
	Subsistence costs	150,00	0,00	0,00	0,00			
	Participants							
	Travel costs	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	900,00						
	Total accommodation costs for this travel	450,00						
	Total subsistence costs for this travel	150,00						
	Total travel	1.500,00						
	3 Technical Meeting							
	Speakers							
	Travel costs	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00			
	Personnel							
	Travel costs	600,00	0,00	0,00	0,00	NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	300,00	0,00	0,00	0,00			
	Subsistence costs	100,00	0,00	0,00	0,00			
	Participants							
	Travel costs	0,00	0,00	0,00	0,00			
	Accommodation costs	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	600,00						
	Total accommodation costs for this travel	300,00						
	Total subsistence costs for this travel	100,00						
	Total travel	1.000,00						
	Total travel costs for this WP	2.400,00						
	Total accommodation costs for this WP	1.200,00						
	Total subsistence costs for this WP	400,00						
	Total travel for this WP	4.000,00						
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	1 Technical Meeting							
	Speakers							
	Travel costs		0,00	0,00	0,00			
	Accommodation costs		0,00	0,00	0,00			
	Subsistence costs		0,00	0,00	0,00			
	Personnel							

	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00					
	Total accomodation costs for this travel	300,00					
	Total subsistence costs for this travel	100,00					
	Total travel	1.000,00					
	Total travel costs for this WP	2.400,00					
	Total accomodation costs for this WP	1.200,00					
	Total subsistence costs for this WP	400,00					
	Total travel for this WP	4.000,00					

WORK PACKAGE 5 IMPLEMENTATION AND SUSTAINABILITY

1 Technical Meeting							
Speakers							
	Travel costs	0,00	0,00	0,00	0,00		
	Accomodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Personnel							
	Travel costs	600,00	0,00	0,00	0,00	NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accomodation costs	300,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00		
Participants							
	Travel costs	1.200,00	0,00	0,00	0,00	NO	Project meeting, 2days, 4 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accomodation costs	600,00	0,00	0,00	0,00		
	Subsistence costs	200,00	0,00	0,00	0,00		
	Total travel costs for this travel	1.800,00					
	Total accomodation costs for this travel	900,00					
	Total subsistence costs for this travel	300,00					
	Total travel	3.000,00					
	Total travel costs for this WP	1.800,00					
	Total accomodation costs for this WP	900,00					
	Total subsistence costs for this WP	300,00					
	Total travel for this WP	3.000,00					


	Total travel costs (all WPs)	8.700,00					
	Total accomodation (all WPs)	4.350,00					
	Total subsistence (all WPs)	1.450,00					
	Total travel and subsistence (all WPs)	14.500,00					

C.2 Equipment

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	C.2.1 Purchase (depreciation/full cost)						
		Costs (actual costs)					
		Depreciation				Also part of other work	

	Price	method (e.g. 36 month or 60 month)	Number of months allocated to the action	0,00	Total (EUR)	packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
Costs (actual costs)							
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b		c	d = a*b*c		
1 [Equipment short name]	0,00	0,00		0%	0,00		
2 [Equipment short name]	0,00	0,00		0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00		
Total equipment for this WP					0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
C.2.1 Purchase (depreciation/full cost)							
Costs (actual costs)							
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
Costs (actual costs)							
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b		c	d = a*b*c		
1 [Equipment short name]	0,00	0,00		0%	0,00		
2 [Equipment short name]	0,00	0,00		0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00		
Total equipment for this WP					0,00		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
C.2.1 Purchase (depreciation/full cost)							
Costs (actual costs)							
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							

		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
		a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00			
	2 [Equipment short name]	0,00	0,00	0%	0,00			
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total rental and leasing				0,00			
	Total equipment for this WP				0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	C.2.1 Purchase (depreciation/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)			Total (EUR)
		a	b	c	d			e =(c/b *d) * a
	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total depreciation				0,00			
	C.2.2 Rental and leasing (rate of use/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
		a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00			
	2 [Equipment short name]	0,00	0,00	0%	0,00			
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total rental and leasing				0,00			
	Total equipment for this WP				0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
	C.2.1 Purchase (depreciation/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)			Total (EUR)
		a	b	c	d			e =(c/b *d) * a
	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total depreciation				0,00			
	C.2.2 Rental and leasing (rate of use/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
		a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00			
	2 [Equipment short name]	0,00	0,00	0%	0,00			

	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement	0,00	
			Total rental and leasing	0,00	 Associated with document Ref. Ares(2022)4356368 - 13/06/2022
			Total equipment for this WP	0,00	
			Total equipment (all WPs)	0,00	
C.3 Other goods, works and services					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			

	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
Total goods, works and services (all WPs)		0,00			
Total purchase costs (all WPs)			14.500,00		
D. Other cost categories					
D.1. Financial support to third parties					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			

	[Support scheme short name]	0,00			
		0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
			Total D.1 (all WPs)	0,00	
			Total other cost categories (all WPs)	0,00	
E. Indirect costs					
		Costs (flat-rate)			

ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	115.792,40
	Flat-rate (%)	7%
	Total indirect costs	8.105,47
Total indirect costs		8.105,47
TOTAL COSTS PARTICIPANT		123.897,87

PROJECT INCOME

EU CONTRIBUTION (GRANT)

	Amount (EUR)
Total costs	123.897,87
Single Funding rate (%)	80%
Maximum EU contribution	99.118,29
Requested EU contribution	99.118,29
EU CONTRIBUTION	99.118,29

REVENUES AND CONTRIBUTIONS BY THIRD PARTIES

Revenues

Income generated by the action

	Amount (EUR)	Description of the income (type of generated income and number of users, etc)
ALL WORK PACKAGES	0,00	
Total income generated by the action	0,00	
Revenues	0,00	

In-kind contributions by third parties

In-kind contributions by third parties

	Amount (EUR)	Description of the contribution (type of contribution, donor, purpose etc)
ALL WORK PACKAGES	0,00	
Total in-kind contributions	0,00	
In-kind contributions	0,00	

Financial contributions by third parties

Financial contributions by third parties

	Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	0,00	

	Total financial contributions	0,00	
	Financial contributions	0,00	
	TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES	0,00	
OWN RESOURCES			
		Amount (EUR)	
	Own resources	24.779,57	
	OWN RESOURCES	24.779,57	
	TOTAL INCOME PARTICIPANT	123.897,87	

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

 Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	4-ST
Participant PIC:	939758796

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE												
	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3	D.1 Financial support to third parties d1		
WP1 COORDINATION, MANAGEMENT AND EVALUATION	4.292,00	0,00	0,00	2.500,00	1.500,00	750,00	250,00	0,00	0,00	0,00	475,44	7.267,44
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	4.292,00	0,00	0,00	1.000,00	600,00	300,00	100,00	0,00	0,00	0,00	370,44	5.662,44
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	21.763,50	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	1.803,45	27.566,95
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	28.272,00	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	2.259,04	34.531,04
WP5 IMPLEMENTATION AND SUSTAINABILITY	42.672,90	0,00	0,00	3.000,00	1.800,00	900,00	300,00	0,00	0,00	0,00	3.197,10	48.870,00
TOTAL COSTS PARTICIPANT	101.292,40	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	8.105,47	123.897,87

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	5-ET
Participant PIC:	954188419

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
Administrative personnel	monthly	5.723,00	0,40	2.289,20			Manager Finance
Technical personnel	monthly	4.492,00	0,25	1.123,00			Executive secretary
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)				3.412,20			
A.2 + A.3 Natural persons under direct contract and seconded persons							
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons				0,00			
A.4 SME owners and natural person beneficiaries without salary							
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary				0,00			
Total personnel for this WP				3.412,20			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	A.1 Employees (or equivalent)						

	Technical personnel	monthly	4.864,00	1,25	6.080,00		NO	Communication expert
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				6.080,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				6.080,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	16.643,00	0,60	9.985,80		YES (WP4, WP5)	Medical director
	Senior experts/advisors/researchers	monthly	8.756,75	0,60	5.254,05		YES (WP4, WP5)	member medical staff
	Technical personnel	monthly	10.726,88	0,60	6.436,13		YES (WP4)	biostatistician
	Technical personnel	monthly	7.310,75	1,05	7.676,29		NO	data manager
	Technical personnel	monthly	5.900,13	0,40	2.360,05		NO	registry employee
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				31.712,32			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				31.712,32			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	16.643,00	0,20	3.328,60		YES (WP3, WP5)	Medical director
	Senior experts/advisors/researchers	monthly	8.756,75	0,20	1.751,35		YES (WP3, WP5)	member medical staff

	Technical personnel	monthly	10.726,88	0,20	2.145,38	YES (WP3)	biostatistician
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				7.225,33		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total natural persons under direct contract and seconded persons				0,00		
	A.4 SME owners and natural person beneficiaries without salary						
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
	Total SME owners and natural person beneficiaries without salary				0,00		
	Total personnel for this WP				7.225,33		
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY						
	A.1 Employees (or equivalent)						
	Senior experts/advisors/researchers	monthly	16.643,00	0,20	3.328,60	YES (WP3, WP4)	Medical director
	Senior experts/advisors/researchers	monthly	8.756,75	0,20	1.751,35	YES (WP3, WP4)	member medical staff
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				5.079,95		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total natural persons under direct contract and seconded persons				0,00		
	A.4 SME owners and natural person beneficiaries without salary						
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
	Total SME owners and natural person beneficiaries without salary				0,00		
	Total personnel for this WP				5.079,95		
Total personnel (all WPs)					53.509,79		
B. Subcontracting costs							
			Costs (actual costs)			Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	1 [Subcontract short name]		0,00				

	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			

Total subcontracting (all WPs) 100.000,00

C. Purchase costs

C.1 Travel and subsistence

	Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
		Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION					
	1 project meeting					
	Speakers					
	Travel costs	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00		
	Personnel					
	Travel costs	600,00	0,00	0,00	NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00		
	Participants					
	Travel costs	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00		
	Total travel costs for this travel	600,00				
	Total accommodation costs for this travel	300,00				

	Total subsistence costs for this travel	100,00					
	Total travel	1.000,00					
	2 project meeting						
	Speakers						
	Travel costs		0,00	0,00	0,00		
	Accommodation costs		0,00	0,00	0,00		
	Subsistence costs		0,00	0,00	0,00		
	Personnel						
	Travel costs	300,00	0,00	0,00	0,00	NO	Project meeting, 2days, 1 person. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	150,00	0,00	0,00	0,00		
	Subsistence costs	50,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	300,00					
	Total accommodation costs for this travel	150,00					
	Total subsistence costs for this travel	50,00					
	Total travel	500,00					
	3 project meeting						
	Speakers						
	Travel costs		0,00	0,00	0,00		
	Accommodation costs		0,00	0,00	0,00		
	Subsistence costs		0,00	0,00	0,00		
	Personnel						
	Travel costs	600,00	0,00	0,00	0,00	NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00					
	Total accommodation costs for this travel	300,00					
	Total subsistence costs for this travel	100,00					
	Total travel	1.000,00					
	Total travel costs for this WP	1.500,00					
	Total accommodation costs for this WP	750,00					
	Total subsistence costs for this WP	250,00					
	Total travel for this WP	2.500,00					
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						

1 stakeholder final dissemination conference					
Speakers					
Travel costs	0,00	0,00	0,00		0,00
Accommodation costs	0,00	0,00	0,00		0,00
Subsistence costs	0,00	0,00	0,00		0,00
Personnel					
Travel costs	600,00	0,00	0,00		0,00
Accommodation costs	300,00	0,00	0,00		0,00
Subsistence costs	100,00	0,00	0,00		0,00
Participants					
Travel costs	0,00	0,00	0,00		0,00
Accommodation costs	0,00	0,00	0,00		0,00
Subsistence costs	0,00	0,00	0,00		0,00
Total travel costs for this travel	600,00				
Total accommodation costs for this travel	300,00				
Total subsistence costs for this travel	100,00				
Total travel	1.000,00				
Total travel costs for this WP	600,00				
Total accommodation costs for this WP	300,00				
Total subsistence costs for this WP	100,00				
Total travel for this WP	1.000,00				

NO	Project final conference, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

WORK PACKAGE 3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

1 Technical Meeting					
Speakers					
Travel costs	0,00	0,00	0,00		0,00
Accommodation costs	0,00	0,00	0,00		0,00
Subsistence costs	0,00	0,00	0,00		0,00
Personnel					
Travel costs	900,00	0,00	0,00		0,00
Accommodation costs	450,00	0,00	0,00		0,00
Subsistence costs	150,00	0,00	0,00		0,00
Participants					
Travel costs	0,00	0,00	0,00		0,00
Accommodation costs	0,00	0,00	0,00		0,00
Subsistence costs	0,00	0,00	0,00		0,00
Total travel costs for this travel	900,00				
Total accommodation costs for this travel	450,00				
Total subsistence costs for this travel	150,00				
Total travel	1.500,00				

NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

2 Technical Meeting					
Speakers					

	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		Associated with document Ref. Ares(2022)4356368 - 13/06/2022
	Subsistence costs	0,00	0,00	0,00	0,00		
	Personnel						
	Travel costs	900,00	0,00	0,00	0,00	NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	450,00	0,00	0,00	0,00		
	Subsistence costs	150,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	900,00					
	Total accommodation costs for this travel	450,00					
	Total subsistence costs for this travel	150,00					
	Total travel	1.500,00					
	3 Technical Meeting						
	Speakers						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Personnel						
	Travel costs	600,00	0,00	0,00	0,00	NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00					
	Total accommodation costs for this travel	300,00					
	Total subsistence costs for this travel	100,00					
	Total travel	1.000,00					
	Total travel costs for this WP	2.400,00					
	Total accommodation costs for this WP	1.200,00					
	Total subsistence costs for this WP	400,00					
	Total travel for this WP	4.000,00					
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS						
	1 Technical Meeting						
	Speakers						
	Travel costs		0,00	0,00	0,00		
	Accommodation costs		0,00	0,00	0,00		

	Subsistence costs		0,00	0,00	0,00			
	Personnel							
	Travel costs	900,00	0,00	0,00	0,00		NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
	Accomodation costs	450,00	0,00	0,00	0,00			
	Subsistence costs	150,00	0,00	0,00	0,00			
	Participants							
	Travel costs	0,00	0,00	0,00	0,00			
	Accomodation costs	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	900,00						
	Total accomodation costs for this travel	450,00						
	Total subsistence costs for this travel	150,00						
	Total travel	1.500,00						
	2 Technical meeting							
	Speakers							
	Travel costs	0,00	0,00	0,00	0,00			
	Accomodation costs	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00			
	Personnel							
	Travel costs	900,00	0,00	0,00	0,00		NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
	Accomodation costs	450,00	0,00	0,00	0,00			
	Subsistence costs	150,00	0,00	0,00	0,00			
	Participants							
	Travel costs	0,00	0,00	0,00	0,00			
	Accomodation costs	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00			
	Total travel costs for this travel	900,00						
	Total accomodation costs for this travel	450,00						
	Total subsistence costs for this travel	150,00						
	Total travel	1.500,00						
	3 Technical meeting							
	Speakers							
	Travel costs	0,00	0,00	0,00	0,00			
	Accomodation costs	0,00	0,00	0,00	0,00			
	Subsistence costs	0,00	0,00	0,00	0,00			
	Personnel							
	Travel costs	600,00	0,00	0,00	0,00		NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
	Accomodation costs	300,00	0,00	0,00	0,00			
	Subsistence costs	100,00	0,00	0,00	0,00			
	Participants							

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			
Total travel costs for this WP	2.400,00			
Total accommodation costs for this WP	1.200,00			
Total subsistence costs for this WP	400,00			
Total travel for this WP	4.000,00			

WORK PACKAGE 5 IMPLEMENTATION AND SUSTAINABILITY

1 Technical Meeting				
Speakers				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Personnel				
Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00
Participants				
Travel costs	1.200,00	0,00	0,00	0,00
Accommodation costs	600,00	0,00	0,00	0,00
Subsistence costs	200,00	0,00	0,00	0,00
Total travel costs for this travel	1.800,00			
Total accommodation costs for this travel	900,00			
Total subsistence costs for this travel	300,00			
Total travel	3.000,00			
Total travel costs for this WP	1.800,00			
Total accommodation costs for this WP	900,00			
Total subsistence costs for this WP	300,00			
Total travel for this WP	3.000,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
NO	Project meeting, 2days, 4 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)


Total travel costs (all WPs)	8.700,00
Total accommodation (all WPs)	4.350,00
Total subsistence (all WPs)	1.450,00
Total travel and subsistence (all WPs)	14.500,00

C.2 Equipment

WORK PACKAGE 1 COORDINATION, MANAGEMENT AND EVALUATION

	C.2.1 Purchase (depreciation/full cost)							Associated with document Ref. Ares(2022)4356368 - 13/06/2022	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Costs (actual costs)					Total (EUR)				
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	0,00						
a	b	c	d	e = (c/b * d) * a						
1 [Equipment short name]	0,00	0	0,00	0%	0,00					
2 [Equipment short name]	0,00	0	0,00	0%	0,00					
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00					
Total depreciation					0,00					
	C.2.2 Rental and leasing (rate of use/full cost)								Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Costs (actual costs)				Total (EUR)					
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)							
a	b	c	d = a*b*c							
1 [Equipment short name]	0,00	0,00	0%		0,00					
2 [Equipment short name]	0,00	0,00	0%		0,00					
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00					
Total rental and leasing					0,00					
Total equipment for this WP					0,00					
WORK PACKAGE 2										
COMMUNICATION DISSEMINATION AND EXPLOITATION										
	C.2.1 Purchase (depreciation/full cost)								Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Costs (actual costs)					Total (EUR)				
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)						
a	b	c	d	e = (c/b * d) * a						
1 [Equipment short name]	0,00	0	0,00	0%	0,00					
2 [Equipment short name]	0,00	0	0,00	0%	0,00					
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00					
Total depreciation					0,00					
	C.2.2 Rental and leasing (rate of use/full cost)								Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Costs (actual costs)				Total (EUR)					
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)							
a	b	c	d = a*b*c							
1 [Equipment short name]	0,00	0,00	0%		0,00					
2 [Equipment short name]	0,00	0,00	0%		0,00					
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00					
Total rental and leasing					0,00					
Total equipment for this WP					0,00					
WORK PACKAGE 3										
ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES										
	C.2.1 Purchase (depreciation/full cost)								Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Costs (actual costs)					Total (EUR)				
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)						
a	b	c	d	e = (c/b * d) * a						
1 [Equipment short name]	0,00	0	0,00	0%	0,00					
2 [Equipment short name]	0,00	0	0,00	0%	0,00					

	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total depreciation				0,00		
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)			
	a	b	c	d = a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total rental and leasing				0,00		
	Total equipment for this WP				0,00		
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)			
	a	b	c	d			
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total depreciation				0,00		
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)			
	a	b	c	d = a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total rental and leasing				0,00		
	Total equipment for this WP				0,00		
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)			
	a	b	c	d			
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total depreciation				0,00		
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)				Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)			
	a	b	c	d = a*b*c			

	a	b	c	d= a*b*c	
1 [Equipment short name]	0,00	0,00	0%	0,00	 Associated with document Ref. Ares(2022)4356368 - 13/06/2022
2 [Equipment short name]	0,00	0,00	0%	0,00	
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00	
Total rental and leasing				0,00	
Total equipment for this WP				0,00	

Total equipment (all WPs)				0,00	
----------------------------------	--	--	--	-------------	--

C.3 Other goods, works and services

WORK PACKAGE 1 COORDINATION, MANAGEMENT AND EVALUATION

	Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
Consumables	0,00			
Conferences, seminars, workshops, trainings & events	0,00			
Information & publications	0,00			
Other expenses				
1 IPR costs	0,00			
2 Bank fees (pre-financing guarantee)	0,00			
3 Audit fees (CFS)	0,00			
4 Project evaluation	0,00			
[5 short name other]	0,00			
[6 short name other]	0,00			
Total goods, works and services for this WP		0,00		

WORK PACKAGE 2 COMMUNICATION DISSEMINATION AND EXPLOITATION

	Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
Consumables	0,00			
Conferences, seminars, workshops, trainings & events	0,00			
Information & publications	0,00			
Other expenses				
1 IPR costs	0,00			
2 Bank fees (pre-financing guarantee)	0,00			
3 Audit fees (CFS)	0,00			
4 Project evaluation	0,00			
[5 short name other]	0,00			
[6 short name other]	0,00			
Total goods, works and services for this WP		0,00		

WORK PACKAGE 3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

	Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
Consumables	0,00			
Conferences, seminars, workshops, trainings & events	0,00			
Information & publications	0,00			
Other expenses				

	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
Total goods, works and services (all WPs)		0,00			
Total purchase costs (all WPs)			14.500,00		
D. Other cost categories					
D.1. Financial support to third parties					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				

E. Indirect costs

		Costs (flat-rate)	
ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	68.009,79	
	Flat-rate (%)	7%	
	Total indirect costs	4.760,69	
Total indirect costs		4.760,69	
TOTAL COSTS PARTICIPANT			72.770,48

PROJECT INCOME

EU CONTRIBUTION (GRANT)

		Amount (EUR)	
	Total costs	72.770,48	
	Single Funding rate (%)	80%	
	Maximum EU contribution	58.216,38	
	Requested EU contribution	58.216,38	
EU CONTRIBUTION		58.216,38	

REVENUES AND CONTRIBUTIONS BY THIRD PARTIES

Revenues

Income generated by the action

		Amount (EUR)	Description of the income (type of generated income and number of users, etc)
ALL WORK PACKAGES	Estimated income generated by the action	0,00	
Total income generated by the action		0,00	
Revenues		0,00	

In-kind contributions by third parties

In-kind contributions by third parties

		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose etc)
ALL WORK PACKAGES	Estimated in-kind contributions by third parties	0,00	
Total in-kind contributions		0,00	
In-kind contributions		0,00	

Financial contributions by third parties

Financial contributions by third parties

		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc.)
ALL WORK PACKAGES	Estimated financial contributions by third parties	0,00	
	Total financial contributions	0,00	
	Financial contributions	0,00	
TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES		0,00	
OWN RESOURCES			
		Amount (EUR)	
	Own resources	14.554,10	
OWN RESOURCES		14.554,10	
TOTAL INCOME PARTICIPANT		72.770,48	

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	5-ET
Participant PIC:	954188419

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE												
	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3	D.1 Financial support to third parties d1		
WP1 COORDINATION, MANAGEMENT AND EVALUATION	3.412,20	0,00	0,00	2.500,00	1.500,00	750,00	250,00	0,00	0,00	0,00	413,85	6.326,05
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	6.080,00	0,00	0,00	1.000,00	600,00	300,00	100,00	0,00	0,00	0,00	495,60	7.575,60
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	31.712,32	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	2.499,86	38.212,18
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	7.225,33	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	785,77	12.011,10
WP5 IMPLEMENTATION AND SUSTAINABILITY	5.079,95	0,00	0,00	3.000,00	1.800,00	900,00	300,00	0,00	0,00	0,00	565,60	8.645,55
TOTAL COSTS PARTICIPANT	53.509,79	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	4.760,69	72.770,48

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	6-ABM
Participant PIC:	994118081

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
Technical personnel	monthly	3.149,00	0,38	1.196,62		YES (WP2, WP3)	Assistant
Administrative personnel	monthly	8.431,00	0,15	1.264,65		NO	Financial controller
	Other						
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)			2.461,27			
	A.2 + A.3 Natural persons under direct contract and seconded persons						
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
	Other						
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons			0,00			
	A.4 SME owners and natural person beneficiaries without salary						
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary			0,00			
	Total personnel for this WP			2.461,27			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	A.1 Employees (or equivalent)						

	Project managers	monthly	8.730,00	0,01	87,30		YES (WP3, WP4)	Leader of project coordination team fro ABM
	Technical personnel	monthly	3.149,00	0,20	629,80		YES (WP1, WP3)	Assistant
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
					Total employees (or equivalent)	717,10		
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
					Total natural persons under direct contract and seconded persons	0,00		
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
					Total SME owners and natural person beneficiaries without salary	0,00		
					Total personnel for this WP	717,10		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	A.1 Employees (or equivalent)							
	Project managers	monthly	8.730,00	0,15	1.309,50		YES (WP2, WP4)	Leader of the project coordination team for ABM.
	Technical personnel	monthly	3.149,00	0,05	157,45		YES (WP1, WP2, WP4)	Assistant
	Senior experts/advisors/researchers	monthly	20.720,00	0,02	414,40		YES (WP4)	Deputy General Director for Medical and Scientific Policy
	Senior experts/advisors/researchers	monthly	10.417,00	0,02	208,34		YES (WP4)	Medical Informatics Advisor
	Senior experts/advisors/researchers	monthly	12.167,00	0,02	243,34		NO	Referent physician for Liver and Small Bowel Transplant,
	Senior experts/advisors/researchers	monthly	14.833,00	0,02	296,66		YES (WP4)	MD Transplant Strategy Division, Expert in kidney transplantation
	Senior experts/advisors/researchers	monthly	8.072,00	0,02	161,44		NO	Head of Data Quality Department
	Senior experts/advisors/researchers	monthly	6.853,00	0,10	685,30		YES (WP4)	Head of Biostatistics and Evaluation Department
	Junior experts/advisors/researchers	monthly	5.310,00	4,50	23.895,00		YES (WP4)	Biostatistician
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
					Total employees (or equivalent)	27.371,43		
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
					Total natural persons under direct contract and seconded persons	0,00		
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
					Total SME owners and natural person beneficiaries without salary	0,00		

		Total personnel for this WP		27.371,43		Associated with document Ref. Ares(2022)4356368 - 13/06/2022	
WORK PACKAGE 4		GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS					
A.1 Employees (or equivalent)							
Project managers	monthly	8.730,00	0,15	1.309,50	YES (WP2, WP3, WP5)	Leader of the project coordination team for ABM.	
Technical personnel	monthly	3.149,00	0,05	157,45	YES (WP1, WP2, WP3, WP5)	Assistant	
Senior experts/advisors/researchers	monthly	11.466,00	0,02	229,32	YES (WP3)	Deputy General Director for Medical and Scientific Policy	
Senior experts/advisors/researchers	monthly	22.401,00	0,02	448,02	YES (WP3)	Medical Informatics Advisor	
Senior experts/advisors/researchers	monthly	14.833,00	0,05	741,65	YES (WP3)	MD Transplant Strategy Division, Expert in kidney transplantation	
Senior experts/advisors/researchers	monthly	6.853,00	0,25	1.713,25	YES (WP3, WP5)	Head of Biostatistics and Evaluation Department	
Technical personnel	monthly	5.310,00	4,50	23.895,00	YES (WP3, WP5)	Biostatistician	
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
		Total employees (or equivalent)		28.494,19			
A.2 + A.3 Natural persons under direct contract and seconded persons							
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
		Total natural persons under direct contract and seconded persons		0,00			
A.4 SME owners and natural person beneficiaries without salary							
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
		Total SME owners and natural person beneficiaries without salary		0,00			
		Total personnel for this WP		28.494,19			
WORK PACKAGE 5		IMPLEMENTATION AND SUSTAINABILITY					
A.1 Employees (or equivalent)							
Project managers	monthly	8.730,00	0,15	1.309,50	YES (WP2, WP3, WP4)	Leader of the project coordination team for ABM.	
Technical personnel	monthly	3.149,00	0,05	157,45	YES (WP1, WP2, WP3, WP4)	Assistant	
Senior experts/advisors/researchers	monthly	13.333,00	0,10	1.333,30	NO	Expert in heart and lung transplantation	
Senior experts/advisors/researchers	monthly	6.853,00	0,10	685,30	YES (WP3, WP4)	Head of Biostatistics and Evaluation department	
Technical personnel	monthly	5.310,00	2,10	11.151,00	YES (WP3, WP4)	Biostatistician	
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
		Total employees (or equivalent)		14.636,55			
A.2 + A.3 Natural persons under direct contract and seconded persons							
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			

Total natural persons under direct contract and seconded persons		0,00		Associated with document Ref. Ares(2022)4356368 - 13/06/2022		
A.4 SME owners and natural person beneficiaries without salary						
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
Total SME owners and natural person beneficiaries without salary				0,00		
Total personnel for this WP				14.636,55		

Total personnel (all WPs)				73.680,54		
----------------------------------	--	--	--	------------------	--	--

B. Subcontracting costs

		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	Study-oriented web-based platform	70.000,00		NO	T1.4 BRAVEST study-oriented web-based platform. Lack of internal expertise to develop a study specific platform under the requirement to be set by WP3
		0,00			
	Total subcontracting for this WP	70.000,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	Medical Writing	10.000,00		NO	T4.1 CNT. ESOT will subcontract an expert in medical writings to support the activity.
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	10.000,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	Cost Analysis	20.000,00		NO	T5.2 Sustainability and cost- effectiveness analysis of the cost impact for healthcare services of the proposed guidelines and recommendations, as compared with the current standard of care.
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	20.000,00			

Total subcontracting (all WPs)				100.000,00		
---------------------------------------	--	--	--	-------------------	--	--

C. Purchase costs

C.1 Travel and subsistence

		Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
			Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	1 project meeting						

Speakers				
Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00
Personnel				
Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

2 project meeting

Speakers				
Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00
Personnel				
Travel costs	300,00	0,00	0,00	0,00
Accommodation costs	150,00	0,00	0,00	0,00
Subsistence costs	50,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	300,00			
Total accommodation costs for this travel	150,00			
Total subsistence costs for this travel	50,00			
Total travel	500,00			

NO	Project meeting, 2days, 1 person. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 project meeting

Speakers				
Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00
Personnel				
Travel costs	600,00	0,00	0,00	0,00

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

	Accommodation costs	300,00	0,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00	0,00		
	Participants							
	Travel costs	0,00	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00						
	Total accommodation costs for this travel	300,00						
	Total subsistence costs for this travel	100,00						
	Total travel	1.000,00						
	Total travel costs for this WP	1.500,00						
	Total accommodation costs for this WP	750,00						
	Total subsistence costs for this WP	250,00						
	Total travel for this WP	2.500,00						
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION							
	1 stakeholder final dissemination conference							
	Speakers							
	Travel costs	0,00	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00	0,00		
	Personnel							
	Travel costs	600,00	0,00	0,00	0,00	0,00	NO	Project final conference, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	300,00	0,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00	0,00		
	Participants							
	Travel costs	0,00	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00						
	Total accommodation costs for this travel	300,00						
	Total subsistence costs for this travel	100,00						
	Total travel	1.000,00						
	Total travel costs for this WP	600,00						
	Total accommodation costs for this WP	300,00						
	Total subsistence costs for this WP	100,00						
	Total travel for this WP	1.000,00						
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	1 Technical Meeting							
	Speakers							
	Travel costs	0,00	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00	0,00		

Personnel				
Travel costs	900,00	0,00	0,00	0,00
Accommodation costs	450,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	900,00			
Total accommodation costs for this travel	450,00			
Total subsistence costs for this travel	150,00			
Total travel	1.500,00			

NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

2 Technical Meeting				
Speakers				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Personnel				
Travel costs	900,00	0,00	0,00	0,00
Accommodation costs	450,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	900,00			
Total accommodation costs for this travel	450,00			
Total subsistence costs for this travel	150,00			
Total travel	1.500,00			

NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 Technical Meeting				
Speakers				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Personnel				
Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

Accommodation costs	0,00	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00	0,00		
Total travel costs for this travel	600,00						
Total accomodation costs for this travel	300,00						
Total subsistence costs for this travel	100,00						
Total travel	1.000,00						
Total travel costs for this WP	2.400,00						
Total accomodation costs for this WP	1.200,00						
Total subsistence costs for this WP	400,00						
Total travel for this WP	4.000,00						

WORK PACKAGE 4 **GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS**

1 Technical Meeting							
Speakers							
Travel costs		0,00	0,00	0,00	0,00		
Accommodation costs		0,00	0,00	0,00	0,00		
Subsistence costs		0,00	0,00	0,00	0,00		
Personnel							
Travel costs	900,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
Accommodation costs	450,00	0,00	0,00	0,00	0,00		
Subsistence costs	150,00	0,00	0,00	0,00	0,00		
Participants							
Travel costs	0,00	0,00	0,00	0,00	0,00		
Accommodation costs	0,00	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00	0,00		
Total travel costs for this travel	900,00						
Total accomodation costs for this travel	450,00						
Total subsistence costs for this travel	150,00						
Total travel	1.500,00						

2 Technical meeting							
Speakers							
Travel costs	0,00	0,00	0,00	0,00	0,00		
Accommodation costs	0,00	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00	0,00		
Personnel							
Travel costs	900,00	0,00	0,00	0,00	0,00	NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
Accommodation costs	450,00	0,00	0,00	0,00	0,00		
Subsistence costs	150,00	0,00	0,00	0,00	0,00		
Participants							
Travel costs	0,00	0,00	0,00	0,00	0,00		
Accommodation costs	0,00	0,00	0,00	0,00	0,00		
Subsistence costs	0,00	0,00	0,00	0,00	0,00		

Total travel costs for this travel	900,00				
Total accomodation costs for this travel	450,00				
Total subsistence costs for this travel	150,00				
Total travel	1.500,00				

3 Technical meeting					
Speakers					
Travel costs	0,00	0,00	0,00		0,00
Accomodation costs	0,00	0,00	0,00		0,00
Subsistence costs	0,00	0,00	0,00		0,00
Personnel					
Travel costs	600,00	0,00	0,00		0,00
Accomodation costs	300,00	0,00	0,00		0,00
Subsistence costs	100,00	0,00	0,00		0,00
Participants					
Travel costs	0,00	0,00	0,00		0,00
Accomodation costs	0,00	0,00	0,00		0,00
Subsistence costs	0,00	0,00	0,00		0,00
Total travel costs for this travel	600,00				
Total accomodation costs for this travel	300,00				
Total subsistence costs for this travel	100,00				
Total travel	1.000,00				
Total travel costs for this WP	2.400,00				
Total accomodation costs for this WP	1.200,00				
Total subsistence costs for this WP	400,00				
Total travel for this WP	4.000,00				

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)

WORK PACKAGE 5 IMPLEMENTATION AND SUSTAINABILITY

1 Technical Meeting					
Speakers					
Travel costs	0,00	0,00	0,00		0,00
Accomodation costs	0,00	0,00	0,00		0,00
Subsistence costs	0,00	0,00	0,00		0,00
Personnel					
Travel costs	600,00	0,00	0,00		0,00
Accomodation costs	300,00	0,00	0,00		0,00
Subsistence costs	100,00	0,00	0,00		0,00
Participants					
Travel costs	1.200,00	0,00	0,00		0,00
Accomodation costs	600,00	0,00	0,00		0,00
Subsistence costs	200,00	0,00	0,00		0,00
Total travel costs for this travel	1.800,00				
Total accomodation costs for this travel	900,00				

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)
NO	Project meeting, 2days, 4 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ substintence costs)

Total subsistence costs for this travel	300,00
Total travel	3.000,00
Total travel costs for this WP	1.800,00
Total accomodation costs for this WP	900,00
Total subsistence costs for this WP	300,00
Total travel for this WP	3.000,00

Total travel costs (all WPs)	8.700,00
Total accomodation (all WPs)	4.350,00
Total subsistence (all WPs)	1.450,00
Total travel and subsistence (all WPs)	14.500,00

C.2 Equipment

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	0,00	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total depreciation					0,00	
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
	a	b	c	d = a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total rental and leasing					0,00	
	Total equipment for this WP					0,00	

WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
	Total depreciation					0,00	
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)						

	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
1 [Equipment short name]	0,00	0,00	0%	0,00		
2 [Equipment short name]	0,00	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
Total rental and leasing				0,00		
Total equipment for this WP				0,00		
WORK PACKAGE 3						
ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
C.2.1 Purchase (depreciation/full cost)						
Costs (actual costs)						
Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
a	b	c	d	e = (c/b *d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00	
2 [Equipment short name]	0,00	0	0,00	0%	0,00	
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
Total depreciation				0,00		
C.2.2 Rental and leasing (rate of use/full cost)						
Costs (actual costs)						
Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
a	b	c	d= a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00		
2 [Equipment short name]	0,00	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
Total rental and leasing				0,00		
Total equipment for this WP				0,00		
WORK PACKAGE 4						
GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS						
C.2.1 Purchase (depreciation/full cost)						
Costs (actual costs)						
Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
a	b	c	d	e = (c/b *d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00	
2 [Equipment short name]	0,00	0	0,00	0%	0,00	
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
Total depreciation				0,00		
C.2.2 Rental and leasing (rate of use/full cost)						
Costs (actual costs)						
Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
a	b	c	d= a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00		
2 [Equipment short name]	0,00	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		

		Total rental and leasing	0,00			
		Total equipment for this WP	0,00		Associated with document Ref. Ares(2022)4356368 - 13/06/2022	
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY					
	C.2.1 Purchase (depreciation/full cost)	Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action		
		a	b	c	d	e = (c/b * d) * a
	1 [Equipment short name]	0,00	0	0,00	0%	0,00
	2 [Equipment short name]	0,00	0	0,00	0%	0,00
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00
		Total depreciation				0,00
	C.2.2 Rental and leasing (rate of use/full cost)	Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)		
		a	b	c	d = a*b*c	
	1 [Equipment short name]	0,00	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00
		Total rental and leasing				0,00
		Total equipment for this WP				0,00
		Total equipment (all WPs)				0,00
	C.3 Other goods, works and services					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION					
		Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00				
	Conferences, seminars, workshops, trainings & events	0,00				
	Information & publications	0,00				
	Other expenses					
	1 IPR costs	0,00				
	2 Bank fees (pre-financing guarantee)	0,00				
	3 Audit fees (CFS)	0,00				
	4 Project evaluation	0,00				
	[5 short name other]	0,00				
	[6 short name other]	0,00				
	Total goods, works and services for this WP	0,00				
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION					
		Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00				
	Conferences, seminars, workshops, trainings & events	0,00				
	Information & publications	0,00				

Other expenses					
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
Other expenses					
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
Other expenses					
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
Other expenses					
	1 IPR costs	0,00			

	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Total goods, works and services (all WPs)		0,00			
Total purchase costs (all WPs)			14.500,00		

D. Other cost categories

D.1. Financial support to third parties

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP		0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP		0,00		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP		0,00		
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			

		0,00			
	Total other cost category D.1 for this WP	0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
			Total D.1 (all WPs)	0,00	
			Total other cost categories (all WPs)	0,00	
E. Indirect costs					
		Costs (flat-rate)			
ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	88.180,54			
	Flat-rate (%)	7%			
	Total indirect costs	6.172,64			
	Total indirect costs	6.172,64			
TOTAL COSTS PARTICIPANT				94.353,18	
PROJECT INCOME					
EU CONTRIBUTION (GRANT)					
		Amount (EUR)			
	Total costs	94.353,18			
	Single Funding rate (%)	80%			
	Maximum EU contribution	75.482,54			
	Requested EU contribution	75.482,54			
	EU CONTRIBUTION	75.482,54			
REVENUES AND CONTRIBUTIONS BY THIRD PARTIES					
Revenues					
Income generated by the action					
		Amount (EUR)			Description of the income (type of generated income and number of users, etc)

ALL WORK PACKAGES	Estimated income generated by the action	0,00	
	Total income generated by the action	0,00	
Revenues		0,00	
In-kind contributions by third parties			
In-kind contributions by third parties			
		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose etc)
ALL WORK PACKAGES	Estimated in-kind contributions by third parties	0,00	
	Total in-kind contributions	0,00	
In-kind contributions		0,00	
Financial contributions by third parties			
Financial contributions by third parties			
		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	Estimated financial contributions by third parties	0,00	
	Total financial contributions	0,00	
Financial contributions		0,00	
TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES		0,00	
OWN RESOURCES			
		Amount (EUR)	
	Own resources	18.870,64	
OWN RESOURCES		18.870,64	
TOTAL INCOME PARTICIPANT		94.353,18	

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	6-ABM
Participant PIC:	994118081

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE

	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories D.1 Financial support to third parties d1	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3			
WP1 COORDINATION, MANAGEMENT AND EVALUATION	2.461,27	0,00	0,00	2.500,00	1.500,00	750,00	250,00	0,00	0,00	0,00	347,29	5.308,56
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	717,10	0,00	0,00	1.000,00	600,00	300,00	100,00	0,00	0,00	0,00	120,20	1.837,30
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	27.371,43	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	2.196,00	33.567,43
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	28.494,19	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	2.274,59	34.768,78
WP5 IMPLEMENTATION AND SUSTAINABILITY	14.636,55	0,00	0,00	3.000,00	1.800,00	900,00	300,00	0,00	0,00	0,00	1.234,56	18.871,11
TOTAL COSTS PARTICIPANT	73.680,54	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	6.172,64	94.353,18

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	7-OVSZ
Participant PIC:	933649251

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
Project managers	monthly	4.500,00	0,50	2.250,00		YES (WP3, WP4, WP5)	Director general
Senior experts/advisors/researchers	monthly	2.300,00	0,50	1.150,00		YES (WP3, WP4, WP5)	Head Nurse
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)				3.400,00			
A.2 + A.3 Natural persons under direct contract and seconded persons							
Select a staff category	monthly	0,00	0,00	0,00			
Select a staff category	monthly	0,00	0,00	0,00			
Other							
[category 1]	monthly	0,00	0,00	0,00			
[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons				0,00			
A.4 SME owners and natural person beneficiaries without salary							
SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary				0,00			
Total personnel for this WP				3.400,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	A.1 Employees (or equivalent)						

	Senior experts/advisors/researchers	monthly	2.000,00	0,50	1.000,00		YES (WP3, WP5)	National coordinator
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				1.000,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				1.000,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	A.1 Employees (or equivalent)							
	Project managers	monthly	4.500,00	5,00	22.500,00		YES (WP1, WP4, WP5)	Director general
	Senior experts/advisors/researchers	monthly	2.300,00	7,00	16.100,00		YES (WP1, WP4, WP5)	Head Nurse
	Senior experts/advisors/researchers	monthly	2.000,00	5,00	10.000,00		YES (WP2, WP5)	National coordinator
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				48.600,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				48.600,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	A.1 Employees (or equivalent)							
	Project managers	monthly	4.500,00	1,00	4.500,00		YES (WP1, WP3, WP5)	Director general
	Senior experts/advisors/researchers	monthly	2.300,00	1,00	2.300,00		YES (WP1, WP3, WP5)	Head Nurse
	Other							
	[category 1]	monthly	0,00	0,00	0,00			

	[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)					6.800,00			
A.2 + A.3 Natural persons under direct contract and seconded persons								
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
Other								
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons					0,00			
A.4 SME owners and natural person beneficiaries without salary								
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary					0,00			
Total personnel for this WP					6.800,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
A.1 Employees (or equivalent)								
	Project managers	monthly	4.500,00	1,00	4.500,00	YES (WP1, WP3, WP4)	Director general	
	Senior experts/advisors/researchers	monthly	2.300,00	0,50	1.150,00	YES (WP1, WP3, WP4)	Head Nurse	
	Senior experts/advisors/researchers	monthly	2.000,00	1,00	2.000,00	YES (WP2, WP3)	National coordinator	
Other								
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
Total employees (or equivalent)					7.650,00			
A.2 + A.3 Natural persons under direct contract and seconded persons								
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
Other								
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
Total natural persons under direct contract and seconded persons					0,00			
A.4 SME owners and natural person beneficiaries without salary								
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
Total SME owners and natural person beneficiaries without salary					0,00			
Total personnel for this WP					7.650,00			
Total personnel (all WPs)					67.450,00			
B. Subcontracting costs								
		Costs (actual costs)				Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities	
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION							
	1 [Subcontract short name]		0,00					
	2 [Subcontract short name]		0,00					
Total subcontracting for this WP			0,00					

WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
Total subcontracting (all WPs)			100.000,00	

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

C. Purchase costs

C.1 Travel and subsistence

	Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
		Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION					
1 project meeting						
Speakers						
	Travel costs		0,00	0,00		
	Accommodation costs		0,00	0,00		
	Subsistence costs		0,00	0,00		
Personnel						
	Travel costs	600,00	0,00	0,00		NO
	Accommodation costs	300,00	0,00	0,00		Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Subsistence costs	100,00	0,00	0,00		
Participants						
	Travel costs	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00		
	Total travel costs for this travel	600,00				
	Total accommodation costs for this travel	300,00				
	Total subsistence costs for this travel	100,00				
	Total travel	1.000,00				

2 project meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	300,00	0,00	0,00	0,00
Accommodation costs	150,00	0,00	0,00	0,00
Subsistence costs	50,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	300,00			
Total accommodation costs for this travel	150,00			
Total subsistence costs for this travel	50,00			
Total travel	500,00			

NO	Project meeting, 2days, 1 person. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 project meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			
Total travel costs for this WP	1.500,00			
Total accommodation costs for this WP	750,00			
Total subsistence costs for this WP	250,00			
Total travel for this WP	2.500,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

WORK PACKAGE 2

COMMUNICATION DISSEMINATION AND EXPLOITATION

1 stakeholder final dissemination conference

Speakers

	Travel costs	0,00	0,00	0,00	0,00					
	Accommodation costs	0,00	0,00	0,00	0,00					
	Subsistence costs	0,00	0,00	0,00	0,00					
Personnel										
	Travel costs	600,00	0,00	0,00	0,00		NO		Project final conference, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	300,00	0,00	0,00	0,00					
	Subsistence costs	100,00	0,00	0,00	0,00					
Participants										
	Travel costs	0,00	0,00	0,00	0,00					
	Accommodation costs	0,00	0,00	0,00	0,00					
	Subsistence costs	0,00	0,00	0,00	0,00					
	Total travel costs for this travel	600,00								
	Total accommodation costs for this travel	300,00								
	Total subsistence costs for this travel	100,00								
	Total travel	1.000,00								
	Total travel costs for this WP	600,00								
	Total accommodation costs for this WP	300,00								
	Total subsistence costs for this WP	100,00								
	Total travel for this WP	1.000,00								
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES									
	1 Technical Meeting									
Speakers										
	Travel costs	0,00	0,00	0,00	0,00					
	Accommodation costs	0,00	0,00	0,00	0,00					
	Subsistence costs	0,00	0,00	0,00	0,00					
Personnel										
	Travel costs	900,00	0,00	0,00	0,00		NO		Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)	
	Accommodation costs	450,00	0,00	0,00	0,00					
	Subsistence costs	150,00	0,00	0,00	0,00					
Participants										
	Travel costs	0,00	0,00	0,00	0,00					
	Accommodation costs	0,00	0,00	0,00	0,00					
	Subsistence costs	0,00	0,00	0,00	0,00					
	Total travel costs for this travel	900,00								
	Total accommodation costs for this travel	450,00								
	Total subsistence costs for this travel	150,00								
	Total travel	1.500,00								
	2 Technical Meeting									
Speakers										
	Travel costs	0,00	0,00	0,00	0,00					
	Accommodation costs	0,00	0,00	0,00	0,00					

	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00					
	Total accomodation costs for this travel	300,00					
	Total subsistence costs for this travel	100,00					
	Total travel	1.000,00					
	Total travel costs for this WP	2.400,00					
	Total accomodation costs for this WP	1.200,00					
	Total subsistence costs for this WP	400,00					
	Total travel for this WP	4.000,00					

WORK PACKAGE 5 IMPLEMENTATION AND SUSTAINABILITY

1 Technical Meeting							
Speakers							
	Travel costs	0,00	0,00	0,00	0,00		
	Accomodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Personnel							
	Travel costs	600,00	0,00	0,00	0,00	NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accomodation costs	300,00	0,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00	0,00		
Participants							
	Travel costs	1.200,00	0,00	0,00	0,00	NO	Project meeting, 2days, 4 persons. Average price per person 500 euro (300€ for fligh A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accomodation costs	600,00	0,00	0,00	0,00		
	Subsistence costs	200,00	0,00	0,00	0,00		
	Total travel costs for this travel	1.800,00					
	Total accomodation costs for this travel	900,00					
	Total subsistence costs for this travel	300,00					
	Total travel	3.000,00					
	Total travel costs for this WP	1.800,00					
	Total accomodation costs for this WP	900,00					
	Total subsistence costs for this WP	300,00					
	Total travel for this WP	3.000,00					

	Total travel costs (all WPs)	8.700,00					
	Total accomodation (all WPs)	4.350,00					
	Total subsistence (all WPs)	1.450,00					
	Total travel and subsistence (all WPs)	14.500,00					


C.2 Equipment

WORK PACKAGE 1 COORDINATION, MANAGEMENT AND EVALUATION

	C.2.1 Purchase (depreciation/full cost)						
		Costs (actual costs)					
		Depreciation				Also part of other work	

	Price	method (e.g. 36 month or 60 month)	Number of months allocated to the action	0,00	Total (EUR)	packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
Costs (actual costs)							
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b		c	d= a*b*c		
1 [Equipment short name]	0,00	0,00		0%	0,00		
2 [Equipment short name]	0,00	0,00		0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00		
Total equipment for this WP					0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
C.2.1 Purchase (depreciation/full cost)							
Costs (actual costs)							
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	e=(c/b*d)*a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
Costs (actual costs)							
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b		c	d= a*b*c		
1 [Equipment short name]	0,00	0,00		0%	0,00		
2 [Equipment short name]	0,00	0,00		0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00		
Total equipment for this WP					0,00		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
C.2.1 Purchase (depreciation/full cost)							
Costs (actual costs)							
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	e=(c/b*d)*a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							

		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
		a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00			
	2 [Equipment short name]	0,00	0,00	0%	0,00			
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total rental and leasing				0,00			
	Total equipment for this WP				0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	C.2.1 Purchase (depreciation/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)			Total (EUR)
		a	b	c	d			e =(c/b *d) * a
	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total depreciation				0,00			
	C.2.2 Rental and leasing (rate of use/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
		a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00			
	2 [Equipment short name]	0,00	0,00	0%	0,00			
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total rental and leasing				0,00			
	Total equipment for this WP				0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
	C.2.1 Purchase (depreciation/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)			Total (EUR)
		a	b	c	d			e =(c/b *d) * a
	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
	Total depreciation				0,00			
	C.2.2 Rental and leasing (rate of use/full cost)							
		Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
		a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00			
	2 [Equipment short name]	0,00	0,00	0%	0,00			

	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement	0,00	
			Total rental and leasing	0,00	 Associated with document Ref. Ares(2022)4356368 - 13/06/2022
			Total equipment for this WP	0,00	
			Total equipment (all WPs)	0,00	
C.3 Other goods, works and services					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			

	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
Total goods, works and services (all WPs)		0,00			
Total purchase costs (all WPs)			14.500,00		
D. Other cost categories					
D.1. Financial support to third parties					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			

	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
			Total D.1 (all WPs)	0,00	
			Total other cost categories (all WPs)	0,00	
E. Indirect costs					
		Costs (flat-rate)			

ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	81.950,00	
	Flat-rate (%)	7%	
	Total indirect costs	5.736,50	
Total indirect costs		5.736,50	
TOTAL COSTS PARTICIPANT			87.686,50

PROJECT INCOME

EU CONTRIBUTION (GRANT)

	Amount (EUR)	
Total costs	87.686,50	
Single Funding rate (%)	80%	
Maximum EU contribution	70.149,20	
Requested EU contribution	70.149,20	
EU CONTRIBUTION	70.149,20	

REVENUES AND CONTRIBUTIONS BY THIRD PARTIES

Revenues

Income generated by the action

	Amount (EUR)	Description of the income (type of generated income and number of users, etc)
ALL WORK PACKAGES	0,00	
Total income generated by the action	0,00	
Revenues	0,00	

In-kind contributions by third parties

In-kind contributions by third parties

	Amount (EUR)	Description of the contribution (type of contribution, donor, purpose etc)
ALL WORK PACKAGES	0,00	
Total in-kind contributions	0,00	
In-kind contributions	0,00	

Financial contributions by third parties

Financial contributions by third parties

	Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	0,00	

	Total financial contributions	0,00	
	Financial contributions	0,00	
	TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES	0,00	
OWN RESOURCES			
		Amount (EUR)	
	Own resources	17.537,30	
	OWN RESOURCES	17.537,30	
	TOTAL INCOME PARTICIPANT	87.686,50	

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	7-OVSZ
Participant PIC:	933649251

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE

	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3	D.1 Financial support to third parties d1		
WP1 COORDINATION, MANAGEMENT AND EVALUATION	3.400,00	0,00	0,00	2.500,00	1.500,00	750,00	250,00	0,00	0,00	0,00	413,00	6.313,00
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	1.000,00	0,00	0,00	1.000,00	600,00	300,00	100,00	0,00	0,00	0,00	140,00	2.140,00
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	48.600,00	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	3.682,00	56.282,00
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	6.800,00	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	756,00	11.556,00
WP5 IMPLEMENTATION AND SUSTAINABILITY	7.650,00	0,00	0,00	3.000,00	1.800,00	900,00	300,00	0,00	0,00	0,00	745,50	11.395,50
TOTAL COSTS PARTICIPANT	67.450,00	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	5.736,50	87.686,50

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	8-INSERM
Participant PIC:	999997833

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

		Costs (actual costs)						
		Type of rate (monthly/other)	Rate (amount)	Time (months/other of work on the action)				Total (EUR)
		a	b	c = a * b				
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION							
	A.1 Employees (or equivalent)							
		monthly			0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				0,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION							
	A.1 Employees (or equivalent)							
		monthly			0,00			

	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				0,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	8.000,00	1,00	8.000,00		YES (WP4)	Senior expert
	Senior experts/advisors/researchers	monthly	8.000,00	1,20	9.600,00		YES (WP4)	Senior expert
	Project managers	monthly	5.000,00	2,00	10.000,00		YES (WP4)	project manager
	Technical personnel	monthly	5.000,00	6,00	30.000,00			Biostatistician
	Technical personnel	monthly	4.000,00	4,00	16.000,00			Data manager
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				73.600,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				73.600,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS							
	A.1 Employees (or equivalent)							
	Senior experts/advisors/researchers	monthly	8.000,00	0,25	2.000,00		YES (WP3)	Senior expert
	Senior experts/advisors/researchers	monthly	8.000,00	0,40	3.200,00		YES (WP3)	Senior expert
	Project managers	monthly	5.000,00	0,40	2.000,00		YES (WP3)	project manager

	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				7.200,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				7.200,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY							
	A.1 Employees (or equivalent)							
					0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total employees (or equivalent)				0,00			
	A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00			
	Select a staff category	monthly	0,00	0,00	0,00			
	Other							
	[category 1]	monthly	0,00	0,00	0,00			
	[category 2]	monthly	0,00	0,00	0,00			
	Total natural persons under direct contract and seconded persons				0,00			
	A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00			
	Total SME owners and natural person beneficiaries without salary				0,00			
	Total personnel for this WP				0,00			
					Total personnel (all WPs)	80.800,00		
B. Subcontracting costs								
			Costs (actual costs)			Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities	
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION							
	1 [Subcontract short name]		0,00					
	2 [Subcontract short name]		0,00					
	Total subcontracting for this WP		0,00					

WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY			
	1 [Subcontract short name]		0,00	
	2 [Subcontract short name]		0,00	
	Total subcontracting for this WP		0,00	
Total subcontracting (all WPs)			100.000,00	

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

C. Purchase costs

C.1 Travel and subsistence

	Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
		Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION					
1 project meeting						
Speakers						
	Travel costs		0,00	0,00		
	Accommodation costs		0,00	0,00		
	Subsistence costs		0,00	0,00		
Personnel						
	Travel costs	600,00	0,00	0,00		
	Accommodation costs	300,00	0,00	0,00		
	Subsistence costs	100,00	0,00	0,00		
Participants						
	Travel costs	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00		
	Total travel costs for this travel	600,00				
	Total accommodation costs for this travel	300,00				
	Total subsistence costs for this travel	100,00				
	Total travel	1.000,00				
					NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

2 project meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	300,00	0,00	0,00	0,00
Accommodation costs	150,00	0,00	0,00	0,00
Subsistence costs	50,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	300,00			
Total accommodation costs for this travel	150,00			
Total subsistence costs for this travel	50,00			
Total travel	500,00			

NO	Project meeting, 2days, 1 person. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 project meeting

Speakers

Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00

Personnel

Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00

Participants

Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00

Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			
Total travel costs for this WP	1.500,00			
Total accommodation costs for this WP	750,00			
Total subsistence costs for this WP	250,00			
Total travel for this WP	2.500,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

WORK PACKAGE 2

COMMUNICATION DISSEMINATION AND EXPLOITATION

1 stakeholder final dissemination conference

Speakers

	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Personnel							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Participants							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accommodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					
	Total travel costs for this WP	0,00					
	Total accommodation costs for this WP	0,00					
	Total subsistence costs for this WP	0,00					
	Total travel for this WP	0,00					
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
	1 Technical Meeting						
Speakers							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Personnel							
	Travel costs	900,00	0,00	0,00	0,00	NO	Project meeting, 2days, 3 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)
	Accommodation costs	450,00	0,00	0,00	0,00		
	Subsistence costs	150,00	0,00	0,00	0,00		
Participants							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	900,00					
	Total accommodation costs for this travel	450,00					
	Total subsistence costs for this travel	150,00					
	Total travel	1.500,00					
	2 Technical Meeting						
Speakers							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		

Personnel				
Travel costs	900,00	0,00	0,00	0,00
Accommodation costs	450,00	0,00	0,00	0,00
Subsistence costs	150,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	900,00			
Total accommodation costs for this travel	450,00			
Total subsistence costs for this travel	150,00			
Total travel	1.500,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

3 Technical Meeting				
Speakers				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Personnel				
Travel costs	600,00	0,00	0,00	0,00
Accommodation costs	300,00	0,00	0,00	0,00
Subsistence costs	100,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	600,00			
Total accommodation costs for this travel	300,00			
Total subsistence costs for this travel	100,00			
Total travel	1.000,00			
Total travel costs for this WP	2.400,00			
Total accommodation costs for this WP	1.200,00			
Total subsistence costs for this WP	400,00			
Total travel for this WP	4.000,00			

NO	Project meeting, 2days, 2 persons. Average price per person 500 euro (300€ for flight A/R, 150€ one or 2 nights in an hotel, 50€ subsistence costs)

WORK PACKAGE 4

GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS

1 Technical Meeting				
Speakers				
Travel costs		0,00	0,00	0,00
Accommodation costs		0,00	0,00	0,00
Subsistence costs		0,00	0,00	0,00
Personnel				

	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	600,00					
	Total accomodation costs for this travel	300,00					
	Total subsistence costs for this travel	100,00					
	Total travel	1.000,00					
	Total travel costs for this WP	2.400,00					
	Total accomodation costs for this WP	1.200,00					
	Total subsistence costs for this WP	400,00					
	Total travel for this WP	4.000,00					

WORK PACKAGE 5 IMPLEMENTATION AND SUSTAINABILITY

1 Technical Meeting

Speakers

	Travel costs	0,00	0,00	0,00	0,00		
	Accomodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		

Personnel

	Travel costs	0,00	0,00	0,00	0,00		
	Accomodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		

Participants

	Travel costs	0,00	0,00	0,00	0,00		
	Accomodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		

	Total travel costs for this travel	0,00					
	Total accomodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					
	Total travel costs for this WP	0,00					
	Total accomodation costs for this WP	0,00					
	Total subsistence costs for this WP	0,00					
	Total travel for this WP	0,00					

	Total travel costs (all WPs)	6.300,00					
	Total accomodation (all WPs)	3.150,00					
	Total subsistence (all WPs)	1.050,00					
	Total travel and subsistence (all WPs)	10.500,00					


C.2 Equipment

WORK PACKAGE 1 COORDINATION, MANAGEMENT AND EVALUATION

	C.2.1 Purchase (depreciation/full cost)	Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	0,00			Total (EUR)
		a	b	c	d			e = (c/b * d) * a

	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total depreciation					0,00		
	C.2.2 Rental and leasing (rate of use/full cost)							
	Costs (actual costs)							
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b		c	d = a*b*c			
	1 [Equipment short name]	0,00	0,00		0%	0,00		
	2 [Equipment short name]	0,00	0,00		0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total rental and leasing					0,00		
	Total equipment for this WP					0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION							
	C.2.1 Purchase (depreciation/full cost)							
	Costs (actual costs)							
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	d	e = (c/b * d) * a			
	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total depreciation					0,00		
	C.2.2 Rental and leasing (rate of use/full cost)							
	Costs (actual costs)							
	Monthly rent/fee	Number of months of use for the action		Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b		c	d = a*b*c			
	1 [Equipment short name]	0,00	0,00		0%	0,00		
	2 [Equipment short name]	0,00	0,00		0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total rental and leasing					0,00		
	Total equipment for this WP					0,00		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES							
	C.2.1 Purchase (depreciation/full cost)							
	Costs (actual costs)							
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	d	e = (c/b * d) * a			
	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total depreciation					0,00		
	C.2.2 Rental and leasing (rate of use/full cost)							
	Costs (actual costs)							

	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
1 [Equipment short name]	0,00	0,00	0%	0,00		
2 [Equipment short name]	0,00	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
Total rental and leasing				0,00		
Total equipment for this WP				0,00		
WORK PACKAGE 4						
GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS						
C.2.1 Purchase (depreciation/full cost)						
Costs (actual costs)						
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP
	a	b	c	d	e=(c/b *d) * a	Description of tasks/activities for which the equipment is needed
1 [Equipment short name]	0,00	0	0,00	0%	0,00	
2 [Equipment short name]	0,00	0	0,00	0%	0,00	
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
Total depreciation				0,00		
C.2.2 Rental and leasing (rate of use/full cost)						
Costs (actual costs)						
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d= a*b*c		
1 [Equipment short name]	0,00	0,00	0%	0,00		
2 [Equipment short name]	0,00	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
Total rental and leasing				0,00		
Total equipment for this WP				0,00		
WORK PACKAGE 5						
IMPLEMENTATION AND SUSTAINABILITY						
C.2.1 Purchase (depreciation/full cost)						
Costs (actual costs)						
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP
	a	b	c	d	e=(c/b *d) * a	Description of tasks/activities for which the equipment is needed
1 [Equipment short name]	0,00	0	0,00	0%	0,00	
2 [Equipment short name]	0,00	0	0,00	0%	0,00	
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	
Total depreciation				0,00		
C.2.2 Rental and leasing (rate of use/full cost)						
Costs (actual costs)						
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d= a*b*c		
1 [Equipment short name]	0,00	0,00	0%	0,00		
2 [Equipment short name]	0,00	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00	

		Total rental and leasing	0,00		
		Total equipment for this WP	0,00	 Associated with document Ref. Ares(2022)4356368 - 13/06/2022	
		Total equipment (all WPs)	0,00		
C.3 Other goods, works and services					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
	Total goods, works and services for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			

	[5 short name other]	0,00			
	[6 short name other]	0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
Total goods, works and services for this WP		0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
Total goods, works and services (all WPs)		0,00			
Total purchase costs (all WPs)			10.500,00		
D. Other cost categories					
D.1. Financial support to third parties					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			

		0,00		
Total other cost category D.1 for this WP		0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION			
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP
	[Support scheme short name]	0,00		
	[Support scheme short name]	0,00		
		0,00		
Total other cost category D.1 for this WP		0,00		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES			
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP
	[Support scheme short name]	0,00		
	[Support scheme short name]	0,00		
		0,00		
Total other cost category D.1 for this WP		0,00		
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS			
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP
	[Support scheme short name]	0,00		
	[Support scheme short name]	0,00		
		0,00		
Total other cost category D.1 for this WP		0,00		
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY			
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP
	[Support scheme short name]	0,00		
	[Support scheme short name]	0,00		
		0,00		
Total other cost category D.1 for this WP		0,00		
			Total D.1 (all WPs)	0,00
			Total other cost categories (all WPs)	0,00
E. Indirect costs				
		Costs (flat-rate)		
	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	91.300,00		

ALL WORK PACKAGES	Flat-rate (%)	7%	Associated with document Ref. Ares(2022)4356368 - 13/06/2022	
	Total indirect costs	6.391,00		
Total indirect costs		6.391,00		
TOTAL COSTS PARTICIPANT			97.691,00	

PROJECT INCOME

EU CONTRIBUTION (GRANT)

	Amount (EUR)	
Total costs	97.691,00	
Single Funding rate (%)	80%	
Maximum EU contribution	78.152,80	
Requested EU contribution	78.152,80	
EU CONTRIBUTION	78.152,80	

REVENUES AND CONTRIBUTIONS BY THIRD PARTIES

Revenues

Income generated by the action

	Amount (EUR)	Description of the income (type of generated income and number of users, etc)
ALL WORK PACKAGES	0,00	
Estimated income generated by the action	0,00	
Total income generated by the action	0,00	
Revenues	0,00	

In-kind contributions by third parties

In-kind contributions by third parties

	Amount (EUR)	Description of the contribution (type of contribution, donor, purpose etc)
ALL WORK PACKAGES	0,00	
Estimated in-kind contributions by third parties	0,00	
Total in-kind contributions	0,00	
In-kind contributions	0,00	

Financial contributions by third parties

Financial contributions by third parties

	Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	0,00	
Estimated financial contributions by third parties	0,00	
Total financial contributions	0,00	

Financial contributions

0,00

TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES

0,00

OWN RESOURCES

Amount
(EUR)

Own resources

19.538,20

OWN RESOURCES

19.538,20

TOTAL INCOME PARTICIPANT

97.691,00

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	8-INSERM
Participant PIC:	999997833

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE

	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3	D.1 Financial support to third parties d1		
WP1 COORDINATION, MANAGEMENT AND EVALUATION	0,00	0,00	0,00	2.500,00	1.500,00	750,00	250,00	0,00	0,00	0,00	175,00	2.675,00
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	73.600,00	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	5.432,00	83.032,00
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	7.200,00	0,00	0,00	4.000,00	2.400,00	1.200,00	400,00	0,00	0,00	0,00	784,00	11.984,00
WP5 IMPLEMENTATION AND SUSTAINABILITY	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
TOTAL COSTS PARTICIPANT	80.800,00	0,00	0,00	10.500,00	6.300,00	3.150,00	1.050,00	0,00	0,00	0,00	6.391,00	97.691,00

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	9-EPHA
Participant PIC:	955484436

01/06/2022 13:12

ATTENTION: This table should be filled out one per participant (beneficiary, affiliated entity)

ATTENTION: This table may ONLY contain eligible costs (i.e. costs that comply with the eligibility rules of the grant agreement that is part of your call documents). At proposal stage and during grant preparation, it should contain estimated costs/income. Costs must be estimated in EUR.

ATTENTION! List each budgeted cost item ONLY once in this table, for the main WP.

ATTENTION! White cells mean that you are required to enter data. Blue cells are calculated automatically.

EU PROJECT BUDGET TABLE (PER PARTICIPANT)

PROJECT COSTS

A. Personnel costs

	Type of rate (monthly/other)	Costs (actual costs)			Total (EUR)	Also working for other work packages? YES/NO and which WP	Description of project role/activities/responsibilities
		Rate (amount)	Time (months/other of work on the action)				
		a	b	c = a * b			
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
	A.1 Employees (or equivalent)						
				0,00			
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				0,00		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total natural persons under direct contract and seconded persons				0,00		
	A.4 SME owners and natural person beneficiaries without salary						
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
	Total SME owners and natural person beneficiaries without salary				0,00		
	Total personnel for this WP				0,00		
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	A.1 Employees (or equivalent)						
	Project managers	monthly	8.000,00	9,25	74.000,00		Project manager

	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				74.000,00		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total natural persons under direct contract and seconded persons				0,00		
	A.4 SME owners and natural person beneficiaries without salary						
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
	Total SME owners and natural person beneficiaries without salary				0,00		
	Total personnel for this WP				74.000,00		
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES						
	A.1 Employees (or equivalent)						
		monthly		0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				0,00		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total natural persons under direct contract and seconded persons				0,00		
	A.4 SME owners and natural person beneficiaries without salary						
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
	Total SME owners and natural person beneficiaries without salary				0,00		
	Total personnel for this WP				0,00		
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS						
	A.1 Employees (or equivalent)						
					0,00		
	Other						
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
	Total employees (or equivalent)				0,00		
	A.2 + A.3 Natural persons under direct contract and seconded persons						
	Select a staff category	monthly	0,00	0,00	0,00		

	Select a staff category	monthly	0,00	0,00	0,00		
Other							
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
Total natural persons under direct contract and seconded persons					0,00		
A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
Total SME owners and natural person beneficiaries without salary					0,00		
Total personnel for this WP					0,00		

WORK PACKAGE 5 IMPLEMENTATION AND SUSTAINABILITY

A.1 Employees (or equivalent)							
					0,00		
Other							
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
Total employees (or equivalent)					0,00		
A.2 + A.3 Natural persons under direct contract and seconded persons							
	Select a staff category	monthly	0,00	0,00	0,00		
	Select a staff category	monthly	0,00	0,00	0,00		
Other							
	[category 1]	monthly	0,00	0,00	0,00		
	[category 2]	monthly	0,00	0,00	0,00		
Total natural persons under direct contract and seconded persons					0,00		
A.4 SME owners and natural person beneficiaries without salary							
	SME owners/natural person beneficiaries without salary	daily	0,00	0,00	0,00		
Total SME owners and natural person beneficiaries without salary					0,00		
Total personnel for this WP					0,00		

Total personnel (all WPs) 74.000,00

B. Subcontracting costs

		Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of subcontracted project tasks/activities
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
Total subcontracting for this WP		0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
Total subcontracting for this WP		0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	1 [Subcontract short name]	0,00			

	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	1 [Subcontract short name]	0,00			
	2 [Subcontract short name]	0,00			
	Total subcontracting for this WP	0,00			

Total subcontracting (all WPs) 0,00

C. Purchase costs

C.1 Travel and subsistence

	Costs (actual costs)	Costs (unit cost)			Also part of other work packages? YES/NO and which WP	Description (e.g. international/not international; place of activity/destination; number of days; number of persons (speakers, personnel and participants whose costs will be covered); transport means; average price per person; subsistence costs/daily allowances)
		Amount per unit	Number of units	Total (EUR)		
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION					
	1 project meeting					
	Speakers					
	Travel costs	0,00	0,00	0,00	0,00	
	Accommodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Personnel					
	Travel costs	0,00	0,00	0,00	0,00	
	Accommodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Participants					
	Travel costs	0,00	0,00	0,00	0,00	
	Accommodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Total travel costs for this travel	0,00				
	Total accommodation costs for this travel	0,00				
	Total subsistence costs for this travel	0,00				
	Total travel	0,00				
	2 project meeting					
	Speakers					
	Travel costs	0,00	0,00	0,00	0,00	
	Accommodation costs	0,00	0,00	0,00	0,00	
	Subsistence costs	0,00	0,00	0,00	0,00	
	Personnel					
	Travel costs	0,00	0,00	0,00	0,00	

	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accomodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					
3 project meeting							
	Speakers						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Personnel						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accomodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					
	Total travel costs for this WP	0,00					
	Total accomodation costs for this WP	0,00					
	Total subsistence costs for this WP	0,00					
	Total travel for this WP	0,00					
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION						
	1 stakeholder final dissemination conference						
	Speakers						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Personnel						
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Participants						
	Travel costs	0,00	0,00	0,00	0,00		

	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accomodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					
	Total travel costs for this WP	0,00					
	Total accomodation costs for this WP	0,00					
	Total subsistence costs for this WP	0,00					
	Total travel for this WP	0,00					

WORK PACKAGE 3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

1 Technical Meeting							
Speakers							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Personnel							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Participants							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accomodation costs for this travel	0,00					
	Total subsistence costs for this travel	0,00					
	Total travel	0,00					

2 Technical Meeting							
Speakers							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Personnel							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
Participants							
	Travel costs	0,00	0,00	0,00	0,00		
	Accommodation costs	0,00	0,00	0,00	0,00		
	Subsistence costs	0,00	0,00	0,00	0,00		
	Total travel costs for this travel	0,00					
	Total accomodation costs for this travel	0,00					

Total subsistence costs for this travel 0,00

Total travel 0,00

3 Technical Meeting

Speakers

Travel costs 0,00 0,00 0,00 0,00

Accommodation costs 0,00 0,00 0,00 0,00

Subsistence costs 0,00 0,00 0,00 0,00

Personnel

Travel costs 0,00 0,00 0,00 0,00

Accommodation costs 0,00 0,00 0,00 0,00

Subsistence costs 0,00 0,00 0,00 0,00

Participants

Travel costs 0,00 0,00 0,00 0,00

Accommodation costs 0,00 0,00 0,00 0,00

Subsistence costs 0,00 0,00 0,00 0,00

Total travel costs for this travel 0,00

Total accommodation costs for this travel 0,00

Total subsistence costs for this travel 0,00

Total travel 0,00

Total travel costs for this WP 0,00

Total accommodation costs for this WP 0,00

Total subsistence costs for this WP 0,00

Total travel for this WP 0,00

WORK PACKAGE 4

GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS

1 Technical Meeting

Speakers

Travel costs 0,00 0,00 0,00 0,00

Accommodation costs 0,00 0,00 0,00 0,00

Subsistence costs 0,00 0,00 0,00 0,00

Personnel

Travel costs 0,00 0,00 0,00 0,00

Accommodation costs 0,00 0,00 0,00 0,00

Subsistence costs 0,00 0,00 0,00 0,00

Participants

Travel costs 0,00 0,00 0,00 0,00

Accommodation costs 0,00 0,00 0,00 0,00

Subsistence costs 0,00 0,00 0,00 0,00

Total travel costs for this travel 0,00

Total accommodation costs for this travel 0,00

Total subsistence costs for this travel 0,00

Total travel 0,00

2 Technical meeting

Speakers					
Travel costs	0,00	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00	0,00
Personnel					
Travel costs	0,00	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00	0,00
Participants					
Travel costs	0,00	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00	0,00
Total travel costs for this travel	0,00				
Total accommodation costs for this travel	0,00				
Total subsistence costs for this travel	0,00				
Total travel	0,00				

3 Technical meeting					
Speakers					
Travel costs	0,00	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00	0,00
Personnel					
Travel costs	0,00	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00	0,00
Participants					
Travel costs	0,00	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00	0,00
Total travel costs for this travel	0,00				
Total accommodation costs for this travel	0,00				
Total subsistence costs for this travel	0,00				
Total travel	0,00				
Total travel costs for this WP	0,00				
Total accommodation costs for this WP	0,00				
Total subsistence costs for this WP	0,00				
Total travel for this WP	0,00				

WORK PACKAGE 5

IMPLEMENTATION AND SUSTAINABILITY

1 Technical Meeting					
Speakers					
Travel costs	0,00	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00	0,00

Personnel				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Participants				
Travel costs	0,00	0,00	0,00	0,00
Accommodation costs	0,00	0,00	0,00	0,00
Subsistence costs	0,00	0,00	0,00	0,00
Total travel costs for this travel	0,00			
Total accommodation costs for this travel	0,00			
Total subsistence costs for this travel	0,00			
Total travel	0,00			
Total travel costs for this WP	0,00			
Total accommodation costs for this WP	0,00			
Total subsistence costs for this WP	0,00			
Total travel for this WP	0,00			

Total travel costs (all WPs)	0,00
Total accommodation (all WPs)	0,00
Total subsistence (all WPs)	0,00
Total travel and subsistence (all WPs)	0,00

C.2 Equipment

WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION							
	C.2.1 Purchase (depreciation/full cost)							
	Costs (actual costs)							
		Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	0,00	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
		a	b	c	d	$e = (c/b * d) * a$		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
	Total depreciation					0,00		
	C.2.2 Rental and leasing (rate of use/full cost)							
	Costs (actual costs)							
		Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
		a	b	c	$d = a * b * c$			
	1 [Equipment short name]	0,00	0,00	0%	0,00			
	2 [Equipment short name]	0,00	0,00	0%	0,00			
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total rental and leasing					0,00			
Total equipment for this WP					0,00			

WORK PACKAGE 2 COMMUNICATION DISSEMINATION AND EXPLOITATION

C.2.1 Purchase (depreciation/full cost)							
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
	Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
	a	b	c	d = a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00			
2 [Equipment short name]	0,00	0,00	0%	0,00			
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
Total rental and leasing				0,00			
Total equipment for this WP					0,00		

WORK PACKAGE 3

ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES

C.2.1 Purchase (depreciation/full cost)							
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement			0,00		
Total depreciation					0,00		
C.2.2 Rental and leasing (rate of use/full cost)							
	Costs (actual costs)				Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)			
	a	b	c	d = a*b*c			
1 [Equipment short name]	0,00	0,00	0%	0,00			
2 [Equipment short name]	0,00	0,00	0%	0,00			
3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00			
Total rental and leasing				0,00			
Total equipment for this WP					0,00		

WORK PACKAGE 4

GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS

C.2.1 Purchase (depreciation/full cost)							
	Costs (actual costs)					Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate or use for the action (100% or less if used also for other purposes)	Total (EUR)		
	a	b	c	d	e = (c/b * d) * a		
1 [Equipment short name]	0,00	0	0,00	0%	0,00		
2 [Equipment short name]	0,00	0	0,00	0%	0,00		

	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total depreciation				0,00		
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)						
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total rental and leasing				0,00		
	Total equipment for this WP				0,00		
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY						
	C.2.1 Purchase (depreciation/full cost)						
	Costs (actual costs)						
	Price	Depreciation method (e.g. 36 month or 60 month)	Number of months allocated to the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed
	a	b	c	d	e =(c/b *d) * a		
	1 [Equipment short name]	0,00	0	0,00	0%	0,00	
	2 [Equipment short name]	0,00	0	0,00	0%	0,00	
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total depreciation				0,00		
	C.2.2 Rental and leasing (rate of use/full cost)						
	Costs (actual costs)						
	Monthly rent/fee	Number of months of use for the action	Rate of use for the action (100% or less if used also for other purposes)	Total (EUR)	Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the equipment is needed	
	a	b	c	d= a*b*c			
	1 [Equipment short name]	0,00	0,00	0%	0,00		
	2 [Equipment short name]	0,00	0,00	0%	0,00		
	3 [Equipment short name]	0,00	ATTENTION! Can be used only if full cost option in the grant agreement		0,00		
	Total rental and leasing				0,00		
	Total equipment for this WP				0,00		
	Total equipment (all WPs)				0,00		
	C.3 Other goods, works and services						
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION						
		Costs (actual costs)			Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much	
	Consumables	0,00					
	Conferences, seminars, workshops, trainings & events	0,00					
	Information & publications	0,00					
	Other expenses						
	1 IPR costs	0,00					
	2 Bank fees (pre-financing guarantee)	0,00					
	3 Audit fees (CFS)	0,00					

	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	20.000,00		NO	definition of project logo and identity, dissemination activities, design of project brochures and newsletters
	Information & publications	7.500,00		NO	Printing of project brochures
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		27.500,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			

	[5 short name other]	0,00			
	[6 short name other]	0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
Total goods, works and services for this WP		0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
		Costs (actual costs)		Also part of other work packages? YES/NO and which WP	Description of tasks/activities for which the goods/services are needed; types of goods services needed; how much
	Consumables	0,00			
	Conferences, seminars, workshops, trainings & events	0,00			
	Information & publications	0,00			
	Other expenses				
	1 IPR costs	0,00			
	2 Bank fees (pre-financing guarantee)	0,00			
	3 Audit fees (CFS)	0,00			
	4 Project evaluation	0,00			
	[5 short name other]	0,00			
	[6 short name other]	0,00			
Total goods, works and services for this WP		0,00			
Total goods, works and services (all WPs)		27.500,00			
			Total purchase costs (all WPs)	27.500,00	
D. Other cost categories					
D.1. Financial support to third parties					
WORK PACKAGE 1	COORDINATION, MANAGEMENT AND EVALUATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 2	COMMUNICATION DISSEMINATION AND EXPLOITATION				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 3	ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)

	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			Associated with document Ref. Ares(2022)4356368 - 13/06/2022
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 4	GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT ORGAN DONATION AND TRANSPLANT SYSTEMS				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
WORK PACKAGE 5	IMPLEMENTATION AND SUSTAINABILITY				
	Financial support to third parties	Costs (actual costs)		Also used for other work packages? YES/NO and which WP	Description of support scheme (estimated number of recipients; maximum amount per recipient)
	[Support scheme short name]	0,00			
	[Support scheme short name]	0,00			
		0,00			
	Total other cost category D.1 for this WP	0,00			
			Total D.1 (all WPs)	0,00	
			Total other cost categories (all WPs)	0,00	
E. Indirect costs					
		Costs (flat-rate)			
ALL WORK PACKAGES	Total estimated direct costs (on which indirect cost flat-rate is based, see GA eligibility article)	101.500,00			
	Flat-rate (%)	7%			
	Total indirect costs	7.105,00			
	Total indirect costs	7.105,00			
TOTAL COSTS PARTICIPANT				108.605,00	
PROJECT INCOME					
EU CONTRIBUTION (GRANT)					
		Amount (EUR)			
	Total costs	108.605,00			
	Single Funding rate (%)	80%			

	Maximum EU contribution	86.884,00	
	Requested EU contribution	86.884,00	
EU CONTRIBUTION		86.884,00	
REVENUES AND CONTRIBUTIONS BY THIRD PARTIES			
Revenues			
Income generated by the action			
		Amount (EUR)	Description of the income (type of generated income and number of users, etc)
ALL WORK PACKAGES	Estimated income generated by the action	0,00	
	Total income generated by the action	0,00	
	Revenues	0,00	
In-kind contributions by third parties			
In-kind contributions by third parties			
		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose etc)
ALL WORK PACKAGES	Estimated in-kind contributions by third parties	0,00	
	Total in-kind contributions	0,00	
	In-kind contributions	0,00	
Financial contributions by third parties			
Financial contributions by third parties			
		Amount (EUR)	Description of the contribution (type of contribution, donor, purpose, etc)
ALL WORK PACKAGES	Estimated financial contributions by third parties	0,00	
	Total financial contributions	0,00	
	Financial contributions	0,00	
	TOTAL REVENUES AND CONTRIBUTIONS BY THIRD PARTIES	0,00	
OWN RESOURCES			
		Amount (EUR)	
	Own resources	21.721,00	
	OWN RESOURCES	21.721,00	
	TOTAL INCOME PARTICIPANT	108.605,00	

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Associated with document Ref. Ares(2022)4356368 - 13/06/2022

Project number:	101056986
Project acronym:	BRAVEST
Participant short name:	9-EPHA
Participant PIC:	955484436

CONSOLIDATED COSTS PER WORK PACKAGE (PER PARTICIPANT)

COSTS PER WORK PACKAGE


	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories D.1 Financial support to third parties d1	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total	
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, work and services c3				
WP1 COORDINATION, MANAGEMENT AND EVALUATION	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	
WP2 COMMUNICATION DISSEMINATION AND EXPLOITATION	74.000,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27.500,00	0,00	7.105,00	108.605,00
WP3 ANALYSIS OF COVID-19 PANDEMIC IMPACT ON PARTICIPATING COUNTRIES	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
WP4 GUIDELINES AND PROSPECTIVE SOLUTIONS FOR BUILDING UP RESILIENT	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
WP5 IMPLEMENTATION AND SUSTAINABILITY	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
TOTAL COSTS PARTICIPANT	74.000,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27.500,00	0,00	7.105,00	108.605,00

EU GRANTS DETAILED BUDGET TABLE (ACTION GRANTS)

Project number:	101056986
Project acronym:	BRAVEST

ATTENTION! Delete columns that do not apply for your grant.

CONSOLIDATED COSTS PER WORK PACKAGE (PROJECT)												
PROJECT COSTS PER WORK PACKAGE												
	A.1 Employees A.2 + A.3 Natural persons under direct contract and seconded persons a1 - a2	A.4 SME owners a3	B. Subcontracting costs b	C. Purchase costs						D. Other cost categories	E. Indirect costs e = flat-rate * (a1 + a2 + a3 + a5 + b [+ c1] + [c1a + c1b + c1c] + c2 + c3 + d1 + d2 + d3 + d4 + d5 + d6)	Total
				C.1 Travel and subsistence c1	C.1 Travel c1a	C.1 Accomodation c1b	C.1 Subsistence c1c	C.2 Equipment c2	C.3 Other goods, works and services c3	D.1 Financial support to third parties d1		
PARTICIPANT [1-ESOT]												
TOTAL COSTS PARTICIPANT (Proposal Step)	129.000,00	0,00	100.000,00	28.000,00	16.800,00	8.400,00	2.800,00	0,00	63.000,00	0,00	22.400,00	342.400,00
TOTAL COSTS PARTICIPANT (Grant Preparation Step)	129.000,00	0,00	100.000,00	28.000,00	16.800,00	8.400,00	2.800,00	0,00	63.000,00	0,00	22.400,00	342.400,00
PARTICIPANT [2-ISS-CNT]												
TOTAL COSTS PARTICIPANT (Proposal Step)	79.933,60	0,00	0,00	25.000,00	15.000,00	7.500,00	2.500,00	0,00	0,00	0,00	7.345,35	112.278,95
TOTAL COSTS PARTICIPANT (Grant Preparation Step)	79.933,60	0,00	0,00	25.000,00	15.000,00	7.500,00	2.500,00	0,00	0,00	0,00	7.345,35	112.278,95
PARTICIPANT [3-ONT]												
TOTAL COSTS PARTICIPANT (Proposal Step)	119.194,56	0,00	0,00	11.500,00	6.900,00	3.450,00	1.150,00	0,00	5.000,00	0,00	9.498,62	145.193,18
TOTAL COSTS PARTICIPANT (Grant Preparation Step)	119.194,56	0,00	0,00	11.500,00	6.900,00	3.450,00	1.150,00	0,00	5.000,00	0,00	9.498,62	145.193,18
PARTICIPANT [4-ST]												
TOTAL COSTS PARTICIPANT (Proposal Step)	101.292,40	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	8.105,47	123.897,87
TOTAL COSTS PARTICIPANT (Grant Preparation Step)	101.292,40	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	8.105,47	123.897,87
PARTICIPANT [5-ET]												
TOTAL COSTS PARTICIPANT (Proposal Step)	53.509,79	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	4.760,69	72.770,48
TOTAL COSTS PARTICIPANT (Grant Preparation Step)	53.509,79	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	4.760,69	72.770,48
PARTICIPANT [6-ABM]												
TOTAL COSTS PARTICIPANT (Proposal Step)	73.680,54	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	6.172,64	94.353,18
TOTAL COSTS PARTICIPANT (Grant Preparation Step)	73.680,54	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	6.172,64	94.353,18
PARTICIPANT [7-OVSZ]												
TOTAL COSTS PARTICIPANT (Proposal Step)	67.450,00	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	5.736,50	87.686,50
TOTAL COSTS PARTICIPANT (Grant Preparation Step)	67.450,00	0,00	0,00	14.500,00	8.700,00	4.350,00	1.450,00	0,00	0,00	0,00	5.736,50	87.686,50
PARTICIPANT [8-INSERM]												
TOTAL COSTS PARTICIPANT (Proposal Step)	80.800,00	0,00	0,00	10.500,00	6.300,00	3.150,00	1.050,00	0,00	0,00	0,00	6.391,00	97.691,00

TOTAL COSTS PARTICIPANT <i>(Grant Preparation Step)</i>	80.800,00	0,00	0,00	10.500,00	6.300,00	3.150,00	1.050,00	0,00	0,00	0,00	6.391,00	97.691,00	
 Associated with document Ref. Ares(2022)4356368 - 13/06/2022													
PARTICIPANT [9-EPHA]													
TOTAL COSTS PARTICIPANT <i>(Proposal Step)</i>	74.000,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27.500,00	0,00	7.105,00	108.605,00
TOTAL COSTS PARTICIPANT <i>(Grant Preparation Step)</i>	74.000,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27.500,00	0,00	7.105,00	108.605,00

ANNEX 2

ESTIMATED BUDGET FOR THE ACTION

Forms of funding	Estimated eligible ¹ costs (per budget category)										Estimated EU contribution ²				
	Direct costs									Indirect costs	Total costs	EU contribution to eligible costs			Maximum grant amount ⁶
	A. Personnel costs		B. Subcontracting costs	C. Purchase costs			D. Other cost categories	E. Indirect costs ³	Funding rate % ⁴	Maximum EU contribution ⁵		Requested EU contribution			
	A.1 Employees (or equivalent)	A.4 SME owners and natural person beneficiaries	B. Subcontracting	C.1 Travel and subsistence			C.2 Equipment	C.3 Other goods, works and services	D.1 Financial support to third parties	E. Indirect costs					
A.2 Natural persons under direct contract	A.3 Seconded persons	Travel		Accommodation	Subsistence										
	Actual costs	Unit costs ⁷	Actual costs	Unit ⁷ or actual costs	Unit ⁷ or actual costs	Unit ⁷ or actual costs	Actual costs	Actual costs	Actual costs	Flat-rate costs ⁸					
	a1	a3	b	c1a	c1b	c1c	c2	c3	d1	e = flat-rate * (a1 + a3 + b + c1a + c1b + c1c + c2 + c3 + d1)	f = a + b + c + d + e	U	g = f * U%	h	m
1 - ESOT	129 000.00	0.00	100 000.00	16 800.00	8 400.00	2 800.00	0.00	63 000.00	0.00	22 400.00	342 400.00	80	273 920.00	273 920.00	273 920.00
2 - ISS - CNT	79 933.60	0.00	0.00	15 000.00	7 500.00	2 500.00	0.00	0.00	0.00	7 345.35	112 278.95	80	89 823.16	89 823.16	89 823.16
3 - ONT	119 194.56	0.00	0.00	6 900.00	3 450.00	1 150.00	0.00	5 000.00	0.00	9 498.62	145 193.18	80	116 154.54	116 154.54	116 154.54
4 - ST	101 292.40	0.00	0.00	8 700.00	4 350.00	1 450.00	0.00	0.00	0.00	8 105.47	123 897.87	80	99 118.30	99 118.30	99 118.30
5 - ET	53 509.79	0.00	0.00	8 700.00	4 350.00	1 450.00	0.00	0.00	0.00	4 760.69	72 770.48	80	58 216.38	58 216.38	58 216.38
6 - ABM	73 680.54	0.00	0.00	8 700.00	4 350.00	1 450.00	0.00	0.00	0.00	6 172.64	94 353.18	80	75 482.54	75 482.54	75 482.54
7 - OVSZ	67 450.00	0.00	0.00	8 700.00	4 350.00	1 450.00	0.00	0.00	0.00	5 736.50	87 686.50	80	70 149.20	70 149.20	70 149.20
8 - INSERM	80 800.00	0.00	0.00	6 300.00	3 150.00	1 050.00	0.00	0.00	0.00	6 391.00	97 691.00	80	78 152.80	78 152.80	78 152.80
9 - EPHA	74 000.00	0.00	0.00	0.00	0.00	0.00	0.00	27 500.00	0.00	7 105.00	108 605.00	80	86 884.00	86 884.00	86 884.00
Σ consortium	778 860.89	0.00	100 000.00	79 800.00	39 900.00	13 300.00	0.00	95 500.00	0.00	77 515.27	1 184 876.16		947 900.92	947 900.92	947 900.92

¹ See Article 6 for the eligibility conditions. All amounts must be expressed in EUR (see Article 21 for the conversion rules).

² The consortium remains free to decide on a different internal distribution of the EU funding (via the consortium agreement; see Article 7).

³ Indirect costs already covered by an operating grant (received under any EU funding programme) are ineligible (see Article 6.3). Therefore, a beneficiary/affiliated entity that receives an operating grant during the action duration cannot declare indirect costs for the year(s)/reporting period(s) covered by the operating grant, unless they can demonstrate that the operating grant does not cover any costs of the action. This requires specific accounting tools. Please immediately contact us via the EU Funding & Tenders Portal for details.

⁴ See Data Sheet for the funding rate(s).

⁵ This is the theoretical amount of the EU contribution to costs, if the reimbursement rate is applied to all the budgeted costs. This theoretical amount is then capped by the 'maximum grant amount'.

⁶ The 'maximum grant amount' is the maximum grant amount decided by the EU. It normally corresponds to the requested grant, but may be lower.

⁷ See Annex 2a 'Additional information on the estimated budget' for the details (units, cost per unit).

⁸ See Data Sheet for the flat-rate.

ANNEX 2a

ADDITIONAL INFORMATION ON UNIT COSTS AND CONTRIBUTIONS

SME owners/natural person beneficiaries without salary (Decision C(2020) 7115¹)

Type: unit costs

Units: days spent working on the action (rounded up or down to the nearest half-day)

Amount per unit (daily rate): calculated according to the following formula:

{EUR 5 080 / 18 days = **282,22**}
multiplied by
{country-specific correction coefficient of the country where the beneficiary is established}

The country-specific correction coefficients used are those set out in the Horizon Europe Work Programme (section Marie Skłodowska-Curie actions) in force at the time of the call (see [Portal Reference Documents](#)).

¹ Commission [Decision](#) of 20 October 2020 authorising the use of unit costs for the personnel costs of the owners of small and medium-sized enterprises and beneficiaries that are natural persons not receiving a salary for the work carried out by themselves under an action or work programme (C(2020)7715).

Travel and subsistence (Decision C(2021)35²)

Travel

Type: unit costs

Units: travel (journeys) for the action

Amount per unit:

standard:


for travel of 50 -399km (inside EU countries):

Country	Unit costs in €	Country	Unit costs in €	Country	Unit costs in €
AT	60	FI	36	PL	20
BE	46	FR	64	PT	40
BG	12	HR	36	RO	16
CZ	20	HU	28	SE	56
DE	64	IE	36	SI	27
DK	76	IT	52	SK	20
EE	16	LT	20		
EL	36	LV	16		
ES	52	NL	49		

² Commission [Decision](#) of 12 January 2021 authorising the use of unit costs for travel, accommodation and subsistence costs under an action or work programme under the 2021-2027 multi-annual financial framework (C(2021)35).

for travel of 50 -399km (land-based; between EU countries):

MS	AT	BE	BG	CZ	DE	DK	EE	EL	ES	FI	FR	HR	HU	IE	IT	LT	LU	LV	NL	PL	PT	RO	SE	SI	SK	
AT				58	65						64	58	58		58					58		58		58	58	
BE					82						82						50		82							
BG								37				36	26										17			
CZ	58				65						64	36	26							20			19		37	21
DE	65	82		65		76					82	65			65		82		65	65					65	
DK					76																		76			
EE																22		22								
EL			37																							
ES											82											54				
FI																								55		
FR	64	82		64	82				82						82		82		82							
HR	58		36	36	65								36		50								36		37	
HU	589		26	26									36		50					26			26		37	26
IE																										
IT	58				65						82	50	50												50	
LT							22											19		20						
LU		50			82						82								82							
LV							22									19				20						
NL		82			65	76					82						82									
PL	58			20	65								26			20		20					20		21	
PT								54																		
RO	58		17	19								36	26							20					21	
SE						76				55																
SI	58			37	65							37	37		50										37	
SK	58			21									26							21		21		37		

 No connection below 400 km

for travel of 50-399km not covered above: EUR 196

for travel of 400 km or more* (air or rail or combined air/rail):

Distance Band	Unit costs in €	Distance Band	Unit costs in €	Distance Band	Unit costs in €
400-600	196	1601-2000	295	4501-6000	637
601-800	209	2001-2500	343	6001-7500	720
801-1200	221	2501-3500	433	7501-10000	961
1201-1600	230	3501-4500	527	10001-Max	1 101

* All distances to be measured using the [rail calculator](#) or [flight calculator](#).

special rates:

for travel from EU countries to EU outermost regions or OCTs:

Remote region	Unit costs in €	Remote region	Unit costs in €	Remote region	Unit costs in €
Aruba	1 343	French Guiana	905	Saint Helena	2 395
Bonaire	1 344	Martinique	958	Saint Martin	939
Curaçao	1 302	Mayotte	1 170	Saint Pierre and Miquelon	1 832
French Polynesia	2 204	New Caledonia	2 065	Wallis and Fotuna	2 398
Greenland	1 118	Réunion	1 040		
Guadeloupe	801	Saba	1 286		

for travel to/from location 400 km or more from nearest airport: increase applicable unit cost by 50%

Accommodation

Type: unit costs

Units: nights spent on travel for the action

Amount per unit:

Country	Accommodation - € per night	Country	Accommodation - € per night	Country	Accommodation - € per night
Albania	101	Greece	107	North Macedonia	95
Algeria	157	Hungary	105	Norway	145
Armenia	115	Iceland	190	Palestine	140
Austria	126	Ireland	139	Poland	103
Azerbaijan	136	Israel	187	Portugal	109
Belarus	108	Italy	114	Romania	109
Belgium	137	Jordan	140	Serbia	105
Bosnia and Herzegovina	90	Kosovo	92	Slovakia	98
Bulgaria	110	Latvia	95	Slovenia	113
Croatia	104	Lebanon	154	Spain	117
Cyprus	120	Libya	146	Sweden	158
Czechia	107	Lichtenstein	135	Switzerland	178
Denmark	158	Lithuania	94	Syria	145
Egypt	152	Luxembourg	163	Tunisia	99
Estonia	107	Malta	141	Turkey	116
Finland	146	Moldova	133	Ukraine	122
France	166	Montenegro	98	United Kingdom	151
Germany	119	Morocco	129		
Georgia	134	Netherlands	133		

Subsistence

Type: unit costs

Units: days spent on travel for the action

Amount per unit ('daily rate'):

Country	Subsistence daily rate in €	Country	Subsistence daily rate in €	Country	Subsistence daily rate in €
Albania	50	Greece	82	North Macedonia	50
Algeria	85	Hungary	64	Norway	80
Armenia	70	Iceland	85	Palestine	60
Austria	102	Ireland	108	Poland	67
Azerbaijan	70	Israel	105	Portugal	83
Belarus	90	Italy	98	Romania	62
Belgium	102	Jordan	60	Serbia	60
Bosnia and Herzegovina	65	Kosovo	60	Slovakia	74
Bulgaria	57	Latvia	73	Slovenia	84
Croatia	75	Lebanon	70	Spain	88
Cyprus	88	Libya	50	Sweden	117
Czech Republic	70	Lichtenstein	80	Switzerland	80
Denmark	124	Lithuania	69	Syria	80
Egypt	65	Luxembourg	98	Tunisia	60
Estonia	80	Malta	88	Turkey	55
Finland	113	Moldova	80	Ukraine	80
France	102	Montenegro	60	United Kingdom	125
Germany	97	Morocco	75		
Georgia	80	Netherlands	103		

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

ISTITUTO SUPERIORE DI SANITA (ISS - CNT), PIC 999978821, established in Viale Regina Elena 299, ROMA 00161, Italy,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement, in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

ORGANIZACION NACIONAL DE TRASPLANTES (ONT), PIC 941056365, established in CALLE SINESIO DELGADO 8, MADRID 28029, Spain,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement, in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

ZAVOD REPUBLIKE SLOVENIJE ZA PRESADITVE ORGANOV IN TKIV SLOVENIJA TRANSPLANT (ST), PIC 939758796, established in ZALOSKA CESTA 7, LJUBLJANA 1000, Slovenia,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement, in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

STICHTING EUROTRANSPLANT INTERNATIONAL FOUNDATION (ET), PIC 954188419,
established in HAAGSE SCHOUW WEG 6, LEIDEN 2332 KG, Netherlands,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'),
under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement,
in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

AGENCE DE LA BIOMEDECINE (ABM), PIC 911988763, established in AVENUE DU STADE DE FRANCE 1, SAINT DENIS LA PLAINE CEDEX 93212, France,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement, in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

ORSZAGOS VERELLATO SZOLGALAT - OVSZ (OVSZ), PIC 933649251, established in KAROLINA UT 19-21, BUDAPEST 1113, Hungary,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement, in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),
PIC 999997833, established in RUE DE TOLBIAC 101, PARIS 75654, France,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement, in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 3

ACCESSION FORM FOR BENEFICIARIES

EUROPEAN PUBLIC HEALTH ALLIANCE (EPHA), PIC 955484436, established in RUE DE TREVES 49-51, BRUXELLES 1040, Belgium,

hereby agrees

to become beneficiary

in Agreement No 101056986 — BRAVEST ('the Agreement')

between EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION (ESOT) and the European Health and Digital Executive Agency (HADEA) ('EU executive agency' or 'granting authority'), under the powers delegated by the European Commission ('European Commission'),

and mandates

the coordinator to submit and sign in its name and on its behalf any **amendments** to the Agreement, in accordance with Article 39.

By signing this accession form, the beneficiary accepts the grant and agrees to implement it in accordance with the Agreement, with all the obligations and terms and conditions it sets out.

SIGNATURE

For the beneficiary

ANNEX 4 EU4H MGA — MULTI + MONO

FINANCIAL STATEMENT FOR [PARTICIPANT NAME] FOR REPORTING PERIOD [NUMBER]

Eligible ¹ costs (per budget category)											EU contribution ²				Revenues	
Direct costs										Indirect costs	Total costs	EU contribution to eligible costs			Total requested EU contribution	Income generated by the action
A. Personnel costs		B. Subcontracting costs	C. Purchase costs			D. Other cost categories	E. Indirect costs ²	Funding rate % ³	Maximum EU contribution ⁴	Requested EU contribution						
A.1 Employees (or equivalent)	A.4 SME owners and natural person beneficiaries	B. Subcontracting	C.1 Travel and subsistence			C.2 Equipment	C.3 Other goods, works and services	D.X Financial support to third parties	E. Indirect costs	Total costs	Funding rate % ³	Maximum EU contribution ⁴	Requested EU contribution	Total requested EU contribution	Income generated by the action	
A.2 Natural persons under direct contract	A.3 Seconded persons		Travel	Accommodation	Subsistence											
Actual costs			Unit costs ⁵	Actual costs	Unit ⁵ or actual costs											Actual costs
a1	a3	b	c1a	c1b	c1c	c2	c3	d1a	e = flat-rate * (a1 + a3 + b + c1a + c1b + c1c + c2 + c3 + d1a)	f = a+b+c+d+e	U	g = f*U%	h	m	n	
XX – [short name beneficiary/affiliated entity]																

The beneficiary/affiliated entity hereby confirms that:
 The information provided is complete, reliable and true.
 The costs and contributions declared are eligible (see Article 6).
 The costs and contributions can be substantiated by adequate records and supporting documentation that will be produced upon request or in the context of checks, reviews, audits and investigations (see Articles 19, 20 and 25).
 For the last reporting period: that all the revenues have been declared (see Article 22).

¹ Please declare all eligible costs and contributions, even if they exceed the amounts indicated in the estimated budget (see Annex 2). Only amounts that were declared in your individual financial statements can be taken into account later on, in order to replace costs/contributions that are found to be ineligible.

² See Article 6 for the eligibility conditions. All amounts must be expressed in EUR (see Article 21 for the conversion rules).

³ If you have also received an EU operating grant during this reporting period, you cannot claim indirect costs - unless you can demonstrate that the operating grant does not cover any costs of the action. This requires specific accounting tools. Please contact us immediately via the Funding & Tenders Portal for details.

⁴ See Data Sheet for the reimbursement rate(s).

⁵ This is the *theoretical* amount of EU contribution to costs that the system calculates automatically (by multiplying the reimbursement rates by the costs declared). The amount you request (in the column 'requested EU contribution') may be less.

⁶ See Annex 2a 'Additional information on the estimated budget' for the details (units, cost per unit).

⁷ See Data Sheet for the flat-rate.

ANNEX 5

SPECIFIC RULES

ETHICS (— ARTICLE 14)

Ethics

Actions involving activities raising ethics issues must be carried out in compliance with:

- ethical principles

and

- applicable EU, international or national law, including Directive [2005/28](#)¹ and Regulation [536/2014](#)².

The beneficiaries must pay particular attention to the principle of proportionality, the right to privacy, the right to the protection of personal data, the right to the physical and mental integrity of a person, the right to non-discrimination, the need to ensure protection of the environment and high levels of human health protection.

Before the beginning of an action task raising an ethical issue, the beneficiaries must have obtained all approvals or other mandatory documents needed for implementing the task, notably from any (national or local) ethics committee or other bodies such as data protection authorities.

The documents must be kept on file and be submitted upon request by the coordinator to the granting authority. If they are not in English, they must be submitted together with an English summary, which shows that the documents cover the action tasks in question and includes the conclusions of the committee or authority concerned (if any).

INTELLECTUAL PROPERTY RIGHTS (IPR) — BACKGROUND AND RESULTS — ACCESS RIGHTS AND RIGHTS OF USE (— ARTICLE 16)

List of background

The beneficiaries must, where industrial and intellectual property rights (including rights of third parties) exist prior to the Agreement, establish a list of these pre-existing industrial and intellectual property rights, specifying the rights owners.

The coordinator must — before starting the action — submit this list to the granting authority.

¹ Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products (OJ L 91, 9.4.2005, p. 13).

² Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (OJ L 158, 27.5.2014, p. 1).

Rights of use of the granting authority on results for information, communication, dissemination and publicity purposes

The granting authority also has the right to exploit non-sensitive results of the action for information, communication, dissemination and publicity purposes, using any of the following modes:

- **use for its own purposes** (in particular, making them available to persons working for the granting authority or any other EU service (including institutions, bodies, offices, agencies, etc.) or EU Member State institution or body; copying or reproducing them in whole or in part, in unlimited numbers; and communication through press information services)
- **distribution to the public** in hard copies, in electronic or digital format, on the internet including social networks, as a downloadable or non-downloadable file
- **editing** or **redrafting** (including shortening, summarising, changing, correcting, cutting, inserting elements (e.g. meta-data, legends or other graphic, visual, audio or text elements extracting parts (e.g. audio or video files), dividing into parts or use in a compilation
- **translation** (including inserting subtitles/dubbing) in all official languages of EU
- **storage** in paper, electronic or other form
- **archiving** in line with applicable document-management rules
- the right to authorise **third parties** to act on its behalf or sub-license to third parties, including if there is licensed background, any of the rights or modes of exploitation set out in this provision
- **processing**, analysing, aggregating the results and **producing derivative works**
- **disseminating** the results in widely accessible databases or indexes (such as through ‘open access’ or ‘open data’ portals or similar repositories, whether free of charge or not.

The beneficiaries must ensure these rights of use for the whole duration they are protected by industrial or intellectual property rights.

If results are subject to moral rights or third party rights (including intellectual property rights or rights of natural persons on their image and voice), the beneficiaries must ensure that they comply with their obligations under this Agreement (in particular, by obtaining the necessary licences and authorisations from the rights holders concerned).

Access rights for the granting authority, EU institutions, bodies, offices or agencies and national authorities to results for policy purposes

The beneficiaries must grant access to their results — on a royalty-free basis — to the granting authority, other EU institutions, bodies, offices or agencies, for developing, implementing and monitoring EU policies or programmes.

Such access rights are limited to non-commercial and non-competitive use.

The access rights also extend to national authorities of EU Member States or associated countries, for developing, implementing and monitoring their policies or programmes in this area. In this case, access is subject to a bilateral agreement to define specific conditions ensuring that:

- the access will be used only for the intended purpose and
- appropriate confidentiality obligations are in place.

Moreover, the requesting national authority or EU institution, body, office or agency (including the granting authority) must inform all other national authorities of such a request.

Access rights for third parties to ensure continuity and interoperability

Where the call conditions impose continuity or interoperability obligations, the beneficiaries must make the materials, documents and information and results produced in the framework of the action available to the public (freely accessible on the Internet under open licences or open source licences).

COMMUNICATION, DISSEMINATION AND VISIBILITY (— ARTICLE 17)

Communication and dissemination plan

The beneficiaries must provide a detailed communication and dissemination plan, setting out the objectives, key messaging, target audiences, communication channels, social media plan, planned budget and relevant indicators for monitoring and evaluation.

Additional communication and dissemination activities

The beneficiaries must engage in the following additional communication and dissemination activities:

- **present the project** (including project summary, coordinator contact details, list of participants, European flag and funding statement and project results) on the beneficiaries' **websites** or **social media accounts**
- for actions involving **publications**, mention the action and the European flag and funding statement on the cover or the first pages following the editor's mention
- for actions involving public **events**, display signs and posters mentioning the action and the European flag and funding statement
- upload the public **project results** to the EU4Health Project Results platform, available through the Funding & Tenders Portal .


SPECIFIC RULES FOR CARRYING OUT THE ACTION (— ARTICLE 18)

Specific rules for blending operations

When implementing blending operations, the beneficiaries acknowledge and accept that:

- the grant depends on the approved financing from the Implementing Partner and/or public or private investors for the project

- they must inform the granting authority both about the approval for financing and the financial close — within 15 days
- the payment deadline for the first prefinancing is automatically suspended until the granting authority is informed about the approval for financing
- both actions will be managed and monitored in parallel and in close coordination with the Implementing Partner, in particular:
 - all information, data and documents (including the due diligence by the Implementing Partner and the signed agreement) may be exchanged and may be relied on for the management of the other action (if needed)
 - issues in one action may impact the other (e.g. suspension or termination in one action may lead to suspension also of the other action; termination of the grant will normally suspend and exit from further financing and vice versa, etc.)
- the granting authority may disclose confidential information also to the Implementing Partner.



This electronic receipt is a digitally signed version of the document submitted by your organisation. Both the content of the document and a set of metadata have been digitally sealed.

This digital signature mechanism, using a public-private key pair mechanism, uniquely binds this eReceipt to the modules of the Funding & Tenders Portal of the European Commission, to the transaction for which it was generated and ensures its full integrity. Therefore a complete digitally signed trail of the transaction is available both for your organisation and for the issuer of the eReceipt.

Any attempt to modify the content will lead to a break of the integrity of the electronic signature, which can be verified at any time by clicking on the eReceipt validation symbol.

More info about eReceipts can be found in the FAQ page of the Funding & Tenders Portal.

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq>